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Abstract 
Kidney transplantation is the gold standard renal replacement therapy for patients with 
end-stage renal disease. Despite advances in immunosuppressive therapy, chronic 
allograft dysfunction remains the commonest cause of renal allograft failure in living 
recipients. The typical pathology of this disease includes chronic inflammation with 
tubular atrophy and interstitial fibrosis. Although the origin of the excess fibroblasts 
and myofibroblasts remains controversial, the process of epithelial to mesenchymal 
transition might play a role. This study was designed to test the linked hypotheses that 
the immunosuppressive drug, Cyclosporine A and graft infiltrating T cells can induce 
allograft pathology by alteration of the bioavailability of fibrogenic TGF-β.  
An initial series of experiments examined the induction of mesenchymal transition by 
treatment of cultured human renal tubular epithelial cells with immunosuppressive 
concentrations of Cyclosporine A. Drug treated cells showed characteristic 
morphological changes associated with increased expression of the mesenchymal 
marker S100A4 and reduced expression of the epithelial marker E-cadherin; similar  
changes were induced by the addition of TGF-β1. The phenotypic change induced by 
Cyclosporine A was not the consequence of an increased response to autocrine TGF-β 
and could not be inhibited by specific blockade of the ALK5 component of the TGF-β 
receptor. Further studies showed in vitro that contact between activated T cells and 
renal tubular epithelial cells could induce mesenchymal transition by a mechanism 
that was dependent on activation of the TGF-β receptor complex. A final series of 
experiments defined a mechanism by which T cells activate latent TGF-β allowing 
subsequent receptor stimulation leading to either T cell or epithelial cells 
differentiation. The latency associated peptide binds to and inhibits native TGF-β but 
can be displaced by both thrombospondin-1 and neuropilin-1, producing active 
TGF-β. In this study it was shown that cytoplasmic thrombospondin-1 is exported and 
expressed on the surface of activated T cells following brief interaction with renal 
tubular epithelial cells; neuropilin-1 was also expressed by a mean 18% of activated 
human T cells. Inhibition of these two molecules with a blocking LSKL peptide 
sequence inhibited the normal response of activated human T cells to latent TGF-β1. 
This study demonstrated that both Cyclosporine A and T cells can induce renal 
epithelial to mesenchymal cell transition. However, the former process seems 
independent of TGF-β whilst the latter requires TGF-β receptor stimulation and might 
be regulated in vivo by T cell-mediated activation of latent TGF-β within the allograft. 
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1.1 History of kidney transplantation
The first successful experimental kidney transplants in animals were reported in 1902 by 
Dr.  Emmerich  Ullmann  in  Vienna;  however,  the  incidence  of  rejection  was  not  mentioned 
(Druml  et  al.,  2002).  Later  in  1923,  Dr.  Carl  Williamson  firstly  examined  a  failed  kidney 
transplant and identified the difference between autografted and allografted kidney. In addition, 
he introduced the term “rejection” and published the histology of a rejecting kidney (Eedy et al., 
2004).
The  first  human-to-human  kidney  transplant  was  performed  in  1933  by  Yuri 
Voronoy, who transplanted a  cadaver kidney  into the medial thigh. However, the kidney graft 
did not function due to an ABO blood group mismatch (Matevossian et  al., 2009). The first 
recorded event in which a transplanted kidney functioned was in 1951. David Hume in Boston 
performed a series of cadaveric kidney transplants into the thigh of recipient patients. All but one 
of these kidneys was rejected within days or weeks; the one exception was a patient in whom the 
kidney functioned for nearly 6 months (Hume et al., 1955). This event provided hope for the 
future as no immunosuppressive therapy was used in this patient. In 1953, a further advance was 
provided by the demonstration that tolerance to an allogeneic skin graft in an adult animal could 
be produced by injecting the foetus with donor strain tissue (Billingham et al., 1953).
The  modern  era  of  clinical  transplantation  began  on  December  1954,  when  Joseph 
Murray  and  his  colleagues  at  Harvard  performed  the  first  kidney  transplantation  between 
identical twin brothers (Murray et al., 1958). Before 1980, the best therapeutic option for patients 
with kidney failure was dialysis; however, despite numerous medical and technical advances, 
patients with kidney failure who were treated with dialysis mostly experience a poor quality of 
life with increased morbidity and mortality. In recent times kidney transplantation has become 
the treatment of choice for patients with end-stage renal disease (ESRD). However, limitations 
such  as  an  inadequate  organ  supply  and  poor  long-term  graft  outcome  remain  important 
problems for kidney transplantation.
1.2 Kidney allograft survival
A successful transplant restores an acceptable quality of life to ESRD patients; this is due 
in part to the availability of potent immunosuppressive drugs. Currently, the number of patients 
with  end-stage  renal  failure  in  the  USA  who  might  be  treated  by  haemodialysis  and 
transplantation comprises 350 new patients per million of population (Figure 1.1) (2010 USRD 
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annual report). This is consistent with the incidence of ESRD in Thailand, which increased from 
30 per million of population in 1997 to 500 per million of population in 2008.
Unfortunately, the supply of kidneys for transplantation is not sufficient to meet demand. 
In  fact,  there  is  an attempt to  expand the supply of  donor  kidneys  by use of living donors, 
expanded  criteria  donors  and  non-heart  beating  donors.  As  a  result,  the  number  of  kidney 
transplant operations has increased. Although the 1-year graft survival has increased to 92-93% 
(Figure 1.2 and Table 1.1) and 96% (Figure 1.3 and Table 1.2) for cadaveric and living donor 
transplantation  respectively,  the  10-year  graft  survival  has  remained  unsatisfactory  at 
approximately 67-70% for cadaveric donor (Figure 1.2 and Table 1.1) and 72-78% for living 
donor organs (Figure 1.3 and Table 1.2).
Figure 1.1 Incidence of ESRD patients from 1980-2008.
The  incidence  of  ESRD  patients  has  gradually  increased  since  1980;  however,  it  has 
remained stable at around 350 per million population since 2000. These data are obtained from 
the 2010 USRD annual report.
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Figure 1.2 Long-term graft survivals in adult recipients for kidney transplant from donors 
after brain death. Data are obtained from the transplant activity report 2009-2010, UK.
Year of transplant % Graft survival
One year Two years Five years Ten years
1996-1998 89 86 79 67
1999-2001 91 89 82
2002-2004 91 90 83
2005-2008 93
Table 1.1 The graft survival at one, two, five and ten years post kidney transplant from 
donors after brain death. Data are obtained from transplant activity report 2009-2010, UK.
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Figure  1.3  Long-term  graft  survivals  in  adult  recipients  for  living  donor  kidney 
transplants in the UK. Data are obtained from transplant activity report 2009-2010, UK.
Year of 
transplant
% Graft survival
One year Two years Five years Ten years
1996-1998 96 95 87 78
1999-2001 95 94 89
2002-2004 96 94 90
2005-2008 96
Table 1.2 The graft survival for one, two, five and ten years post kidney transplant from 
living donors. Data are obtained from transplant activity report 2009-2010, UK.
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1.3 Kidney biology
The kidney is  one of the most  highly differentiated organs in the body.  Its  functions 
include endocrine functions, regulation of blood pressure and intraglomerular hemodynamics, 
solute and water transport,  acid-base balance, and the removal of waste or drug metabolites. 
Renal  development  starts  when  a  branch  of  the  ureteric  bud  invades  an  aggregate  of 
mesenchymal cells called the metanephric mesenchyme. The ureteric bud cells differentiate into 
the epithelia of the collecting duct, whilst the metanephric mesenchymal cells differentiate into 
the epithelia of the rest of the nephron (Oliver et al., 2002). In the adult kidney, epithelial cells 
are the most frequent cells; they play a critical role in kidney function. Loss of epithelial integrity 
can lead to kidney dysfunction. Other  cells  which  are  contained  in  the  kidney  include 
mesangial,  vascular  smooth  muscle,  endothelial,  renal  medullary  interstitial  cells, 
myofibroblasts, fibroblasts, macrophages, and neurons (Oliver et al., 2002).
The nephron is the functional unit of the kidney. Each human kidney normally contains 
approximately 0.6x106 - 1.4x106 nephrons. These nephrons can be divided into two types based 
on their origins: cortical nephrons and juxtamedullary nephrons. Each nephron consists of two 
main components: the renal corpuscle and the renal tubules.
1.3.1 Renal tubular system
Renal tubules are composed of three main parts: the proximal tubule, the loop of Henle 
and the distal tubule (Figure 1.4). The main function of the tubules is maintaining homeostasis of 
acid-base, fluid and electrolytes by the mechanisms of secretion and reabsorption.
1.3.1.1 Proximal renal tubule
The proximal tubule is the initial part of the tubular system, connecting to the glomerulus. 
This tubule is divided into two parts on the basis of morphology: a proximal convoluted part 
(Pars convolute) and a straight part (Pars recta). The most distinctive feature of the proximal 
tubule  is  the presence of  microvilli  or  brush border  at  the luminal  surface.  These microvilli 
increase the luminal surface area in order to enhance the reabsorptive capacity. Proximal tubular 
epithelial  cells  are  also  able  to  produce  specific  enzymes,  including  gamma-glutamyl 
transpeptidase (GGT) and alkaline phosphatase. 
1.3.1.2 Loop of Henle
The loop of Henle is comprised of a thin and thick limb. The thin limb is responsible for 
the maintenance of a hypertonic medullary interstitium in order to dilute or concentrate the urine. 
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This part of the tubule originates near the corticomedullary junction and is formed by flat and 
simple cuboidal epithelial cells.
1.3.1.3 Distal tubule
The distal tubule is composed of three segments: the thick ascending limb of the loop of 
Henle, the macula densa and the distal convoluted tubule. The epithelial cells which line the 
ascending limb contain large mitochondria for Na+  (sodium ion) reabsorption. These cells are 
attached to each other by tight junctions and adherens junctions, but desmosomes are absent. The 
distal convoluted tubule is lined with a cuboidal epithelium containing numerous mitochondria 
and is similar to the proximal tubule, except that there is no brush border in the distal tubule. The 
macula densa is a specialized region of the thick ascending limb which plays an important role in 
volume  homeostasis  through  the  rennin-angiotensin-aldosterone  system.  Following  the  distal 
tubule is the connecting tubule which connects the distal tubule and collecting duct.  
Figure 1.4 Diagram illustrating the renal tubular system. The image is adapted from Brenner 
and Rector’s the kidney 8th edition.
1.3.2. Intercellular junctions
The renal tubular epithelium is organized as a contiguous monolayer of cuboidal cells 
which are attached to each other by intercellular junctions on the apical side and connected to the 
basement membrane on the basal side. The intercellular junctions of the epithelium, which play a 
major role in maintaining cell polarity and integrity, comprise three different cell-cell contact 
structures: tight junctions, adherens junctions and desmosomes (Xu et al., 2009) (Figure 1.5).
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1.3.2.1 Tight junctions
A tight junction is an intercellular junction structure at the lateral side close to the apical 
surface of the epithelial cell. Functions of tight junctions include providing intercellular sealing, 
controlling paracellular diffusion and preventing intramembrane diffusion between the apical and 
basolateral  surfaces.  Tight  junctions  consist  of  transmembrane  proteins,  including  occludin, 
claudins and junctional adhesion molecules, and peripheral membrane proteins such as zonula 
occludens (ZO), which interact with each other to form a complex network (Shin et al., 2006). 
Occludin  and claudins  are  essential  structures  of  the  intercellular  tight  junction  strands.  ZO 
provides the strength and integrity of tight junctions by interacting with actin filaments (Xu et 
al., 2009).
1.3.2.2 Adherens junctions
Adherens  junctions  are  located  immediately  below  the  tight  junctions  on  the 
basolateral surface of the epithelial cells. Previous studies suggest that the formation of adherens 
junctions is essential for the assembly of tight junctions (Troxell et al., 2000); thus, alteration of 
the adherens junctions modulates tight junction formation and the epithelial paracellular barrier. 
The  adherens  junctions  are  important  for  normal  functions  of  epithelium such as  providing 
strong adhesive links between cells via homotypic interaction of E-cadherin, and maintaining 
apical-base axis and polarity (Baum et al., 2011).  
Cadherins  are  Ca2+-dependent  adhesion  molecules  essential  for  the  induction  and 
maintenance of the adherens junctions (Angst et al., 2001). The transmembrane adhesion protein 
E-cadherin is the major cadherin expressed by epithelial cells, including renal epithelial cells 
(Veerasamy et al., 2009). The extracellular domain of E-cadherin interacts with the adjacent cells 
through homotypic interactions,  whereas the cytoplasmic tail is associated with β-catenin, an 
intercellular protein that binds to α-catenin, which interacts with the actin cytoskeleton (Xu et al., 
2009).  Loss  of  E-cadherin  expression  is  recognized  as  one  of  the  key  events  of  epithelial 
transformation (Yang et al., 2001).
β-catenin is also an intracellular signal transduction molecule that mediates signalling in 
the Wnt growth factor pathway. Signalling through the canonical Wnt pathway is initiated by 
secreted  Wnt  proteins  which  bind  to  a  transmembrane  receptors  encoded  by frizzled  genes. 
Activation of the receptor leads to phosphorylation of dishevelled protein which associates with 
axin and this complex prevents glycogen synthase kinase 3β (GSK3β) from phosphorylating β-
catenin  (Liu  et  al.,  2010).  Unphosphorylated  β-catenin  escapes  E3 ubiquitin  ligase-mediated 
proteosomal  degradation,  forms  a  complex  with  transcription  factors  and  regulates  gene 
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expression. The complex of β-catenin with T cell factor (TCF) has been shown in a number of 
studies to promote epithelial to mesenchymal transition (EMT) (Liu et al., 2010). 
1.3.2.3 Desmosomes
Desmosomes  are  intercellular  adhesion  complexes  located  on  the  lateral  surface  of 
epithelial  cells.  A desmosome  is  characterized  by  transmembrane  proteins  and  desmosomal 
plaque proteins that link the structure to the intermediate filament cytoskeleton (Delva et al., 
2009). Desmogleins and desmocollins are cadherin transmembrane proteins which mediate cell 
adhesion  by their  extracellular  domains,  whereas  the  cytoplasmic  domains  interact  with  the 
plakophilin and plakoglobin proteins, which are also associated with desmosomal plaque protein, 
desmoplakin, providing a link to keratin intermediate filaments (Delva et al., 2009).
Figure 1.5 Schematic demonstrating the main types of intercellular junction in epithelial 
cells. 
The  tight  junction  contains  transmembrane  proteins  that  link  to  the  actin  cytoskeleton. 
Adherens junctions are formed by homophilic interaction between E-cadherin molecules and are 
associated to the actin filament through β and α-catenins. Desmosomes consist of desmosomal 
cadherins  linked  to  keratin  intermediate  filaments  and  integrate  the  intermediate  filament 
network across the epithelial sheet. This image is from Kobielak and Fuchs, 2004.
1.4 Mechanism of T cell activation
T lymphocytes (T cells) play a key role in cell-mediated immune responses, including 
cell-mediated  rejection  following  kidney  allotransplantation.  Most  graft-infiltrating  T  cells 
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during acute renal allograft rejection are effector T cells which are generated by the activation of 
naive  or  cross-reactive  memory  T  cells.  This  T  cell  activation  involves  the  recognition  of 
allogeneic class I and class II MHC antigens on appropriate antigen presenting cells.
1.4.1 Major histocompatibility complex 
The major histocompatibility complex (MHC) contains a series of genes which encode 
class I MHC antigens which are present on the surface of almost every cell in the human body. 
Class II  MHC antigens are  also encoded by genes in the MHC, but  the expression of these 
antigens  is  normally  restricted  to  haematogenous  antigen  presenting  cells.  Together  these 
histocompatibility  antigens  play  an  important  role  in  determining  the  outcome  of  organ 
allotransplantation. When the donor and recipient differ in their histocompatibility antigens, there 
is a potential for allograft rejection (Apostolopoulos et al., 2008). The human MHC genes are 
present on chromosome 6. In humans, the MHC antigens are called human leukocyte antigens 
(HLA). The class I antigens include HLA-A, HLA-B, and HLA-C, and the class II antigens 
include HLA-DP, HLA-DQ and HLA-DR (Figure 1.6).
Figure 1.6 Human leukocyte antigens are encoded on chromosome 6.
1.4.1.1 MHC class I molecules
Class I MHC antigens are composed of a polymorphic glycosylated heavy α chain which 
is  noncovalently  bound  to  nonpolymorphic  light  chain  β2-microglobulin.  The  heavy  chain 
anchors the MHC complex to the cell membrane and contains three extracellular domains (α1, 
α2 and α3), a hydrophobic transmembrane region and a short cytoplasmic tail (Figure 1.7A). 
The MHC class I molecules are expressed on the cell surface of almost all nucleated cells. The 
foreign antigens presented by MHC class I molecules are recognized by host CD8+  T cells. In 
addition, MHC class I molecules typically bind peptide epitopes derived from proteins in the 
cytoplasm of cells, including viral proteins (Apostolopoulos et al., 2008).
1.4.1.2 MHC class II molecules
The class II MHC antigens have a similar overall structure to class I antigens, but are 
composed of polymorphic α and β chains (Figure 1.7 B). The class II molecules are normally 
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expressed  only  on  professional  antigen-presenting  cells  (APCs),  including  dendritic  cells,  B 
lymphocytes  and  macrophages.  However,  during  an  inflammatory response,  some other  cell 
types  may be induced to  express MHC class  II  proteins by the action of cytokines  such as 
interferon (IFN)-γ (Kimmel et al., 2003). MHC class II molecules typically bind extracellular 
peptides.
1.4.2 Minor histocompatibility antigens (miHA)
The observation that T cells recognize peptide epitopes in the context of presentation by 
MHC antigens explains why MHC-matched graft  tissues can be rejected on the basis  of the 
expression of minor histocompatibility antigens (miHA). These antigens are now understood to 
consist of graft-specific peptides which are presented by MHC antigens. The classical example is 
the H-Y antigen which allows female recipients to recognize MHC-matched male cells. This was 
first  demonstrated  in  animal  models  (Barth  et  al.,  1956),  but  may also play a  role  in  acute 
rejection of human kidney allograft tissue (Kim et al., 2009).
Figure 1.7 Structure of MHC class I and class II antigens
(A) MHC class  I  antigens  consists  of  polymorphic  α  chains  (α1,  α2  and α3)  noncovalently 
attached to β2-microglobulin. (B) MHC class II antigens consists of polymorphic α chains (α1 
and α2) attached to polymorphic β chains (β1 and β2). This image is taken from Alfzali et al., 
2007.
1.4.3 Antigen presenting cells
T cell activation is achieved by specific recognition of a peptide-MHC antigen complex 
displayed on the surface of specialized antigen presenting cells. APC can be divided into two 
groups: professional APC and non-professional APC. Professional antigen presenting cells are 
defined as cells of haematopoietic origin which express costimulatory molecules and MHC class 
11 | P a g e
Chapter 1: Introduction
I and class II molecules. These cells include dendritic cells (DC), macrophages and B cells, and 
are  specialized  to  initiate  T  cell  activation  (Resigno,  2010).  Among  the  professional  APC, 
activated DC are the most potent stimulators of naïve T cells due to their high level expression of 
MHC class I and class II antigens and costimulatory molecules (Ingulli, 2010). Non-professional 
APC include epithelial cells, endothelial cells  and  stromal  cells  which  normally  do  not 
express  MHC  class  II  unless  they  are stimulated by the proinflammatory cytokine IFN-γ 
(Resigno et al., 2010). Activation of naive T cells requires two signals delivered by the APC. The 
first  signal  is  antigen-specific  and  delivered by the  T cell  receptor.  The  second signal  is  an 
antigen nonspecific signal triggered by the interaction of cell-surface costimulatory molecules on 
a professional APC with corresponding receptors on the T cell (Pilat et al., 2011).
1.4.4 Allorecognition
T cells need to be activated in order to proliferate and differentiate to effector T cells. 
However, the activation process requires an encounter between T cells and foreign peptide-MHC 
complexes on antigen presenting cells.  Three pathways of alloantigen recognition have been 
described (Safinia et al., 2010): the direct pathway in which recipient T cells recognize intact 
allogeneic peptide-MHC complexes expressed on the surface of donor APC (Game et al., 2002), 
the indirect pathway in which recipient T cells recognize peptides derived from allogeneic MHC 
molecules presented by self APC (Gökman et al., 2008), and the semi-direct pathway in which 
recipient DC acquire intact allogeneic antigen-MHC complexes from donor cells and present 
these to recipient T cells (Herrera et al., 2004) (Figure 1.8).
1.4.4.1 Direct allorecognition
In  order  for  recipient  T  cells  to  directly  bind  to  intact  allogeneic  peptide-MHC 
complexes, donor APC must migrate out of the graft to make direct contact with recipient T cells 
within secondary lymphoid tissue. The importance of donor APC in causing graft rejection was 
demonstrated by prolonged survival of donor-derived APC-depleted allogeneic thyroid grafts in 
the absence of immunosuppression (Lafferty et al., 1976). This result supports the importance of 
the direct pathway, as stimulation of recipient T cells is dependent on donor APCs. In addition, 
an adoptive transfer experiment in T cell deficient SCID and Rag-/- mice showed that acute CD4+ 
T cell-mediated rejection required donor MHC class II molecules. Furthermore,  MHC  class  II 
deficient  mice  also  rejected  grafts  when  reconstituted  with CD4+  T cells, suggesting that 
direct  recognition  plays  an  important  role  during  acute  rejection  (Pietra  et  al.,  2000).  It  is 
believed that the direct pathway is responsible for early rejection because of the high frequency 
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of T cells capable of recognizing allogeneic MHC on donor dendritic cells (DCs) (Caballero et 
al.,  2006).  However,  donor DCs are  depleted rapidly after  engraftment  due to apoptosis  and 
elimination by the recipient immune system (Hornick et al., 1998; Caballero et al., 2006).
1.4.4.2 Indirect allorecognition
In  contrast  to  the  direct  pathway,  the  indirect  pathway  of  allorecognition  describes 
recipient APC presenting donor MHC-derived peptides complexed with self-MHC molecules to 
recipient T cells. Foreign antigens can be processed by three mechanisms. Firstly, antigens  from 
the  graft  are  shed  into  the  circulation  and  engulfed  by recipient DC within secondary 
lymphoid tissues. Secondly, donor cells migrate to secondary lymphoid organs and are captured 
by recipient DC for antigen processing and presentation. Thirdly, recipient APC migrate into the 
graft, take up antigens and then migrate to secondary lymphoid tissues.
Evidence supporting the indirect pathway was provided by MHC class II-deficient skin 
grafts which were rejected rapidly by normal recipients (Auchincloss et al., 1993). Importantly, 
removal of recipient CD8+  cells or CD4+  cells showed that CD4+  cells were involved in, and 
required for, this rapid rejection (Auchincloss et al., 1993). Since the donor grafts lacked class II 
MHC molecules, recipient CD4+T cells must recognize donor antigens presented in association 
with recipient class II molecules. 
1.4.4.3 Semi-direct allorecognition
Recently, a number of publications have shown that intact donor cell-surface molecules, 
including MHC, can be transferred to recipient APC leading to activation of T-cells which can 
directly recognise allograft cells (Jiang et al., 2004). 
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Figure 1.8 Diagram shows direct, indirect and semi-direct allorecognition pathways.
(A) Direct pathway. Intact foreign MHC on donor APC binds CD4+ and CD8+ recipient T cells; 
CD4+ T cells  provide  help  for  the  effector  function  of  CD8+ T cells.  (B)  Indirect  pathway. 
Recipient APCs present processed donor peptides to CD4+  T cells.  (C) Semi-direct  pathway. 
Cell-to-cell  contact  between  donor  and  recipient  APC  may  transfer  intact  allogeneic  MHC 
antigens. The image is taken from Safinia et al., 2010.
1.4.5 The immune response
When an alloantigen is recognized by any of the pathways described above, effector T 
cells are activated leading to allograft destruction. This alloresponse results from the activation 
of either naïve T cells or memory T cells. It has been reported that 40-50% of circulating T cells 
in humans has a memory phenotype (McFarland et al., 2000). A re-transplant model in mice 
demonstrated a more severe immune response resulting from the activation of memory T cells 
than from naïve T cells (Liang et al., 2010). Activated T cells can generate a range of  effector 
mechanisms. These include cellular (delayed-type) hypersensitivity (DTH), contact-dependent T-
cell cytotoxicity and humoral (antibody and complement) immunity (Afzali et al., 2007) (Figure 
1.9).
Following activation, CD4+ T cells secrete interleukin (IL)-2 which induces naive T cells 
to become T helper 0 (Th0) cells. Combination of IL-2 with IFN-γ and IL-12 or IL-4 causes 
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these Th0 cells to differentiate into two subsets: T helper 1 (Th1) and T helper 2 (Th2) cells 
respectively. Th1 cells help CD8+T cell activation and macrophage-dependent DTH responses, 
whilst Th2 cells are typically responsible for humoral responses and eosinophil activation (Le 
Moine et al., 2002). Following activation, CD8+T cells become cytotoxic and destroy target cells 
by two main mechanisms: the release of perforin and granzymes and activation of the Fas-Fas 
ligand system.
Naive B cells  can be activated in a T cell-dependent and T cell-independent manner 
depend on the nature of antigens (Benson et al., 2007). Most alloantigens are T cell-dependent. 
Therefore, B cells need to process antigen and present antigen-MHC class II complex to Th2 
cells  resulting  to  B  cell  proliferation,  plasma  cell  differentiation  and  the  production  of 
allospecific antibodies. 
Figure 1.9 The central role played by T cell activation in allograft immunity.
CD8+T cells become activated cytotoxic T cells. Activated CD4+T cells differentiate to T helper 
cells and secrete multiple cytokines leading to delayed-type hypersensitivity and alloantibody 
responses. This image is obtained from Sayegh, 1999.
15 | P a g e
Chapter 1: Introduction
1.5 Banff classification of renal allograft pathology 
Kidney allograft biopsy provides essential information for diagnosis among many causes 
of acute or chronic allograft  dysfunction.  Therefore,  standardization of renal allograft  biopsy 
interpretation is necessary for treatment decisions and also for clinical trials. In 1991, a group of 
pathologists,  nephrologists  and  transplant  surgeons  met  in  Banff,  Canada,  to  formulate  the 
nomenclature and classification of renal allograft pathology. Since then, a Banff meeting has 
been held every two years to review and update the criteria for the diagnosis of renal allograft 
pathology.  The  most  recent  update  of  the  Banff  classification  was published  in  2009 and is 
detailed below (Sis, 2010). 
1.5.1 Banff 2009 classification 
In order to define the Banff rejection adequate biopsy specimens are required. These must 
contain two cores of tissue with cortex containing ≥ 10 glomeruli and ≥ 2 arteries. The pathology 
is scored as follows: 
1. Normal kidney 
2. Antibody-mediated rejection (ABMR) 
2.1  C4d  deposition  and  the  presence  of  circulating  anti-donor  antibodies  but 
without morphologic evidence of acute rejection. 
2.2 Acute ABMR 
a.  Type  I:  C4d+,  presence  of  anti-donor  antibodies  with  ATN  (acute 
tubular necrosis)-like minimal inflammation. 
b.  Type  II:  C4d+,  presence  of  anti-donor  antibodies  and  leukocytes  in 
peritubular capillaries (PTC).
c.  Type  III:  C4d+,  presence  of  anti-donor  antibodies  with  transmural 
arteritis. 
2.3  Chronic  active  ABMR:  C4d+,  presence  of  anti-donor  antibodies  with 
morphological changes including glomerular double contour, peritubular capillary 
basement  membrane  multilayering,  interstitial  fibrosis  and  tubular  atrophy 
(IF/TA) and arterial fibrous thickening. 
3. Borderline changes: tubulitis (mononuclear cell infiltration in tubular epithelial cells) 
with minimal interstitial infiltration 
4. T cell-mediated rejection (TCMR) 
4.1 Acute TCMR 
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a. Type IA: interstitial infiltration (>25%) with moderated tubulitis (>4 
mononuclear cells/ tubular cross section) 
b.  Type  IB:  interstitial  infiltration  (>25%)  with  severe  tubulitis  (>10 
mononuclear cells / tubular cross section) 
c. Type IIA: mild to moderate intimal arteritis 
   d. Type IIB: severe intimal arteritis (>25% of lumen occlusion) 
e. Type III: transmural arteritis 
4.2 Chronic TCMR: arterial intimal fibrosis with mononuclear cell infiltration in 
fibrosis (chronic allograft arteriopathy). 
5. Interstitial fibrosis and tubular atrophy (IF/TA) without specific causes. 
5.1 Grade I: Mild IF/TA (<25% of cortical area) 
5.2 Grade II: Moderate IF/TA (26-50% of cortical area) 
5.3 Grade III: Severe IF/TA (>50% of cortical area) 
6. Other: change not due to rejection 
1.6 T-cell mediated rejection (TCMR)
According to the Banff classification (section 1.5.1), TCMR is defined by infiltration of 
recipient  mononuclear  cells  into  the  renal  tubules  (tubulitis),  arterioles  (endotheliolitis)  and 
interstitium (Figure 1.10), followed by functional deterioration of the renal allograft. According 
to recent data, 19% of renal allograft fibrosis resulted from TCMR. In addition, 5.8% of this 
subgroup eventually progressed to renal allograft loss (El-Zoghby et al., 2009)
1.6.1 Mechanism of leukocyte recruitment
Infiltration  of  inflammatory  cells  into  the  renal  allograft  tubular  epithelium  is  the 
hallmark of the alloimmune response leading to tubular injury, interstitial fibrosis and subsequent 
chronic  allograft  dysfunction.  Leukocyte recruitment  from the blood into the graft  tissues is 
essential  for  development  of  TCMR.  Recruitment  of  lymphocytes  across  the  vascular 
endothelium is a complex process, as described below.
17 | P a g e
Chapter 1: Introduction
Figure 1.10 Microscopic analysis demonstrating histology of TCMR.
(A) Periodic acid-Schiff staining showing mononuclear cells infiltrating renal tubules (tubulitis; 
white arrow) and the interstitial tissues (black arrow). (B) Periodic acid-Schiff staining showing 
subendothelial infiltration with >25% luminal occlusion (severe intimal arteritis). These images 
were obtained from Dr Helen Robertson, personal communication.  
1.6.1.1 Leukocyte tethering and rolling 
The first steps of T cell recruitment include leukocyte tethering and rolling along the 
vessel wall, which is mediated primarily by interactions between selectin and selectin ligands. 
The selectins are a calcium-dependent, type I transmembrane glycoproteins. Three selectins have 
been  identified:  E-selectin,  P-selectin  and  L-selectin  which  were  originally  discovered  in 
endothelial  cells,  platelets  and leukocytes  respectively (Kelly et  al.,  2007).  The selectins  are 
upregulated on the surface of endothelial cells by inflammatory cytokines such as tumor necrosis 
factor (TNF)-α and IL-1β (Thurman, 2007).
1.6.1.2 Leukocyte adhesion 
Chemoattractant cytokines or chemokines are responsible increasing leukocyte adhesion 
to the apical surface of endothelial cells. Chemokines induce specific leukocyte recruitment to 
the  affected  area  during  inflammation.  In  the  early  phase  after  transplantation,  the 
proinflammatory cytokines TNF-α and IL-1β are released by allograft endothelial cells and renal 
epithelial cells as a consequence of ischemia/reperfusion injury and tissue trauma (Thurman et 
al., 2006). Subsequently, proinflammatory cytokines induce local chemokine secretion. Several 
chemokines have been observed in renal allograft biopsies during acute rejection and chronic 
allograft nephropathy, including CCL-2 (MCP-1), CCL-3 (MIP-1α), CCL-4 (MIP-1β), CCL-5 
(RANTES) (Robertson et al., 2000), CCL-13 (MCP-4) (Chakravorty et al., 2001), CCL-20 (MIP-
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3α)  (Woltman  et  al.,  2005),  CXCL-5  (ENA-78)  (Schmouder  et  al.,  1995),  CXCL-8  (IL-8) 
(Sibbring et al., 1998), CXCL-10 (Lazzeri et al., 2005), MIF (Lan et al., 1998) and CX3CL1 
(Gao et al., 2006).
Proinflammatory cytokines and chemokines activate integrin expression by leukocytes 
and  also  increase  integrin  adhesion.  Critical  adhesion  molecules  on  leukocytes  include  the 
integrins leukocyte function associated molecule-1 (LFA-1) and very late antigen-4 (VLA-4). 
Endothelial counter-receptors for these adhesion molecules are intercellular adhesion molecules 
(ICAM)-1 and ICAM-2, and vascular cell adhesion molecule-1 (VCAM-1) respectively; these 
are  also  up-regulated  by cytokine  stimulation  (Kelly  et  al.,  2007),  leading  to  firm adhesion 
between recipient leukocytes and allograft endothelial cells.
1.6.1.3 Intraluminal crawling 
This is a step in which leukocytes move from the primary adhesion site to the nearest 
endothelial cell junction in order to begin diapedesis (Schenkel et al., 2004).
1.6.1.4 Leukocyte transendothelial migration 
This  is  a  final  step  in  which  leukocytes  cross  the  endothelial  wall  and  enter  the 
interstitium.  This  process  can  occur  by two  different  pathways:  paracellular  or  transcellular 
migration.  Paracellular  diapedesis  is a process by which leukocytes and endothelial  cells  co-
ordinately  disassemble  endothelial  cell-cell  junctions  leading  to  a  gap  formation  between 
endothelial cells. However, transcellular diapedesis is the process by which leukocytes migrate 
directly  through  individual  endothelial  cells  via  a  transcellular  pore  without  disrupting  the 
endothelial cell-cell junction (Carman, 2009).
1.6.2 CD103+CD8+ T cells: a predominant T cell population in renal tubulitis
A characteristic of TCMR is deterioration of the renal allograft associated with interstitial 
infiltration by mononuclear cells and penetration of T lymphocytes through the tubular basement 
membrane to contact the epithelial cells (Racusen et al., 1999). It has long been recognized that 
CD8+ T  cells  are  the  predominant  intratubular  T  cell  population  (Robertson  et  al.,  1996). 
Previous studies have shown the expression of CD8 mRNA by T cells in urine during acute renal 
allograft rejection (Vasconcellos et al., 1998; Yannaraki et al., 2006), suggesting a role for these 
cells during graft rejection. Although CD8+  T cells are a main population of graft infiltrating T 
cells, CD8 blockade could not abolish graft rejection whilst blockade of CD4 did reduce the 
severity of rejection (Lee et al., 1994; Pietra et al., 2000). It remains unclear whether CD4+  T 
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cells provide help for a CD8+ T cell effector response or CD4+  T cells play a key role in the 
effector phase of an immune response.
Previous studies have shown that the αE(CD103)β7 integrin (termed CD103) defines a 
subset of largely intratubular CD8+ effector T cells during renal allograft rejection (Hadley et al., 
1997). This integrin was first identified by its expression on T cells in the gut mucosa where it is 
expressed by >95% of intestinal intraepithelial lymphocytes and  ∼40% of lymphocytes in the 
lamina propia (Cerf-Bensussan et al., 1987). In addition, it has been shown that E-cadherin is the 
adhesive counter-receptor for CD103. The majority of CD103-/-  mice accept islet cell allografts, 
suggesting a potential role for CD103 in CD8-mediated allograft destruction. 
In humans, CD103 is expressed by only a small number (2%) of circulating T cells (Cerf-
Bensussan et al., 1987), but it is strikingly up-regulated on intratubular T cells during allograft 
rejection (Hadley et  al.,  1997). It  has been demonstrated  in vitro that  TGF-β can induce the 
expression of CD103 by activated human T cells (Wong et al., 2003). In addition, CD8+ T cells 
expressing  a  dominant-negative  TGF-β  receptor  showed  little  CD103  expression  following 
migration into the allograft,  suggesting a role  of TGF-β as a key factor  in the regulation of 
CD103 (Wang et al., 2005).
1.6.3 The role of CD103+CD8+ T cells in renal allograft rejection
Normally, cytotoxic T lymphocytes (CTL), which include predominantly CD8 and some 
of CD4 T cells, mediate lysis of target cells by two main mechanisms: exocytsis of cytotoxic 
granules  and  receptor-ligand  binding  between  Fas  and  Fas  ligand  (Groscurth  et  al.,  1998). 
Cytotoxic granules contain perforin and granzymes; perforin is a pore-forming protein which is 
inserted into target cell membranes leading to pore formation, granzymes are serine proteases 
which enter the target cell via a perforin pore leading to apoptotic cell death. T cells expressing 
mRNA encoding perforin have been identified within the tubules during renal allograft rejection 
(Robertson et al., 1996). Following antigen recognition, CTL also express Fas ligand (FasL) on 
their cell surface either by de novo synthesis or transformation of inactive FasL to an active form 
(Groscurth et  al.,  1998).  The FasL binds  to  its  receptor  expressed on surface of  target  cells 
resulting in caspase activation and target cell apoptosis. This is consistent with cytotoxic profile 
found in rejecting graft biopsies (Robertson et al., 1996; Einecke et al., 2005). Both of these 
processes  require  adhesive  interaction between T cells  and their  target.  During tubulitis  this 
adhesion could be stabilised by interaction between the CD103 integrin and E-cadherin. 
Recent studies have suggested that CD103 is not essential for tubular damage following 
kidney transplantation since CD103-/- recipient mice develop similar histological lesions to wild-
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type mice (Einecke et al., 2006). It has also been shown that expression of the CD103 receptor, 
E-cadherin  is  reduced  during  allograft  rejection,  indicating  a  reduced  potential  for  tubular 
epithelial cells to bind CD103+ T cells (Einecke et al., 2006). Interestingly, the extent of tubulitis 
and tubular damage was unchanged in mice lacking perforin, granzymes and CD103, suggesting 
a cell contact-dependent cytotoxic mechanism is not required for graft destruction (Einecke et 
al.,  2006).  However,  the  Fas/FasL  interaction  and  CD4+ T  cell-mediated  delayed-type 
hypersensitivity could still contribute to graft failure in this system.
1.6.4 The role of T cells in renal fibrosis
It has been reported that tubulointerstitial fibrosis is associated with renal infiltration by 
inflammatory cells such as T cells and macrophages in human and experimental kidney diseases 
(Strutz et al., 1994). This suggests a role for immune cells in the development of fibrosis. A 
recent study showed evidence to support a direct role for CD4+ T cell in renal fibrosis (Tapmeier 
et al., 2010). Depletion of CD4+ T cells reduced interstitial expansion and collagen deposition 
following  unilateral  ureteric  obstruction  (UUO).  In  addition,  RAG-/- mice,  which  are  T cell 
deficient,  showed  a  reduction  of  interstitial  collagen  deposition  in  the  UUO  model.  This 
protective effect  was decreased after  reconstitution by CD4+ T cells  (Tapmeier  et  al.,  2010). 
Interestingly, the expression of TGF-β was similar in both RAG-/- mice and after CD4+ T cells 
reconstitution. However the expression of TGF-β does not reflect TGF-β activity. It is possible 
that latent TGF-β might be activated in CD4+ T cell reconstitution mice more than in RAG-/- 
mice. 
A previous study showed a close association between intratubular T cells and epithelial 
cells showing characteristics associated with early EMT in human renal allograft biopsy sections. 
This study also demonstrated in vitro that a model intraepithelial T-cell line could induce EMT 
by a TGF-β-dependent mechanism (Robertson et al.,  2004). However, it  is not clear whether 
these T cells secreted active TGF-β or activated latent TGF-β that was already generated in the 
cell culture model.
1.7 Specific causes of renal allograft loss
The reason for the lack of improvement in long-term outcome of kidney transplantation 
remains unclear but is likely to be multifactorial. A recent longitudinal study, mainly of  living 
donor kidney allograft recipients (72.5%), has identified specific causes of late kidney graft loss 
(El-Zoghby et al., 2009). According to this study, death with a functioning graft is the leading 
cause of late renal allograft loss (43.4%). The causes of graft loss not due to patient death differ 
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between  living  and  cadaveric  donors.  Following  live  donation,  most  grafts  are  lost  as  a 
consequence of glomerular diseases (40%) and interstitial fibrosis and tubular atrophy (IF/TA) 
(24%), whereas for cadaveric donors, IF/TA (43%) and glomerular diseases (32%) are the most 
common causes of graft failure (Figure 1.11). Although the once common term “chronic allograft 
nephropathy” has now been changed in order to identify the specific causes of renal allograft 
fibrosis, it is clear that graft fibrosis remains a major problem following kidney transplantation.
Figure 1.11  Causes of loss of functioning grafts in recipients of allogeneic kidneys from 
living donors (open bars) or deceased donors (black bar). This image is from EL-Zoghby et 
al., 2009.
1.7.1  Causes  of  renal  allograft  loss  due  to  interstitial  fibrosis  and tubular 
atrophy (IF/TA).
In  the  subgroup  of  graft  loss  due  to  fibrosis,  rejection  (predominantly  cell-mediated 
rejection), is the leading cause of failure; this is followed by BK virus nephropathy (Figure 1.12). 
Interestingly,  the incidence of calcineurin inhibitor nephrotoxicity observed in this study was 
very low compared to a previous study performed using kidney graft biopsies from patients who 
received kidney-pancreas transplants during the period 1987-2000 (Nankivell et al., 2003). Most 
of  the  patients  in  this  earlier  study received  Cyclosporine-based  immunosuppression  (77.5% 
Cyclosporine, 22.5% Tacrolimus) and 98.6% of this cohort showed some evidence of calcineurin 
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inhibitor nephrotoxicity after 10 years. Cyclosporine-induced nephrotoxicity will be discussed in 
chapter 3.
Figure  1.12  Bar graph demonstrating  the  specific  causes  of  renal  allograft  loss  due  to 
interstitial fibrosis and tubular atrophy. This image is adapted from El-Zoghby et al., 2009.
1.8 Interstitial fibrosis and tubular atrophy (IF/TA)
In  kidney allograft  biopsies,  the  extent  of  renal  IF/TA is  one  of  the  most  important 
prognostic factors of graft failure (Müller et al., 2000). Protocol biopsies studied between 1998 
and 2004 showed that the prevalence of moderate to severe fibrosis was 13% at 1 year and 17% 
at 5 years. In addition, mild fibrosis at 1 year progressed to severe fibrosis at 5 years in 23% of 
allografts (Stegall et al., 2011). These results demonstrate that interstitial fibrosis remains a major 
problem in the current era of transplantation.
Fibrosis is part of the kidney’s normal response to injury. This wound healing process is 
normally resolved with restoration of renal architecture and the recovery of function. However, 
in  some circumstances  this  process  can  lead  to  irreversible  loss  of  tissue  function.  Fibrosis 
involves  an  excessive  accumulation  of  extracellular  matrix  (ECM),  primarily collagen type 
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I, in response to sustained inflammation after injury, and usually results in loss of function when 
normal tissue is replaced with scar tissue (Wynn et al., 2007). Previously, it was believed that the 
fibrogenesis process resulted from an imbalance between collagen synthesis and degradation and 
that a reduction in protease activity can result in fibrosis. However, it is now clear that fibrosis is 
a multifactorial process of which abnormal matrix synthesis is only a part. An experimental study 
has shown that abnormal collagen synthesis  in kidneys  is  transient whilst  the density of the 
matrix  can continue to increase (Hewitson et  al.,  1998).  Some studies have also shown that 
whilst  the matrix  metalloproteinases  (MMP) are  responsible  for  ECM degradation,  knockout 
mice do not  have a  fibrotic  phenotype (Ronco et  al.,  2007).  Additionally,  overexpression of 
MMP2 can induce fibrosis (Cheng et al., 2006). Despite the controversial role for MMPs in the 
pathogenesis of fibrosis, MMP expression has often presented in experimental models (Lovett et 
al., 1992) of human renal disease (Shiau et al., 2006).
1.8.1 Origin of the fibroblast
Mesenchymal cells are the principle ECM-producing cells involved in fibrosis (Becker et 
al., 2001). In kidney fibrosis, the interstitial fibroblasts activate glomerular mesangial cells and 
vascular smooth muscle cells which are associated with interstitial fibrosis, glomerulosclerosis 
and vascular sclerosis (Becker et al., 2001). However, the interstitial fibroblasts are more crucial 
for IF/TA in progressive renal diseases than other cell types. Fibroblasts can be derived from 
several sources. These include local proliferation of resident fibroblasts (Hewitson et al., 1995), 
recruitment  of  blood-borne  precursors  (Grimm et  al.,  2001),  transformation  of  renal  tubular 
epithelial and endothelial cells by epithelial to mesenchymal transition (EMT) (Liu et al., 2004) 
and endothelial to mesenchymal transition (Zeisberg et al., 2008) respectively, and migration of 
precursors from the perivascular region (Humphrey et al., 2010) (Figure 1.13).
1.8.1.1 Local interstitial fibroblasts
Initial  data concerning the origin of fibroblasts  was obtained from experiments using 
parabiotic  rats  which  suggested  that  fibroblasts  were  unlikely to  derive  from hematogenous 
precursors but from resident interstitial fibroblast (Ross et al., 1970). More recent data using a 
murine unilateral ureteric obstruction (UUO) model demonstrated during the first day following 
UUO that resident peritubular fibroblasts  also differentiate into myofibroblasts  (Picard et  al., 
2008). 
1.8.1.2 Bone marrow-derived fibroblasts
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A study using bone marrow transgenic mice demonstrated that after myocardial ischemia, 
24% of all myofibroblasts involved in scar formation are derived from the bone marrow (van 
Amerongen et al., 2008). Furthermore, a recent study using the UUO model of renal fibrosis 
demonstrated that stressed renal tubular epithelial  cells  induced expression of the chemokine 
CXCL16,  leading  the  recruitment  of  bone  marrow-derive  fibroblast  precursors  (Chen et  al., 
2011). 
1.8.1.3 Endothelial mesenchymal transition (EndoMT)
It has been reported that endothelial cells can transform to fibroblasts and contribute to 
renal fibrosis.  Zeisberg and colleagues observed that 30-50% of fibroblasts  co-expressed the 
endothelial marker CD31 and markers of fibroblasts and myofibroblasts, including S100A4 and 
α-SMA,  in  three  different  models  of  renal  fibrosis  (Zeisberg  et  al.,  2008).  A transgenic, 
endothelial  cell  fate-tracing  technique  also  confirmed  the  presence  of  EndoMT  in  fibrotic 
kidneys (Zeisberg et al., 2008).
1.8.1.4 Transition from epithelial cells
Evidence of epithelial to mesenchymal transition (EMT) was first provided in 1995 by 
the cloning of fibroblast specific protein-1 (FSP-1 or, more generally, S100A4), a member of the 
S100 protein family (Strutz et  al.,  1995).  The promoter/enhancer  region driving this  gene is 
active in fibroblasts but not in epithelium, mesangial cells or embryonic endoderm, indicating 
that FSP-1 is a specific marker for fibroblasts (Strutz et al., 1995). A landmark study supporting 
the existence of EMT was performed by Iwano and colleagues who used genetic mapping to 
investigate  EMT  in  vivo (Iwano et  al.,  2002).  This  study used  the  GGT-Cre driver  to  label 
proximal tubular cells and the Rosa26 reporter (R26R) with the bacterial LacZ gene as a marker 
of cell fate. Following UUO-induced renal fibrosis, approximately 38% of S100A4-positive cells 
expressed LacZ staining, suggesting that many interstitial fibroblasts were derived from GGT-
labelled tubular epithelial cells (Iwano et al., 2002). Most in vitro studies support a role for EMT 
in  fibrogenesis,  however  a  recent  in  vivo fate-tracing  study  has  raised  some  doubt  by 
demonstrating that pericytes are a major source of interstitial fibroblasts during renal fibrosis 
(Humphrey et al., 2010).
1.8.1.5 Pericytes or perivascular fibroblasts
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A recent  study  used  transgenic  mice  with  three  different  cre-driver  lines:  Six2-cre 
labelled all epithelial cells except those of the collecting duct, Hoxb7-cre labelled epithelial cells 
from the  collecting  duct  and  FoxD1-cre  labelled  renal  pericytes  or  perivascular  fibroblasts. 
Following UUO injury there was no evidence that any  α-SMA-positive cells expressed LacZ 
staining, suggesting that no myofibroblast was derived from renal epithelial cells. In contrast, 
FoxD1-cre labelled cells expressed α-SMA predominantly in the interstitial area. This suggests 
that FoxD1-labelled cells or pericytes were converted into myofibroblasts in this model of UUO-
induced renal fibrosis (Humphrey et al., 2010). 
Although the origin of renal interstitial fibroblast in renal fibrosis remains controversial, 
numerous previous papers and ongoing studies have supported the existence of EMT in vitro. 
The details of EMT will be discussed in section 1.8.
Figure 1.13 Potential origins of matrix-producing cells causing renal allograft fibrosis. The 
image is obtained from Strutz et al., 2006.
1.9 Epithelial to mesenchymal Transition (EMT)
EMT  is  a  biological  process  that  allows  a  mature  epithelial  cell  to  undergo  the 
biochemical  changes  required  to  produce  a  mesenchymal  cell.  These  include:  enhanced 
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migratory capacity, invasiveness, elevated resistance to apoptosis, and increased production of 
ECM components (Yang J and Liu Y, 2001). Multiple processes are required in order to complete 
EMT.  These  include  activation  of  transcription  factors,  expression  of  specific  cell-surface 
proteins, reorganization and expression of cytoskeletal proteins, production of ECM-degrading 
enzymes,  and changes in  the expression of specific microRNAs, for example miR-200a and 
miR-141 which are known to prevent renal fibrosis (Wang et al., 2011).
1.9.1 Characteristics of EMT
Four key steps at the cellular level are essential for EMT (Figure 1.14):
1.9.1.1 Loss of the epithelial intercellular junction
Tubular  epithelial  cells  are  normally polygonal  in  shape and tightly attached to  each 
other, forming an epithelial sheet through cell adhesion mechanisms. One of the first changes in 
epithelial  cell  transformation is the suppression of E-cadherin expression (Yang J and Liu Y, 
2001).  E-cadherin, a transmembrane glycoprotein predominantly located in adherens junctions, 
is considered a marker of differentiated epithelial phenotype by several studies (Zeisberg et al., 
2003; Arias et  al., 2001);  E-cadherin is essential  for maintaining epithelial  polarity and tight 
junction development (Tunggal et al., 2005). The cytoplasmic domain of E-cadherin associates 
with the actin cytoskeleton through β-catenin molecules (section 1.3.2). Disassembly of the E-
cadherin/catenin interaction leads to epithelial  disruption,  phenotypic alteration and enhanced 
cell  proliferation  (section  1.3.2.2).  Although  several  papers  have  suggested  that  loss  of  E-
cadherin results in EMT, a recent paper showed that E-cadherin reduction may not always lead to 
this transition as a consequence of the activation of an antagonistic BMP-7 signalling pathway 
(Veerasamy et al., 2009). 
1.9.1.2 De novo expression of mesenchymal markers
One of the important features of EMT is the acquisition of fibroblast or myofibroblast 
markers by cells which retain a recognizable epithelial phenotype. This is termed intermediate 
stage EMT.  Several molecules have been used to identify fibroblasts in both in vivo and in vitro 
studies; these include S100A4, α-SMA, vimentin and HSP47.
1.9.1.2.1 S100A4/FSP-1
Fibroblast specific protein 1 (FSP-1) in mouse or S100A4 in human was identified as a 
gene specifically expressed in fibroblasts by subtractive and differential mRNA hybridization 
(Strutz et al., 1995). S100A4 belongs to the S100 superfamily of cytoplasmic calcium-binding 
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proteins (Garrett et al., 2006). The S1004 protein monomer has a molecular weight of 10-12 kDa 
but generally forms homodimers or heterodimers within cells (Marenholz et al., 2006). S100A4 
is  localized  in  the  nucleus,  cytoplasm,  and  the  extracellular  space.  However  cytoplasmic 
expression is observed in the majority of S100A4-expressing cells. S100A4 protein plays a role 
in  the  regulation  of  a  wide  range  of  biological  effects  including  cell  motility,  contractility, 
differentiation and survival (Schneider et al., 2008). 
S100A4  has  both  intracellular  and  extracellular  effects  which  are  likely  to  involve 
different mechanisms. It has been shown that intracellular S100A4 interacts with cytoskeletal 
proteins such as actin and myosin leading to increased cell motility (Tarabykina et al., 2007). It 
has also been shown that S100A4 protein is released from several cell types (Schmidt-Hansen et 
al., 2004; Cabezón et al. 2007). The paracrine effects of S100A4 can be divided into 3 groups: 
firstly, increasing cell motility by a direct effect on cytoskeletal gene expression (Belot et al., 
2002) and by increasing the expression of matrix metalloproteinases (MMPs) which degrade 
extracellular matrix proteins allowing cell migration (Schmidt-Hansen et al., 2004); secondly, 
increasing cell proliferation and differentiation, at least in neurons and cardiac myocytes (Fang et 
al., 2006; Schneider et al., 2007); and thirdly, preventing apoptotic cell death (Schneider et al., 
2007).
S100A4 was first introduced as a marker for epithelial cells undergoing EMT in kidney 
fibrosis  in  1995 (Strutz  et  al.,  1995).  However,  the  use of  S100A4 expression  to  define  all 
fibroblasts produced by EMT is now debatable since it has been observed that the interstitium of 
kidney contains fibroblasts which do not express S100A4 (Le Hir et al., 2005). It has also been 
reported that myofibroblasts do not express S100A4 (Picard et al., 2008). Furthermore, several 
studies  have  reported  the  expression  of  S100A4  by various  normal  human  cells,  including 
monocytes  (Cabezón  et  al.,  2007),  macrophages  (Österreicher  et  al.,  2011),  T  lymphocytes 
(Cabezón et al., 2007), neutrophilic granulocytes (Cabezón et al., 2007), and endothelial cells 
(Semov et al., 2005). 
1.9.1.2.2 Vimentin
Vimentin is an intermediate filament protein which forms one of the components of the 
cytoskeleton. It is normally expressed by mesenchymal cells (Steinert et al., 1988). However, a 
study  of  human  kidney  biopsies  has  reported  the  presence  of  vimentin  staining  in  normal 
glomerular epithelial cells (Essawy et al., 1997).  In addition, adult epithelial cells transiently 
express  vimentin  in  response to  various  insults  (Witzgall  et  al.,  1994).  Furthermore,  in  vivo 
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studies have demonstrated that vimentin is commonly expressed in injured tubular cells (Gröne 
et  al.,  1987).  Damaged renal tubular cells,  which express vimentin,  can retain an epithelioid 
basolateral border (Witzgall et al., 1994; Zhu et al., 1996).
1.9.1.2.3 α-smooth muscle actin (α-SMA)
Alpha-smooth muscle actin (α-SMA) is the characteristic actin isoform found in several 
cell  types,  including vascular  smooth muscle  cells,  pericytes,  lens  epithelial  cells,  mesengial 
cells, and myofibroblasts. However, α-SMA has not been recognized in nomal tubular epithelial 
cells (Gabbiani et al., 1981; Skalli et al., 1989). The expression of α-SMA is an excellent marker 
of myofibroblasts (Desmouliere et al., 1992). The role of α-SMA expression is to upregulate the 
contractility of cells, and increased expression of α-SMA directly correlates with increased force 
generation by myofibroblasts (Hinz et al., 2001). α-SMA expression is upregulated by several 
growth  factors,  including  fibroblast  growth  factor  (FGF)-2,  angiotensin  II  and  TGF-β1; 
conversely,  platelet-derived  growth  factor  (PDGF)  and  epidermal  growth  factor  (EGF) can 
inhibit α-SMA expression (Barrientos et al., 2008).
1.9.1.2.4 Heat shock protein 47 (HSP47)
HSP47 is a member of the serpin superfamily of serine proteinase inhibitors. This protein 
is  thought  to  be  a  molecular  chaperone  involved  in  the  synthesis  of  collagen molecules. 
Expression of HSP47 in injured tubules has been used as a marker for collagen synthesis in 
EMT.  However,  HSP47  is  not  specific  for  collagen  type  I  (Nagata  et  al.,  2003),  which  is 
commonly found in fibrotic tissue, but is also associated with collagen type IV which is present 
in the normal tubular basement membrane.
1.9.1.3 Disruption of the tubular basement membrane (TBM)
The  renal  tubular  basement  membrane  contains  an  abundance  of  collagen  type  IV. 
Integrity of the TBM is required for the maintenance of a polarized epithelial phenotype, with the 
disruption of type IV collagen leading to EMT (Zeisberg et al., 2001). It has been reported that 
infiltrating mononuclear  cells  and interstitial  fibroblasts  secrete  MMP-2 and MMP-14 which 
specifically cleave collagen type IV and laminin in  the basement  membrane.  This  facilitates 
degradation of the tubular basement membrane and enhances EMT (Yang et al., 2001; Zeisberg 
et al., 2004). Furthermore,  in vitro  studies demonstrate that, without TGF-β, MMP-2 alone is 
capable of inducing renal tubular epithelial cell transformation (Cheng et al., 2003).
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1.9.1.4. Enhanced migration and the invasive capacity of transformed cells
Disruption of the TBM is of fundamental importance for clearing a path for transformed 
renal tubular epithelial cells to migrate towards the interstitium. In addition, reorganization of the 
actin cytoskeleton and induction of α-SMA expression provides the potential for these cells to 
acquire  the  capacity for  contractility,  leading  to  migration  and invasion  (Yang et  al.,  2001). 
Furthermore, transformed epithelial cells acquire S100A4, which also promotes motility.
Figure  1.14  Diagram showing four key steps  during tubular epithelial  to  mesenchymal 
transition.
EMT is a multi-step process which includes: 1) loss of epithelial adhesion properties, 2) de novo 
expression  of  α-SMA and  actin  reorganization,  3)  disruption  of  the  TBM, and 4)  enhanced 
migration and invasive capacity of the transformed cells. This image is obtained from Yang et al., 
2001.
1.9.2 Classification of EMT
Since March 2008, EMT has been categorized into three subtypes based on the biological 
process and biomarker expression (Figure 1.15).
1.9.2.1 Type 1 EMT
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EMT type I is associated with implantation, embryo formation and organ development 
processes  which  are  organized  in  order  to  produce  diverse  cell  types  with  mesenchymal 
phenotypes (Zeisberg et al., 2009). Type 1EMT normally does not cause fibrosis or induce an 
invasive phenotype but transforms primitive epithelial  cells  into mesenchymal cells  (primary 
mesenchyme) required for gastrulation, organogenesis and subsequent development of secondary 
epithelia.
1.9.2.2 Type 2 EMT
This type of EMT initially starts as a part of a normal wound healing process which 
produces fibroblasts in order to repair damaged tissue following injury. However, type II EMT 
can be associated with chronic inflammation which prolongs the process leading to excessive 
fibrosis and damage of the tissue architecture. This process might be relevant to the chronic renal 
allograft dysfunction associated with IF/TA (Robertson et al., 2004). 
1.9.2.3 Type 3 EMT
This type of EMT occurs in epithelial cancer cells that have previously undergone genetic 
and epigenetic changes which lead to the development of tumours. Cells generated  by  type  3 
EMT  may  invade  and  metastasize  via  the  circulation or lymphatic system.  
1.9.3 Mediators of type 2 EMT
EMT can be induced or regulated by various growth and differentiation factors, including 
TGF-β, fibroblast growth factor (FGF)-2, hepatocyte growth factor (HGF) and PDGF (Zavadil et 
al.,  2005).  Among  these,  TGF-β  is  a  major  inducer  of  EMT during  embryogenesis,  cancer 
progression and fibrosis. The molecular pathways activated by TGF-β during the development of 
type 2 EMT in renal tubular epithelial cells are complex and may not be the same in different cell 
types (Fan et al., 1999; Okada et al., 1997). 
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Figure 1.15 Diagram shows different types of EMT.
Type 1 EMT is seen when primitive epithelial cells transition into mesenchymal cells that form 
the  diaspora  of  the  basic  body  plan,  following  gastrulation  or  neural  crest  migration.  This 
primary mesenchyme can be re-induced to form secondary epithelia by an MET. Type 2 EMT is 
seen when secondary epithelial cells populate interstitial spaces with resident or inflammation-
induced fibroblasts. Type 2 EMT can occur over extended periods of time and can eventually 
destroy an affected organ if the primary insult is not removed or attenuated. Type 3 EMT is seen 
when secondary epithelial  cells  transform into cancer cells  that  later  undergo the EMT with 
migration and invasive capacity. This image is taken from Zeisberg et al., 2009.
1.9.3.1 Transforming growth factor β (TGF-β)
TGF-β  is  a  multifunctional  cytokine  that  exerts  a  variety  of  biological  activities 
depending on the target cell type. It is well known that TGF-β is central to the induction of 
fibrosis  in  many tissues,  including the kidney.  TGF-β-induced EMT was first  recognized by 
modelling in vitro. Following addition of TGF-β, the morphology of mouse mammary epithelial 
cells changed from cuboidal to an elongated spindle shape. In addition, these TGF-β-treated cells 
showed  increased  expression  of  the  mesenchymal  markers  fibronectin  and  vimentin  and 
decreased expression of the epithelial markers E-cadherin, ZO-1 and desmoplakin (Miettinen et 
al., 1994). All isoforms of TGF-β (TGF-β1, TGF-β2 and TGF-β3) share the capacity to induce 
EMT in epithelial cells (Miettinen et al., 1994; Valcourt et al., 2005).
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Several observations have indicated that activation of the Smad signalling pathway is 
strongly associated with EMT. An  in vitro  study using transfected murine mammary epithelial 
cells showed that increased ectopic expression of Smad2 or Smad3 with Smad4 induces EMT 
whereas a dominant-negative Smad2, Smad3 and Smad4 blocked TGF-β-induced EMT (Valcourt 
et al., 2005). Moreover, a study in human proximal tubular cells demonstrated that inhibitory 
RNA against Smad2/3 can block TGF-β-induced EMT in vitro (Phanish et al., 2006).
 
1.9.3.2 Connective tissue growth factor (CTGF)
CTGF is a matrix-associated, heparin-binding protein which was originally isolated from 
the conditioned medium of human umbilical vein endothelial cells (Bradham et al., 1991). CTGF 
plays  an  important  role  in  the  regulation  of  cell  proliferation,  apoptosis,  embryogenesis, 
differentiation,  and wound healing  and is  expressed in  various  human tissues,  including  the 
kidney (Goldschmeding et al., 2000).
It has been reported that CTGF functions as a downstream mediator of TGF-β, acting 
specifically on connective tissue cells (Grotendorst et al., 1997). Blockade of CTGF partially 
inhibits TGF-β induced EMT  in vitro  and  in vivo  (Burns et al., 2007; Burns et al., 2006). In 
addition, blocking CTGF by using CTGF antisense oligonucleotides can decrease the expression 
of fibronectin, collagen type I and α-SMA gene expression and also reduces the development of 
interstitial fibrosis areas in the UUO model, despite the sustained expression of TGF-β (Yokoi et 
al., 2004).
1.9.3.3   Integrin-linked kinase (ILK)
ILK  is  a  serine/threonine  kinase  that  regulates  various  cellular  processes  including 
adhesion, migration, differentiation and survival (Wu et al., 2001). It has been reported that the 
induction  of  ILK plays  a  role  in  TGF-β1  and  CTGF-mediated  EMT (Liu  et  al.,  2008).  In 
addition, TGF-β can induce ILK expression in renal tubular epithelial cells by a mechanism that 
is dependent on intracellular Smads (Li et al., 2003) and CTGF (Liu et al., 2007).
1.10 Transforming growth factor-β
TGF-β is a ubiquitously expressed and multifunctional cytokine that not only plays a 
central role in EMT regulation, but also regulates the development, differentiation, and survival 
of most cell types and tissues (Blobe et al., 2000).
The TGF-β superfamily contains two subfamilies  defined by structural  similarity and 
their specific signalling pathway: firstly, the TGF-β, Activin and Nodal subfamily and secondly, 
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the  BMP (bone  morphogenetic  protein),  GDF  (growth  and  differentiation  factor)  and  MIS 
(muellerian inhibiting substance) subfamily.  Members of the TGF-β superfamily play crucial 
roles  in  biological  and  immunological  functions  through  activation  of  complex  signalling 
pathways. Disturbance of their signalling has been implicated in several developmental disorders 
and in various human diseases including cancer, fibrosis and auto-immune diseases (Blobe et al., 
2000).
There are three isoforms of TGF-β termed TGF-β1, TGF-β2, and TGF-β3, which all act 
through an intracellular signalling cascade of Smad family proteins via ligand-induced activation 
of TGF- β receptor kinases (Böttinger et al., 2002). The three TGF-β isoforms TGF- β1, TGF-β2 
and TGF-β3 have different functions which do not overlap. For example, TGF-β1 knockout mice 
develop  severe  autoimmune-like  inflammatory  diseases  (Kullkarni  et  al.,  1993).  TGF-β2 
deficient  mice  suffer  from  perinatal  mortality  and  a  wide  range  of  developmental  defects 
including cardiac,  lung,  craniofacial,  limb,  spinal  cord,  eye,  inner  ear  and urogenital  defects 
(Sandford et al., 1997). TGF-β3 null mice have cleft palates and delayed lung development due 
to  defects  in  branching  morphogenesis  and cell  differentiation  (Kaartinen  et  al.,  1995).  This 
suggests that a large number of TGF-β functions cannot be compensated for by other family 
members.
1.10.1 Latent TGF-β 
Normally, almost all TGF-β isoforms are secreted as an inactive latent complex called 
small latent complex (SLC), which contains the C-terminal mature TGF-β (molecular weight 
25kDa)  and  the  N-terminal  latency  associated  peptide  (LAP)  (molecular  weight  75-80kDa) 
(Annes et al., 2003). Before secretion, mature TGF-β is cleaved from the LAP by a furin-like 
endoproteinase  in  the  Golgi  apparatus  (Dubois  et  al.,  1995).  However,  the  LAP  remains 
associated with the TGF-β dimer by non-covalent interactions (Annes et  al.,  2003),  and this 
interaction inhibits  the  activity of  TGF-β (Figure  1.16).  The LAP domain contains  three  N-
glycosylated asparagine residues and three cysteine residues which are essential for dimerization 
of LAP monomers (Lawrence et al., 2001). Mutation of these cysteines prevents the association 
of LAP and mature TGF-β, leading to active TGF-β secretion (Lawrence et al., 2001). In addition 
to conferring latency, LAP is essential for the folding and secretion of the TGF-β precursor. In 
most cells, the SLC is bound to a large glycoprotein, latent TGF-β binding protein (LTBP) via 
disulphide bonds between LAP and LTBP. This complex is called the large latent complex (LLC) 
which was first discovered in platelets in 1988 (Miyazono et al., 1988; Wakefield et al., 1988). 
Most cells secrete TGF-β in the form of the large latent complex (LLC) (Koli et al., 2001). 
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LTBP-1 plays a central role in the processing and secretion of TGF-βs (Miyazono et al., 
1992), and LTBP-1 is co-expressed with TGF-β1 in the kidney (Taipale et al., 1994; Koski et al., 
1999). A study using a phorbol ester-stimulated human erythroleukemia cell line showed that the 
small  latent  TGF-β complex is  secreted very slowly with the majority retained in  the Golgi 
apparatus (Miyazono et al., 1991). However, LTBPs are secreted rapidly, and association with the 
SLC enhances the secretion of latent TGF-β (Taipale et al., 1994; Miyazono et al., 1991). LTBPs 
also  have  a  role  in  targeting  latent  TGF-β  to  the  extracellular  matrix (Saharinen et al., 
1998).  Interaction  between  growth  factors  and  ECM  molecules  is  a  major  mechanism  for 
regulation of growth factor activity. Fibronectin is required for the assembly of LTBP-1 to ECM 
(Dallas et al., 2005). This interaction is mediated by heparan sulphate proteoglycan through the 
heparin binding sites on both fibronectin and LTBP-1 (Chen et al., 2007). Mature TGF-β needs 
to be released from the latent complex in order to bind to TGF-β receptor and subsequently 
trigger biological responses. The detail of latent TGF-β activation is in section 1.10.
1.10.2 TGF-β receptors
TGF-βs transduce their signals across the cell membrane into the nucleus through type I 
(TβR-I) and type II (TβR-II) serine/threonine kinase receptors (Derynck and Zhang, 2003). To 
date, five type II receptors and seven type I receptors (Activin-receptor-like kinases, ALKs) have 
been identified in humans. At least two type II receptors and two type I receptors are needed for 
signalling  (Luo  and  Lodish,  1996).  Both  type  I  and  type  II  receptor  kinases  are  organized 
sequentially into an N-terminal extracellular ligand binding domain, a transmembrane region, 
and a C-terminal serine/threonine kinase domain. Besides type I and type II receptors, TGF-β 
ligands can bind to type III receptors (Betaglycans). Betaglycan is the most abundant TGF-β 
receptor on the cell surface where it functions as an accessory receptor that binds and presents 
TGF-β to its signalling receptors (Derynck and Zhang, 2003). The type III receptor can bind all 
three TGF-β isoforms, though it  has a higher affinity for TGF-β2 than TGF-β1 and TGF-β3 
(Chiefetz and Massague, 1991).
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Figure 1.16 Structure of the small and large latent TGF-β complexes.
TGF-β is synthesized as a precursor molecule consisting of the C-terminal mature TGF-β and N-
terminal LAP. TGF-β is cleaved from its propeptide by furin-like endoproteinase during 
secretion; however, mature TGF-β remains associated with LAP by non-covalent binding, 
forming the small latent complex. The large latent complex contains the small latent complex 
which is covalently bound to an LTBP. This image is taken from Hyytiäinen et al., 2004. 
1.10.2 TGF-β receptors
TGF-βs transduce their signals across the cell membrane into the nucleus through type I 
(TβR-I) and type II (TβR-II) serine/threonine kinase receptors (Derynck and Zhang, 2003). To 
date, five type II receptors and seven type I receptors (Activin-receptor-like kinases, ALKs) have 
been identified in humans. At least two type II receptors and two type I receptors are needed for 
signalling  (Luo  and  Lodish,  1996).  Both  type  I  and  type  II  receptor  kinases  are  organized 
sequentially into an N-terminal extracellular ligand binding domain, a transmembrane region, 
and a C-terminal serine/threonine kinase domain. Besides type I and type II receptors, TGF-β 
ligands can bind to type III receptors (Betaglycans). Betaglycan is the most abundant TGF-β 
receptor on the cell surface where it functions as an accessory receptor that binds and presents 
TGF-β to its signalling receptors (Derynck and Zhang, 2003). The type III receptor can bind all 
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three TGF-β isoforms, though it  has a higher affinity for TGF-β2 than TGF-β1 and TGF-β3 
(Chiefetz and Massague, 1991).
1.10.3 Smads
Smads are a group of transcription factors that interact with and modulate the activity of 
the  TGF-β receptor  complex.  The  Smad proteins  are  homologues  of  the  drosophila  protein, 
mothers  against  decapentaplegic  (MAD)  and  the  C.  elegans  protein  SMA.  The  name  is  a 
combination of  these  two.  The  Smad proteins  are  a  family of  transcription factors  found in 
vertebrates, insects and nematodes (Heldin et al., 1997). The Smad family can be divided into 
three subfamilies:
1.10.3.1 Receptor-regulated (R)-Smads
R-Smads  are  directly  phosphorylated  by  type  1  TGF-β  receptors  through  their 
intracellular kinase domain, leading to R-Smad activation. R-Smads include Smad2 and Smad3, 
which are normally activated by TGF-β (Figure 1.20), activin and nodal signalling, except in 
endothelial cells in which TGF-β signalling can also activate Smad1 and Smad5 (Miyazawa et 
al., 2002). Smad1, Smad5 and Smad8 are normally activated by the BMP/GDP subfamily.
1.10.3.2 Common partner (Co)-Smads 
Smad4 is the only known mammalian Co-Smad. Smad4  binds  to  the  activated  R-
Smads  and  facilitates  translocation  of  the heterotrimeric complex into the nucleus.
1.10.3 Inhibitory (I)-Smads
Smad6  and  Smad7  function  by inhibiting  the  downstream  signal  from  type  I 
TGF-β receptors, thereby  acting  as negative regulators of signalling mediated by the TGF-β 
superfamily of ligands.
1.10.4 The TGF-β/Smad signalling pathway
A TGF-β ligand initiates signalling by binding the type II receptor on the cell surface. 
This interaction allows type II receptors to recruit the type I receptor to form a hetero-tetrameric 
complex  with  the  ligand.  Upon  recruitment,  the  type  II  receptor  phosphorylates  the  type  I 
receptor on a specific GS domain which contains a series of glycine-serine repeats. The activated 
type I receptor then propagates the signal inside the cell through phosphorylation of the R-Smads 
(Smad2 and Smad3)  which then form a heteromeric complex with the Co-Smad (Smad4) to 
facilitate translocation into the nucleus, where they associate and cooperate with transcription 
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factors  to  activate or  repress  target  gene transcription  (Figure 1.17) (Feng and Derynck, 
2005). For regulation, there are I-Smads (Smad6 and Smad7) which negatively regulate TGF-β 
signalling. Smad7 competes with R-Smad to bind to the type I receptor, whereas Smad6 prevents 
the R-Smad from binding to the Co-Smad by interacting with Smad4.
1.10.5 Non-Smad signalling-mediated EMT
Although most studies report that Smads are necessary for the development of TGF-β-
dependent EMT in tubular epithelial cells, activation of non-Smad pathways such as the RhoA 
(RHOA;  Ras  homologue  gene  family,  member  A),  MAPK  and  PI3K  signalling  cascades 
(Derynck and Zhang, 2003) can also contribute to development and progression of the epithelial 
transition (Zhang et al., 2009).
Figure 1.17 Diagram showing the intracellular signaling mechanism of the TGF-β/Smad 
pathway.
(a)  TGF-β  binds  to  TβR-II  with  the  aid  of  TβR-III.  After  the  binding,  TβRII  recruits  and 
phosphorylates  TβR-I,  resulting  in  the  phosphorylation  (P)  of  Smad2  and  Smad3. 
Phosphorylated  Smad2  and  Smad  3  then  form  a  heteromeric  complex  with  Smad4  and 
translocate to the nucleus. This Smad complex regulates gene transcription with the association 
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of  transcription  factors,  co-activators  and  co-repressors.  (b)  Smad6  and  Smad7  bind  to  the 
receptor and inhibit phosphorylation. The image is taken from Heldin et al., 1997.
1.11 Latent TGF-β activation
Increased  TGF-β  expression  is  seen  in  conditions  including  fibrotic  diseases  and 
neoplastic  disorders,  and  often  correlates  with  clinical  disease  severity  (Wang  et  al.,  2005). 
However, increased expression of TGF-β is not sufficient to increase TGF-β activity, because all 
three TGF-β isoforms are expressed in tissues as inactive latent precursors. The extracellular 
activity of TGF-β is regulated by the conversion of latent TGF-β to active TGF-β. This activation 
can occur through physical processes and biological activation. 
1.11.1 Physical activation of latent TGF-β
1.11.1.1 Activation by pH
Many studies have shown that latent TGF-β is activated by acid (Lyons et  al.,  1988; 
Miyazono et al., 1988; Brown et al., 1990). This probably results from denaturation of the LAP 
protein,  which  disturbs  the  interaction  between  LAP  and  TGF-β.  Previous  studies  of  the 
activation of latent TGF-β in a fibroblast-conditioned medium have demonstrated that a small 
fraction of total TGF-β was active over the range of pH 4-5 (Lyons et al., 1988). Another study 
of  the activation  of  purified  human platelet-derived latent  TGF-β1 by pH suggested  that  no 
activation was observed above pH 3.5 (Miyazono et al., 1988). More recently it was shown that 
latent TGF-β was activated both below pH 3.1 and above pH 11.9 (Brown et al., 1990). 
1.11.1.2 Heat activation
Heating is an effective method for activating latent TGF-β. According to an in vitro study, 
heat  activation of  latent  TGF-β generates  greater  activity than acid activation (Brown et  al., 
1990). The optimal temperature is 70-80°C for 10 minutes; thermal denaturation of mature TGF-
β occurs above 80°C (Brown et al., 1990).
1.11.1.3 Activation by reactive oxygen species (ROS)
It has been shown that latent TGF-β1can be activated by ROS both in vitro by ionizing 
radiation or using a metal-catalyzed ascorbate system, and in vivo by irradiation, (Barcellos-Hoff 
et al., 1996). It has been suggested that hydroxyl radicals induce modifications which disable 
LAP binding, leading to exposure of the active growth factor.
1.11.2 Activation of TGF-β by integrins
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Integrins are a large family of cell adhesion and signalling receptors. Individual integrins 
comprise an α and β subunit in non-covalent interaction; there are 18 α subunits and 8 β subunits 
that can form at least 24 different heterodimeric transmembrane receptors. These transmembrane 
receptors provide a structural  and functional bridge between the extracellular  matrix and the 
intracellular cytoskeleton. In addition, they can transfer information from the ECM to the cell 
interior  or  vice  versa  and  are  also  involved  in  cell  adhesion,  maintenance  of  morphology, 
migration, proliferation, survival, differentiation, and invasion (Hynes, 2004). Four  integrins, 
including αvβ3 (Asano et al., 2005), αvβ5 (Asano et al., 2006), αvβ6 (Munger et al., 1999) and 
αvβ8 (Mu et al., 2002) have been shown to  bind latent TGF-β in vitro via an integrin-binding 
RGD amino acid sequence motif present in the LAP region of the latent complex.
A study in mice carrying a mutation in the RGD integrin-binding motif (Tgfb1  RGE/RGE  
mice)  demonstrated  a  similar  phenotype  to  Tgfb1-/-  mice  (Yang  et  al.,  2007).  This  finding 
suggests that integrin-mediated activation of latent TGF-β1 is absolutely essential for TGF-β1 to 
function  during  development  and  to  control  the  immune  system  in  vivo.  However,  as  the 
integrin-binding RGD motif is present in the latent forms of TGF-β1 and TGF-β3, but not TGF-
β2, it seems that an alternative mechanism must be responsible for the activation of latent TGF-
β2.
Besides  the β subunit,  the αv integrins are  also important  in  TGF-β activation.  Mice 
lacking  a  functional  integrin  αv  gene  (Itgav–/–  mice)  develop  identical  abnormalities  in 
vasculogenesis and cleft  palate as seen in  Tgfb1−/−  and  Tgfb3−/−  mice (Dickson et  al.,  1995; 
Kaartinen et al., 1995). This suggests αv integrins are necessary for the activation of TGF-β in  
vivo.
1.11.2.1 αvβ3 and αvβ5 integrins
αvβ3 and αvβ5 integrins can be expressed by many different cell types. Mice lacking 
either αvβ3 or αvβ5 do not show any defect associated with decreased TGF-β activation (Huang 
et al., 2000; Reynolds et al., 2002). However, evidence suggests that both αvβ3 and αvβ5 can 
activate latent TGF-β expressed by fibroblastic cells. Dermal fibroblasts from patients with the 
autoimmune disease scleroderma show enhanced expression of αvβ3 and αvβ5, and increased 
TGF-β activation; this was inhibited by antibodies against the αvβ3 and αvβ5 integrins (Asano et 
al.,  2006;  Wipff  et  al.,  2007).  The  expression  of  αvβ5  by  dermal  fibroblast  results  in 
transformation to a myofibroblastic phenotype as a consequence of increased TGF-β activity 
(Asano  et  al.,  2006).  Moreover,  αvβ5  integrin-mediated  activation  of  TGF-β  produces  lung 
fibroblast  to  myofibroblast  differentiation  during  pulmonary  fibrosis  (Scotton  et  al.,  2009). 
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However, this area remains controversial as recent data have shown that mice lacking both the 
αvβ3 and αvβ5 integrins are not protected from bleomycin-induced pulmonary fibrosis (Atabai et 
al., 2009).
1.11.2.2 αvβ6 integrin
The αvβ6 integrin is predominantly expressed by activated epithelial cells. This integrin 
is  thought  to  be important  for  localized activation  of  latent  TGF-β on the  epithelial  surface 
(Munger et al., 1999). Study of Itgb6–/– mice demonstrated a mild inflammatory phenotype which 
was limited to the skin and lung (Huang et al., 1996). Additionally, macrophages from Itgb6–/–  
mice  showed  defects  in  lung  phospholipid  clearance,  resulting  from reduced  αvβ6 integrin-
mediated  activation  of  TGF-β  (Koth  et  al.,  2007).  Furthermore,  Itgb6–/–  mice  developed 
periodontal disease due to reduced TGF-β activation by αvβ6 integrin-expressing oral epithelial 
cells  (Ghannad  et  al.,  2007).  Thus,  αvβ6-mediated  TGF-β  activation  seems  important  for 
controlling the functions of this cytokine at epithelial barriers. Normally, basal expression of the 
αvβ6 integrin is low, but expression of this integrin is increased when tissue injury occurs. The 
αvβ6  integrin  has  been  implicated  in  the  pathology  of  several  different  models  of  disease 
resulting from tissue damage. Studies using integrin Itgb6–/– mice, or blocking antibodies against 
αvβ6 show protection from pulmonary fibrosis (Munger et al., 1999), renal fibrosis (Hahm et al., 
2007) and liver fibrosis (Patsenker et al., 2006; Wang et al., 2007).
1.11.2.3 αvβ8 integrin
The  αvβ8  integrin  is  expressed  by  many different  cell  types,  including  neurons  and 
neuroepithelial cells (Proctor et al., 2005), astrocytes (Cambier et al., 2005), airway epithelial 
cells and fibroblasts (Araya et al., 2006; Neurohr et al., 2006), and dendritic cells and CD4+  T-
cells of the immune system (Travis et al.,  2007). Expression of the αvβ8 integrin and αvβ8-
mediated TGF-β activation by astrocytes is  important in controlling brain angiogenesis,  with 
activated TGF-β acting upon endothelial cells (Cambier et al., 2005).  TGF-β activation by the 
αvβ8 integrin is also required to regulate neurovascular homeostasis in the adult brain (Su et al., 
2010). These findings suggest an essential role for αvβ8 integrin-mediated TGF-β activation in 
regulating brain vascular development and function in health and disease. Itgb8-/- mice show cleft 
palate, as occurred in Tgfb3-/-mice, and defects in yolk sac vasculogenesis similar to Tgfb1-/- mice 
(Dickson et al., 1995; Kaartinen et al.,  1995). Interestingly, mice that express a non-integrin-
responsive  TGF-β1  and  lack  TGF-β3  (Tgfb1RGE/RGE;  Tgfb3-/-)  have  abnormal  vascular 
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morphogenesis identical to Itgb8-/- mice, as well as the expected abnormalities of the single TGF-
β null mice (Cambier et al., 2000). Expression of the αvβ8 integrin has also been reported for 
some  dendritic  cells.  Failure  of  the  expression  of  this  integrin  by  dendritic  cells  allows 
autoimmune colitis to develop in mice, suggesting a specific role for TGF-β activation by αvβ8 
integrin expressing dendritic cells in the development of immunoregulatory T cells (Travis et al., 
2007).
1.11.2.4 The mechanism of integrin-mediated TGF-β activation
As described above, almost all latent forms of TGF-β interact with integrins via an RGD 
integrin-binding motif in the LAP region of the latent complex. However, evidence suggests that 
different integrins can activate TGF-β by two different methods.
1.11.2.4.1 Mechanical induction of active TGF-β by integrins
Cell culture models have shown that activation of the latent TGF-β complex by the αvβ5 
(Wipff et al.,  2007)  and  αvβ6  (Munger et al.,  1999)  integrins  is  not  prevented  by  protease 
inhibitors,  indicating  that  cleavage  of  latent   TGF-β  is  not  required. Furthermore, active 
TGF-β is not released into the culture medium from cells expressing the αvβ6 integrin (Munger 
et  al.,  1999),  leading to the hypothesis that  integrin binding to the latent complex induces a 
conformational change to allow active but still  complex-bound TGF-β to bind to its specific 
receptor. Evidence now points to a role for cell contraction in the activation of TGF-β via the 
αvβ5 and αvβ6 integrins. An intact actin cytoskeleton is required for TGF-β activation by these 
integrins, as TGF-β activation is reduced by treatment with the actin polymerization inhibitor 
cytochalasin D (Munger et al., 1999; Wipff et al., 2007), whereas cell contraction stimulating 
agents such as thrombin, angiotensin-II and endothelin-1, can enhance TGF-β activation by the 
αvβ5  integrin  (Wipff  et  al.,  2007).  Stimulation  of  the  protease-activated  receptor-1  (PAR1) 
pathway in lung epithelial cells by thrombin or other PAR1 agonists enhances TGF-β activation 
by the αvβ6 integrin (Jenkins, 2006) (Figure 1.18). This enhancement requires signalling via the 
Rho kinase (ROCK) signalling  pathway (Jenkins  et  al.,  2006),  which  is  important  in  actin–
myosin cell contractility.
These data suggest that activation of TGF-β via αvβ5 and αvβ6 integrins requires: (i) the 
binding between LAP and integrin on the outside of the cell, which allows generation of a force 
by the actin cytoskeleton connected to the cytoplasmic domain of the integrin, and  (ii) binding 
between LTBP-1 and the ECM which creates an opposing holding force. Applying both of these 
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forces to the LLC may lead to a conformational change in the complex that allows TGF-β to bind 
to its receptor.
Figure  1.18  The  association  between  thrombin  and  the  αvβ6  integrin  in  latent  TGF-β 
activation. 
Platelets  release  thrombin  which  acts  on  epithelial  PAR1,  leading  to  RhoA-induced  actin 
polymerization and cytoskeletal contraction against the cytoplasmic domain of the β6 subunit of 
the αvβ6 integrin. This interaction results in conformational changes in the integrin-latent TGF-β 
complex which allow active TGF-β to bind to its specific receptor. This image is taken from 
Jenkins, 2008.
1.11.2.4.2 Protease-mediated activation of TGF-β by αvβ8 integrins
It  has  been  observed  that  not  all  integrins  activate  latent  TGF-β  by  inducing  a 
conformational change. The cytoplasmic domain of the αvβ8 integrin does not connect to the 
actin cytoskeleton, suggesting that actin-mediated cell contraction does not play a major role in 
TGF-β activation by this integrin (Mu et al., 2002). It has been observed that proteolytic cleavage 
of LAP by the cell surface MMP14 or transmembrane matrix-metalloprotease-1 (MT-MMP1) is 
crucial  in  the  generation  of  active  TGF-β  in  αvβ8-expressing  cells  (Mu et al.,  2002). 
Furthermore, a study using a co-culture model of foetal tracheal epithelial cells and fibroblasts 
showed a high level of active TGF-β, which was significantly inhibited by anti-MMP and anti-
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αvβ8 (Araya et al., 2006). A further study using human bronchial epithelial cells suggested that 
IL-1β may have a role in αvβ8-mediated TGF-β activation by an MMP14 dependent mechanism 
(Araya  et  al.,  2007).  The transcription factors SP1 and SP3, and the activating transcription 
factor 2 (ATF2) have been identified as key promoters of β8 integrin transcription (Markovic et 
al., 2010). A study in fibroblasts using SP3 knockdown showed a reduction in αvβ8 expression. 
Furthermore,  the  αvβ8 integrin  may function by presenting latent  TGF-β to  MMP14,  which 
causes  proteolytic  cleavage  LAP  and  releases  active  TGF-β  (Figure  1.19).  However,  the 
particular stimuli that enhance β8 integrin and MMP14 expression in different cell types leading 
to αvβ8-mediated TGF-β activation are unknown.
The activation of  TGF-β by the  αvβ8 integrin  releases  active  TGF-β from the  latent 
complex. However, the role of MMP14 in αvβ8-mediated TGF-β activation has only been tested 
in cells originating from the lungs and airways (Mu et al., 2002; Araya et al., 2007) and the 
generality of this mechanism remains to be established.
Figure 1.19 Role of MMP14 in αvβ8-mediated latent TGF-β activation.
The αvβ8 integrin binds the RGD sequence on latent TGF-β. The αvβ8 integrin then presents the 
latent  TGF-β  to  MMP14,  which  proteolytically  digests  LAP and  allows  the  active  TGF-β 
molecule to bind with the receptor. This image is obtained from Jenkins et al., 2006.
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1.11.3 Activation of TGF-β by Thrombospondin-1
Thrombospondin-1  (TSP-1)  is  a  matricellular  glycoprotein  which  is  expressed  in 
conditions such as wound healing, angiogenesis and neoplasia (Bornstein, 2001). It has been 
shown in vitro that TSP-1 expression is regulated by growth factors including PDGF, FGF-2 and 
TGF-β (Soula-Rothhut et al., 2005).
A previous study comparing TSP-1 null  mice with TGF-β1 null mice demonstrated a 
similarity of organ pathology, in particular in the lung and pancreas (Crawford et  al.,  1998). 
Moreover, administration of a TSP-1 inhibitor to wild type mice showed similar pathology to 
TGF-β null mice (Crawford et al.,  1998). It has also been shown that TSP-1 activates latent 
TGFβ by  forming  a  direct  interaction  with  the  latent  TGF-β complex  which  induces  a 
conformational rearrangement which exposes active TGF-β. The mechanism of TSP-1-induced 
latent TGF-β activation is discussed in chapter 5.
1.12 Evidence of latent TGF-β activation during kidney allograft rejection
A number of reports have demonstrated increased expression of TGF-β mRNA and 
protein associated with the tubules after kidney transplantation (Robertson et al., 2001; Özdemir 
et  al.,  2005).  However  it  is  also  clear  that  the  biological  response  to  this  growth  factor  is 
dependent on activation of the latent growth factor within the kidney.
1.12.1 The role of the αvβ6 integrin in kidney transplantation
The αvβ6 integrin has been implicated in the pathogenesis of several kidney diseases, 
including  chronic  fibrosis  after  transplantation.  The normal  adult  kidney expresses  only low 
levels of the αvβ6 integrin but it has been suggested that this integrin is expressed by tubular 
epithelial  cells  of  the  proximal  tubule,  loop  of  Henle  and  collecting  duct  during  kidney 
development (Arend et al., 2000).  
A recent study of gene expression in renal allograft biopsy specimens has demonstrated 
that increased expression of a set of genes is prognostic of late graft failure (Einecke et al., 2007) 
Importantly,  the gene with the fourth greatest  prognostic value in this  study encoded the β6 
integrin chain, suggesting an important role for activation of latent TGF-β in the progression of 
this disease. It is notable that increased expression of the β3 integrin chain (see section 1.10.2.1) 
was also prognostic of graft failure, but less so than the β6 integrin. This result is consistent with 
a previous immunohistochemical study which showed increased expression of the β6 integrin 
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kidney allografts with subclinical or clinical rejection. Importantly, the expression of this integrin 
was greatly increased on remnant  tubular  epithelial  cells  during  the development  of  fibrosis 
associated with chronic allograft rejection (Trevillian et al., 2004).
Col4A3−/− mice  provide  a  model  of  the  autosomal  recessive  Alport  syndrome  and 
develop progressive glomerulonephritis accompanied by the accumulation of extracellular matrix 
and fibroblasts, resulting in kidney fibrosis. It has been demonstrated that these mice express 
high  levels  of  the  αvβ6  integrin.  Addition  of  an  αvβ6  blocking  antibody  inhibited  the 
accumulation  of  activated  fibroblasts  and  deposition  of  extracellular  matrix,  as  well  as  the 
expression of TGF-β, suggesting a role for the αvβ6 integrin in TGF-β regulation in this disease 
(Hahm et al., 2007).
Another study using UUO-induced renal fibrosis showed that interstitial fibrosis was 
reduced in β6 integrin-/-  mice compared to wild-type mice. In addition, phosphorylated Smad 2 
and  active  TGF-β  were  markedly reduced  in  the  β6  integrin  deficient  mice,  indicating  that 
inhibition of the function of the β6 integrin can prevent renal fibrosis through TGF-β regulation 
(Ma et al., 2003). 
1.12.2 Thrombospondin-1-induced latent TGF-β in kidney fibrosis
Recent  data  suggest  that  thrombospondin-1  plays  a  potential  role  in  latent  TGF-β 
activation by mesangial cells in the kidney (Tada and Isogai, 1998). A previous study showed 
that  experimental  mesangial  cell  proliferative  glomerulonephritis  induced  by  an  anti-Thy1 
antibody was associated with de novo expression of TSP-1 and increased TGF-β expression 
(Hugo et  al.,  1995).  However,  addition  of  a  TSP-1  blocking  peptide  reduced  active  TGF-β 
expression and the level of phosphorylated Smad 2 (Daniel et al., 2004). Furthermore, TSP-1 
siRNA-transfected  cells  decreased  their  expression  of  active  TGF-β and  deposited  less 
extracellular matrix (Daniel et al., 2003). Besides the anti-Thy1 model, diabetic nephropathy in 
TSP-1-/- mice showed less expression of active TGF-β and structural changes compared to wild 
type mice (Daniel et al., 2007). These suggest that TSP-1 is an endogenous activator of TGF-β in 
experimental glomerulonephritis and diabetic nephropathy in vivo.
1.13 The association between Cyclosporine A and TGF-β production
Recent  protocol  biopsy  data  has  shown  that  0.6%  of  renal  allografts  are  lost  by 
interstitial fibrosis resulting from Cyclosporine nephropathy (El-Zoghby et al., 2009). Although 
it seems that the recent incidence of Cyclosporine nephrotoxicity has been markedly decreased, 
it  is  clear  that  Cyclosporine  nephropathy is  associated  with  tubular  atrophy and interstitial 
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fibrosis  (see  Chapter  3).  It  has  also  been  suggested  that  Cyclosporine  is  associated  with 
increased production of TGF-β. A study of human renal graft biopsies demonstrated increased 
expression of TGF-β in biopsies from patients with Cyclosporine treatment (Mohamed et al., 
2000). Furthermore, the renal function and structural damage was improved by administrating a 
specific TGF-β neutralising antibody in a mouse model of chronic Cyclosporine nephropathy 
(Ling et al., 2003).
The  exact  mechanism  of  Cyclosporine-induced  TGF-β  secretion  is  incompletely 
understood.  However,  several  factors  have  been  shown to  increase  TGF-β secretion  during 
Cyclosporine-induced renal  graft  fibrosis.  A study in  rats  on a  low sodium diet  showed the 
deposition of extracellular matrix and increased expression of TGF-β following Cyclosporine 
treatment,  whilst  rats  on a  normal  sodium diet  remained normal  (Shihab et  al.,  1997).  This 
suggests a role for the renin-angiotensin system in TGF-β expression in Cyclosporine-induced 
renal  fibrosis.  In  addition,  it  has  been  shown  that  addition  of  L-arginine  reduced  TGF-β 
expression  and  deposition  of  extracellular  matrix  in  rat  with  chronic  Cyclosporine 
nephrotoxicity,  indicating  a  role  of  nitric  oxide  in  TGF-β expression  (Shihab  et  al.,  2000). 
Aldosterone  has  also  been  reported  to  induce  TGF-β expression.  Treatment  of  rats  with 
Cyclosporine  and  a  mineralocorticoid  receptor  antagonist  down-regulated  TGF-β expression 
compared to rats with Cyclosporine treatment (Macunluoglu et al., 2008). Chronic Cyclosporine 
nephrotoxicity  is  often  associated  with  macrophage  infiltration.  A study  using  macrophage 
depleted rats showed a reduction of TGF-β expression, although expression of the myofibroblast 
marker, α-SMA did not change (Carlos et al., 2010). Interestingly, an  in vitro study showed a 
direct effect of Cyclosporine on TGF-β production by several cell lines, including renal tubular 
epithelial  cells  (Esposito et  al.,  2000;  Mohamed et  al.,  1999).  This observation suggests that 
calcineurin might  be  involved in  regulating TGF-β expression (Esposito  et  al.,  2000).  Since 
TGF-β is a key cytokine for EMT-mediated organ fibrosis, renal allograft fibrosis associated with 
Cyclosporine  nephrotoxicity  may  be  induced  by  EMT  following  activation  of  the  TGF-β 
signalling pathway. 
1.14 Hypothesis
Kidney  transplantation  is  the  treatment  of  choice  for  patients  with  end-stage  renal 
disease.  Despite advances in transplant medicine,  late allograft  loss is still  a major problem. 
Recent  data  has  shown that  10-year  renal  graft  survival  is  approximately 65% in  cadaveric 
transplantation and 80% in living donor transplantation. Besides death with a functioning graft, 
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chronic allograft failure is the most common cause of renal allograft loss in living recipients. The 
typical pathology of chronic allograft dysfunction includes chronic inflammation with tubular 
atrophy and interstitial fibrosis. 
Interstitial fibrosis is defined by an accumulation of extracellular matrix proteins in the 
interstitium leading  to  distortion  of  the  renal  architecture.  This  ECM is  produced by active 
fibroblast  or  myofibroblasts.  Currently,  the  origin  of  these  interstitial  fibroblasts  remains 
controversial although, several sources of fibroblasts have been proposed, including epithelial 
mesenchymal  transition  (EMT),  endothelial  mesenchymal  transition  (EndoMT),  resident 
interstitial fibroblasts, bone marrow-derived fibroblasts and pericytes or perivascular fibroblasts. 
However, the process of epithelial to mesenchymal transition might play a role in renal allograft 
fibrosis since a previous study has shown that 30% of interstitial fibroblasts are derived from 
renal epithelial cells (Iwano et al., 2002). 
This study was designed to test the linked hypotheses that  Cyclosporine A and graft-
infiltrating T cells  can induce allograft  fibrosis  through induction of  epithelial  mesenchymal 
transition by alteration of the bioavailability of fibrogenic TGF-β.
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1.15 Aim and Objectives
The  overall  aim of  this  study was  to  investigate  the  pathogenic  role  of  epithelial  to 
mesenchymal transition in allograft  fibrosis  after  kidney transplantation.  Initial  investigations 
were  designed  to  demonstrate  the  development  of  EMT  by  specific  causes  including 
Cyclosporine A and graft-infiltrating T cells, and also to understand the involvement of the key 
profibrotic cytokine TGF-β in this process. In the final part  of this study,  the mechanism by 
which  activated  T cells  can  activate  latent  TGF-β leading  to  either  T cell  or  epithelial  cell 
differentiation was determined. 
1.15.1 Objectives
The main experimental objectives of this study are to:
• Investigate the possibility that Cyclosporine A can induce epithelial to mesenchymal 
transition of renal proximal tubular epithelial cell lines.
• Determine the mechanism by which a model intraepithelial T-cell line induces epithelial 
to mesenchymal transition of a renal proximal tubular epithelial cell line.
• Identify the potential mechanisms by which activated T cells mediate the activation of 
latent TGF-β.
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Chapter 2: Materials & Methods
2.1 Tissue culture techniques
Tissue culture was performed under aseptic conditions in a class II laminar flow cabinet 
(Telstar Life Sciences). All items used were sprayed with 70% ethanol on entry and removal 
from the cabinet, including gloves. Tissue culture materials were either purchased as sterile or 
were sterilised by autoclaving at 121°C and 15 PSI (pound per square inch) for 15 minutes prior 
to use. Cell lines were routinely passaged (dependent on cell type; see subsequent individual 
sections for details) and frozen stocks were maintained in liquid nitrogen. Each of the seven cell 
lines used in this study required different cell culture media (Table 2.1). All culture medium was 
pre-warmed in a water bath at 37°C prior to use. All cells were cultured in a humidified 5% CO
2 
incubator at 37ºC. Cells were seeded into either 25cm2 or 75cm2 tissue culture flasks. Cells were 
monitored daily using an inverted microscope.
2.1.1 General maintenance of cell lines
2.1.1.1 Adherent cells
Adherent  cells  are  anchorage-dependent  and grow as  a monolayer  on the horizontal 
surface  of  tissue  culture  flasks  (CELLSTAR,  Greiner  Bio-One).  When  they  reached 
approximately 80% confluence, the cells were passaged at a ratio of 1:3-1:4 depending on cell 
type. Briefly, cell culture medium was removed and the cells were washed gently two times 
with 10ml of sterile, pre-warmed PBS (Sigma). The cells were harvested from the culture flask 
by  incubation  with  5ml  of  pre-warmed  0.25%  (v/v)  trypsin  and  0.02%  (v/v) 
ethylenediaminetetraacetic  acid  (Trypsin/EDTA;  Sigma)  solution  for  5  minutes  at  37°C. 
Following incubation, 15ml of pre-warmed complete culture medium (section 2.1.2) was added 
to the flask in order to neutralise trypsin activity and the suspension was agitated gently. The 
cell suspension was then centrifuged at 500 x g for 5 minutes. The supernatant was discarded 
and the  cell  pellet  resuspended in  1ml  of  pre-warmed appropriate  culture  medium (section 
2.1.2). Cells were counted by using a haemocytometer (section 2.1.3) and an optimum number 
seeded (section 2.2) into either 25cm2 flasks or 75cm2 culture flasks.
2.1.1.2 Suspension cells
Suspension cells are free-floating in culture medium and many are hematogenous cell 
lines. These cells were cultured in vertical culture flasks. They were passaged when the cell 
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density reached 2×106   cells/ml.  Briefly cells  were collected in a plastic universal  container 
(Scientific  Laboratory  Supplies,  UK)  and  centrifuged  at  500  x  g  for  5  minutes.  The 
supernatant was discarded and the cell pellet was resuspended in 1ml pre-warmed appropriate 
culture medium. Cells were counted by using a haemocytometer and an optimal number was 
transferred to new flasks.
2.1.2 Culture medium
2.1.2.1 Roswell Park Memorial Institute (RPMI)-1640 Medium, HEPES 
Modification
RPMI-1640 medium was developed by Moore et al. at Roswell Park Memorial Institute 
(Moore  and  Hood,  1993).  RPMI-1640  medium,  HEPES  (4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid) Modification (Sigma, UK) contains 25mM HEPES buffer. For 
complete RPMI-1640 medium, buffered medium was supplemented with 10% heat- inactivated 
foetal bovine serum (FBS), antibiotics (100IU/ml Penicillin and 100µg/ml Streptomycin) and 
2mM L-glutamine (all obtained from Sigma). Complete RPMI 1640 medium was stored at 4°C 
for further use.
2.1.2.2 Dulbecco’s Modified Eagle Medium (DMEM)/Nutrient F-12 Ham
This medium contains a 1:1 mixture of DMEM and Ham’s F-12 Nutrient with 3.15g/l D-
glucose,   15mM   HEPES,   L-glutamine   and   sodium   bicarbonate   (Sigma).   It   was 
supplemented with 100IU/ml Penicillin, 100µg/ml Streptomycin, 5% FBS and 5ml of ITS-X 
(10mg/l  insulin,  5.5mg/l  transferrin,  6.7µg/l  sodium  selenite  and  2.0g/l  ethanolamine) 
(Gibco, Invitrogen); this medium is referred to as complete DMEM/F-12 medium, when used 
for cell  culture.  This medium was used to grow renal tubular epithelial  cell  lines including 
HKC-8 and HK-2 cells. 
2.1.2.3 Renal Epithelial Cells Growth Medium (REGM™) BulletKit
This is a defined medium for growing primary human renal tubular epithelial cells. It 
contains  renal  epithelial  cell  basal  medium  (REBM™,  Lonza)  and  the  following  growth 
supplements  (SingleQuots™,  Lonza);  human  Epidermal  Growth  Factor  (hEGF)  0.5  ml, 
Hydrocortisone  0.5  ml,  Epinephrine  0.5  ml,  Insulin  0.5  ml,  Triiodothyronine  0.5  ml, 
Transferrin  0.5  ml;  GA-1000 (Gentamicin and Amphotericin-B) 0.5 ml and FBS 2.5 ml  per 
500ml of REBM™.
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2.1.2.4 Dulbecco’s Modified Eagle Medium (DMEM)
The  DMEM  used  in  this  study  contained  1g/l  D-glucose  and  3.7g/l  sodium 
bicarbonate (Sigma) but no phenol red. The complete DMEM was supplemented with 2mM L-
glutamine, 100IU/ml Penicillin, 100µg/ml Streptomycin and 10% FBS when it was used to 
grow cells.
2.1.2.5 X-VIVO™ Medium
X-VIVO™ (Lonza) is  a serum-free medium specific for T lymphocytes.  It  contains 
Lglutamine, gentamicin and phenol red.
Medium and
Supplements
Cell lines
HK-2 and
HKC-8
HRCE MOLT-16,
MFB-F11 
and PBMC
T cell MDA-
231
Medium DMEM/F-12 REBM™ RPMI 1640 X-Vivo™ DMEM
phenol 
red-free
FBS 5% - 10% - 10%
Glutamine 2mM - 2mM - 2mM
Penicillin
Streptomycin
100IU/ml
100µg/ml
-
-
100IU/ml
100µg/ml
-
-
100IU/ml
100µg/ml
ITS-X (100x) 5 ml - - - -
SingleQuots™ - 1 set - - -
Table 2.1 Medium and supplements used for cell culture.
2.1.3 Cell counting
Cell  density  was  evaluated  by using  a  Neubauer  Haemocytometer  (Weber  England) 
which consists of two chambers, each containing 9 squares (Figure 2.1A). The central counting 
area of the haemocytometer contains 25 large squares. When counting, only those cells on the 
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lines  of  two  sides  of  the  large  square  were  counted  (Figure  2.1B).  Cells  were  harvested, 
resuspended  in  phosphate  buffer  saline  (PBS)  and  a  10μl  aliquot  was  transferred  to  the 
haemocytometer. The number of cells was counted in the four corners plus the middle square in 
the central square and the average was taken and multiplied by 5 to include all 25 squares and 1 
x 104  to obtain the number of cells per ml. For example, if total cell count is 50 cells in 5 
squares:
Total cell number = 5 x 50 x 104 = 2.5 x 106 cells/ml
Trypan blue (a potent carcinogen) is a dye used to distinguish viable and dead cells. Viable cells 
exclude the dye while non-viable cells absorb the dye and appear blue. In order to check cell 
viability, cells  were  mixed  with  0.1%  Trypan  blue  (Sigma)  and  the  proportion  of  viable 
(dye excluding) cells was recorded.
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A B
Figure 2.1 Cell counting by haemocytometer.
(A) Haemocytometer counting chamber with nine large squares and five counting areas in the 
central square. (B) For cells on the borders on counting areas, only two sides of border lines 
were counted.
2.1.4 Mycoplasma testing
Cell  lines  were  tested  for  mycoplasma  infection  using  the  MycoAlert  Mycoplasma 
Detection Assay (Promega) according to the manufacturer’s instruction. Briefly, 2ml of culture 
supernatant  was  transferred  into  a  plastic  universal  tube  and  centrifuged  at  500 x  g  for  5 
minutes.  Then, 100µl of cleared supernatant was transferred into a microcentrifuge tube, with 
the addition of 100µl of the mycoplasma reagent,  and incubated at  room temperature for 5 
minutes. The microcentrifuge tube was inserted into a luminometer and the result was recorded 
as reading A. Then, 100µl of mycoplasma substrate was added and incubated for 10 minutes. 
The luminescence was read again and recorded as reading B. The ratio between reading A and 
reading B was then calculated. A ratio < 1 indicated an uninfected cell line. No infected cell 
lines were detected during this study.
2.1.5 Cell storage
To maintain a stock of cryopreserved cell  lines, cell  stocks were preserved in liquid 
nitrogen. Cells were frozen at ∼90% confluence (determined by light microscopy). Cell culture 
medium was removed and cells  washed gently with 10 ml of pre-warmed PBS. Cells  were 
detached from the surface of the flask using 5ml trypsin/EDTA. 15ml of pre-warmed culture 
medium were then added to the flask and the cell  suspension was agitated gently.  The cell 
suspension was centrifuged at 500 x g for 5 minutes. The supernatant was discarded and the cell 
pellet was resuspended in 1ml of freezing medium containing 10% dimethylsulfoxide (DMSO) 
(Sigma) and 90% FBS (v/v), and then 0.5ml of cell suspension was  transferred to conservation 
vials (Corning). The vials were cooled at a rate of -1°C per minute by holding in a freezing 
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container (Mr. Frosty, Nalgene, Hereford, UK) at -80°C for 24 hours. Following this, the vials 
were transferred and stored in a liquid nitrogen freezer until required.
2.1.6 Reviving frozen cells
Cell stocks (see section 2.1.5) were removed from the liquid nitrogen store and rapidly 
thawed in a 37°C water bath. Cells were resuspended in 10ml pre-warmed culture medium and 
agitated gently. The cell suspension was centrifuged at 500 x g for 5 minutes to form a pellet. 
The  supernatant  was  discarded and the  pellet  resuspended  in  pre-warmed  complete  culture 
medium. Cells were seeded as required into 75cm2 tissue culture flasks. The final volume of the 
culture flask was made up to 20ml with pre-warmed culture medium. Cells were maintained at 
37°C in a humidified atmosphere (5% CO
2 
in air). Once the cells had reached ∼90% confluence 
or a cell density of 2x106  cells/ml (determined by light microscopy), they were passaged as 
detailed in section 2.1.1 and routine culture commenced.
2.2 Cell lines
2.2.1 HKC-8 cell line
This is an immortalised human renal tubular epithelial cell line developed by Dr. Johng 
S. Rhim (Racusen et al., 1997). The parental cells were isolated from normal renal cortex and 
then  exposed  to  adenovirus  12:SV40 hybrid  virus.  This  cell  line  is  a  non-producer  of  the 
immortalising virus and is non-tumorigenic. In addition, the properties of proximal renal tubular 
epithelium,  including  biochemical  parameters,  transport  activities  and  immunohistochemical 
staining for epithelial markers, have been demonstrated in this cell line (Racusen et al., 1997). 
Furthermore, this cell line has been widely used as a model for renal proximal tubular epithelial 
cells in other studies, for example Ca2+ signalling (Turvey et al., 2010) and fibrosis (Tan et al., 
2008).  HKC-8 cells  were cultured in DMEM/F-12 HAM medium supplemented with 0.5µg 
insulin,  0.275µg  transferrin,  0.385pg  selenium  (ITS-X,  GIBCO,  Invitrogen),  100IU/ml 
Penicillin,  100µg/ml Streptomycin and 5% FBS. This cell  line was split  in  a  1:3 ratio  and 
cultured in 75cm2  tissue culture flasks. Originally, HKC-8 cells were maintained in DMEM/F-
12 HAM with 2% FBS, insulin, transferrin, selenite and hydrocortisone (Racusen et al., 1997). 
However, it has also been shown that HKC-8 cells grown in DMEM/F-12 HAM with 5% FBS 
displayed characteristics of differentiated proximal renal tubular epithelial cell (Bland et al., 
1999). 
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2.2.2 HK-2 cell line
This line of immortalised human proximal renal tubular epithelial cells was produced 
from primary renal tubular cells which were extracted from normal adult human renal cortex, 
then  exposed  to  a  recombinant  retrovirus  containing  the  human  papilloma  virus  (HPV 16) 
E6/E7 genes.  This  cell  line  has  functional  and phenotypic  characteristics  of  proximal  renal 
epithelial cells (Ryan et al., 1994) which are comparable to the HKC-8 cell line (Racusen et al., 
1997). In this study HK-2 cells were cultured in DMEM/F-12 HAM with 5% FBS and similar 
supplements to those used for the HKC-8 cell  line.  Although this  medium differs  from the 
supplemented  serum-free keratinocyte  medium suggested  in  the  original  paper,  more recent 
studies  of  differentiated  cell  functions  have  routinely  used  the  DMEM/F12  HAM medium 
described in the current report (Shimizu et al., 2011). 
2.2.3 Human renal cortical epithelial cells (HRCE)
Clonetic™ HRCE was purchased from Lonza. These primary renal cells were extracted 
from normal renal cortex. The characteristics of epithelial cells were demonstrated by positive 
cytokeratin staining (Clonetic™ Renal Epithelial Cell System, Lonza). Clonetic™ HRCE cells 
arrived frozen and were thawed at 37° in a water bath for less than 2 minutes or until the ice 
was melted. The cells were then resuspended in the cryovial and seeded at a density of 2,500 
cells/cm2  into 75cm2  tissue culture flasks which contained 15ml of a specific culture medium 
(BulletKit®) with supplement (SingleQuots®) solution (section 2.1.2.3). HRCE cells were sub-
cultured as described above (section 2.1.1), except the centrifugation was decreased to 220g. 
The seeding density for HRCE was 2,500 cells/cm2 and the culture medium was changed every 
second day.  Cells were used for between 3-5 passages.
2.2.4 Peripheral Blood Mononuclear cells (PBMC)
Human peripheral blood mononuclear cells (PBMC) are circulating blood cells which 
have  a  single  nucleus,  such  as  lymphocytes  and  monocytes.  PBMC was  isolated  from the 
venous blood of healthy volunteers in accordance with Ethics committee approval. Blood was 
heparinised and separated by density centrifugation (Noble et al., 1967) as described in section 
3.3.1. PBMC were cultured in RPMI 1640 complete medium.
2.2.5 T cells
T cells were isolated from the whole blood of healthy volunteers in accordance with 
Ethics committee approval, using the RosetteSep® human T cell enrichment cocktail (StemCell 
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Technologies) as described in section 2.2.5.1. These cells were activated using Dynabeads® 
Human T-Activator CD3/CD28 (Invitrogen). T cells were routinely cultured in serum-free X-
VIVO™ medium (Lonza).
2.2.5.1 Human T cell isolation from whole blood
The RosetteSep Human T cell Enrichment Cocktail isolates T cells from whole blood 
by a negative selection mechanism. Tetrameric antibody complexes (TACs) play a key role by 
cross-linking CD16, CD19, CD36, CD56, CD66b and glycoprotein A on red blood cells (RBCs) 
to form “immunorosettes” containing unwanted cells  and RBCs (Figure 2.2). The increased 
density of the unwanted cell-RBC complex allows separation by density gradient centrifugation.
T cells were isolated from the venous blood of healthy volunteers by using RosetteSep T Cell 
Enrichment Cocktail. 
Blood was mixed with heparin (Sigma) at a final concentration of 100units/ml to prevent 
coagulation.  RosetteSep T  cell  Enrichment  Cocktail  was  added  to  heparinised  blood  at 
50µl/ml and incubated at room temperature for 20 minutes. The sample was then diluted with an 
equal volume of sterile PBS (phosphate buffered saline) containing 2% BSA (2% BSA/PBS), 
followed by layering over a Lympholyte®-H (density gradient 1.077g/ml, Cedarlane, VHBio). 
The sample was centrifuged at 1200 x g for 20 minutes to separate the unwanted cells and 
RBCs. The density medium : plasma interface layer, which contained enriched T cells,  was 
removed. The enriched cells were washed with 2% BSA/PBS by centrifugation at 600 x g for 10 
minutes. The T cells pellet was resuspended in complete RPMI 1640 medium. (Figure 2.3)
Figure 2.2 Mechanism of T cell isolation from whole blood by RosetteSep Human T cell 
Enrichment Cocktail. 
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Panel A shows the structure of the tetrameric antibody complex which consists of two binding 
domains which recognize RBCs and unwanted cells. Panel B shows the crosslinked complex 
between unwanted cells and multiple RBCs forming the immunoresette. This image is taken 
from the RosetteSep information sheet.
2.2.6 MDA231 cell line
MDA231 is a breast cancer cell line which was established from the pleural effusion of a 
51-year-old Caucasian female patient with breast adenocarcinoma (Brinkley et al., 1980). This 
cell  line was cultured in  phenol  red-free DMEM complete  medium since phenol  red has an 
oestrogenic  activity  which  might  disturb  cell  proliferation  (Walsh-Reitz  and  Toback,  1992). 
These cells were split at a ratio of 1:3 and grown in 75cm2  tissue culture flasks. MDA231 cells 
are used widely as a cell model for neuropilin-1 (NRP-1) expression (Glinka et al., 2011).
2.2.7 MFB-F11 cell line
MFB-F11 cells are embryonic fibroblasts from Tgfb-/-  mice transfected with a plasmid 
containing  TGF-β  responsive  Smad-binding  elements  coupled  to  a  secreted  alkaline 
phosphatase reporter gene (SBE-SEAP). The MFB-F11 cell line was produced in order to assess 
the activity of TGF-βs, including TGF-β1, TGF-β2 and TGF-β3. These cells are not induced by 
latent TGF-β or other members of the TGF-β family such as activin, nodal, BMP-2 and BMP-6 
(Tesseur et al., 2006). MFB F-11 cells were cultured in RPMI 1640 complete medium. Cells 
were passaged twice a week at the ratio 1:4-1:5 in 75cm2 tissue culture flasks.
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Figure 2.3 T cells isolation procedure.
The purity of isolated T cells was measured after staining with a fluorochrome-conjugated anti-
CD3  antibody  (Dako)  and  analyzed  by  flow  cytometry  as  described  in  section  2.7.  The 
percentage of CD3+ T cells in the enriched cell population was routinely greater than 97%. This 
image is taken from the RosetteSep information sheet.
10 | P a g e
Chapter 2: Materials and methods
Figure 2.4 Flow cytometric analysis of the percentage of CD3+ T cells 
after whole blood isolation. 
T cells were isolated according to the RosetteSep T cell Enrichment Cocktail protocol. Then, 
the isolated T cells were stained with monoclonal anti-CD3 antibody (red histogram) and an 
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appropriate isotype control (open histogram). Analysis showed that the isolated cells contained 
more than 97% CD3+ T cells.
2.3 Molecular biology techniques
2.3.1 RNA biology
Ribonucleic acid (RNA) is made up of a long chain of nucleotides. Each nucleotide 
consists of a nucleobase, a ribose sugar and a phosphate group. RNA can be divided into 3 types 
based  on  their  functions.  (i)  Messenger  RNA (mRNA)  is  transcribed  from DNA by RNA 
polymerase enzyme and serves as a template for the synthesis of proteins. (ii) Ribosomal RNA 
(rRNA) is one of 2 main components of ribosomes; the other is proteins (ribosomes = rRNA + 
proteins). These ribosomes become associated with mRNA in the cytoplasm. (iii) Transfer RNA 
(tRNA) contains a specific amino acid at one end and anticodon region which recognises and 
binds mRMA at one end. The tRNA binds to the mRNA codon and transfers amino acids to the 
ribosomes in order to synthesise protein. It is mRNA that was of particular interest in this study, 
since it represents gene expression in physiological and pathological conditions.  Therefore,  it 
allows  measurement  of  changes  in  gene  expression  after  the treatment of cells with a 
variety of cytokines. The TRI-Reagent technique was used to extract cellular RNA.
2.3.2 RNA extraction
Total RNA was extracted following an adaptation of the TRI-Reagent method (technical 
bulletin MB205, Sigma). Confluent cells in 25cm2 tissue culture flasks were washed twice with 
5ml of ice-cold PBS. 1ml of ice-cold PBS was added to the flasks and the cells were harvested 
mechanically from the surface using a cell scraper. The cell suspension was centrifuged at 500 x 
g for 5 minutes to form a pellet. The supernatant was removed by pipetting. The cell pellet was 
lysed in an Eppendorf tube using 1ml of TRIzol-Reagent (Sigma), and the lysate was passed 
several times through a pipette until homogeneous. The lysate was allowed to stand at room 
temperature for 5 minutes to ensure complete dissociation of nucleoprotein complexes. 200µl of 
chloroform was added and the sample shaken vigorously by hand for 15 seconds. The sample 
was left  at room temperature for 15 minutes and was then centrifuged at 12000 x g for 15 
minutes at 4°C. The centrifugation separates the sample into 3 phases: a red bottom organic 
phase (containing proteins), an interphase (containing DNA) and a colourless upper aqueous 
phase (containing RNA). The aqueous phase was transferred to a fresh tube and 0.5ml of 2-
propanol was added to the sample and gently mixed together. The sample was left at  room 
temperature for 10 minutes and then centrifuged at  12000 x g for 10 minutes  at  4°C.  The 
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supernatant was removed by aspiration and the RNA pellet washed in 1ml of 75% ethanol. The 
sample was vortexed briefly and centrifuged at 7500 x g for 5 minutes at 4°C. The supernatant 
was aspirated and the RNA pellet was allowed to air dry for 10-15 minutes. The RNA was 
dissolved by resuspension in 20µl of RNase (Ribonuclease)-free water (Sigma). The RNA was 
either reverse transcribed immediately or stored at -80°C until required.
2.3.3 Determination of quality and quantity of RNA
The RNA sample should be free of contaminating substances, including proteins, DNA, 
phenol, ethanol and salts. Contamination can decrease the efficiency of reverse transcription, 
leading to reduced amplification. RNA purity can be evaluated from the ratio of the absorbance 
at 260nm and 280nm (A
260
/A
280
); this was measured using a nanodrop spectrophotometer (No-
1000 NanoDrop®) (Figure 2.5). In the spectrophotometer, a sample is exposed to ultraviolet 
light at 260nm (for nucleic acid) and 280nm (for proteins), and a photo-detector measures the 
light that passes through the sample. Pure RNA should have an A
260
/A
280  
ratio in the range of 
1.7-2.1.  In  addition,  the A
260
/
A230  
ratio  can be used to  exclude contamination with proteins, 
phenol  and  chaotropic  salts  such  as  guanidinium isothiocyanate,  which  absorb  UV light  at 
230nm. The value of the A
260
/A
230 
ratio should be around 2. The nanodrop spectrometer can also 
be used to estimate RNA concentrations.
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Figure 2.5 RNA purity and concentration measurement by Nanodrop specrophotometry.
This image is representative of RNA samples, and shows an A260/280 ratio of 2.00, The 260/230 
ratio was 2.16 and the RNA concentration was 2183.38ng/µl.
2.3.4 Determination of RNA integrity
Isolation of intact RNA is essential for gene expression analysis. The method used to 
assess the integrity of total  RNA is to run an RNA sample on an agarose gel  stained with 
ethidium bromide  (EtBr)  (Sigma).   Briefly,  a  1% agarose  gel  was  made by combining  1g 
agarose  powder  (Sigma)  with  100ml  of  1xTAE  (Tris-acetate-EDTA)  buffer  solution.  The 
agarose was completely dissolved by heating in a microwave oven at high power for 2 minutes 
and then partly cooled in running tap water. 3μl of 25mM EtBr was added to the warm 1% 
agarose  and  mixed  well  together.  The  1%  agarose  solution  was  poured  into  a  minigel 
electrophoresis  tray  with  a  20-well  separation  comb.  The  agarose  solution  was  allowed  to 
solidify for at  least  45 minutes  at  room temperature.  The agarose gel  tray was put  into an 
electrophoresis  tank  (Mini-Sub®  Cell  GT,  BIO-RAD)  and  submerged  in  1  x  TAE  buffer 
solution. The comb was removed from the gel. 12μl of 1 kilobase pair (kb) DNA ladder was 
applied to the first well. 1μg of RNA sample was mixed with 2μl of 6x gel loading dye and 
RNase-free water to a total volume of 12μl. 100V of electricity was applied to run the gel for 1 
hour. The gel was viewed under UV light. Intact RNA should display clear ribosomal bands of 
28s rRNA and 18s rRNA at ~1.7kb and ~ 800bp (base pair), respectively (Figure 2.6) with little 
degradation or smearing of the bands.
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Figure 2.6 Quality of representative RNA samples.
This image shows the ethidium bromide stained RNA separated in a 1% agarose gel. The two 
clear bands in each lane are 28s rRNA and 18s rRNA which are located at 1.7 Kb and 800bp 
respectively.
2.3.5 Reverse transcription of RNA
Reverse  transcription  (RT)  is  a  process  in  which  single-stranded  RNA is  reverse 
transcribed into double-stranded complementary DNA (cDNA). The cDNA produced from this 
reaction can be used for PCR amplification. Four reagents are needed for cDNA production. 
These  include  mRNA  as  a  template,  dNTPs  (dGTP,  dCTP,  dATP  and  dTTP),  reverse 
transcriptase and primers. Three different types of primers can be used for the RT reaction:
(1) Oligo (dT),  which binds  only at  the  poly-A tail  of  mRNA; therefore,  cDNA from this 
primer predominantly contains the 3' end of the gene. If the gene is very long, the 5' end is 
probably not transcribed.
(2) Random hexamers  prime  randomly  along  the  entire  length  of  mRNA,  producing  short 
cDNA fragments. The benefit of this primer is increasing the probability of transcription of the 
5' end of the gene to cDNA. It also produces cDNA even if there is no poly (A) tail in the 
sequence, such as 18s rRNA.
(3) Sequence-specific primers bind only to one specific mRNA sequence.
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This  study used oligo (dT)
12-18  
and random hexamers  as primers for  real-time PCR, 
depending on the sequence. The oligo (dT)
12-18  
was used routinely, whereas random hexamers 
were used to prime 18s rRNA because of the absence of poly (A) tail in 18s rRNA. Reverse 
transcriptase  is  an  RNA  dependent  DNA  polymerase  which  synthesises cDNA from RNA 
in the 5´ to 3´direction. SuperScript®III Reverse Transcriptase (Invitrogen) is purified from E. 
coli expressing the gene of Moloney-Murine Leukaemia Virus (M-MLV). To generate cDNA 
from mRNA for a 20µl reaction volume, 1µg of starting RNA template was first denaturated for 
10 minutes at 70°C in the presence of 200ng random hexamer (Fermentas) or 0.5µg oligo (dT
12-
18
) (Invitrogen) primers and 0.5mM dNTPs (Invitrogen). The mixture was cooled to 4°C for 2 
minutes and then 1×First-Stand buffer (Invitrogen), 0.01M DTT (Dithiothreitol) (Invitrogen) 
and  200units  SuperScript™  III  reverse  transcriptase  (Invitrogen)  were  added,  followed  by 
subsequent incubation at 50°C for an hour. The DTT is used to stabilise enzymes and other 
proteins which posses free sulfhydryl (Chen et al.,  2004). It is used in reverse transcriptase 
reaction  to  reduce  disulphide  bonds  in  RNases  which  are  needed  for  maintaining  stability, 
thereby inhibiting RNase activity and preserving mRNA for the reaction.  The reaction was 
inactivated by heating at 70°C for 15 min. When the reaction was primed by random hexamers, 
the mixture was incubated for 5 min at 25°C before incubating at 50°C.
Component Volume/Reaction (µl)
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Oligo(dT)
12-18 
(0.5µg/µl) or random hexamer (0.2µg/µl) 1.0
dNTPs (10mM each dNTP) 1.0
5 x first strand buffer (250 mM Tris-HCl (pH 8.3), 375 mM
KCl, 15 mM MgCl
2
)
4.0
DTT (0.01M) 1.0
SuperScript™ III (200units/µl) 1.0
RNase free water 2.0
Template RNA (100ng/µl) 10.0
Total volume 20.0
Table 2.2 Components required for the cDNA synthesis process.
2.4 Polymerase Chain Reaction
The polymerase chain reaction (PCR) is a technique to amplify a piece of DNA by in  
vitro  enzymatic replication in order to generate thousands or millions of copies of a specific 
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DNA sequence. Typically, PCR consists of a series of 20-40 cycles. Before the cycle is started, 
the reaction mixture is heated to 95°C for 5 minutes in order to activate DNA polymerase. The 
cycle then begins with a denaturation step which consists of heating the reaction to 95°C for 1 
minute. This disrupts the DNA strands by breaking the hydrogen bonds. After denaturing the 
DNA, the temperature is reduced to around 60°C for 30 seconds in order to allow binding 
between the primers and the single strand DNA template. This is the annealing step. Then, the 
temperature is increased to 72°C, which is an optimum temperature for DNA polymerase to 
synthesise a new DNA strand in the 5´ to 3´ direction. This is the extension or elongation step.
2.4.1 Real-time PCR
Real-time PCR is a technique for detection and quantification of the amplified DNA as 
the reaction progresses in real time, in contrast to standard PCR, in which the product of the 
reaction is detected at the end. A basic PCR reaction consists of three phases: (i) the exponential 
phase, which shows the exact accumulation of PCR product at every cycle, (ii) the linear phase, 
in which the reaction is slowing due to consumed components and (iii) the plateau phase, in 
which the reaction stops and the products start to degrade (Figure 2.7). Real-time PCR detects 
the  accumulation  of  specific  PCR products  during  the  reaction;  thus,  the  data  is  measured 
during the exponential phase of the PCR reaction. Standard PCR measures the accumulation of 
the PCR products after the PCR reaction or the plateau phase, which provides less quantitative 
data than the real-time PCR.
Figure 2.7 Three phases of the PCR reaction. 
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The PCR process can be divided into three stages (i) exponential amplification, (ii) linear and 
(iii) plateau stage. (Image taken from the Applied Biosystems tutorial)
2.4.2 Real-time PCR detection chemistry
Several  methods  have  been  developed  for  the  detection  of  DNA amplification.  The 
method  used  in  this  study  is  called  TaqMan®-based  detection  or  fluorogenic  5´  nuclease 
chemistry. This method was first reported by researchers at Cetus Coporation in 1991 (Holland 
et  al.,  1991)  and subsequently  developed  by Applied  Biosystems  for  research  applications. 
Principally,  the  TaqMan®  chemistry  uses  a  fluorogenic  probe  to  enable  detection  of  the 
accumulating  PCR product  during  PCR cycles.  TaqMan  probes  are  oligonucleotides  20-30 
bases long containing a reporter fluorescent dye on the 5´ end and a quencher dye on the 3´ end. 
As long as the quencher and the fluorophore are close together, the fluorescence emitted by the 
reporter dye is inhibited by the quencher by a process termed FRET (Fluorescence Resonance 
Energy Transfer). However, during the PCR reaction, the TaqMan probe is cleaved by the 5´ 
nuclease activity of DNA polymerase, resulting in separation of the reporter and quencher dye 
which allows the signal emission from the reporter dye (Figure 2.8).
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Figure 2.8 TaqMan® Probe based assay.
TaqMan® probe contains a fluorescent reporter (R) dye and a quencher (Q) at the 5´and 3´ ends 
respectively (A).  When the  probe  is  intact,  the  proximity of  the  quencher  dye  reduces  the 
fluorescent emitted by the reporter  dye by FRET (B).  During the extension step,  the DNA 
polymerase cleaves the reporter dye from the probe (C). Once separated for the quencher, the 
reporter dye emits its characteristic fluorescence (D). Image taken from the Applied Biosystems 
tutorial.
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2.4.3 TaqMan® Gene Expression Assays
This study used TaqMan® gene expression assays with predesigned and preformulated 
primers and probes by Applied Biosystem (Table 2.3). Most of the used primers were intron 
spanning primers as indicated by the “_m1” suffix (Table 2.3); therefore they could not detect 
genomic DNA sequences. TaqMan® Gene Expression assays contain a 20x mix of 2 unlabelled 
PCR  primers  and  FAM™  dye-labelled  TaqMan®  MGB  probes.  Quantification  of  gene 
expression using TaqMan® gene expression assays is performed as the second step in a two-step 
reverse  transcription-polymerase  chain  reaction  (RT-PCR)  protocol  on  any  ABI  PRISM® 
Sequence Detection System Instrument.
All TaqMan® gene expression assays were optimised to work with TaqMan® universal 
PCR  master  mix  and  with  complementary  DNA  (cDNA).  The  real-time  PCR  reaction 
components  for  a  single  20µl  reaction  96-well  plate  were  prepared.  Briefly, TaqMan® gene 
expression probes and primers, TaqMan® gene expression master mix and cDNA template were 
mixed together in an RNase-free 1.5ml microcentrifuge tube by brief centrifugation (Table 2.4). 
Then, 20µl of each PCR reaction was transferred into the well of a 96-well   plate   (in   triplicate) 
including   no   template   controls   (NTCs)   followed   by centrifugation. The plate was then 
loaded into the ABI PRISM® Sequence Detection System instrument. The PCR reactions were 
run with the universal thermal cycling parameters (Table 2.5).
ASSAY ID REPORTER
DYE
REPORTER
QUENCHER
GENE NAME
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Hs99999901_s1 FAM NFQ 18S rRNA
Human 18S rRNA
Hs99999905_m1 FAM NFQ GAPDH
Glyceraldehyde-3-Phosphate
Dehydrogenase
Hs00171257_m1 FAM NFQ TGF-β1
Transforming growth factor beta1
Hs00559580_m1 FAM NFQ CD103
Integrin, alpha E (human mucosal 
lymphocyte antigen 1)
Hs00203958_m1 FAM NFQ FOXP3
Forkhead box P3
Hs01546494_m1 FAM NFQ NRP-1
Neuropilin-1
Hs00386448_m1 FAM NFQ LTBP-1
Latent TGF –β binding protein 1
Hs00962908_m1 FAM NFQ TSP-1
Thrombospondin 1
Table  2.3  TaqMan®  Gene  Expression  Assays  (TaqMan®  MGB  probes,  FAM™  dye- 
labeled)
PCR reaction mix
component
Volume per well
                      (20µl reaction)
Final concentration
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2x TaqMan® Universal
Master Mix
10µl 1x
20x TaqMan® Gene
Expression Assay
1µl 1x
cDNA template diluted in
RNase-free water
9µl -
Total 20µl -
Table 2.4 PCR reaction mix components.
Real-time
PCR system
Reaction
plate
Reaction
volume
Thermal cycling reaction
Parameter Polymerase
activation
PCR (40 cycles)
Denature Anneal/extend
Temp.(°C) 95 95 60
ABI 
PRISM®
7000 system
96-well
       standard
20µl Time
       (mm:ss)
10:00 0:15 1:00
Table 2.5 Standard parameters for TaqMan® Gene Expression Assays.
2.4.4 Real-time PCR quantification
The two general types of real-time PCR quantification strategies are termed absolute and 
comparative quantification. This study used the latter method to measure changes in the level of 
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gene expression. The relative quantification method determines the changes of target gene levels 
in a sample of interest compared to a control or untreated sample, and expresses this relative to 
the level of an endogenous control gene. Ideally, the endogenous control gene should be stably 
expressed at the same level in all study samples and unaffected by other parameters such as 
experimental  conditions.  A housekeeping  gene  encodes  a  protein  essential  for  basic  cellular 
function in all human cells and is normally selected for use as an endogenous control. Common 
endogenous sequences used in real-time PCR are 18s ribosomal RNA (18s rRNA), β-actin and 
glyceraldehydes 3-phosphate dehydrogenase (GAPDH). However, it has been reported that the 
expression level of these genes may vary among tissues or cell types during cell proliferation 
and organ development (Thellin et al., 1999). In this study, the GAPDH gene, which is the most 
common endogenous control gene used for analysis of renal tissue (Schmid et al., 2003) and 
shows the lowest variability (Cui et al., 2009), was used as an endogenous control for renal cell 
lines. For T lymphocytes, 18s rRNA, which has been reported as the most stable housekeeping 
sequence in these cells (Bas, 2004), was used as the endogenous control.
2.4.4.1 Relative quantification by the arithmetic formulas.
The relative or comparative quantification method requires the C
T 
(Cycle threshold) value 
and application of arithmetic formulas to achieve a result. The C
T  
is defined as the number of 
cycles required for the fluorescence signal to exceed the background level. Calculation of the 
level of expression of the target gene is based on comparison of the C
T 
values of activated and 
control cells. The C
T 
values of both the control and the samples of interest are first normalised to 
the endogenous housekeeping or reference gene. In order to obtain a valid result, the efficiency of 
both the target amplification and the reference amplification used in the experiment has to be 
greater  than  90%  and  approximately  equal.  The  method  of  PCR  efficiency  assessment  is 
described in section 2.4.4. Below are the steps used to calculate the comparative C
T 
 (∆∆C
T
)
Step 1: To calculate the mean and standard deviation values of the replicate samples.
The mean C
T 
values and standard deviations are calculated by using Microsoft® Excel software.
Step 2: To calculate the ∆CT value.
The ∆C
T 
is calculated as follows:
ΔCT = CT (target) - CT (reference) 
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Step 3: To calculate the standard deviation of the ∆CT value.
The standard deviation (SD) of the ∆C
T 
value is calculated from the standard deviations of
 the 
target and the reference values by using the following formula:
SD = (SDtarget2 + SDreference2)1/2
Step 4: To calculate the ∆∆CT values.
The ∆∆C
T 
value is calculated as:
∆∆CT = ∆CT (treated sample) - ∆CT (non-treated sample) 
Step 5: To calculate the standard deviation of ∆∆CT values.
The calculation of ∆∆C
T 
involves the subtraction of the ∆C
T 
calibrator (non-treated) sample.
 This 
is subtraction of an arbitrary constant; thus, the SD of the ∆∆C
T 
value is similar to the SD of the 
∆C
T 
value.
2.4.4.2 Relative quantification by REST 2009 software
In 2002, the relative expression software tool (REST) was established as a new tool for 
relative gene quantification (Pfaffl et al., 2002). REST compares two samples, with replicate data 
in  the  treated  and  non-treated  groups,  and  calculates  the  relative  expression  ratio between 
them (Figure  2.9).  The  mathematical  model  is  based on the  mean C
T  
deviation  between the 
treated  and  non-treated  group  of  target  genes,  normalised  by  the  mean  C
T  
deviation  of  the 
reference gene (Pfaffl et al., 2002).  Furthermore, the reaction efficiency is calculated on the basis 
of the dilution method (see 2.4.5). The statistical  significance is tested by a Pair  Wise Fixed 
Reallocation Randomisation Test and plotted using standard error (SE) estimation via a complex 
Taylor algorithm (from REST-gene quantification information).
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Figure 2.9 Comparative quantification of gene expression using REST software.
Panel A shows a comparison of CD103, Foxp3, TGF-β1 and TSP-1 mRNA between treated and 
non-treated samples in triplicate data, and was normalised to the C
T  
value of 18s rRNA. Panel B 
is a box and whisker plot showing the median change (and interquartile ranges) in  relative gene 
expression.
2.4.5 Real-time PCR amplification efficiency
2.4.5.1  Amplification  efficiency  calculated  using  an  arithmetic 
formula.
In order to obtain the valid ∆∆C
T 
values, the amplification efficiency must be determined 
and both the target and reference genes should have approximately equal values. The efficiency 
of PCR can be evaluated by performing a dilution series experiment. The C
T 
values are plotted 
against cDNA concentration and the slope of the plot is calculated to determine the amplification 
efficiency. The efficiency of the PCR should be between 90-100%, which means that the slope 
between  the  linear  phases  of  amplification  graphs  should  be  between  -3.6  and  -3.1.  The 
efficiency of the PCR reaction depends on some variables, including the quality of the primers 
and length of the amplicon (Wong et al., 2005). Less than 90% efficiency does not exclude valid 
results but an optimised system is recommended. Assays used in the present work were designed 
by Applied Biosystems. The efficiency of PCR reaction was determined from the equation:
Efficiency = 10(-1/slope)–1
The slope -3.25 indicates that the efficiency of the real-time PCR reaction was higher than 90% 
(Figure 2.10).
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Figure 2.10 Representative amplification plots and a standard curve for real-time PCR 
detection of 18s rRNA in diluted samples. 
The standard curve is graphically represented  by a semi-log regression line plot of C
T  
value 
versus  log  of  input  nucleic  acid  (a  slope  of  -3.25  indicates  a  PCR  reaction  with  100% 
efficiency).
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2.4.5.2  Amplification  efficiency  calculated  using  REST 
software
PCR efficiency values are not only determined by fitting a regression line to a subset of 
data points in the log-linear phase, but also by applying REST software. The dilution series 
experiment was performed in triplicate. The mean C
T  
values and the standard concentration 
were completed, and then the software calculated the reaction efficiency which should be in a 
range between 0.9-1.0 (Figure 2.11).
Figure 2.11 Reaction efficiency of TaqMan® Gene Expression Assay calculated using 
REST 2009 software.
Each standard concentration was performed in triplicate and the standard CP (crossing point, 
equivalent terminology for C
T
) results are mean (n=3). The good value of reactive efficiency 
should be in range 0.9-1. This high efficiency result (0.9575) is representative of all the gene 
expression values assayed in this study.
2.5 Immunohistochemistry
Immunohistochemistry is a technique which demonstrates the localisation of antigens in 
tissue sections or cells in culture (immunocytochemistry), by the use of specific antibodies to 
detect individual antigens. Bound antibodies can be visualised by means of a marker such as a 
fluorescent dye or enzyme. This study used both immunofluorescence and immunoperoxidase 
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staining;   the   latter   method   was   used   specifically for the experiments in chapter 5 and 
will be described later.
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2.5.1 Immunofluorescence staining
This  technique  was  used  to  detect  antigens  on  cultured  cells  using  specific  primary 
antibodies. The distribution of the antigens was visualised by laser scanning confocal microscopy 
after the addition of fluorochrome-labelled secondary antibodies.
2.5.1.1 Gelatin coating 4-chamber slides
In  the  initial  stages  of  this  research,  there  was  a  problem  with  cell  attachment,  in 
particular HKC-8 and HK-2 cells,  during the washing steps involved in immunofluorescence 
staining experiments. In order to improve cell attachment, the chamber slides were coated with a 
0.1% gelatin  solution  (Sigma).  Gelatin  is  a  heterogeneous  mixture  of  water  soluble  proteins 
which  contains  collagen.  The  0.1% gelatin  solution  was  prepared  from 2% gelatin  solution 
(G1393, Sigma) by diluting in PBS and was sterilised in the autoclave (at 121°C for 15 minutes) 
before use. The 4-chamber slides for immunofluorescence staining were coated with a sterile 
0.1% gelatin solution. Briefly, 0.5ml of 0.1% gelatin solution was added to each well and left at 
room temperature in the tissue culture  hood for  a  minimum of 1  hour.  Excess solution was 
removed and the slides were allowed to air dry in a sterile area for 1 hour.
2.5.1.2 Cell preparation
Cells  were  grown on  0.1% gelatin  coated  chamber  slides  until  80% confluence  was 
reached. For some experiments the cells were then treated with cytokines such as TGF-β1 for 72 
hours. The culture medium was removed and the cells were washed twice with PBS buffer. The 
cells were then fixed, as described in section 2.5.1.3.
2.5.1.3 Cell fixation
In order  to ensure free access of the antibody to  its  antigen,  cells  must be fixed and 
permeabilized. The fixation immobilises the antigens and retains the cellular architecture. Several 
fixatives  are  commonly  used,  with  selection  dependent  on  the  nature  of  the  antigen  being 
examined and on the properties of the antibody used. Fixation methods are generally divided into 
two classes: organic solvents and cross-linking reagents. Organic solvents such as alcohols and 
acetone  remove  lipids,  dehydrate  the  cells  and  precipitate  proteins  within  the  cellular 
architecture.  Cross-linking  reagents  (such  as  paraformaldehyde)  form intermolecular  bridges, 
normally through free amino groups, thus creating a network of linked antigens. Cross-linkers 
preserve cell structure better than organic solvents, but may reduce the antigenicity of some cell 
components, and require the addition of a permeabilization step, to allow access of the antibody 
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to  the  specimen.  This  study  used  acetone  and  paraformaldehyde  fixation  for  HKC-8  and 
MDA231 cells respectively.
Briefly, HKC-8 cells were fixed in pre-cooled acetone at -20°C for 10 minutes. The fixed 
cells  were  allowed  to  air  dry  before  washing  in  PBS.  MDA231  cells  were  fixed  in  4% 
paraformaldehyde at room temperature for 10 minutes and were then rinsed briefly with PBS 
before being permeabilized with 0.2% Triton X-100 in PBS for 10 minutes at 4°C.
2.5.1.4 Immunofluorescence procedure
In  order  to  reduce  non-specific  binding  of  immunoglobulin  (IgG),  fixed  cells  were 
incubated in 1% bovine serum albumin (BSA, Sigma) in PBS at room temperature for 1 hour. 
Cells were then incubated with primary antibodies (Table 2.6) diluted in 1%BSA/PBS overnight 
at  4°C.  Primary  antibodies  were  mouse  monoclonal  anti-E-cadherin  1:50  (BD Biosciences), 
mouse monoclonal anti-α SMA 1:100 (Sigma), rabbit polyclonal anti-S100A4 1:100 (Dako) and 
rabbit  polyclonal  anti-pSmad  2/3  1:100  (Santa  Cruz).  Control  sections  were  incubated  with 
1%BSA/PBS in place of primary antibodies. Slides were washed in PBS for 15 minutes with 3 
changes of PBS. The cells were then incubated with secondary antibodies (Table 2.6); polyclonal 
rabbit  anti-mouse  IgG  FITC-conjugated  (1:100)  or  polyclonal  goat  anti-rabbit  IgG  FITC-
conjugated (1:150) in the dark at room temperature for 1 hour. The cells were washed in PBS for 
15 minutes with 3 changes of PBS. A nuclear counterstain with 4', 6- diamidino-2-phenylindole 
(DAPI) was applied by incubating with cells  at  room temperature for 2 minutes.  Cells  were 
washed  again  in  PBS  for  5  minutes.  Cells  were  covered  with  anti-fade  mounting  medium 
(DAKO), overlaid with a coverslip and stored at 4°C in the dark until analysis.
2.5.2 Laser scanning confocal microscopy (LSCM)
Immunofluorescence  staining  was  analysed  by  laser  scanning  confocal  microscopy 
(LSCM). LSCM is a technique for obtaining high-resolution optical images with depth selectivity 
(Paddock, 2000). The basic concept of confocal microscopy was originally developed by Marvin 
Minsky  from  the  mid-1950s  until  the  late  1980s (Minsky,  1988);  advances  in computer and 
laser technology have now been applied to confocal microscopy (Amos et al., 2003). The basis 
for  confocal  microscopy is  the  elimination of  out-of-focus  light  or  flare  in  the specimen by 
spatial filtering. Briefly, a laser beam passes through a light source pinhole and is then focused by 
an objective lens into a small focal volume on the surface of the specimen. The returning light is 
focused by an objective lens into a detector pinhole. Any light that passes though the second 
pinhole stimulates a low noise photomultiplier. This second pinhole prevents light from above or 
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below the plane of focus from striking the photomultiplier (Paddock, 2000).  The LSCM uses a 
laser for a light source; illumination and detection are confined to a single, diffraction-limited, 
point in the specimen. This point is focused in the specimen by an objective lens and scanned 
using some form of scanning device. Points of light from the specimen are detected by sensitive 
photomultiplier  tube detectors (PMT), which are positioned behind a pinhole,  and the output 
from the PMT is built into an image by the computer.
Figure 2.12 The principle of confocal microscopy. 
The confocal microscope eliminates the out- of-focus light by means of a confocal "pinhole" 
situated in front of the photomultiplier detector which acts as a spatial filter and allows only the 
in-focus part of the light to be imaged. Light from above and below the plane of focus of the 
object is eliminated from the final image. This image is taken from Paddock, 2000.
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This study used the confocal microscopy technique to detect antibody conjugated with 
fluorescent markers to show the relative distribution of epitopes of interest in cells or tissues. A 
control  section,  which  showed negative  staining,  was  obtained  from cells  stained  only  with 
fluorescent  dye-conjugated  secondary  antibody  (Figure  2.13).  In  addition,  quantitative 
measurement of fluorescence intensity was performed using Leica software.
Figure 2.13 Microscopic immunofluorescence staining image of a control monolayer.
The blue nuclear label conferred by DAPI was visualized via ultraviolet laser excitation (A), 
while  (B)  was  visualized  for  fluorescein  labelling  via  laser  excitation  at  480nm.  Cells  were 
stained by FITC-conjugated secondary antibody and DAPI without primary antibody. The slides 
were visualized by confocal microscopy with x63 objective lens magnification.
2.5.3 Quantification of immunofluorescence intensity
To quantify the immunofluorescence intensity from the microscopic immunofluorescence 
image,  20  areas  were  randomly selected  and measured  for  immunofluorescence  intensity by 
Leica confocal softwate (LCS Lite version 2.6). The results were reported as mean ± SEM.
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Concentration Company
Primary antibodies
Mouse monoclonal anti-E-cadherin
Rabbit polyclonal anti-S100A4
Mouse monoclonal anti-α SMA
Rabbit monoclonal anti-neuropilin-1
Mouse monoclonal anti-CD3
Mouse polyclonal anti-pSmad 2/3
1:50
1:100
1:100
1:100
1:50
1:100
BD Biosciences Dako
Sigma
       Abcam
      Dako
Santa Cruz
Secondary antibodies
Polyclonal rabbit anti-mouse immunoglobulin
(FITC conjugated)
Polyclonal goat anti-rabbit immunoglobulin
(FITC conjugated)
1:100
1:150
      Dako
     Sigma
Table  2.6  Primary  and  secondary  antibodies  used for  microscopic  immunofluorescence 
staining.
2.6 Western Blotting
Western blotting or protein immunoblotting is a technique used to detect specific proteins 
in tissue or cell preparations. Polyacrylamide gel electrophoresis is used first to separate native 
or denatured proteins, and then the proteins are transferred to a hydrophobic polyvinylidene 
difluoride  (PDVF)  (GE  Health  Life  Sciences)  membrane  where  they  are  detected  using 
antibodies specific for the target protein.
2.6.1 Preparation of protein lysates from cultured cells
A lysis  buffer  containing  detergent,  salt,  buffer,  protease  inhibitor  and  phosphatase 
inhibitor  is  generally  required  to  lyse  cells,  solubilise  protein  and  prevent  protein  and 
phosphoprotein  degradation.  In  addition to  lysis,  cells  can  be broken down mechanically by 
sonication.  To prepare  lysates,  confluent  cells  from 25cm2  tissue  culture  flasks  were washed 
twice in cold PBS and tharvested with a cell scraper. The cells were then resuspended in 50-
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100µl of lysis buffer which contained CelLytic M (Sigma), Protease Inhibitor Cocktail (Roche) 
and Halt Phosphatase Inhibitor Cocktail (Pierce). The lysate was vortexed every 10 minutes for a 
total of 30 minutes on ice. The lysate was then sonicated at amplitude 10 (MSE Soniprep 150, 
SANYO) for 30 seconds on ice. The lysate was then centrifuged at 16000 x g at 4°C for 20 
minutes. The clear supernatant was transferred to a new tube and the protein lysate was stored at 
-80°C.
2.6.2 Protein quantification
Protein  concentration  was measured using the  Pierce  BCA protein  assay kit  (Thermo 
Scientific).  The  Pierce  BCA Protein  Assay  is  a  detergent-compatible  formulation  based  on 
bicinchoninic acid (BCA) for the colorimetric detection and quantitation of total protein. This 
method combines the reduction of Cu+2  to Cu+1  by protein in an alkaline medium (the biuret 
reaction) with a highly sensitive and selective colorimetric detection of the cuprous cation (Cu+1) 
by bicinchoninic acid. The protein quantification was performed according to the instructions for 
the Pierce BCA protein assay kit. Briefly, 200µl of BCA working solution was loaded into the 
well of a flat 96-well plate and 25µl of standard or unknown proteins were added into each well 
in triplicate. The mixture was incubated at 37°C for 30 minutes. The protein concentration was 
measured with a microplate reader at a wavelength of 562nm (Figure 2.15). A standard curve of 
protein concentrations  against  absorbance was plotted using known concentrations  of  bovine 
serum albumin (Sigma).
Figure 2.14 Pierce BCA protein assay procedure. 
200µl of BCA working reaction was loaded into 96-well  plate and then 25µl of standard or 
unknown proteins were added to each well. The mixture was incubated at 37°C for 30 minutes. 
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The protein concentration was measured using a microplate reader at 562nm. (This image is 
taken from the Pierce BCA protein assay kit instructions)
Figure 2.15 Standard protein dose response curve generated using the Pierce BCA assay.
2.6.3 Separation of proteins by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE).
Antibodies  used  for  western  blotting  typically  recognise  epitopes  within  denatured 
proteins. In order to denature protein,  the anionic detergent sodium dodecyl  sulfate (SDS) is 
added to the loading buffer, and the mixture boiled at 95°C for 5 minutes. After the denaturing 
process, SDS-PAGE maintains the denatured state of polypeptides and allows the separation of 
proteins by their molecular weight. In the presence of SDS, proteins become negatively charged 
and move towards a positively charged electrode through the polyacrylamide mesh of the gel. 
Proteins move differently through the gel matrix depending on their size: the smaller the protein 
the  more  rapid  the  movement.  Gels  containing  a  low percentage  of  acrylamide  are  used  to 
separate  larger  proteins,  whereas  small  proteins  separate  better  in  high percentage  gels.  The 
proteins  in  this  study were  separated  by  SDS-PAGE using  the  Hoefer  Mighty  Small™  gel 
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apparatus (GE Healthcare). Gels for SDS-PAGE were made from 10% resolving or separating 
gels and 5% stacking gels (Table 2.7). Protein samples were treated with an equal volume of 
sample loading dye (Table 2.8) heated to 95°C for 5 minutes and briefly spun prior to loading 
onto the gel. Prestained protein molecular weight markers (Fermentas) were used in one lane to 
determine the molecular weight of the proteins. SDS-PAGE was performed in 1x running buffer 
(Table 2.8), with protein migration driven at 100V through the stacking gel and then at 150V 
through the resolving gel.
2.6.4 Coomassie Blue staining of polyacrylamide gels
It  is  possible  to  visualise  protein  bands  within  SDS-PAGE  gels  by  coomassie blue 
staining. Briefly, gels were stained for 1 hour with a solution containing 30% methanol, 10% 
acetic acid and 0.1% coomassie-brilliant-blue R250 (Sigma). The gels were then destained with 
30% methanol and 10% acetic acid for a further 2 hours, or for longer if required.
2.6.5 Western blotting
Following separation by SDS-PAGE, the proteins were transferred from the gel onto a 
PVDF membrane  (Hybond-P,  GE Health  Science)  by wet  transfer.  Prior  to  the  transfer,  the 
membrane  was  pre-soaked  in  methanol  for  10  seconds,  rinsed  in  water  and  equilibrated  in 
1×transfer  buffer.  The  gel  and  the  aligned  PVDF membrane  were  sandwiched  between pre-
soaked sponges and pre-soaked filter papers in a blotting tank (Hoefer TE series, Pharmacia) and 
protein transfer was carried out at 4˚C at 100V overnight. After transfer, the PVDF membrane 
was blocked in 5% dried skimmed milk (Marvel) in Tween-Tris buffer solution (TTBS) (pH7.6) 
for  total  protein or  5%BSA/TTBS (for  phosphoprotein)  for  1  hour  at  room temperature  and 
incubated overnight with primary antibodies in 5% milk/TTBS or 5% BSA/TTBS rocking at 
4°C.  Primary  antibodies  and their  working  dilutions  are  indicated  in  the  appropriate  results 
chapter. To remove unbound antibodies, blots were washed 3 times in TTBS for 5 minutes each. 
Appropriate HRP (Horseradish peroxidise)-conjugated secondary antibodies were then applied in 
5% milk/TTBS or 5%BSA/TTBS for 1  hour at  room temperature,  followed by 3 washes  in 
TTBS. The ECL-Plus reagent (GE Healthcare) was used for signal development according to the 
manufacturer’s instructions. Signals were captured on x-ray film (Fuji, NIF RX-100).
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Reagent 5% Stacking gel (ml) 10% Resolving gel (ml)
Deionised water 5.5 7.90
1.5M Tris-base, pH 8.8 - 5.00
1M Tris-HCl, pH 6.8 1.00 -
10% SDS 0.08 0.20
30% Acrylamide  (29:1
 Acrylamide:Bisacrylamide)
1.30 6.70
10% Ammonium Persulphate 0.08 0.20
TEMED 0.008 0.008
Total 8ml 20ml
Table 2.7 Components of the resolving and separating gels
Buffer recipes
6x Loading buffer
Tris HCl, pH 6.8  300 mM 
SDS 12% 
Bromophenol blue  0.6% 
Glycerol  60%
Dithiothreitol (DTT) 600 mM
5x Running Buffer
Tris base 15.1g
10% SDS 50ml 
Glycine 94g 
Water 1000ml
10x Transfer Buffer
Tris base  30.3g 
Glycine 144g 
Water 1000ml
1x TTBS
Tris base  2.42g 
NaCl  8.4g 
Tween 20 1ml 
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Water 1000ml
Table 2.8 Composition of Western blot buffer solutions.
2.7 Bioactive TGF-β measurement
TGF-β  is  secreted  as  a  latent  pro-peptide  complex,  which  requires activation to 
expose  or  release  bioactive  TGF-β  peptides  (section  1.4.6).  Several  methods  have  been 
developed to detect  bioactive TGF-β, such as enzyme-linked immunosorbent  assay (ELISA), 
radioimmunoassay and the use of reporter cells (Abe, 1994). 
One of the most popular TGF-β bioassays is based on an ability to induce expression of 
plasminogen activator  inhibitor-1 (PAI-1).  Mink lung epithelial  cells  were transfected with a 
truncated  PAI-1  promoter  fused  to  the  firefly  luciferase  reporter  gene  (Abe  et  al.,  1994). 
However, the disadvantage of this assay is that these cells can be induced by other growth factors 
(Abe et al., 1994; Van Waarde et al., 1997). Recently, a highly sensitive and specific bioassay has 
been described (Tesseur et al., 2006). This TGF-β bioassay uses a specific cell line called MFB-
F11, which is a  fibroblast cell line isolated from TGF-β-/- mouse embryos which has been stably 
transfected with a construct consisting of a synthetic promoter element containing twelve Smad 
responsive CAGA boxes, and a TGF-β-inducible DNA sequence, linked to a secreted alkaline 
phosphatase (SEAP) reporter gene (Figure 2.16). This assay has been shown to be specific for 
TGF-β1, TGF-β2 and TGF-β3 but  not for other  related TGF-β family members.  In addition, 
MFB-F11 cells detect bioactive TGF-β in biological samples and in cell co-culture systems, but 
do not respond to latent TGF-β. The MFB-F11 cell line was kindly provided for this study by Dr 
Ina  Tesseur  (Stanford  University,  USA).  This  study used  MFB-F11  to  detect  active  TGF-β 
present in cell culture supernatants of renal epithelial cells and T cells unless otherwise indicated.
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Figure 2.16 Scheme showing the establishment of the MFB-F11 cell line.
An embryonic fibroblast cell line obtained from TGF-β-/- mice (MFB-F11) was transfected with 
a construct consisting of a promoter containing SMAD binding elements linked to a secreted 
alkaline phosphatase reporter gene (SEAP). After stimulation with exogenous TGF- β, MFB-
F11 cells  produce  SEAP which  can  be  further  quantified  following reaction  with  pNPP or 
Phospha-Light™ (section 5.3).
2.7.1 TGF-β bioassay protocol
The TGF-β bioassay procedure was adapted from an original publication (Tesseur et al., 
2006). This study used 2 different substrates for alkaline phosphatase detection: P- Nitrophenyl 
Phosphate  (pNPP,  Sigma) and Phospha-Light™ (Applied Biosystem).  Details  of the Phophs-
Light™ assay will  be described in  section 5.3.  pNPP is  the most common substrate  used in 
alkaline  phosphatase-based  enzyme  immunoassays,  allowing  colour  changes  to  be  easily 
quantified using a spectrophotometer.
Briefly,  4x104  MFB-F11 cells  were  seeded  in  96-well,  flat  bottom plates  using  cell 
culture  conditions  optimal  for  the  MFB-F11  cell  line  (section  2.2.7).  Following  overnight 
culture, the cells were washed twice with PBS and incubated in 50μl serum-free RPMI for 4 
hours at  37°C. Following this  incubation,  serial  dilutions  of human recombinant  TGF-β (0-
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1000pg/ml) or test samples were added to the MFB-F11 cells in a total volume of 100μl. To test 
the  putative  presence  of  the  latent  form of  TGF-β,  heat  activation  of  some  samples  was 
performed by heating to 80°C for 5 minutes (Zamora et al., 2007). The MFB-F11 cells were 
incubated with test samples and a standard serial dilution of TGF-β for 48 hours. After 48 hours, 
100µl of supernatant was transferred to a new plate for 10 minutes at 65°C for heat inactivation 
of endogenous alkaline phosphatase activity.  The samples were then mixed with four times 
concentrated pNPP solution prepared according to the manufacturer’s instructions. The reaction 
was incubated at 37°C for various periods and absorbance at 405nm was analysed. A standard 
curve was established in each assay using known concentrations of TGF-β from 0- 1000pg/ml 
(Figure 2.17).
Figure  2.17  Standard  curve  of  TGF-β  concentration  using  the  MFB-F11 
bioassay.
MFB-F11  cells  were  incubated  with  TGF-β  for  the  period  of  48  hours.  Following  heat- 
inactivation, cell culture supernatants were mixed with pNPP substrate. The reaction was read at 
405nm after 24 hour incubation. The results show the mean and the error bars are SEM (n=3). 
This graph is a representative of 3 separate experiments.
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2.7.2 Efficacy of a TGF-β receptor type I inhibitor assessed using the 
MFB-F11 bioassay
As described in section 1.4.6, signalling by the TGF-β family is mediated by type I and 
type  II  transmembrane  TGF-β  receptors.  Ligand  interaction  with  a  homodimer  of  type  II 
receptors recruits and activates the homodimeric type I receptor (activin receptor-like kinase; 
ALK). The unique combination of type I and type II receptors confers the specificity of ligand 
signalling (Piek et al., 2001). For example, TGF-βs preferentially activate ALK-5. To inhibit 
signalling,  an  ALK-5 inhibitor  was  applied  in  some experiments  in  order  to  determine  the 
potential role of TGF-β signalling.
SB-505124 is a small molecule inhibitor which was developed as a competitive inhibitor 
of the ATP binding site of ALK-5 (DaCosta et al., 2004). According to a previous study, SB-
505124  selectively  inhibits  ALK-4  and  ALK-5  which  respond  to  activin  and  the  TGF-βs 
respectively; these receptors do not respond to the BMPs (DaCosta et al., 2004).
The MFB-F11 bioassay was used to test efficacy and optimise the concentration of SB-
505124. Briefly, 4x104 MFB-F11 cells were seeded in 96-well flat bottom plate. After overnight 
culture, semi-confluent cells were pre-treated with SB-505124 (0-5µM) for 1 hour. Following 
this pre-treatment, 0.5ng/ml of TGF-β was added to each well and incubated for 48 hours. The 
supernatant was collected and processed as described in section 2.7.2. From this experiment, it 
is clear that a concentration of 0.5-1.0µM of the AKL-5 inhibitor inhibits TGF-β signalling to 
baseline levels (Figure 2.12); this concentration is consistent with published results (DaCosta et 
al., 2004).
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Figure 2.18 TGF-β bioassay analysis to optimize use of the ALK-5 inhibitor
Confluent MFB-11 cells were incubated with a concentration range of ALK-5 inhibitor (0-5µM) 
in the presence of TGF-β1 at a fixed concentration of 0.5ng/ml for 48 hours. The response to 
TGF-β1 was evaluated by measuring SEAP activity at 405nm after incubation with pNPP. The 
plot  shows mean values  (N=3) and the error  bars are  SEM. These results  are  from a single 
experiment.
2.8 Immunofluorescence Flow cytometry
Immunofluorescence flow cytometry is a powerful technique for the measurement of a 
range of parameters for single cells within a suspension. The flow cytometer uses laminar flow 
and hydrodynamic focusing to generate a fluid stream containing cells, which are constrained 
within a limited cross sectional area as they pass through one or more beams of monochromatic 
(typically  laser)  light.  Some of  this  light  is  unaltered  in  wavelength  but  either  reflected  or 
scattered by the cells  and measured using photomultipliers. The reflected or forward scatter 
(FSC)  signal  is  proportional  to  the  area  or  size  of  the  cells,  whilst  the  side  scatter  (SSC) 
provides a measure of cytoplasmic granularity. Depending on the instrument used, further light 
can be absorbed, re-emitted and detected at a different wavelength by a range of fluorochromes, 
which   can  be  attached  to  individual  cells  either  chemically  or  immunochemically.  These 
fluorescence signals provide a measure of the amount of each fluorochrome associated with 
individual cells.
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The flow cytometers used in this project used excitation wavelengths of 488 and 635nm 
and were able  to  collect  fluorescence signals  emitted by the following fluorochromes:  FITC 
(519nm), PE  (phycoerythrin)  (576nm),  PI  (617nm)  and  APC  (allophycocyanin) (660nm) 
(Table 2.9).
Fluorochrome Laser Laser
Excitation
(nm)
Florescence
channel
Excitation
peak (nm)
Emission
peak (nm)
Fluorescein
(FITC)
Argon 488 FL-1 Green 495 519
Phycoerythrin
(PE)
Argon 488 FL-2 Yellow 566 576
Propidium
Iodide (PI)
Argon 488 FL-3 Orange 351 617
Allophycocyanin
(APC)
Red
Diode
635 FL-4 Red 650 660
Table 2.9 Fluorochrome absorption and emission spectra for the BD FACSCalibur.
2.8.1 Immunofluorescence staining for flow cytometry
Flow cytometry was performed using a BD FACSCalibur with twin laser and four 
colour  detection  (BD  Biosciences).  Cells  were  labelled  with  fluorochrome-conjugated 
antibodies and prepared as single cells in suspension (details of labelling intracellular antigens 
appear in section 5.3). Briefly, adherent cells were harvested by incubating with pre-warmed 
non-enzymic dissociation solution (Invitrogen) for 5-10 minutes. These cells were then washed 
in 2%FBS/PBS twice and resuspended in 2%FBS/PBS at a concentration of 1x106  cells/ml. 
100µl  of  cells  were  incubated  with  fluorochrome-conjugated  antibodies  (Table  2.9)  at  an 
appropriate concentration (Table 2.10) for 30 minutes on ice. Following this incubation, the 
cells  were  washed  twice  in  2%FBS/PBS  by  centrifugation  at  500xg  for  5  minutes.  If  a 
secondary antibody was required, it was incubated with cells at 4°C in the dark for 1 hour and 
the washing step was repeated. Then, the cell pellet was resuspended in 400µl of 2%BSA/PBS. 
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For control samples, cells were incubated  with  isotype  control  antibodies  at  an appropriate 
concentration.
Antibodies Concentration Company
Primary antibodies
Mouse monoclonal anti-neuropilin-1 APC-conjugates
Mouse monoclonal anti-CD103 FITC-conjugated
Mouse monoclonal anti-LAP (TGF-β1) PE-conjugated
Mouse monoclonal anti-TSP-1 Biotin-conjugated (A6.1)
1:10
1:10
1:10
1:10
Miltenyi Bioec
EuroBiosciences
R&D System
Abcam
Isotype control
Mouse IgG1 isotype control APC-conjugated
Mouse IgG2A isotype control FITC-conjugated
Mouse IgG1 isotype control PE-conjugated
Mouse IgG1 isotype control biotin-conjugated
1:10
1:10
1:10
1:10
Miltenyi Biotec
Ebioscience
Ebioscience
R&D System
Secondary antibody
Streptavidin FITC-conjugated 1:50 Ebioscience
Table 2.10 Details of the isotype control antibodies, primary antibodies and secondary 
antibodies used in flow cytometry experiments.
2.8.2 Flow cytometric analysis
This study analysed FCM data using WinMDI (Window Multiple Document Interface) 
version 2.9, which was produced by Joe Trotter of the Scripps Research Institute. Cells  are 
commonly analysed  for  five  parameters  including  forward  scatter  (FSC),  side scatter 
(SCC), FITC, PE and APC fluorescence (Figure 2.19).
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Figure 2.19 Histogram analysis of flow cytometry by WinMDI 2.9 software. 
Cells were processed for immunofluorescence staining as describe above. This image shows the 
histogram of unstained cells (red) overlayed with an isotype control-stained sample. This is a 
representative control sample for all flow cytometry experiments.
2.8.3 Flow cytometric analysis of cell death using Propidium Iodide (PI) 
PI is an agent which can penetrate dead cells followed by alteration of its fluorescence 
characteristics after intercalation into genomic DNA. Following this  intercalation, PI can be 
excited using the argon laser with fluorescence detected in channels FL2 or FL3. 
Briefly, cells were harvested as described in 2.9.1. After the last washing step, the cell 
pellet  was  resuspended  in  a  PBS  buffer  containing  PI  at  a  concentration  of  1µg/ml.  This 
suspension was immediately analysed by flow cytometry.
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2.9 Statistical Analysis
Before choosing a statistical test to analyse experimental results, the nature of the data 
must first be considered. Parametric data conform to a normal or Gaussian distribution, whilst 
non-parametric data do not. Whilst it is difficult formally to demonstrate the normality of small 
sample sizes, most biological processes do conform to this distribution. However, non-parametric 
tests must be used for obviously skewed data, perhaps containing off-scale values. The statistical 
tests used to analyse data in this study have been divided into 3 groups.
2.9.1 Description of the scatter of individual data samples
Most of the results in this study were judged parametric and were described as mean ± 
standard error of the mean (SEM).
2.9.2 Comparison between two samples
2.9.2.1 Parametric distribution
• The unpaired Student’s t test was used to compare the mean of two unmatched groups of 
data.
• The paired Student’s t test was used to compare two matched groups of data containing 
paired samples handled in parallel. For example, values collected with and without cytokine 
stimulation of T cells isolated from individual blood donors are treated as paired data. 
2.9.2.2 Nonparametric distribution
• Mann-Whitney test. This is the nonparametric equivalent to the unpaired Student’s t test.
• Wilcoxon test. This is the nonparametric equivalent to a paired Student’s t test.
2.9.3 Comparison between three or more groups of experimental data.
One-way analysis  of variance or ANOVA was used to determine the significance of 
differences between multiple groups of data. The significance of differences between individual 
sets of data was examined by application of an appropriate post-test.  
2.9.4 P value
All  statistical  analysis  was  performed  using  GraphPad  Prism  version  5  (GraphPad 
Software, San Diego, USA) with the threshold probability (P) value (alpha) set at 0.05. With a P 
value of less than 0.05 there is less than a 5% chance of observing between identical groups a 
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difference as large as was actually measured. At this level, differences between groups were 
considered significant.
2.9.5 Statistical Power
The statistical power shows the probability of which the test will reject null hypothesis 
when  the  null  hypothesis  is  false.  This  study  calculated  the  statistical  power  by  using  a 
calculator from DSS research web site.
 (http://www.dssresearch.com/KnowledgeCenter/toolkitcalculators/statisticalpowercalculators.a
spx)
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Chapter 3:  A Potential Role of EMT in Cyclosporine-
induced Renal Allograft Fibrosis
3.1 Introduction
The  suppression of allograft rejection is a goal of organ transplantation. Thus, the 
development of efficient immunosuppressive drugs is the key  for maintaining successful 
allograft  function.  Since the  introduction  of  calcineurin inhibitors (CNI),  short-term renal 
allograft survival has improved, though long-term renal allograft survival remains a  major 
problem.  CNI, which act by  inhibiting calcineurin function, consists of two  main drugs, 
Cyclosporine and Tacrolimus. This study focuses on Cyclosporine because it has been widely 
used and is associated with more complications.
Cyclosporine  and  Tacrolimus  differ  in  molecular  structure  and  intracellular  binding 
receptors.  Cyclosporine (C
62
H
111
N
11
O
12
,)  is a  hydrophobic, cyclic undecapeptide, with a 
molecular weight of 1202.64 Daltons. It was first discovered during a screening programme for 
new antibiotics and  isolated from the soil fungus, Tolypocladium inflatum Gams.  Its 
immunosuppressive activity was discovered later by J.F. Borel in 1976 (Borel and Baumann, 
1994; Stähelin, 1996) and it was subsequently approved for clinical use to prevent rejection in 
organ transplantation in 1983 (Kapturczak et al.,  2004). Tacrolimus was discovered  in 1984 
from the fermentation broth of a Japanese soil sample containing the bacterium Streptomyces 
tsukubaensis (Kino et al., 1987). Since i t s  introduction in clinical practice, C yclospor ine 
has  had a significant impact on immune modulation therapy  in transplant medicine, 
autoimmune  diseases and inflammatory  disorders. Currently,  both  Cyclosporine  and 
Tacrolimus are important in the prevention of allograft rejection. In addition,  approximately 
90% of patients have  been discharged post transplantation on a CNI-based 
immunosuppressive regimen (Andreoni et al., 2007).
3.2 Mechanism of action of Cyclosporine
During an immune response, activation of the  T cell receptor (TCR) results in an 
increase of intracellular free calcium ion which then triggers the activation of calcinuerin, a 
calcium-dependent serine/threonine phosphatase  enzyme. In the physiological state,  activated 
calcineurin dephosphorylates the cytoplasmic  component of the nuclear factor of  activated T 
cells  (NFATc).  After  this  dephosphorylation,  NFATc translocates  from  cytoplasm  to the 
nucleus, where it associates with the nuclear NFAT (NFATn) causing activation of the 
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transcription of genes coding for IL-2 and related cytokines (Gaffen and Liu, 2004). These 
cytokines, in particular IL-2, play an important role in the proliferation and differentiation of 
effector T cells which destroy the donor graft.
Figure 3.1 Scanning electron microscopy image of Tolypocladium inflatum Gams (A) and 
the structure of cyclic polypeptide Cyclosporine (B). These images are from Petcher et al. 
1976.
Following administration, Cyclosporine enters through the cell membrane and binds to 
its receptor,  cyclophilin, in the cytoplasm. Tacrolimus  forms  a  complex  with  its  cytosol 
receptor  FKBP-12.  Both  cyclophilin  and FKBP-12 are immunophilins, a highly  conserved 
family of proteins which have peptidyl-prolyl cis-trans isomerase (PPIase) activity (Fisher et 
al., 1989; Wang and Heitman, 2005). Cyclophilin and FKBP-12 a r e  present abundantly in 
most c e l l s  in the human body (Ryffel, 1993) and have high affinity for calcineurin. Blocking 
calcineurin  by  Cyclosporine-cyclophilin  and  Tacrolimus-FKBP-12  complexes  leads  to 
inhibition of NFATc dephosphorylation. As a result, the migration of NFATc to the nucleus is 
inhibited and the association of NFATc with NFATn  cannot occur  (Figure 3.2). 
Consequently, IL-2 production is inhibited, which is essential for activation and proliferation 
of lymphocytes (Ho et al., 1996). Inhibition of the calcineurin-NFAT pathway by Cyclosporine 
and Tacrolimus is  not  specific  to immune cells  but  can also lead to toxic changes in other 
organs, including nephrotoxicity (Liu et al., 2007).
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Figure 3.2 Mechanism of action of Cyclosporinend Tacrolimus.
Cyclosporine   binds   to   Cyclophylin,   whereas   Tacrolimus   binds   to   FKBP-12   in   cell 
cytoplasm. These complexes block calcineurin activity  leading to the inhibition of IL-2 
production.
3.3 Incidence of Cyclosporine nephrotoxicity
Since 1988, the short-term outcome of kidney grafts has substantially  improved 
(Hariharan et al., 2000).  Hariharan and co-workers reported that one-year graft survival from 
deceased donors increased from 75.7% to 87.7% and also the rate for living  donor grafts 
increased from 88.8% to 93.9% (Hariharan et al., 2000). This significant improvement is 
due in part to the potent immunosuppressive effect of Cyclosporine, which has contributed to a 
significant reduction in acute rejection episodes. However, there have been several studies 
which report potential renal toxicity in kidney and other organ transplantation (Myers et al., 
1988; Nankivell et al., 2004).
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In fact, Cyclosporine has been associated with numerous  adverse reactions including 
hypertension, hyperlipidemia, gingival hyperplasia, kidney (Marcén et  al., 2001) and liver 
dysfunction (Klintmalm  et  al., 1981). However, nephrotoxicity  is a major side effect of 
Cyclosporine. The  clinical nephrotoxicity of Cyclosporine was first reported in patients 
receiving kidneys from cadaveric donors who showed the characteristics of acute toxicity, such 
as reversible renal dysfunction mediated by  hemodynamic change (Klintmalm et al., 1981). 
Two years later, long term nephrotoxicity of Cyclosporine including tubulointerstitial injury 
followed by focal glomerular sclerosis was described in heart transplant patients who received 
Cyclosporine for  longer than  12  months (Myers  et  al., 1984). Since  then, several studies 
involved in chronic Cyclosporine nephrotoxicity have been published and strategies to reduce 
toxicity have emerged (Nankivell et al., 2004).
The incidence of chronic Cyclosporine nephrotoxicity  has been reported by several 
groups. For example, kidney-pancreas transplant patients were studied by protocol biopsy for 
up to 10 years.  Evidence of CNI toxicity, including  arteriolar hyalinosis,  glomerulosclerosis 
and interstitial damage, was reported as 76.4%, 93.5% and 96.8% at 1 year, 5 years and 10 
years, respectively (Nankivell et al., 2004). H ow ev e r,  a  more recent study was conducted 
using a larger patient cohort  and  showed  that 31% of graft loss at 5  years after 
transplantation resulted from interstitial fibrosis and tubular atrophy (IF/TA). I n contrast to 
the other studies, CNI nephrotoxicity (0.6%) was not a major contributor to late graft loss (El-
Zoghby et  al.,  2009).  The different incidences of CNI  nephrotoxicity might be explained 
according to the following factors:
(1) Subjects: Nankivell et al (2004) performed kidney biopsies in patients with kidney and 
pancreas transplantation, whilst the more recent study (El-Zoghby et al., 2009) recruited only 
patients  with  kidney  transplantation.  The  different  transplant  procedures  might  affect  the 
dosage and level of calcineurin inhibitors.
(2) Immunosuppressive  drugs:  Although  both  studies  used  calcineurin  inhibitors  as 
immunosuppressive drugs, Cyclosporine was a main drug in Nankivell study and Tacrolimus 
was used in another study.
(3) Improved diagnostic  techniques, such as molecular diagnosis for BK polyomavirus,  or 
C4d marker  for humoral  rejection, allow more specific identification of the  causes of graft 
failure.
Several papers have suggested that Tacrolimus has an ability to induce nephrotoxicity similar 
to that of  Cyclosporine (Khanna  et  al., 2002; Shimizu  e  al., 2008). However,  human 
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(Cantarovich et al., 2005)  and animal studies (Bagnis et al., 1997) have shown a weaker 
vasoconstrictive and fibrogenic  effect of  Tacrolimus than Cyclosporine. In addition, clinical 
trials in renal transplantation have  shown better  renal function and graft survival in 
Tacrol imus treated patients compared with Cyclosporine (Cantarovich et al., 2005; Shihab 
et al., 2008). Furthermore, a recent protocol biopsy study reported fewer, less severe and less 
progressive chronic histological change in kidney transplantation patients, despite  using 
Ta c r o l i m u s  as the main immunosuppressive drug (Stegall  et  al., 2011). To date, the 
reasons for these differences are still incompletely understood.
3.4 Cyclosporine nephrotoxicity
Two types of Cyclosporine nephropathy have been described: acute nephrotoxicity and 
chronic nephrotoxicity, based on the time of onset of toxicity and histological manifestations.
3.4.1 Acute Cyclosporine nephropathy
The acute form of Cyclosporine nephrotoxicity  results from renal vasoconstriction, 
which is induced by an imbalance of local vasoactive substances. Rat models of experimental 
Cyclosporine nephrotoxicity demonstrated the constriction of afferent arterioles following 
Cyclosporine treatment. As a result, there is constriction of renal arterioles, followed by a 
decline in renal function. This acute toxicity is reversible and depends on the concentration 
of Cyclosporine.  There are three forms of acute Cyclosporine nephrotoxicity: functional 
toxicity, tubular toxicity and vascular toxicity.
3.4.1.1 Functional toxicity
This is the earliest form of acute Cyclosporine nephrotoxicity. The typical characteristics of 
functional toxicity include clinical renal allograft dysfunction, such as glomerular filtration 
rate reduction and increased serum creatinine but without histological abnormality.
3.4.1.2 Toxic tubulopathy
Patients usually present with acute renal allograft dysfunction with high serum 
Cyclosporine levels.   The typical histological finding of tubular toxicity is isovolumetric 
vacuolisation in  most of  the  proximal tubules. These symmetrical vacuoles in the tubular 
cytoplasm result from an enlargement of endoplasmic reticulum and an increase of lysosomes 
(Mihatsch et al., 1998).
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3.4.1.3 Vascular toxicity
Cyclosporine has direct toxicity to endothelial cells, resulting in two types of 
vasculopathy:  acute  arteriolopathy and  thrombotic microangiopathy (Liptak and Ivanyi, 2006). 
Acute arteriolopathy usually  affects only afferent arterioles. A common histological finding is 
swelling  and vacuolation of endothelial cells and also vacuolation, necrosis and  apoptosis of 
myocytes which  are then replaced  by plasma protein  insudates (hyalinisation).  Thrombotic 
microangiopathy can be characterised by the existence of thrombi in the lumen of arterioles 
and glomerular capillaries.
3.4.2 Chronic Cyclosporine-induced nephrotoxicity
The chronic toxicity of Cyclosporine usually presents with slow, insidious and 
irreversible renal allograft dysfunction. In contrast to the acute form, chronic Cyclosporine 
toxicity is not only characterised by renal vasoconstriction, but also by permanent structural 
damage.   This  chronic form typically  involves 3 parts of the kidney graft, including nodular 
hyalinosis  (vessels),  striped  fibrosis  (interstitium and  tubule)  and  glomerular  sclerosis 
(glomerulus).
3.4.2.1 Nodular hyalinosis
This arteriopathy is characterised by nodular hyaline (glassy  translucent substance) 
deposition in the tunica media of afferent arterioles, which contain smooth muscle  cells and 
elastic fibre, leading to smooth muscle cell damage. The necrotic arteriolar smooth muscle cells 
are then replaced by focal or circular or bead-like plasma protein deposits on the walls of the 
afferent arterioles (Figure 3.3).
6 | P a g e
Chapter 3: A potential role of EMT in Cyclosporine-induced 
renal allograft fibrosis
Figure 3.3 Microscopic image of chronic Cyclosporine nephrotoxicity.
The black arrow shows nodular or beads-like medial hyalinosis of afferent arteriole. The image 
is from Liptak and Ivanyi, 2006.
3.4.2.2 Interstitial fibrosis and tubular atrophy
Recently, the IF/TA caused by  non-immunologic factors has been classified as a 
subtype of medullary ray injury (MRI) (Kobayashi et  al., 2010). Striped fibrosis in renal 
allograft is reported as a consequence of chronic Cyclosporine nephrotoxicity-associated MRI. 
The  striped fibrosis is defined by the presence of ischemic tubular atrophy  and interstitial 
fibrosis areas, alternating with relatively normal tubules and interstitium (Figure 3.4).
3.4.2.3 Glomerular sclerosis
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There are many  manifestations of glomerular involvement, such as glomerular 
hypertrophy, mesangial matrix expansion, capillary  collapse and/or focal segmental or focal 
global sclerosis.
Figure 3.4 Microscopic image of chronic Cyclosporine-induced nephrotoxicity.
The dotted line shows the transition between areas of IF/TA and intact tubule. The yellow 
arrows demonstrate the nodular hyalinosis. The image is obtained from Kobayashi et al. 2010.
3.5 Pathogenesis of chronic Cyclosporine-induced nephrotoxicity
To date, several hypotheses have been proposed to explain the pathogenesis of chronic 
Cyclosporine nephrotoxicity. However, the exact mechanisms are not clearly  understood. 
Nevertheless, the most likely  aetiologies are chronic  low  grade  ischemia  and TGF-β up-
regulation (Ling et al., 2003).
3.5.1 Chronic low grade ischemia
It has been demonstrated that chronic ischemia induced by Cyclosporine resulted from 
an  imbalance of vasoactive substances by  increasing  the  expression  of  vasoconstrictive 
mediators  including  renin-angiotensin aldosterone system (RAAS), endothelin-1 (ET-1) 
(Ramirez et al., 2000) and TXA2 (Thromboxane A2) (Kim et al., 1997), as well as a reducing 
8 | P a g e
Chapter 3: A potential role of EMT in Cyclosporine-induced 
renal allograft fibrosis
vasodilators such as PGI2 (Prostacyclin), PGE2 (Prostaglandin E2) (Rogers et al., 1988) and 
NO (Nitric oxide) (Kurus et al., 2005). 
Consequently, the resulting renal vasoconstriction results in both renal dysfunction and 
hypoxia. Renal ischemia promotes reactive oxygen species (ROS) production that contributes to 
structural damage by increasing apoptosis and cellular tubular injury.
3.5.2 TGF-β up-regulation
TGF-β is a key  cytokine implicated in the pathogenesis of fibrosis in chronic kidney 
diseases, including chronic Cyclosporine nephropathy. Studies from our group and others have 
shown that Cyclosporine is associated with an up-regulation of TGF-β expression (Mohamed et 
al., 2000).  Furthermore, the renal function and structural damage were ameliorated by 
administrating a  specific TGF-β neutralising antibody in a mouse model of chronic 
Cyclosporine nephropathy (Ling et al., 2003).
The exact mechanism of Cyclosporine-induced TGF-β secretion is incompletely 
understood. However, multiple hypotheses have been proposed, such as angiotensin II (Pichler 
et al., 1995;  Shihab et al., 1997) and aldosterone activation (Bobadilla and Gamba, 2007), 
macrophage infiltration (Lim et  al.,  2004) and direct cell toxicity  (Esposito  et  al., 2000). 
However,  a  study using  rat  model  of  type  I  diabetes  showed that inhibition  of  calcineurin 
reduced glomerular extracellular matrix accumulation (Gooch et al., 2003). In addition, TGF-β 
induced  accumulation  of  extracellular  matrix  via  ROS  generation,  calcium  influx  and 
calcineurin activation (Gooch et al., 2004). Therefore, a mechanism of Cyclosporine induced 
TGF-β production by renal tubular epithelial has remained controversy.
3.5.3 Role of Cyclosporine on CTGF expression
CTGF is a pro-fibrotic growth factor which acts downstream of TGF-β. Previous studies 
suggested that CTGF played a role in TGF-β1-induced EMT during organ fibrosis (Burns et al., 
2006; Burns et  al.,  2007). Blocking CTGF expression reduced the expression of fibronecin, 
collagen and α-SMA in the UUO mouse model (Yokoi et al., 2004). In addition, a study using 
human  renal  cell  line  (HK-2)  showed  increased  CTGF  mRNA  expression  following 
Cyclosporine treatment during Cyclosporine-induced EMT in vitro (McMorrow et al., 2005). 
However, some paper showed a negative role of CTGF in chronic Cyclosporine nephrotoxicity. 
Rat  experimental  chronic  nephrotoxicity showed no difference  of  CTGF mRNA expression 
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between control and rats with Cyclosporine treatment (Shihab et al., 2006). Therefore, it seems 
that a role of Cyclosporine in CTGF regulation remains unknown.
3.5.4 Calcineurin-NFAT pathway
Nodular hyalinosis is one of the manifestations of chronic Cyclosporine-induced renal 
injury (section 3.4.2).  This arterial hyalinosis results from the replacement of necrotic smooth 
muscle cells in the vascular wall by plasma proteins. A study in a rat model of Cyclosporine 
nephrotoxicity  demonstrated the process of arteriolar hyalinosis, starting with the granular 
eosinophilic transformation of smooth muscle cells in afferent arterioles, followed by  the 
vacuolisation of smooth muscle  cells and subsequent hyaline  deposition (Young et al., 1995). 
The underlying mechanisms responsible for  smooth muscle  cell necrosis are not yet clear. 
However, it has been observed that the changes in smooth muscle cells may be associated 
with several factors, including the function of calcineurin-NFAT in smooth muscle cells (Graef 
et  al., 2001; Nieves-Cintrón  et  al., 2007), prolonged  arteriolar  vasoconstriction and direct 
toxicity of Cyclosporine.
Recent data have suggested an important role for the calcineurin-NFAT signalling 
pathway in chronic Cyclosporine nephropathy, though this has not been fully defined. It has 
been suggested that nuclear localisation of NFAT plays an important role in the acquisition 
and maintenance of smooth muscle  cell differentiation and arterial remodelling. Moreover,  it 
also has been reported that there is an association between NFAT and COX-2; the COX-2 gene 
promoter contains binding sites for NFAT, indicating that NFAT is involved in the regulation of 
COX-2 gene expression (Sugimoto et al., 2001).  NFAT is inhibited by Cyclosporine, leading 
to a decrease in COX-2 expression and, consequently, renal vasoconstriction.
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Figure  3.5  Diagram  demonstrating  the  pathogenesis  of  chronic  Cyclosporine 
nephrotoxicity.
3.5.5 Cyclosporine-induced epithelial mesenchymal transition
It  is  widely  accepted  that  TGF-β  is  a  key  cytokine  for  fibrogenesis  including  renal 
allograft  fibrosis  due  to  Cyclosporine  nephrotoxicity.  TGF-β induces  interstitial  fibrosis by 
several mechanisms, including:
(i) Accelerating fibroblast proliferation which leads to an increase in the production of 
extracellular matrix.
(ii) Decreasing the  degradation  of ECM  by down regulating the  matrix 
metalloproteinase enzymes.
Current evidence shows that EMT is one  of the important  mechanisms for TGF-β 
induced organ fibrosis (Kalluri and Neilson, 2003). EMT is described as a multistep process 
in  which epithelial  cells lose  their  epithelial phenotypes and acquire  mesenchymal 
characteristics (see section 1.8). The losses of epithelial characteristics which are commonly 
observed  during  EMT are  morphological  change  from typical  cuboidal-shaped  epithelia  to 
elongated spindle-shaped fibroblast-like cell and reduction of intercellular adhesion molecules 
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such  as  E-cadherin. The  mesenchymal  markers  which  are  commonly  used  to  identify 
fibroblasts include S100A4 and α-SMA.
According to the previous  data, TGF-β is up-regulated in chronic Cyclosporine 
nephrotoxicity  both in vivo and in vitro  (Mohamed  et  al., 2000; Esposito  et  al., 2000). 
Therefore, Cyclosporine might have a direct effect on renal tubular epithelial cells by inducing 
EMT. This is supported by in vitro studies in renal proximal  tubular  epithelial cell lines 
(Slattery  et  al., 2005; McMorrow  et  al., 2005). In addition, recent data  has  shown that 
Cyclosporine-induced EMT is inhibited by BMP-7, which is a TGF-β antagonist, by down 
regulating the expression of  connective tissue growth factor, a downstream mediator of  TGF- 
β1 (Xu et al., 2010). Since the effect of Cyclosporine-induced TGF-β production is most likely 
cell/tissue specific, thus this study chose a different cell line to investigate this issue.
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3.6 Aim
EMT has been proposed as an important mechanism for fibrogenesis. This leads to the 
hypothesis that Cyclosporine may induce EMT in renal tubular cells, resulting in 
interstitial fibrosis in chronic Cyclosporine nephrotoxicity.
This  study will determine the  pathogenic role of EMT  in  chronic  Cyclosporine 
nephrotoxicity by:
• Demonstration that EMT can be induced in renal epithelial cell lines by TGF-β1.
• Demonstration of the characteristics of EMT in renal epithelial cell lines at both 
protein and molecular levels after Cyclosporine treatment.
• Demonstration of the association between Cyclosporin and bioactive TGF-β1 levels.
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3.7 Materials and Methods
All detail of materials used in this chapter is shown in chapter 2. The following methods 
were designed for experiments performed only in this chapter.
3.7.1 Peripheral blood mononuclear cell (PBMC) preparation
All PBMCs contain a single round nucleus. These cells primarily include lymphocytes 
and monocytes. They  are usually  isolated from anti-coagulated whole blood by  density 
gradient centrifugation in a ficoll-400/sodium metrizoate solution of density 1.077g.cm-3, with 
the PBMCs floating at the interface.
3.7.1.1 PBMC preparation procedure
Briefly, the fresh whole blood was supplemented with heparin at a concentration of 
1unit/ml of blood. The heparinised blood was then diluted with serum free RPMI at a ratio of 
1:1. After that, 7 ml of Lympholyte-H was layered under 10 ml of diluted blood followed by 
centrifugation at 800g  at room temperature for 20 minutes with the brake off. The interfacial 
cells were collected and transferred into a new universal tube (Figure 3.11). The cells were 
washed twice in serum free RPMI by centrifugation at 600g for 10 minutes at room temperature. 
The cells were then resuspended in complete RPMI at 1 x 106cells/ml for experiments.
Figure 3.6 Peripheral mononuclear cells preparation
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3.7.2 Thymidine incorporation assay
The  amount of  DNA in a cell must double  prior  to mitotic  division. This process 
involves the systhesis of new DNA which provides a route to the quantification of cell 
division within a  population of  cells in a  culture. Thymidine  is a  nucleoside  which is 
incorporated specifically into DNA. If an excess of thymidine, which has been labelled with a 
radioactive isotope (typically tritium), is provided in the cell culture medium, this isotope will 
be incorporated during DNA synthesis. Subsequent detection of the decay of this isotope in 
DNA, which has been isolated from the cells, provides a signal which is proportional to the rate 
of cell proliferation.
3.7.2.1 Thymidine incorporation assay procedure
Safety rules for working with radioisotopes include wearing protective clothes, the use 
of suitable shielding materials while handling the radioisotope, monitoring  contamination 
before and after experiments, disposing of radioactive waste appropriately and recording used 
radioisotopes in a log book. These rules were obeyed throughout this work. 1μCi (37 kBq) of 
3H-thymidine was added to each well of stimulated-PBMCs in a 96-well plate and incubated 
for 6 hours in a humidified 5% CO2  incubator at 37ºC for 6 hours. The 3H-thymidine- 
exposed cells were harvested by filtration onto the glass fibre filter. Following drying in an 
oven (60°C/4 hours), the filter was placed in a plastic bag  with β scintillation fluid and 
analysed in a β scintillation counter. Data were recorded as counts per minute (cpm).
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3.8 Results
3.8.1 Morphological changes in HKC-8 cells after exposure to TGF-β1
One  of  the  key  characteristics  of  EMT  is  morphological  changes  from  epithelial 
cobblestone-like to fibroblast-like appearance. Since TGF-β1 is recognised as a key mediator of 
EMT, treatment of renal epithelial cells with TGF-β1 might result to changes of renal epithelial 
morphology.
Initially, the features of EMT were examined in the HKC-8 cell line following TGF-β1 
treatment. HKC-8 cells were grown in 25 cm2  tissue culture flasks until they reached 80% 
confluence. Then these s e m i - confluent cells were incubated with 5ng/ml of TGF-β1 for 72 
hours. The morphology of cells was viewed by inverted microscopy. 
Normally, like other epithelial cells, HKC-8 appeared as a single layer of cube-like cells 
with large spherical  nuclei (Figure 3.7A).   Changes in morphology became apparent after 48 
hours. However,  the epithelial cells were strikingly transformed to elongated spindle-shaped 
cells following 72  hours  of  TGF-β1 treatment (Figure 3.7B).  This  suggests  that  TGF-β1 
induces reorganization of the epithelial cell’s cytoskeleton.
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Figure 3.7 Morphological manifestations of renal tubular epithelial cells following TGF-
β1 treatment.
The light microscopic analysis of the morphology of HKC-8 incubated in complete medium 
or medium containing TGF-β1 at a final concentration 5ng/ml for 72 hours. The normal cells 
(A) exhibited the  cobblestone-like  appearance, whereas the cells with TGF-β1 treatment (B) 
adopted a bipolar morphology. The images were taken at x 200 magnification. The results are 
representative of 2 similar experiments.
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3.8.2 TGF-β1 disrupted cell-cell adhesion between renal epithelial cells
Cell junctions are a specific characteristic of epithelial cells. These structures consist of 
protein complexes, especially E-cadherin, which maintains cell-cell contact and epithelial cell 
polarity (section 1.3.2). It has been suggested that loss of epithelial adhesion molecule is an 
early sign of EMT development (Aresu et al., 2008). Therefore, E-cadherin expression might be 
reduced following TGF-β1 treatment. In this  experiment,  cells were grown on 0.1%gelatin-
coated slides in order to increase the attachment between epithelial cells and the surface of the 
slides.  Gelatin,  which  mainly consists  of  hydrolysed  collagen type  I,  is  commonly used  to 
enhance cell attachment during in vitro study. It has been shown that gelatine has no effect on 
epithelial monolayer and tight junction molecule expression (Zhang et al., 2009). 
1  x 105 HKC-8 cells were seeded  onto 0.1% gelatine-coated chamber slides until 
semi-confluence was reached.  TGF-β1 was then  added  at the concentration  5ng/ml and 
incubated with HKC-8 cells for 72 hours. After washing, the cells were fixed in cold acetone 
at -20˚C for 10 minutes, and the slides were a i r - dried. Non-specific antibody binding was 
blocked by incubating with 1%BSA/PBS for 1 hour. Subsequently, the cells were incubated 
with mouse monoclonal anti-E-cadherin antibody (clone Ber-ACT8) for 1 hour, followed by 
FITC-conjugated monoclonal anti-mouse IgG antibody for  1 hour; control sections were 
incubated with secondary  antibody only. The slides were viewed by  confocal microscopy at 
times 63 magnifications. 
Most of normal renal tubular epithelial cells contacted each other and formed typical 
cobblestone-like  islands.  The  linear staining  pattern of E-cadherin was  apparent  along the 
points of cell-cell contact (Figure 3.8A). In contrast, with TGF-β1 treatment, the cells became 
scattered with  no expression of  E-cadherin on the  cell  membranes.  In  addition,  E-cadherin 
molecules seemed to move from the cell surface into the cytoplasm of treated cells  (Figure 
3.8B). 
Figure  3.8 Confocal immunofluorescence analysis of E-Cadherin expression in renal 
tubular cells.
Semi-confluent   HKC-8   cells   were  incubated   in   complete   medium   (A)   or   medium 
containing  5ng/ml of  TGF-β1 for 72 hours (B). In normal cells, the  E-cadherin was 
predominantly localized   at   cell-cell   junction   (Green).   After   TGF-β1   treatment,   E-
cadherin    almost  disappeared from the cell junction. Nuclei were visualized by  4’, 6-
diamidino-2-phenylindole DAPI stain (Blue). The images were taken at x63 magnification. 
The results are the representative of 3 similar experiments.
3.8.3 TGF-β1-induced de novo expression of mesenchymal markers
Another feature of EMT is de novo expression of mesenchymal markers. It is accepted 
that  S100A4/FSP-1  and α-SMA are markers for  fibroblast  and myofibroblast  respectively 
(Vongwiwatana et al., 2005).   Other cell types can express S100A4 such as macrophage and 
leukocytes (Le Hir, et al. 2005). However, S100A4 appears as a marker of cells in fibrogenesis, 
at  least  in  epithelial  cells  undergoing  EMT because S100A4 expression precedes  complete 
EMT (Okada et al., 1997), transfection of S100A4 in tubular epithelium results in conversion 
to mesenchymal phenotypes (Strutz et al., 1995) and siRNA S100A4 reduces fibrosis (Okada 
et al., 1997). Since there were only renal tubular epithelial cells present in this experiment, thus 
S100A4 was chosen as one of the markers of mesenchymal cells.
HKC-8 cells were grown in chamber slides until semi-confluence (70-80% confluence) 
was reached. They were then incubated with 5ng/ml of TGF-β1 for 72 hours. The expression of 
S100A4 and α-SMA were detected by microscopic examination after immunofluorescence 
staining. Cells were  stained with polyclonal rabbit anti-human S100A4 antibody  and 
monoclonal mouse anti-human α-SMA (clone 1A4)  antibodies and their  appearance was 
visualised by confocal microscopy and compared with non-treated control cells. 
S100A4 expression appeared at a low level in the cytoplasm of normal HKC-8 cells 
while α-SMA expression was absent.  Following TGF-β1 treatment,  S100A4 expression was 
generally increased in cytoplasm of HKC-8 cells (figure 3.9). However, α-SMA was present as 
microfilament-like structures in only a proportion of the cells (figure 3.10). 
This  study observed  a  different  pattern  of  S100A4 and α-SMA expression  by renal 
epithelial cells. S100A4 was generalized present by nearly all HKC-8 cells, while α-SMA was 
expressed  by  some  HKC-8  cells.  This  probably  suggested  that  some  S100A4-positive 
fibroblasts were transformed into a reversible activated state. However, it was clear that TGF-β1 
was able to induce both S100A4 and α-SMA expression in renal tubular epithelial cells.
Figure  3.9 Microscopic immunofluorescence analysis of S100A4 expression in  renal 
tubular epithelial cells.
Semi-confluent   HKC-8   cells   were  incubated   in   complete   medium   (A)   or   medium 
containing 5ng/ml of TGF-β1 for 72 hours (B). The S100A4 was faintly appeared in cytoplasm 
of normal cells (Dark green). However, the significant expression of S100A4 was observed in 
TGF-β1 treated cells (Bright green). Nuclei were visualized by DAPI stain (Blue). The images 
were taken at x63 magnification. The results are the representative of 3 similar experiments.
Figure 3.10 Microscopic immunofluorescence analysis  of α-SMA expression in renal 
tubular epithelial cells.
Semi-confluent   HKC-8   cells   were  incubated   in   complete   medium   (A)   or   medium 
containing 5ng/ml of TGF-β1 for 72 hours (B). There was no α-SMA expression observed 
in normal cells. However, the microfilamentous bundles of α-SMA were expressed after TGF-
β1 treatment. Nuclei were visualized by DAPI stain (Blue). The images were taken at x 63 
magnification. The results are the representative of 2 similar experiments.
3.8.4 The effect of TGF-β1 on E-cadherin expression by Western blot.
This  experiment  was  performed in  order  to  confirm that  E-cadherin  expression  was 
reduced in the presence of TGF- β1. Semi-confluent HKC-8 cells were incubated with 5ng/ml 
of  TGF-β1  for  72  hours  before  performing  protein  lysis  (section  2.6.1).  The  E-cadherin 
expression was detected by Western blot analysis and compared to control cells. Equal protein 
loading was demonstrated by probing for the expression of the 50kDa housekeeping protein, α-
tubulin. 
The western blot showed a single band of E-cadherin protein in normal HKC-8 cells. 
However, following TGF-β1 treatment, the 120kDa E-cadherin band was less dense compared 
to the one of normal cells (Figure 3.11). This confirmed that TGF-β1 could induce the loss of 
this epithelial cell marker, one of key features of EMT
Figure 3.11 Comparison of E-cadherin expression between normal cells and TGF-β1-
treated cells by Western Blotting.
Western blot analysis demonstrated that normal HKC-8 cells expressed  the  E-cadherin (lane 
A); however this adhesion protein was reduced in the presence of TGF-β1 5ng/ml for 72 
hours (lane B). Equal loading between the lanes was validated by the detection of α-tubulin. 
These results are representative of 2 similar experiments.
3.8.5 The mitogenic response of PBMCs to Muromonab-CD3 (OKT3) and 
Cyclosporine
Before  starting  experiments  with  Cyclosporine,  the  immunosuppressive  effect  of 
Cyclosporine was examine by 3H-Thymidine incorporation assay to demonstrate the activity of 
the drug. 
OKT3 is a murine monoclonal antibody that specifically reacts with the T cell receptor-
CD3 complex on the surface of T cells.  Human T cells are activated by interaction with plate-
bound OKT3, leading to mitogenic T cell proliferation. 
This study was performed in 2 stages.  Firstly, a mitogenic concentration of OKT3 was 
defined by measurement of the proliferative response of treated human T cells.  Secondly, the 
concentration of Cyclosporin required to inhibit this mitogenic response was measured.
PBMCs were isolated from human whole blood and then incubated with OKT3 at a 
concentration ranging from 0-10µg/ml for 72 hours. T cell proliferation was then measured by 
quantification of 3H-thymidine incorporation. Stimulation of PBMC with OKT3 induced a 
marked proliferative response (Figure 3.12). It was clearly seen that OKT3 at 10ng/ml could 
induce proliferation of PBMCs; however, this study chose OKT3 at concentration 20ng/ml for 
induction of PBMC proliferation because it is a widely recommended concentration (Lee and 
Molinaro, 2003).
Next, PBMCs were incubated with 20ng/ml of OKT3 in the presence of a range of 
concentrations of Cyclosporine for 72 hours followed by  application  of  the 3H-thymidine 
incorporation assay protocol (section 3.8.2). Cyclosporine was able  to inhibit OKT3-induced 
PBMC proliferation  with an IC50  value of  between 0.01 and 0.1ng/ml (Figure  3.13). In 
addition, the maximal inhibition of T cell proliferation was at a concentration  above 1μg/ml. 
However,  Cyclosporine at  a concentration 5µg/ml was used in further experiments on the 
basis of results from a previous study (McMorrow et al., 2005).
Figure 3.12 3H-Thymidine incorporation analysis of the mitogenic response of T cells to 
OKT3.
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood followed by 
incubating with OKT3 20ng/ml for 72 hours. The stimulated leukocytes were incubated with 
3H-Thymidine for 6 hours before counting radioactivity. The plots show mean results, the 
error bars represent the SEM. These results are from one of 2 similar experiments.
Figure 3.13 3H-Thymidine incorporation analysis showing  suppression of the mitogenic 
response of T cells by Cyclosporine.
Peripheral blood mononuclear cells were isolated from human whole blood and followed by 
incubating with OKT3 at an optimal 20ng/ml in the presence of different concentrations of 
Cyclosporine for 72 hours. The stimulated leukocytes were incubated with 3H-Thymidine for 6 
hours before counting the radioactivity. The plots show mean results and the error bars are 
the SEM. The results are representative of 2 similar experiments.
3.8.6 Effect of Cyclosporine on renal epithelial cell proliferation.
The  effect  of  Cyclosporine  on  proliferation  of  renal  tubular  epithelial  cells  was 
investigated by counting cells in culture. Briefly, 2x104 of HKC-8 cells were grown in a 12-well 
plate until 80% confluence was reached. Then, the cells were incubated with Cyclosporine at a 
concentration of 10ng/ml, 100ng/ml, 1μg/ml and 5μg/ml. Control cells were grown in medium 
and a medium containing  0.1% ethanol (vehicle control, VC).  Cells were harvested in 
trypsin/EDTA and directly counted using a haemocytometer at 0, 24, 48 and 72 hours  after 
Cyclosporine treatment. 
Cyclosporine  had  no  effect  on  growth  and  proliferation  of  HKC-8  cells  at 
concentration less than 5μg/ml. However, Cyclosporine at concentration 5µg/ml inhibited the 
proliferation of HKC-8 cells at 48 and 72 hours after treatment (Figure 3.14). It was clear that 
the suppressive effect  on renal  tubular  epithelial  cells  required a  very high concentration of 
Cyclosporine compared to immune cells. The proliferative capacity of epithelial cells seemed to 
be  calcineurin-independent  since  the  immunosuppressive  activity  was  much  lower  around 
0.05ng/ml  (Figure 3.13).  Normally,  the therapeutic  level  of  Cyclosporine used in  humans is 
approximately 200ng/ml in whole blood. This observation suggested that the suppressive effect 
of Cyclosporine on the proliferation of non-lymphocytic  cells,  renal  tubular  cells  was  much 
higher than the human blood Cyclosporine level.  However,  this  study does not exclude the 
possibility that  in vivo tissue hypoxia due to renal vasoconstriction might be responsible for 
tubular cell death during chronic Cyclosporine nephrotoxicity despite at the lower concentration 
than those in this study.
Figure 3.14 Bar graph illustrating the  effect of Cyclosporine on renal tubular  epithelial 
cells proliferation.
Semi-confluent HKC-8 cells were grown in complete medium or medium containing with 
0.1%  ethanol  and Cyclosporine at the final concentration of 10ng/ml, 100ng/ml, 1ug/ml and 
5ug/ml. Viable control and stimulated cells were counted using a haemocytometer after 0, 
24, 48 and 72 hours. The maximum concentration of Cyclosporine significantly suppressed 
cells proliferation at 48 and 72 hours (* = p < 0.05, ** = p < 0.01).  The bars show mean 
results and the error bars  show  the  SEM.  These results  are representative of 2  similar 
experiments.
3.8.7 Effect of Cyclosporine on renal epithelial cells viability.
The  cytotoxicity  of  Cyclosporine  on  renal  tubular  epithelial  cells was assessed by 
propidium iodide (PI) staining  using  flow cytometric analysis. Confluent HKC-8 cells were 
incubated with 0.1% ethanol and Cyclosporine at a concentration of 10ng/ml, 100ng/ml, 1μg/ml 
and 5μg/ml for 72 hours. Control cells were grown in complete medium. The treated cells were 
harvested by a non-enzymatic method and stained with PI for 15 minutes.  The stained cells were 
immediately verified by flow cytometry (FL-2 channel). The quadrants were set using unstained 
cell samples andwere then applied for all conditions. 
Cells in left upper quadrant represented dead cells, most likely necrotic cells, while cells in 
the right lower quadrant were mainly viable cells. In normal condition, approximately 88% of 
HKC-8 cells were alive and 5% were dead after 72 hours culture. The proportion of dead cells was 
not different among normal, vehicle control and Cyclosporine-treated cells (Figure 3.15). 
However, some dead cells might have been lost during the centrifugation step of the cell 
harvesting process; results from this assay might be underestimated. The alternative studies such 
LDH cytotoxic assay and apoptosis assay probably are required to support this experiment.
Figure 3.15 The effect of Cyclosporine on renal tubular epithelial cells viability.
HKC-8 cells were incubated with the medium (a) or medium in the presence of 0.1% ethanol 
(b) or Cyclosporine at the concentration of 10ng/ml (c), 100ng/ml (d), 1µg/ml (e) and 5µg/ml 
(f) for 72 hours. The stimulated cells were then incubated with PI before analyzing by flow 
cytometry.  Panel  A  shows  a  density plot  indicating  the  viability of  HKC-8  in  the  FL2 
channel. Panel B shows a bar graph illustrating the percentage of HKC-8 dead cells. The bars 
are the mean results and the error bars are the SEM. These results are from a single experiment.
3.8.8 Morphological changes following Cyclosporine treatment
A change in the morphology of epithelial cells is often used as a defining feature of 
EMT (Liu et al., 2004). This study (section 3.9.1) has already shown that HKC-8 cells adopt 
morphology typical of fibroblasts following TGF-β1 treatment. A further study was performed 
to  examine  any  change  in  the  morphology  of  these  cells  following  treatment  with 
Cyclosporine. 
Semi-confluent  HKC-8  cells  were  grown  in  medium  or  medium  containing 
Cyclosporine at a concentration of 5µg/ml for 72 hours. The morphology of the HKC-8 cells 
was then examined under an inverted microscope.
Cells  cultured  in  basal  medium  showed  typical  cobblestone  morphology  (Figure 
3.16A). Cells cultured in medium containing Cyclosporine for 72 hours showed an elongated 
spindle-like  morphology  (Figure  3.16B).  This  suggests  that,  in  vitro,  a  fibroblast-like 
morphology  could  be  induced  in  renal  tubular  epithelial  cells  following  Cyclosporine 
treatment.  The  morphological  changes  produced  by  Cyclosporine  were  similar  to  those 
induced by TGF-β1, indicating that Cyclosporine-induced morphological changes might be 
produced by TGF-β1.
Figure  3.16  Morphology  of  renal  tubular  epithelial  cells  following  Cyclosporine 
treatment.
The light microscopic analysis of the morphology of HKC-8 incubated in complete medium 
or medium containing Cyclosporine at a final concentration 5µg/ml for 72 hours. The normal 
cells (A) exhibited  the  cobblestone-like  appearance, whereas the cells with Cyclosporine 
treatment  adopted an elongated spindle-shaped  morphology (B). The images were taken at x 
200 magnification. The results are representative of 2 similar experiments.
3.8.9  Effect  of  Cyclosporine on  adherent  molecule  expression  in  renal 
epithelial cells
It  has  already  been  demonstrated  that  E-cadherin, one of the main components 
constituting an adherent junction in epithelial cells, was disrupted by treatment with TGF-β1. 
Cyclosporine might have a similar effect on epithelial cells as TGF-β1. Therefore, the effect 
of  Cyclosporine on E-cadherin expression was determined using microscopic 
immunofluorescence techniques. 
Semi-confluent HKC-8 cells were incubated with Cyclosporine at concentrations of 
10ng/ml, 100ng/ml, 1μg/ml and 5μg/ml for 72 hours in chamber slides. Control and vehicle-
treated control cells were grown in medium or medium containing 0.1% ethanol respectively. 
Then, cells were stained with monoclonal mouse anti-E-cadherin antibody, followed by  anti-
mouse IgG FITC conjugated antibody (for detail of method see 2.5.1.4). E-cadherin expression 
(green fluorescence) was detected by confocal microscopy at 63 times magnification. 
In normal HKC-8 cells, the typical linear pattern of E-cadherin was present at cell-cell 
junctions within confluent islands of epithelial cells (Figure 3.17A). In the presence of ethanol 
and Cyclosporine concentration less than 1µg/ml, the expression of E-cadherin was not different 
compared to control cells. However, treatment HKC-8 cells with Cyclosporine at concentrations 
of  1  and 5µg/ml  clearly  reduced E-cadherin  expression  (Figure  3.17 E-F).  In  addition,  the 
immunofluorescence intensity was quantitatively measured using Leica confocal software and 
showed a significant reduction of E-cadherin expression by cells treated with 1 and 5µg/ml of 
Cyclosporine (Figure 3.17G).  Although loss  of  E-cadherin is  an important  characteristic  of 
EMT, it has been suggested that this is not necessarily followed by a change to a fibroblast 
phenotype (Veerasamy et al., 2009). Therefore, further experiments were performed to identify 
fibroblast marker expression by Cyclosporine-treated cells.
Figure 3.17 The expression of E-cadherin in renal tubular epithelial cells after 
Cyclosporine treatment.
The representative micrographic immunofluorescence analysis of E-caherin (Green) expression 
in HKC-8 cells incubated in normal medium (A) with 0.1% ethanol (B)  or Cyclosporinet the 
concentration of 10ng/ml (C), 100ng/ml (D), 1µg/ml (E) and 5µg/ml  (F)  for 72  hours.  The 
images were taken at x63 magnification.  A bar graph (G) illustrating the immunofluorescence 
intensity of E-cadherin which was highly expressed in normal cells and significantly declined 
in the presence of Cyclosporinet 5µg/ml. The bars are the mean results and the error bars are 
the SEM. These results are representative of 2 similar experiments.
3.8.10 Effect of Cyclosporine on de novo mesenchymal marker expression.
Acquisition of fibroblast phenotypes is one of the characteristics of EMT. The  next 
experiment was performed to determine whether Cyclosporine could change the phenotype of 
epithelial cells. Confluent HKC-8 cells were incubated with Cyclosporine at a concentration of 
10ng/ml, 100ng/ml, 1μg/ml and 5μg/ml for 72 hours. Further cells were incubated with control 
and vehicle control  media. Cells then were stained with rabbit monoclonal anti-S100A4, 
followed  by  anti-rabbit IgG FITC conjugated antibodies. The expression of S100A4 was 
visualised by confocal microscopy at x63 magnification. 
Untreated HKC-8 cells showed slightly increased expression of cytoplasmic  S100A4 
similar to cells in the vehicle control (Figure 3.18A-B). The diffuse cytoplasmic expression of 
S100A4 increased when cells were treated with Cyclosporine. The level of S100A4 expression 
was dose-dependent and reached a maximum level at a Cyclosporine concentration of 1μg/ml. 
Surprisingly, however, S100A4 expression was reduced when cells were treated with 5μg/ml 
Cyclosporine. 
It  was  not  clear  why  the  expression  of  S100A4  markedly  reduced  at  Cyclosporine 
concentration  5µg/ml.  However,  this  might  be  involved  with  the  time-course  of  protein 
expression,  post-translation  processing,  intra-individual/  inter-culture  variability  and  the 
inhibition of cell proliferation.
Figure 3.18 The expression of S100A4 in renal tubular epithelial cells after Cyclosporine 
treatment.  
The   representative   micrographic   immunofluorescence   analysis   of   S100A4 (Green) 
expression  in  HKC-8  cells  incubated  in  normal  medium  (A) with 0.1% ethanol  (B) or 
Cyclosporine at a concentration of 10ng/ml (C), 100ng/ml (D), 1µg/ml (E) and 5µg/ml (F) for 
72 hours. The images were taken at x63 magnification. (G) is a bar graph illustrating the 
immunofluorescence intensity  of S100A4.  The bars show the mean results and the error bars 
are the SEM. (*** = p < 0.001). The results are representative of 3 similar experiments.
3.8.11 SB-505124 partially prevented the loss of E-cadherin expression after 
Cyclosporine treatment
Cyclosporine was able to induce loss of E-cadherin expression.  A similar result was 
observed for TGF-β1-treated cells. Therefore, it might be possible that Cyclosporine reduces 
E-cadherin expression as a consequence of  activation of the TGF-β1 receptor.  Functions  of 
TGF-β require  activation  of  TGF-β receptors  including  TGFβRI  and  TGFβRII  (Section 
1.9.2). In order to determine an association between Cyclosporine and TGF-β1, a selective 
inhibitor of the TGF-β type I receptor (SB-505124; ALK5 inhibitor), was added together with 
Cyclosporine. Confluent HKC-8 cells were incubated with 5μg/ml of Cyclosporine with or 
without 1 - h o u r  pre-treatment with 1μM of SB-505124 (see section 2.7.2) for 72 hours. E-
cadherin expression was assessed by microscopic immunofluorescence staining and visualised 
by confocal microscopy at x63 magnification. 
E-cadherin expression almost completely  disappeared following 72  hours  of 
Cyclosporine treatment;  this loss  was par t ia l ly  prevented  by SB-505124 treatment 
(Figure 3.19C). Quantitative analysis of E-cadherin expression i n  t he  p r e s en ce  o f  S B -
5 05 12 4  also showed significantly greater expression compared to drug-treated cells without 
the TGF-β type I receptor inhibitor (Figure 3.19D).
It  is  clear  that  pre-treatment with  the TGF-β type I receptor inhibitor partially 
attenuated the loss of E-cadherin expression, suggesting that Cyclosporine-induced loss of E-
cadherin expression might be mediated by the TGF-β signalling pathway.
Figure 3.19 The preventive  effect of ALK5 inhibitor  (SB-505124) on E-cadherin 
expression after Cyclosporine treatment
The  representative  micrographic  immunofluorescence  analysis of  E-cadherin  expression 
(Green) in HKC-8 cells incubated with medium (A) or medium containing Cyclosporine 
5µg/ml in the absence (B) or presence of SB-505124 pre-treatment (C). The images were taken 
at x63 magnification. (D) The bar graph illustrating the mean fluorescence intensity of E-
cadherin which was significantly  reduced after Cyclosporine treatment. However this effect 
could be significantly prevented by pre-treatment with SB-505124. The bars show mean 
results and  the error bars are the SEM. The results are representative of 3 similar 
experiments. (* = p < 0.05 compared to control and # = p < 0.05 compared to Cyclosporine, 
ANOVA).
3.8.12 Pre-treatment  with SB-505124 failed to reduce  S100A4 expression 
after Cyclosporine treatment.
This study has been shown that S100A4 expression was induced by both Cyclosporine 
and  TGF-β1  treatment.  In  this  experiment  confluent HKC-8 cells were treated with 
Cyclosporine 5μg/ml for 72 hours with or without 1  h o u r  o f  pre-treatment with 1μM of 
SB-505124. S100A4 expression was detected by immunofluorescence staining  and visualised 
by confocal microscopy at x63 magnification. 
Cyclosporine-treated cells  obviously up-regulated  S100A4  expression  compared  to 
untreated cells (Figure 3.20A-B). However, pre-treatment with ALK5 inhibitor before adding 
Cyclosporine  had  no  effect  on  this  S100A4  induction  (Figure  3.20C).  In  addition,  the 
quantitative  measurement of mean fluorescence intensity  showed a significantly  increased 
expression of  S100A4 in both the Cyclosporine  and ALK5  inhibitor pre-treatment group 
(Figure 3.20D). 
Although the  ALK5 inhibitor was able to partially  prevent the loss of E-cadherin 
produced  by  Cyclosporine, a  similar effect on  S100A4  expression was not  observed.  This 
suggests that induction of S100A4 expression does not require the activation of TGFβRI. 
Figure   3.20  The   preventive   effect   of   SB-505124   on   S100A4   expression   after 
Cyclosporine treatment
The representative immunofluorescence analysis of S100A4 expression (Green) in HKC-8 cells 
incubated with medium (A) or medium containing Cyclosporine 5µg/ml in the absence (B) or 
presence of 1µM of SB-505124 pretreatment (C). The images were taken at x60 magnification. 
(D)  shows  the  bar  graph  illustrating  the  mean  fluorescence  intensity  of S100A4 which 
was significantly increased after Cyclosporine treatment. There was no protective effect of 
SB-505124 on S100A4 expression. The bars are mean results and the error bars are the SEM. 
The results are representative of 2 similar experiments. (** = p < 0.01 compared to  control, 
ANOVA).
3.8.13 The expression of S100A4 gene in HKC-8 cells following Cyclosporine 
and TGF-β1 treatment
This study demonstrated the expression of S100A4 protein by HKC-8 following both 
TGF-β1  and  Cyclosporine  treatment.  This  experiment  was  performed  to  investigate  the 
expression of S100A4 in molecular level by the quantitative real-time PCR.
Semi-confluent HKC-8 cells were incubated with 5µg/ml of Cyclosporine. The control 
samples were non-treated HKC-8 cells, while the positive control were cells treated with 5ng/ml 
of TGF-β1.  The treatment  period  was  24 hours  in all groups. GAPDH was used as an 
endogenous housekeeping gene to normalise mRNA levels between samples (Section 2.4.4). 
Real-time PCR showed that  TGF-β1 treated cells significantly up-regulated S100A4 
mRNA level.  However, treatment  HKC-8  cells  with  Cyclosporine  did not show any 
difference of  S100A4  mRNA expression  compared to the  untreated  HKC-8 cells (Figure 
3.21). 
This  study  showed  that  the  high  level  expression  of  S100A4  protein  produced  by 
treatment with Cyclosporin A did not correlate well with changes in at the mRNA level. This 
suggests the involvement of post translational regulation. 
Figure 3.21 The expression of S100A4 mRNA after Cyclosporine and TGF-β1 treatment.
Confluent HKC-8 cells were grown in medium or medium containing 5µg/ml of 
Cyclosporine or  5ng/ml of TGF-β1 for 24 hours. The S100A4 mRNA level  was 
normalized to GAPDH mRNA and was presented as mean ± SEM (n=3). The S100A4 mRNA 
was significantly up- regulated in TGF-β1 treatment group, in contrast to the Cyclosporine 
treatment group which showed similar S100A4 gene level compared to control. The results 
are representative of 3 similar experiments. (** = p < 0.01 compared to control, ANOVA)
3.8.14 TGF-β1 expression by three different renal tubular epithelial cell lines 
following Cyclosporine and TGF-β1 treatment
This  study was performed to  determine  whether  treatment  of  3  renal  cell  lines  with 
Cyclosporine increases expression of the TGF-β1 gene.
Semi-confluent HKC-8, HK-2 and HRCE (section  2.2.3) were  incubated  in medium 
alone or medium containing 5μg/ml of Cyclosporine or 5ng/ml of TGF-β1 for 24 hours. RNA 
was extracted from stimulated renal epithelial cells and DNA was synthesised. GAPDH was used 
as a control housekeeping gene. 
The TGF-β1 gene was significantly up-regulated in all TGF-β1 treated cells. However 
none of the Cyclosporine treated cells increased TGF-β1mRNA expression compared to the 
untreated cells (Figure 3.22). These results probably suggested that TGF-β1 did not mediate the 
transformation of epithelial cells but either other TGF-β subtype or other mediators might play a 
role in Cyclosporine-induced EMT in this cell model.
Figure 3.22 The comparison of real-time PCR analysis of the TGF-β1 mRNA expression 
among three different renal epithelial cell lines.
The semi-confluent HK-2, HKC-8 and HRCE cells were incubated in medium and medium 
containing 5µg/ml of Cyclosporine or 5ng/ml of TGF-β1 for 24 hours. The TGF-β1 mRNA was 
normalized to GAPDH mRNA and was presented as mean ± SEM (n=3). The TGF-β1 gene 
was significantly up-regulated after TGF-β1 treatment in all 3 cell lines. In contrast, there was 
no change of TGF-β1 mRNA level in Cyclosporine treatment group compared to control. The 
results are representative f 3 similar experiments. (*** = p < 0.001 compared to control)
3.8.15 The effect of Cyclosporine on active TGF-β1 protein production by 
renal epithelial cells
This study has shown that Cyclosporine is able to induce the loss of E-cadherin and 
increase  S100A4 expression by renal epithelial cell lines; similar results were also  obtained 
following TGF-β1 treatment. Therefore, it seems that Cyclosporine has a direct effect on renal 
tubular epithelial cells which might be mediated by TGF-β1. However, the generation of mRNA 
encoding TGF-β1 could not be demonstrated by real-time PCR. It is possible that Cyclosporine 
can alter the expression of other isoforms of TGF-β or the response to preformed TGF-β1 by 
activating the latent protein.  
The cell-based MFB-F11 assay is a TGF-β bioassay which has ability to measure all forms 
of active TGF-β. Normally, TGF-β is secreted in a latent form and needs to be activated before 
binding to a receptor. This study selected  heat as a latent TGF-β activator (section 1.10.1.2). 
Therefore, results from all experiments were shown as a comparison between non-activated and 
activated samples of each medium.
Initially, the basic TGF-β level was observed in complete medium, serum-free medium, 
0.1%  ethanol and 5μg/ml of Cyclosporine  as a baseline  control. Only  complete medium 
contained any TGF-β activity, which was probably derived from foetal bovine serum (Figure 
3.23). After that, the measurement of TGF-β in supernatant from Cyclosporine treated HKC-8 
cells  was  performed. Confluent HKC-8 cells were  incubated with  serum-free medium 
containing 0.1% ethanol and 5μg/ml of Cyclosporine for 72 hours, and then supernatant was 
collected and processed following protocol, by  being activated and further  incubated with 
confluent MFB-F11 cells for  48 hours. These reporter cells produced alkaline  phosphatase 
which was detected by using a luminometer measured at 405 nm. 
After activating by heat,  all  groups showed high level of TGF-β and there was no 
difference between the groups (Figure 3.24). T h i s  e x p e r i m e n t  showed that HKC-8 
cells could produce TGF-β and, interestingly, Cyclosporine did not enhance TGF-β secretion by 
renal tubular epithelial cells compared to the control.
Figure 3.23 Bioassay analysis of active TGF-β level of reagents in a cell free experiment.
Semi-confluent MFB-F11 cells were incubated in complete medium or serum free medium with 
or  without 0.1% ethanol or Cyclosporine 5µg/ml for  48 hours. Medium containing  serum 
showed significant higher level of TGF-β1 after activated at 80°C for 10 minutes. In contrast, 
there was   no   increase   of  active   TGF-β1   in   serum   free   medium,   the   vehicle   and 
Cyclosporine  after activation. The bars represent mean results (n=3) and the error bars means 
SEM. The results are representative of 3 similar experiments. (*** = p < 0.001)
Figure 3.24 Bioassay analysis of the bioactive TGF-β level in culture medium of renal 
tubular epithelial cells after Cyclosporine treatment.
Semi-confluent HKC-8 cells were  incubated in serum free medium with or without 0.1% 
ethanol  and Cyclosporine 5µg/ml for 72 hours. The supernatants were collected and an 
aliquot was activated by heat before incubating with MFBF-11 cells for 48 hours. The TGF-β1 
level was significantly  increased  in  all  3  groups  of  HKC-8  cells  (B).  However, there was 
no difference among them. The bars are mean results (n=3) and error bars are SEM. 
These results are representative of 3 similar experiments. (*** = p < 0.001)
3.8.16 Active TGF-β1 detection from the culture medium of Cyclosporine 
treated HKC-8 cells by ELISA
In order to support the findings from the TGF-β bioassay, the measurement of the 
TGF-β level was repeated  by using an ELISA kit (R&D  system). The ELISA kit  activates 
latent form of TGF-β by acidification method and detects all TGF-β isoforms including TGF-
β1, TGF-β2 and TGF-β3.
Semi-confluent HKC-8 cells were incubated with serum free medium with or without 
0.1% ethanol or 5μg/ml of Cyclosporine for 72 hours. The supernatant from treated cells was 
collected and processed following the instructions provided with the kit. The results showed no 
difference of active TGF-β level in the control, vehicle control and Cyclosporine (Figure 3.25). 
The findings from this study suggested that Cyclosporine could not induce HKC-8 to increase 
TGF-β production.
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Figure 3.25 ELISA assay analysis of active TGF-β1 level from supernatant of HKC-8 cells.
Confluent  HKC-8 cells  were incubated in  serum free medium and medium containing 0.1% 
ethanol or Cyclosporine 5µg/ml for 72 hours. The supernatants were collected and processed for 
ELISA. The ELISA showed no difference in TGF-β1 production in the presence of medium, 
0.1%ethanol and CsA. The bars are mean results (n=3) and error bars are SEM. The results are 
from a single experiment.
3.9 Summary and discussion
3.9.1 Results summary
EMT was induced in renal tubular epithelial cell lines by  TGF-β1, leading to 
morphological change, loss of the  cell-cell adhesion molecule, E-cadherin,  and de novo 
expression of mesenchymal phenotypes, S100A4 and α-SMA.
• An immunosuppressive concentration of Cyclosporine had no effect on the viability 
of renal tubular epithelial cells.
• A high concentration of Cyclosporine (5μg/ml) significantly suppressed renal tubular 
epithelial cell proliferation at 48 and 72 hours.
• Cyclosporine induced EMT-like changes in renal tubular epithelial cells, including the 
loss of E-cadherin expression and up-regulation of S100A4.
• The TGF-β1 receptor type I inhibitor, SB-505124 partially prevented E-cadherin 
disruption   by Cyclosporine.   However,   this   protective   effect   did not affect the expression 
of S100A4.
• S100A4 mRNA was significantly up-regulated after treatment with TGF-β1  while 
Cyclosporine did not change S100A4 mRNA expression compared to the control cells.
• Cyclosporine-treated cells did not up-regulate TGF-β1 mRNA expression in contrast to 
TGF-β1-treated cells which showed a significant up-regulation of the TGF-β1 gene.
• The  MFB-F11  bioassay  demonstrated  that  active  TGF-β  level was not strikingly 
increased in the supernatant from Cyclosporine treated renal tubular epithelial cells compared 
to untreated cells.
• An ELISA assay showed no significant  increase of active TGF-β level  in HKC-8 
culture medium following Cyclosporine treatment compare to untreated cells.
3.9.2 Discussion
Cyclosporine is a potent immunosuppressive drug which is widely  used in organ 
transplantation, producing greatly enhanced kidney allograft survival (Krönke et al., 1984). In 
addition, it is increasingly being introduced for the treatment of autoimmune diseases such a 
psoriasis  (Maza et  al.,  2011)  and rheumatoid  arthritis  (Migliore et  al.,  2010).  However,  the 
major  limiting factor in the use of Cyclosporine is chronic nephrotoxicity  which leads to 
irreversible renal  failure,  characterised  by extensive tubulointerstitial  fibrosis (Myers  et  al., 
1988).
It  has  been  demonstrated  that  EMT plays a significant role in TGF-β-mediated 
fibrosis (Iwano et al., 2002). Chronic cyclosporine nephrotoxicity induces a similar pathology 
(Slattery  et  al., 2005). In this study, it was  demonstrated that exposure to Cyclosporine 
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induced an EMT-like event in human proximal tubular cell lines. This study showed that the 
characteristics of EMT were present after treating HKC-8 cells with TGF-β1. These included 
(i) morphological change from cuboidal epithelial cells to e l o n g a t e d  spindle-shaped 
cells, (ii) decreased E-cadherin expression and (iii)  up-regulation of S100A4 expression by 
immunofluorescence staining. This  is consistent  with findings of previous studies (Yang and 
Liu, 2001).
The  immunosuppressive  potential  of  Cyclosporine  was  demonstrated  using  a  3H-
Thymidine  incorporation  assay.  The  IC50  of  Cyclosporine  was  approximately  0.05ng/ml. 
However, this might not reflect the optimal concentration to use in this study since it has been 
shown that renal fibrosis often associated with high blood level of Cyclosporine. Although the 
therapeutic level of Cyclosporine is approximately 200ng/ml, which is very low compared to 
the concentration used in this study, the metabolism of this drug in the human body and in vitro 
are  different.  This  study  followed  previous  studies  which  suggested  that  Cyclosporine  at 
concentration  5µg/ml  could  induce  EMT  in  the  proximal  renal  tubular  cell  line,  HK-2 
(McMorrow et al., 2005; Slattery et al., 2005). Therefore, most of the experiments in this study 
used Cyclosporine at 5µg/ml for determining the role of Cyclosporine in the induction of EMT 
in HKC-8 cells.
The effects of cyclosporine on the proliferation and viability of HKC-8 cells were also 
evaluated.  It  was shown that 5µg/ml of Cyclosporine suppressed  cell  proliferation after  48 
hours, whereas there was no effect on cell viability. This was in contrast to the previous study 
which showed no effect of 5µg/ml Cyclosporine to both proliferation and vitality on HK-2 
cells  (McMorrow  et  al.,  2005).  This  probably  resulted  from  the  different  cell  lines, 
although they were both derived from human proximal renal tubular cells. In addition, it 
has been reported that trans-activation of  p21 mediates the  arrest of the  cell cycle following 
Cyclosporine-induced p53  accumulation  (Lally  et  al., 1999). A previous study in human 
proximal tubular epithelial cells  (PTEC) suggested that cell death was observed using 
Cyclosporine at a concentration higher than 10μg/ml (Bakker et al., 2002). Since the highest 
concentration used in this study was 5μg/ml, this might explain why significant cell death was 
not observed.
E-cadherin is an epithelial cell specific intercellular adhesion molecule. Several studies 
have demonstrated that E-cadherin is an important determinant for maintenance of the epithelial 
p he no t yp e  (Zeisberg et al., 2003; Arias, 2001). Furthermore, the transition of an epithelial 
cell into a mesenchymal phenotype is shown  by  changes in the reciprocal  expression of E-
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cadherin and S100A4. E-cadherin expression gradually decreases while  S100A4 expression 
increases (Zeisberg et al., 2003). The current study showed decreased expression of E-cadherin 
protein following Cyclosporine treatment;  this was similar to the results produced by TGF-β1 
treatment. However, it has been demonstrated that loss of E-cadherin does not always lead to 
an acquisition of mesenchymal-like phenotypes (Veerasamy et al., 2009). Thus, demonstration 
of mesenchymal marker expression was essential to identify EMT.
S100A4 has been reported to be a marker for fibroblasts (Strutz et al., 1995) though it 
also can be expressed by several types of immune cells including monocytes, lymphocytes and 
macrophages. However,  renal  tubular  epithelial  cells  normally do  not  express  S100A4, 
thus S100A4 was used in this study model. In the HKC-8 cell line, the S100A4 protein was 
up-regulated following Cyclosporine treatment for 72 hours. However, this up-regulation was 
not seen at the  mRNA level,  whereas  TGF-β1-treated cells showed significantly increased 
S100A4 mRNA. In addition, this study showed that a different concentration of Cyclosporine 
showed different effect on S100A4 expression, for example Cyclosporine at 1µg/ml strongly 
induced S100A4 expression while Cyclosporine at 5µg/ml induced less intensity of S100A4 
expression. This might be explained by several mechanisms including (i) the variability of post-
translational  process  of  S100A4 protein;  (ii)  the  non-specificity  of  S100A4 as  a  fibroblast 
marker (Le Hir et al., 2005); (iii) the high concentration of Cyclosporine might have effect on 
proliferation of HKC-8 cells; and (iv) the time-course expression of low and high concentration 
of Cyclosporine might be different. 
S100A4 belongs to a family  of EF-hand calcium-binding proteins, which are well 
known to be multifunctional proteins. However the main function of S100A4 is enhanced cell 
migration and invasion (Schneider et al., 2008). The wide range of functions is due in part to 
the formation of various complexes both within and outside the cell. One such mechanism is 
heterodimerisation. Examples include  the  interaction between S100A4  and S100A1  from 
mouse mammary adenocarcinoma cell lines (Tarabykina  et  al., 2000), the heterodimer 
formation between S100B and S100A6 in human melanoma cell lines (Yang et al., 1999), and 
the association  between S100A8 and S100A9, which regulate  the adhesion of neutrophil 
(Newton and Hogg, 1998). In addition, a recent study of rheumatoid arthritis patients found the 
up-regulation of S100A4 in synovial fluid. Interestingly, this S100A4 was present in different 
conformational forms; however, the majority was a high molecular weight form (tetramer or 
higher) (Klingelhöfer et al.,  2007). Therefore, it is possible that a huge  amount of  S100A4 
expression from immunofluorescence staining was a complex form of S100A4 protein which is 
processed  through  various  post-translational modifications such  as phosphorylation, 
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deamidation,  glutathionylation or cysteinylation (Haugen  et  al., 2008). Furthermore, the 
S100A4 may  be  associated with other proteins such as tropomyosin, p37, p53, methionine 
aminopeptidase, liprinβ1, CCN3 and myosin heavy chain (Haugen et al., 2008). Analysis of the 
expression of mRNA encoding S100A4 by quantitative RT-PCR demonstrated constitutive 
high level expression of this sequence (with Ct  of 25), but this  did  not change following 
treatment of the cells with Cyclosporine. By  contrast, immunohistochemistry showed a  clear 
increase in the  expression of  S100A4 in the  cytoplasm of  cells. This discontinuity between 
mRNA and protein levels is consistent with post-transcriptional regulation of the expression of 
S100A4 which may be related to the increased stability of this protein after complex formation 
within the cell. A previous study has shown that a significant reduction in the mRNA encoding 
S100A4 mediated by  transfection with shRNA, resulted in  no significant change  in the 
expression of  macromolecular  S100A4 complexes (although the  expression  of monomeric 
S100A4 was reduced) (Rygiel et al., 2010).
TGF-β is a major inducer of EMT during development, carcinogenesis and fibrosis. 
TGF-β1 was first reported as an inducer of EMT in normal mammary  epithelial cells 
(Miettinen et al., 1994). Since then, TGF-β1 has been shown to mediate EMT in  vitro in a 
number of different epithelial cells, including renal proximal tubular cells (Fan et al., 1999). 
This study demonstrated that Cyclosporine treatment led to changes in cell morphology and E-
cadherin and  S100A4 protein expression similar to those produced by  TGF-β1 treatment. 
However, in the current study, when the TGFβRI was blocked with SB-505124, no change 
in S100A4 protein  expression was observed, though the reduction of expression  of  E-
cadherin protein was partially inhibited.  This  study did  not  demonstrate  the  effect  of  SB-
505124 on the expression of E-cadherin, S100A4 and α-SMA. This limitation made the results 
of the SB-505124 experiment hard to interpret. 
In  real-time  PCR, the  Cyclosporine  treated  PTEC did not express TGF-β1 mRNA, 
whereas TGF-β1 was significantly up-regulated in TGF-β1 treated cells. Furthermore, the 
level of active TGF-β was determined by both MFB-F11 bioassay and the ELISA method. 
These assays showed no significant level of active TGF-β in culture medium Cyclosporine-
treated PTEC. Although the effects of Cyclosporine were mediated in large parts via induction 
of TGF-β1, other studies could not confirm  the  mediation by  TGF-β1 (Strutz personal 
communication). It is possible that other mediators such as ILK (Integrin-link kinase) (Li et 
al., 2003)  and IGF-2 (Insulin growth factor-2)  (Arciniegas et al., 2006) may be involved in 
EMT induction.
54 | P a g e
There  are  other  studies  investigating  the  association  between  Cyclosporine  and 
EMT   in   renal  epithelial cells. However these studies typically use HK-2 proximal renal 
tubular cells which show similar characteristics to the HKC-8 cells used in the current study 
(Slattery et al., 2005; McMorrow et al., 2005). These previous studies showed that Cyclosporine 
at  a  concentration of  5μg/ml  was not toxic  to HK-2 cells. In  addition, treatment with this 
concentration of Cyclosporine led to a change in epithelial morphology which was supported 
by the rearrangement of F-actin and β-catenin. Furthermore, Cyclosporine induced a reduction 
in E-cadherin expression and the up-regulation of  α-  SMA,  TGF-β and CTGF mRNA 
expression. These changes were inhibited by pre-treatment with a TGF-β neutralising antibody 
(McMorrow  et  al., 2005), suggesting not only an important role  for TGF-β, but also the 
existence of TGF-β during  Cyclosporine-induced epithelial transformation.  However, an 
isotype-matched antibody control was not described in the paper; thus, the inhibitory effect of 
TGF-β neutralising antibody might be compromised. In contrast, TGF-β expression at mRNA 
and protein levels was not observed in the current study despite using a similar Cyclosporine 
concentration and treatment time. However, the current study  does support a role  for 
Cyclosporine-induced renal tubular epithelial transformation in vitro.
55 | P a g e
Chapter 4: A potential role for EMT in T cell-induced renal 
allograft fibrosis
Chapter 4: A potential role for EMT in T cell-induced renal 
allograft fibrosis
4.1   Introduction
The two most common causes of long-term renal allograft loss are death with 
functioning graft and chronic allograft dysfunction (CAD) (Cornell and Colvin, 2005). 
CAD  is  defined as  a functional and  morphological deterioration  of renal allograft 
function starting at least 3 months after transplantation (Safinia et al., 2010). The causes 
of CAD can be classified into immune dependent and non-immune dependent factors. 
An example of the latter is chronic CsA nephrotoxicity, which was discussed in chapter 
3. This chapter will focus on the impact of immune dependent factors, in particular the 
role of T cell-mediated CAD.
4.2  Fibrosis: a final common pathway for chronic renal  allograft 
dysfunction
The pathology of CAD is associated with fibrotic changes in the renal allograft, 
which include  global or segmental glomerulosclerosis, hyaline material deposition in 
small arteries or arterioles or interstitial fibrosis and tubular atrophy (IF/TA) (Solez et 
al., 2007). Graft fibrosis is a final common pathway which results from both immune 
and non-immune mediated graft injury. Previously, renal graft fibrosis was described as 
chronic allograft nephropathy (CAN). However, this term was misused as a diagnosis 
for graft fibrosis from all causes instead of defining the specific causes, and the term 
IF/TA is now used to describe fibrosis with unidentified causes (Solez et al., 2007).
4.2.1 The relationship between cellular rejection and graft fibrosis
It is clear that the incidence of acute rejection has progressively been reduced, 
in contrast to long-term graft survival which remains unchanged. Interestingly, several 
papers have  reported the potential impact of  acute rejection on CAD, despite the low 
rate of acute rejection (Nankivell et al., 2001; Meier-Kriesche et al., 2004; Khalkhali et 
al., 2010). This might be explained by the observation that renal function after rejection 
episodes does  not return to baseline after treatment (Meier-Kriesche  et  al., 2004). 
Additionally, in an era  of protocol biopsies, the histology  of subclinical rejection 
(SCR), which is characterized by tubulointerstitial mononuclear cell infiltration without 
concurrent functional deterioration (Sis et al., 2010), has been observed in the first 
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three weeks  after  transplantation  in 31% of normal function grafts (Krejčí  et  al., 
2011). Moreover, several papers have reported an association between the presence of 
SCR and chronic tubulointerstitial damage and development of IF/TA (Nankivell et 
al., 2001; Nankivell et al., 2004; Shishido et al., 2003). Graft survival rates with SCR 
were 88.4% and 62.3% at 1 year and 10 years respectively, whereas 1-year and 10-
year normal graft survival rates  were  97.9% and  96.2% (Choi  et  al.,  2005). 
Interestingly, true chronic rejection, defined by persistent SCR for 2 or more years, 
appeared in only 5.8% of patients (Nankivell  et  al.,  2004). Therefore, it remains 
possible that T cells are involved in renal allograft fibrosis.
4.2.1.1 Alloreactive CD8+T lymphocytes target renal tubular epithelial 
cells during acute T cell-mediated rejection
T cell-mediated rejection is characterised by interstitial infiltration by T cells 
(Sis et al., 2010). According to the Banff classification, diagnosis of T cell-mediated 
rejection (TCMR) is based on histological assessment of the infiltrate, including the 
presence  of lymphocytes in renal tubules (tubulitis),  the  interstitial area  or the 
subendothelial arteries or arterioles (endothelialitis) (Solez et al., 2007). The extent of 
inflammatory cell infiltration is used in the Banff system for diagnosing and grading the 
severity of rejection and, additionally, also correlates with graft function (Racusen et 
al., 1999).
In situ  hybridisation  has shown that CD8+ cytotoxic T lymphocytes (CTL) are 
the predominant infiltrating T cells in renal tubules during acute TCMR (Robertson et 
al., 1996). A subsequent study  has shown CD103 (the αEβ7 integrin) expression by 
approximately 60-70% of intratubular CD8+T cells (Hadley et  al., 1997); the αEβ7 
integrin is known to promote interactions between lymphocytes with epithelial cells 
(Hadley  et  al.,  1997).  This  integrin  was first  identified  in  human intraepithelial 
lymphocytes (IEL) in the gut (Cerf-Bensussan et al., 1987), but it is expressed by only 
about 2% of circulating T cells (Cerf-Bensussan et al., 1987).
It has been suggested that the αEβ7 integrin mediates adhesion of IEL to 
epithelial cells through the specific ligand, E-cadherin (Cepek et al., 1994). E-Cadherin 
is a tissue-restricted adhesion protein expressed specifically by many  epithelial cells 
(Corps et  al., 2003);  see section 1.3.2. The engagement of CD103 on CTL with E-
cadherin promotes cell lysis via cytotoxic  granule release.  Cytotoxic  granules released 
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from  CTL contain perforin and granzymes. Perforin forms pores in the cell 
membrane of the epithelium in order to allow granzymes entry into the cell, resulting in 
cell lysis (Halloran, 2010). A study of mouse kidney allografts has demonstrated the 
association between severe tubular deterioration and CD103+CTL. However this was 
not mediated by  αEβ7 integrin/E-cadherin adhesion or granzyme-perforin cytotoxic 
mechanisms but by a cell contact-independent mechanism related to delayed-type 
hypersensitivity and tubulitis (Einecke et al., 2006).
4.2.1.2   Interleukin (IL)-15 supports long-lived CD103+ CD8+ T cells
As described in section 4.1.2, a longitudinal study  has observed that 5.8% of 
subclinical rejection persisted in kidney grafts for 2 or more years (Nankivell et al., 
2004). A study of human kidney graft biopsy tissue has also shown that renal tubular 
epithelial cells up-regulate IL-15 expression from 10% at baseline to 35% during 
acute  rejection,  as  well  as  during  the  post  rejection  period  (Wong  et  al.,  2003). 
Furthermore, intratubular T cells co-expressed both CD8 and the α-chain of the  IL-15 
receptor during acute rejection (Wong et al., 2003). The basic functions of IL-15 are to 
activate and promote clonal T cell expansion and to suppress apoptotic T cell deletion 
(Robertson  et  al.,  2003). However, IL-15 alone cannot induce CD103+CD8+T cell 
differentiation,  which  requires TGF-β that is produced locally by renal tubular 
epithelial cells (Wong  et  al.,  2003). Therefore, synergy between IL-15 and TGF-β 
maintains the population of  intratubular CD103+CD8+ T cells after acute rejection. 
These cells might induce chronic IF/TA.
4.2.1.3 TGF-β links intraepithelial CD8+T cells and renal graft 
fibrosis
It is known that stressed renal tubular epithelial cells produce  a  range of 
cytokines, such as IL-6 and IL-1β, and chemokines including CCL-2, CCL-3, CCL-4, 
CCL-5, and in particular TGF-β (Robertson et al., 2004). This locally produced TGF-β 
has  an ability to induce CD103 expression by intratubular CD8+T cells during acute 
rejection. Data from our group also support TGF-β-induced CD103 expression in  
vitro (Figure 4.1). Furthermore, once acute rejection has subsided, synergy between 
TGF-β and IL-15 supports the long-term survival of a relatively quiescent memory 
CD8+T-cell population. A study of renal allograft tissue sections has shown that the 
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presence of intratubular CD8+T cells is commonly associated with S100A4-expressing 
renal tubular epithelial cells (Figure 4.2) (Robertson et al., 2004). Further in  vitro 
experiments have shown that a model intraepithelial T cell line  can directly induce 
tubular epithelial cells to undergo transformation to fibroblasts  and  myofibroblasts 
(Robertson et al., 2004). Currently, EMT is recognized as a potential mechanism for the 
pathogenesis of fibrogenesis in the kidney. It is clear that TGF-β is  essential for the 
development of bo th  C D 103 + T ce l l s  and  EMT.
Figure 4.1 Graph demonstrating the percentage of CD103-expressing T cells.
During allogenic MLR, fewer  than 8% of CD8+T cells and 2.5% of CD4+T cells 
expressed CD103. However, after TGF-β1 treatment, the proportion  of CD103 
expressing cells increased, with 52% of CD8+T cells expressing CD103; the 
proportion of CD4+ T cells expressing CD103 had also increased to 22%. This image is 
taken from Wong et al, 2003. 
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Figure 4.2 Co-localization of CD8+T cells (black) and S100A4-expressing (red) 
tubular epithelial cells during acute renal allograft rejection. The image is obtained 
from Robertson et al., 2004.
4.3   The co-expression of CD103 and LAP on the surface of T cells
CD103+CD8+T cells have been implicated in renal allograft destruction during 
acute rejection. However, in a rat liver transplantation study, CD103+CD8+  T  cells 
shared functions and mechanisms with regulatory T cells (Treg) (Lu et al., 2009). It 
has been demonstrated that the αEβ7 integrin was upregulated on CD8+  T cells after 
liver transplantation and these cells remained in the graft recipient for a long time (Lu et 
al., 2009). Moreover, an in vitro study has shown that TGF-β or alloantigen induce 
CD103+CD8+  Treg. In  addition,  the  immunoregulatory  activity  of  Treg was 
shown to be cell-cell contact dependent manner (Lu et al., 2009).
LAP (latency associated peptide) is cleaved from the N-terminal sequence of the 
precursor TGF-β protein by the action of furin proteases during  protein maturation 
(section  1.7.1).  An  in  vitro  study has  shown that  activated  CD4+CD25+ T cells  to 
produce both surface-bound and secreted TGF-β (Nakamura et al., 2001). It has been 
observed that regulatory T cells function by a cell-to-cell contact dependent mechanism 
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(Thornton and Shevach, 1998). The surface TGF-β may be  activated by molecules on 
the T cell surface or target cell surface, then the active TGF-β binds to its receptor 
for signal transduction and the induction of phenotypic differentiation.
A recent study  of SLE (systemic lupus erythematosus) patients with 
haematopoietic stem cell transplantation has reported an increase of  CD8+Foxp3+Treg 
post transplantation.  This CD8+  Treg showed more suppressive  effects than 
CD4+CD25+ T cells and highly expressed both CD103 and LAP (Zhang et al., 2009).
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4.4 Aim
Chronic cellular infiltration is one of the key factors in kidney allograft fibrosis. 
The origin of these fibroblasts remains unclear. However, EMT is one of the potential 
mechanisms for the fibrosis.
This study will define the potential of T cells to induce de-differentiation 
(EMT) of human renal tubular epithelial cells by:
• Demonstration that EMT can be induced in renal epithelial cell lines by human T 
cells.
• Demonstration that TGF-β signalling is associated with T cell-mediated EMT.
• Demonstration of the expression of CD103 and LAP on the MOLT-16 T cell 
line and human primary T cells.
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4.5 Material and Methods
4.5.1Cell lines
4.5.1.1 MOLT-4 cell line
The MOLT-4 T cell line was established from cells taken from a 19-year old 
male patient with a relapse of acute lymphoblastic leukaemia, following multidrug 
chemotherapy (Minowada and Moore, 1975). This cell line does not produce 
immunoglobulin or Epstein-Barr virus, but has tumorigenic capacity (Minowada et al., 
1972). MOLT-4 T cell line belongs to the intermediate thymocyte category based on 
expression of CD1, CD2, CD5 and CD6 on more than 50% of the cells. Minority of 
MOLT-4 T cells express CD4 and CD8 but CD3 is negative (Minowada et al., 1985). 
MOLT-4 T cells were grown in RPMI 1640 complete medium (section 2.2) in a 
vertical 75 cm2 tissue culture flask. They were passaged as described in section 
2.1.1.2 at a ratio of 1:4 when the cell density reached over 2x106cells/ml. The culture 
medium was changed every 2-3 days. These cells were used as a CD103- control T cell 
line.
4.5.1.2 MOLT-16 T cell line
The MOLT-16 T cell line is a human leukemic T cell line which was established 
from the peripheral blood of a 5-year-old girl with T cell acute lymphoblastic leukaemia 
(T-ALL) (Drexler and Minowada, 1989). MOLT-16 T cells are round or elongated with 
single cells growing in suspension. MOLT-16  T  cell  line  appears  to  have  an 
immature thymocyte phenotype which includes  the absence of CD1,  CD4 and 
CD8, and the presence of CD2, CD3, CD5 and CD7 (Minowada et al., 1985. In 
addition, it has been demonstrated that MOLT-16 T cells also expressed CD103 
and  LAP  on  their  cell  surface  (Rygiel  et  al.,  2008).  MOLT-16 T  cells were 
cultured in RPMI 1640 complete medium in 75cm2 tissue culture flasks in a vertical 
position and split at a ratio of 1:3 when the cell density reached 2x106cells/ml.
4.5.2 Immunocytochemistry
4.5.2.1 Immunofluorescence staining for cell co-culture system
In order to examine the induction of EMT by T cells, HKC-8 cells were 
seeded in 4-well plastic  chamber slides. When the HKC-8 cells reached a semi-
confluent stage, 1x105 MOLT-16 T cells were added to each well. After 72 hours’ co-
culture, the slides were washed in PBS three times. Cells were then fixed in pre-cooled 
acetone at -20°C for 10 minutes, and then air-dried. The fixed cells were processed as 
described in section 2.5.2.4.
4.5.2.2 Addition of SB-505124 to the cell co-culture system
TGF-β signaling and its role  in T cell-mediated EMT was investigated by 
applying the ALK5 inhibitor SB-505124 (section 2.7.2). Briefly, HKC-8 cells were 
cultured in chamber slides until they reached a semi-confluent stage. An optimal 1 µM 
of SB-505124 was added and incubated with the HKC-8 cells at 37°C for 1 hour. After 
the pre-treatment, MOLT-16 T cells were then added and co-cultured with HKC-8 cells 
for 72 hours. The cells were washed in PBS three times and then fixed and stained as 
described in section 2.5.2.
4.5.3 Compensation for two-colour flow cytometry
The emission spectra of fluorescent dyes are broad. While the peak emission is 
clearly  separated for each dye, there is considerable overlap between dyes. In this 
study, fluorescein (FITC) and phycoerythrin (PE) dyes were used to detect two different 
antigens on the same cell. It has been shown that some of the light emitted by FITC 
passes through the filter used for PE; this is called spectrum overlap (Figure 4.3). The 
result of this spectrum overlap is that cells labelled with FITC will appear to have some 
PE fluorescence. In order to obtain a correct representation of the data, a  correction 
(colour compensation)  is required. The  compensation was established  by  running 
unstained cells and cells stained with each antibody-fluorochrome conjugate 
individually (single stain) and analyzing the data using 2-colour dot plots (Figure 
4.4A). The compensation settings were adjusted by  keeping the stained cells in line 
with the unstained background  cells and parallel to the  appropriate axis.  For FITC- 
conjugated, antibody stained cells, the FL2-%FL1 setting was adjusted so that the FL1 
cells were horizontally aligned with the FL1 negative (Figure 4.3B). Then, with the PE-
conjugated antibody stained cells, the FL1-%FL2 setting was adjusted until the  FL2 
cells were vertically  aligned with the FL2 negative cells (Figure 4.4C).   The 
compensation was then fine-tuned by running 2-colour control samples stained with 
FITC and PE monoclonal antibodies (Figure 4.4D).
Figure 4.3 The emission spectra of fluorescein (FITC) and phycoerythrin (PE) 
fluorescent overlap.
The image is obtained from flow cytometry-A basic introduction book, Michael G 
Ormerod (h  t t  p ://   f l o  wb  o  o   k. d  e  n  o   v o   s o   ft w   a r e.  c  o  m   / ).
Figure 4.4 Two colour compensation for flow cytometry.
The compensation settings were adjusted by running individually stained samples to 
adjust the compensation (A). For FITC-conjugated antibody stained cells, the FL2-
%FL1 setting was adjusted so that the FL1 cells were horizontally aligned with the 
FL1 negative (B). Then, with the PE-conjugated antibody stained cells, the FL1- 
%FL2 setting was adjusted until the FL2 cells were vertically  aligned with the FL2 
negative cells (C). The setting was again adjusted with the dual colour stained samples 
(D). (From basic information on fluorescence compensation, the UC Berkeley Campus, 
US)
4.5.4 Fluorescence-activated cell sorting (FACS)
FACS is a specialised type of flow  cytometry, which can separate and isolate 
cells that are phenotypically  different from each other, based on the specific light 
scattering and/or fluorescent characteristics of each cell.
The process begins by placing the cell suspension into a tube and forcing the 
cells to enter a narrow flowing stream of liquid. The cells travel down the nozzle 
which is vibrated at an optimal frequency to produce drops at a fixed distance from 
the nozzle. As the cells flow down the stream of liquid, they  are scanned by a laser. 
Some of the laser light is scattered by  the cells and  detected  by  a  number  of 
photomultiplier  tubes;  this signal  is used to count the cells. This scattered light can 
also be used to measure cell size.
If the separation of a subpopulation of cells is required, the cells of interest are 
typically  defined using an antibody linked to a fluorescent dye, which binds to an 
antigen on the surface of the cells of interest. The laser light excites the dye which emits 
a colour of light that is detected by the photomultiplier tube, or light detector.  By 
collecting the information from the light (scatter and fluorescence) a computer can 
determine which cells are to be separated and collected. As the drop forms, an electrical 
charge is applied to the stream and the  new drop will form with that charge.  The 
charged drops are then deflected left or right by  charged electrodes for collection in 
sample tubes (Figure 4.5).
This study focused on separating TGF-β treated T cells into CD103- and CD103+ 
sub-populations. Briefly, T cells were isolated from the blood of healthy volunteers 
(section 2.2.5). Resting T cells were then activated with CD3/CD28 Dynabeads® for 72 
hours. After the activation, activated T cells were incubated with 10ng/ml of TGF-β for 
72  hours. After the incubation, the cells were  incubated with anti-CD103 FITC- 
conjugated antibody (1:10) for 30 minutes on ice. The cells were washed in PBS and 
resuspended in 2%FBS/PBS. The cell suspension was sorted by FACSAria II sorter (BD 
Biosciences) (Figure 4.6).
Figure 4.5 Diagram of fluorescence-activated cell sorting.
Specific cells are detected using fluorochrome-conjugated antibodies and deflected 
left or right on the basis of electrical charges applied appropriately  to the cell- 
containing  liquid droplets. (Image obtained from Department of Biology, Davidson 
College, NC)
Figure 4.6 Histograms analysing the expression of CD103 after T cell sorting.
Activated T cells were treated with 10ng/ml of TGF-β for  72 hours. After  the 
incubation, the cells were stained with anti-CD103 FITC-conjugated antibody, and then 
sorted for CD103- (A) and CD103+ T cells (B) with the FACSAria II sorter. Each shaded 
histogram shows the result of labelling with isotype-matched  control antibodies;  the 
open histograms show CD103 labelling.
4.6 Results
4.6.1 MOLT-16 T cells express the αEβ7 integrin (CD103) on their cell 
surface
In order to investigate the biological function of CD103+T cells, a series of 
experiments was performed using  the MOLT-16 T cell line which constitutively 
expresses this integrin (Rygiel et al., 2008); a CD103-ve T cell line, MOLT-4, was used 
for control. The phenotype  of  both  of  these  cell  lines  was  validated  prior  to  use 
by immunofluorescence flow cytometry. 
Briefly, cells were washed in 2%FBS/PBS and the cell density adjusted to 1x106 
cells per ml.  100µl of cell suspension were incubated with mouse monoclonal anti-
CD103 FITC conjugated antibody (1:10) (clone  2G5,  Eurobiosciences)  and  mouse 
IgG
2A 
isotype control antibody (1:10) on ice for 30 minutes. After washing in 
2%FBS/PBS two times, CD103 expression was measured by flow cytometry (BD 
FACSCalibur). 
The flow  cytometric  analysis  suggested  that MOLT-16 T  cel ls  expressed 
CD103 uniformly while no CD103 was present on MOLT-4 T cells (Figure 4.7).
Figure  4.7  Histograms  demonstrating the expression of the αEβ7 integrin 
(CD103) T cell lines.
MOLT-16 (A) and MOLT-4 (B) T  cells were incubated with CD103 antibody  and 
analysed  by flow cytometry.  The CD103 was highly expressed in MOLT-16 T cells, 
whereas CD103 was not expressed by MOLT-4 T cells. The results were representative 
of 3 similar  experiments. The shaded histogram shows fluorescence produced by 
labelling  with an  isotype-matched  control antibody;  the open  histogram  shows 
experimental labelling.
4.6.2 Loss of E-cadherin expression by renal epithelial cells co-cultured with 
MOLT-16 T cells
One of the main characteristics of EMT is a decrease in the expression of the epithelial 
marker, E-cadherin (section 1.8.1). Therefore,  a series of experiments was conducted 
to  examine  the  effect  of  MOLT-16  T cells  on  the  expression  of  E-cadherin  by 
HKC-8 cells.
Semi-confluent HKC-8 cells were co-cultured with 1x105  MOLT-16 T  cells in 
chamber slides for 72 hours. For the positive control, HKC-8 cells were incubated in medium 
containing TGF-β 5ng/ml. Cells were washed and then fixed in pre-cooled acetone at -20°C 
for 10 minutes. The fixed cells were incubated with mouse monoclonal anti-E-cadherin 
antibody (1:50) at 4°C overnight. After washing three times in PBS, cells were incubated with 
mouse polyclonal IgG FITC-conjugated antibody (1:100) for 1 hour at room temperature. The 
slides were then viewed by laser scanning confocal microscopy (section 2.5.2). 
E-cadherin  was  expressed  along  the  boundary  between  epithelial  cells  in  fully-
developed epithelial monolayers (Figure 4.8A). This cell-surface expression of E-cadherin by 
HKC-8 cells was reduced by both co-cultured with MOLT-16 T cells and treatment with TGF-
β1 (Figure 4.8B-C). Quantitative analysis of fluorescence intensity also showed a significant 
reduction of E-cadherin expression after co-culture with T cells and TGF-β1 treatment (Figure 
4.8D).  However,  following  the  co-culture  with  MOLT-16  T  cells,  E-cadherin  was  still 
expressed  by some  HKC-8  cells.  This  probably  suggested  that  MOLT-16  T cells  did  not 
contact some HKC-8 cells.
The similar down-regulation of E-cadherin produced by MOLT-16 co-culture and TGF-
β1 treatment suggests a common mechanism, with the T cells potentially presenting TGF-β to 
the renal cell line. 
Figure 4.8 Micrographic immunofluorescence staining analysis  of E-cadherin 
expression in a cell co-culture experiment.
Semi-confluent HKC-8 cells were incubated in medium with or without TGF-β1 5ng/ml 
ad co-cultured with MOLT-16 T cells for 72 hours. The immunofluorescence staining 
showed the expression of E-cadherin at cell junction of control cells (A). Its expression 
was reduced and internalized after co-culture with MOLT-16 T cells (B)  and TGF-β1 
treatment (C). The microscopic pictures were taken from the confocal microscope at x 
63 magnification. The  bar graph (D) shows the quantitative  measurement of mean 
fluorescence intensity which significantly declined in co- culture and treatment groups. 
The bars are means (n=4) and the error bars are SEM. These results are representative of 
3 similar experiments. (** = p < 0.01)
4.6.3  MOLT-16   T  cell   line-induced   S100A4   expression   in   renal 
epithelial cells
This study has already shown that MOLT-16 T cells might induce EMT by reducing 
E-cadherin  expression  by  confluent  HKC-8  cells.  A further  series  of  experiments  was 
performed to determine whether MOLT-16 T cells can induce expression of the mesenchymal 
marker, S100A4. 
The expression of S100A4 was measured in HKC-8 cells co-cultured with MOLT-16 
T  cells. Semi-conf luen t  HKC-8  ce l l s  were  co-cul tured  wi th  MOLT-16  T 
ce l l s  and  were then  processed as described in  section 4.4.3. The fixed cells  were 
incubated with rabbit polyclonal anti-S100A4  antibody (1:100) (DAKO) at 4°C overnight. 
After washing the cells were incubated with FITC-conjugated anti-rabbit IgG (1:150) at room 
temperature for 1 hour. 
There was an absence of S100A4 expression in normal HKC-8 cells (Figure 4.9A). 
However, the expression of S100A4 by HKC-8 cells was up-regulated during co-culture with 
MOLT-16 T cells or by treatment with TGF-β1 (Figure 4.9B-C). In addition,  quantitative 
measurement of fluorescent intensity showed a significant increase of S100A4 expression in 
HKC-8 cells following either MOLT-16 T cells co-culture or TGF-β1 treatment (Figure 4.9C-
D). However, MOLT-16 T cells did not induce S100A4 in all cells, probably suggested that 
S100A4-negative HKC-8 cells did not interact with MOLT-16 T cells.
These  results  are  consistent  with  a  model  in  which  MOLT-16 T cells  can  induce 
S100A4 by a mechanism involving presentation of TGF-β.
Figure 4.9 Micrographic immunofluorescence staining analysis of S100A4 expression 
in co-culture experiment.
The  semi-confluent  HKC-8  cells  were  incubated  in  medium  with  or  without 
TGF-β1 5ng/ml for 72 hours. The S100A4 expression (Green) was nearly absent in 
control cells (A). However, its expression was increased by co-culture with MOLT-16 
cells (B) or TGF-β1 treatment (C). The microscopic pictures were taken from the 
confocal microscope at x 63 magnification. The bar graph (D) shows the quantitative 
measurement of mean fluorescence intensity  which significantly  increased in co- 
culture and treatment groups. The bars are means (n=4) and the error bars are SEM. 
These results are representative of 3 similar experiments. (** = p < 0.01, *** = p
<0.001)
4.6.4 α-SMA was expressed by HKC-8 cells co-cultured with MOLT-16 T 
cells
Since  lymphoma  cells  such  as  MOLT-16  T  cells  are  known  to  express  S100A4 
(Tulchinsky et al., 1995), another mesenchymal marker was required to confirm that addition 
of T cells can induce EMT in vitro. The expression of  α-SMA is frequently used to define 
myofibroblast;  the  induction  of  this  marker was also  examined by  immunofluorescence 
staining. 
Semi-confluent  HKC-8 cells were co-cultured with MOLT-16 for  72 hours. Cells 
were  fixed (section 4.3.1) and incubated with mouse monoclonal anti-α-SMA antibody 
(1:100) at 4°C overnight. Following this incubation, the cells were washed and incubated with 
mouse polyclonal IgG FITC-conjugated antibody (1:100) at room temperature for 1 hour. 
α-SMA expression  was  not  present  in  any  normal  HKC-8  cells  (Figure  4.10A). 
However, some of the HKC-8 cells expressed α-SMA following co-culture with MOLT-16 T 
cells or TGF-β1 (Figure 4.10B-C).
Although α-SMA was not expressed by all HKC-8 in the presence of MOLT-16 T cells, 
the induction of this marker in some cells provides further evidence that culture with T cells can 
induce EMT leading to myofibroblast formation. The heterogeneity of α-SMA induction by 
culture with both TGF-β1 and T cells is consistent with the observation  in vivo that not all 
epithelial cells express this marker during the induction of EMT (Okada et al., 2000).
Figure  4.10  Micrographic  immunofluorescence  staining  analysis  of  α-SMA 
expression in co-culture experiment.
The   semi-confluent   HKC-8   cells   were   incubated   in   medium  with   or   without 
TGF-β1 5ng/ml for 72 hours. The  α-SMA expression (Green) was absent in control 
cells (A). However, it appeared in as the microfilament-like structure in the presence of 
MOLT-16 cells (B)  and TGF-β1 (C). The microscopic pictures were taken from the 
confocal microscope at x 63 magnification. The results are representative from 3 similar 
experiments.
4.6.5   MOLT-16 induced EMT via the TGF-β signalling pathway
Currently, TGF-β has been reported as a major inducer of the EMT during renal 
allograft fibrosis (Liu et al., 2010). According to the above results, co-culture of MOLT-16 T 
cells  and HKC-8 cells resulted in loss of the epithelial marker E-cadherin and acquisition of 
the mesenchymal markers S100A4 and α-SMA. Similar phenotypic changes were produced by 
treatment  of  HKC-8  cells  with  TGF-β1,  suggesting  that  this  growth  factor  may  also  be 
involved in the phenotypic transition produced by T cells. 
In order to determine the contribution of TGF-β signalling in  the T cell  co-culture 
model, HKC-8 cells were pre-treated with the TGFβR1 (ALK5) antagonist,  SB-505124 at 
a concentration of 0.1, 0.5 and 1µM at 37°C for 1 hour. After this pre-treatment, HKC-8 cells 
were co-cultured with MOLT-16 T cells for 72 hours. The cells were then fixed and incubated 
with anti-E-cadherin (1:50), anti-S100A4 (1:100)  and anti-α-SMA (1:100) antibodies at 4°C 
overnight. After washing, the  cells were incubated with appropriate secondary  antibodies at 
room  temperature  for  1 hour.  The  expression  of  E-cadherin,  S100A4  and  α-SMA were 
examined by confocal microscopy at time 63 magnification.
Normal  HKC-8 cells  expressed E-cadherin at  the point  of  cell-cell  contact  (Figure 
4.11A)  but  neither  S100A4  (Figure  4.12A)  nor  α-SMA (Figure  4.13A)  were  expressed. 
Following co-culture with MOLT-16 T cells, there was a loss of E-cadherin expression at the 
cell borders (Figure 4.11B) and an increase in the expression of S100A4 (Figure 4.12B) and 
α-SMA (Figure 4.13B). However, addition of SB-505124 at a concentration of 1µM partially 
prevented the loss of E-cadherin (Figure 4.11E), and also reduced the induction of S100A4 
(Figure 4.12E) and α-SMA (Figure 4.13E).
Inhibition  of  the  phenotypic  transition  produced by treatment  of  HKC-8 cells  with 
MOLT-16 T cells by blockade of TGF-β signalling suggests that these T cells at least partially 
induce EMT by a TGF-β dependent mechanism.
Figure 4.11 Microscopic immunofluorescence images demonstrating the effect of
ALK5 inhibitor on E-cadherin expression.
Semi-confluent HKC-8 cells were co-cultured with MOLT-16 cells in the  absence or 
presence of ALK-5 inhibitor at concentration 0.1, 0.5 and 1uM. The control was HKC-
8 cells grown in normal medium. The images were taken from confocal microscope at x63 
magnification. The control (A) showed linear expression of E-  cadherin at the  cell borders 
which then changed to punctuated expression following MOLT-16 co-culture (B). The ALK-
5 inhibitor at 0.1μM (C) and 0.5μM (D) did not recover the cell border staining of E-cadherin 
in the presence of MOLT-16 cells. However, some staining at cell borders was shown with 
ALK-5 inhibitor 1μM  E). The  images were taken by the confocal microscopy  at x63 
magnification. The results are representative of 3 similar experiments.
Figure 4.12 Immunofluorescence micrographic images demonstrating the effect 
of ALK5 inhibitor on S100A4 expression.
Semi-confluent HKC-8 cells were co-cultured with MOLT-16 cells in the absence or presence 
of ALK-5 inhibitor at concentration 0.1, 0.5 and 1µM. The control (A) showed no staining of 
S100A4. This antigen was induced in the cytoplasm after MOLT-16 co-culture (B). In the 
presence of ALK-5 inhibitor at 0.1 (C), 0.5 (D) and  1μM (E),  S100A4 expression was 
reduced and appeared punctuate. The images were taken by the confocal microscopy at x63 
magnification. The results are representative of 3 similar experiments.
Figure 4.13 Immunofluorescence micrographic images demonstrating the effect 
of ALK5 inhibitor on α-SMA expression.
Semi-confluent HKC-8 cells were co-cultured with MOLT-16 cells in the absence or presence 
of ALK5 inhibitor at concentration 0.1, 0.5 and 1µM. The control (A) showed no staining of 
α-SMA. However, α-SMA was present in microfilament bundles in the presence of MOLT-16 
(B). The ALK5 inhibitor did not inhibit the induction of α-SMA expression at 0.1μM (C), but 
the increase in α-SMA  expression produced  by  co-culture   with  MOLT-16  T  cells   was 
inhibited  when  the  ALK5 inhibitor was present at 0.5uM (D) and 1μM (E). The images were 
taken by the  confocal microscopy  at x63 magnification. The results are representative of 3 
similar experiments.
4.6.6   LAP was expressed by MOLT-16 T cell line
From the above results, MOLT-16 T cells  partially induced EMT by activation of the 
TGF-β signalling pathway. It has been observed that TGF-β is predominantly produced from 
renal  epithelial cells during rejection (Robertson et al., 2001), and is normally secreted in an 
inactive form complexed with LAP (Section 1.9.1). However, it has also been observed that 
MOLT-16 T cells express LAP (Rygiel et al., 2010), suggesting that these cells present TGF-β 
to renal epithelial cells (Oida et al., 2003). 
In order to determine the expression of latent TGF-β, MOLT-16 and MOLT-4 T cells 
were grown in serum-free  medium for 72 hours. These cells were then incubated with mouse 
monoclonal anti-LAP FITC-conjugated antibody  (1:10) for 30  minutes on ice. After the 
washing step, the cells were examined by flow cytometry. 
There was minimal expression of LAP on the surface of MOLT-4 T cells (Figure 4.14A). 
However, the MOLT-16 T cell line expressed this antigen (Figure 4.14B). Since this study did not 
use MOLT-4 as a negative control in co-culture studies, the suggestion that LAP on surface of 
MOLT-16 T cells played a role in MOLT-16 T cell-induce EMT remains inconclusive.
Figure 4.14 Flow cytometric analysis of LAP expression on l y m p h o m a T cell 
lines.
MOLT-4 and MOLT-16 cells were cultured in serum free RPMI 1640 for 72 hours. 
Cells were stained with anti-LAP PE-conjugated antibody for 30 minutes on ice. Very 
few of MOLT-4 T cells expressed LAP (A) whereas the majority of MOLT-16 T cells 
expressed LAP on their  cell  surface  (B). The shaded histogram shows fluorescence 
produced  by labelling with an isotype-matched control antibody; the open histogram 
shows experimental labelling. These results are representative of 2 similar independent 
experiments.
4.6.7   TGF-β1 induced CD103 expression on primary T cells
This study has already shown that the MOLT-16 T cell line expresses CD103 at a 
high  level.  In  this  study  a  series  of  experiments  was  performed  to  examine  antigen 
expression by primary human T cell lines..
In order to determine the conditions in which human T cells express CD103, T 
cells were isolated from healthy volunteer blood and processed as described in section 
2.2.5. The resting T cells were activated with CD3/CD28 Dynabead® for 72 hours. After 
the activation, some of the activated T cells were  incubated in medium  containing 
10ng/ml TGF-β1 for 72 hours. These T cells were then incubated with monoclonal anti-
CD103 FITC-conjugated antibody (1:10) for 30 minutes on ice. Cells were examined for 
CD103 expression by flow cytometry. 
Approximately 7.6 ± 1.3% (mean ± SEM, n=4) of CD3/CD28 activated T cells 
expressed CD103 in the absence of TGF-β1 (Figure 4.15A). However, following TGF-β1 
stimulation, 45.7 ± 6.6% (mean ± SEM, n=4) of the activated T cells expressed CD103 
expression on their cell surface  (Figure 4.15B). Quantification of CD103 expression is 
shown in and demonstrates significant induction of CD103 expression by TGF-β1 (Figure 
4.15C). 
These results are consistent with previous data from our group and others (Hadley 
et al., 2001; Wong et al., 2003) suggest that the induction of CD103 observed on T cells 
which have penetrated renal tubules during rejection is dependent on local expression of 
TGF-β1.
Figure 4.15 Flow cytometric analysis of the  expression of CD103  by human 
primary T cells.
The  isolated human T cells were activated with CD3/CD28 for  72 hours and then 
incubated in medium or medium containing  TGF-β1 10ng/ml for 72 hours before 
analyzing by flow cytometry. A small number of activated T cells expressed CD103 
on their cell surface (A). In contrast, TGF-β1 treated T cells increased the expression of 
CD103 (B). The bars (C) show mean and the error bars are SEM. The shaded histogram 
shows fluorescence produced by labelling with an isotype-matched control antibody; 
the open histogram shows experimental labelling. The  quadrants were  set from the 
isotype control. (** = p<0.01). These results are representative of 4 similar experiments.
4.6.8   The expression of LAP by primary human T cells
Results in section 4.4.6 demonstrated that MOLT-16 T cells express cell surface 
LAP which might be involved TGF-β-mediated induction of  EMT. A further series of 
experiments was performed to measure the expression of LAP by primary human T 
cells.
To determine whether primary T cells express LAP or not, T cells were isolated 
from the blood of healthy volunteers. After the isolation, the T cells were activated with 
CD3/CD28 Dynabeads® for 72 hours, followed by incubation with TGF-β1 at 10ng/ml 
for 72 hours.  These cells were then incubated with anti-LAP monoclonal  antibody 
conjugated with PE (R&D system) for 30 minutes on ice. LAP expression was detected 
by flow cytometry. 
A small proportion of both activated T cells [16.43% ± 1.03 (mean ± SEM, n = 
4 and activated T cells which had been cultured with TGF-β1 [10.43 ± 1.05% (mean ± 
SEM, n  =  4)  expressed  LAP  on  the  cell  surface  (Figure 4.16A-B).  In  addition, 
comparison  of  LAP  expression  between  these  two  groups  showed  no  statistical 
difference using the paired t-test method (Figure 4.16C). The data from this experiment 
provided 98.3% power (alpha = 0.05, two-tail).This suggests that TGF-β1 is not required 
for LAP expression by activated human T cells.
The statistical power was calculated by using a calculator from DSS research web site. 
(http://www.dssresearch.com/KnowledgeCenter/toolkitcalculators/statisticalpowercalcul
ators.aspx)
Figure 4.16 Flow cytometry analysis of the expression of LAP compared between
CD3/CD28 activation and TGF-β1 treatment.
CD3/CD28 activated T cells were incubated in medium with absence or presence of 
TGF-β1 10ng/ml for 72 hours of activated T cells. A small population of activated T 
cells (A) and activated T cells with TGF-β1 stimulation (B) expressed LAP. There was 
no difference between control and treatment groups  (C).  The bars show mean  results 
and error bars  are SEM. The shaded  histogram shows fluorescence produced by 
labelling with an isotype-matched control  antibody; the open histogram  shows 
experimental  labelling. The quadrants were determined from the appropriate isotype 
antibody control samples. The results are representative of 4 similar  experiments with 
different blood donors (Paired t-test, alpha = 0.05, 98.9% power).
4.6.9   The co-existence of CD103 and LAP on primary T cells
CD103  and LAP are  potentially  associated with  T cell-induced  EMT. 
Interestingly,  a study  of SLE patients concluded  that  there  was  an increase of 
CD103+LAP+CD8+ Treg after Hematopoietic stem cell transplantation (HSCT) (Zhang 
et al., 2009). However, no data has been reported for CD103+LAP+ T cells in vitro. This 
series  of  experiments  was  performed  to  explore  the  potential  relationship  between 
CD103 and LAP on the surface of human T cells.
The co-expression of surface molecules on both activated and TGF-β treated T 
cells were measured by flow cytometry. Human  T cells were isolated,  activated with 
Dynabeads® and then stimulated with TGF-β1, as described in section 4.3.8. Cells were 
then incubated with both FITC  conjugated  anti-CD103 and PE-conjugated  anti-
LAP antibodies for 30 minutes on  ice,  followed  by  flow  cytometric  analysis. 
Appropriately  conjugated  isotype  control  antibodies  were  used  to  set  the  analysis 
quadrants.
Two-colour  flow cytometric  analysis  demonstrated  that  a  small  proportion  of 
activated T cells expressed LAP (Figure 4.17); as in section 4.6.8, the proportion of LAP 
expressing T cells was not altered by treatment of the cells with TGF-β1. A majority of 
the  small  population  of  CD103+ T  cells  observed  in  non-TGF-β1  induced  cultures 
expressed LAP. However, a similar small proportion of CD103+ and CD103-  T cells in 
TGF-β1 treated cultures expressed LAP. This experiment provides no evidence that the 
CD103 induced on activated T cells  by TGF-β treatment is associated with a similar 
induction of LAP. 
Figure 4.17 Flow cytometric analysis of the co-expression of CD103 and LAP in 
activated T cells and TGF-β1 treated T cells.
CD3/CD28 activated T cells were incubated in medium with or without 10ng/ml of 
TGF-β1 for 72 hours. In activated T cells, 13.8% of CD103-  T cells expressed LAP 
(A). After TGF-β1 treatment, LAP was expressed in 17% of CD103+Tcells (B). The 
results are representative of 2 similar experiments. The quadrants were set by analysing 
of samples after labelling with isotype control antibodies.
4.6.10 Examination of LAP expression by T cells sorted into CD103+ and 
CD103- fractions
In order to examine further the expression of LAP by CD103+ and CD103- T 
cells, these T cell subsets were separated after TGF-β treatment by FACS as described 
in section 4.3.4.  The sorted cells were then  stained  with anti-LAP PE-conjugated 
antibody (1:10) and analysed using a FACSCalibur flow cytometer.
As in Figure 4.17, it was found that only a small sub-population of the separated 
CD103+ and CD103- T cells expressed LAP (Figure 4.18). In the case of CD103- T cells 
(Figure 4.18A) 14.9 ± 0.4% (mean ± SEM) of the cells expressed LAP, whilst 11 ± 1.8% 
(mean  ±  SEM)  of  CD103+T  cells  expressed  this  antigen  (Figure  4.18B). 
These  data  were  not  significantly  different  (Figure  4.18C;  P>0.05;  n=3 
separated experiment; analysed by paired t-test).  
On the basis of this  data it  can be concluded that a small  proportion 
of  activated  T cells  does  express  LAP.  However,  this  LAP is  not  induced 
by  treatment  with  TGF-β1  and  is  not  preferentially  expressed  by  CD103 
expressing T cells following treatment with TGF-β1. 
Figure 4.18 Flow cytometry analysis of LAP expression in CD103 sorting T cells. 
CD3/CD28 activated T cells were incubated with TGF-β1 10ng/ml for 72 hours and 
then sorted for CD103- and CD103+T cells. The sorted T cells were examined for 
LAP  expression  by flow cytometry. The percentage of LAP positive T cells in 
CD103-   T cells (A) and CD103+   T cells (B) were minimal in both groups. There 
was no significant difference of LAP expression between these two groups (C). The 
quadrants were set  using isotype-matched  control labelling. The  results are 
presented in mean ± SEM (n=3) and are representative of 3 independent 
experiments.
4.7 Summary and discussion
4.7.1 Results summary
• The MOLT-16 T cell line expressed cell surface CD103, providing a good model 
for  the  CD103  expressing  T cells  found  within  renal  tubules  during  renal  allograft 
rejection.  Immortalised  proximal  renal  tubular  cells  showed changes  consistent  with 
EMT as a consequence of incubation with the MOLT-16 T cell line. 
• Inhibition of the TGF-β receptor partially blocked the EMT induced by MOLT-
16  T cells.  Treatment  of  activated  T  cells  with  TGF-β1  induced  the  expression  of 
CD103.
• A small  proportion  of  primary  human  T  cell  lines  expressed  latent  TGF-β 
following CD3/CD28 activation.  .
The  expression  of  latent  TGF-β  by activated  T cells  was  not  increased  by 
incubation with TGF-β1. The expression of latent TGF-β1 by TGF-β1 treated T 
cells was similar in the CD103+ and CD103- subpopulations. 
4.7.2 Discussion
Tubulitis is defined as the accumulation of mononuclear leukocytes within the 
renal tubular compartment (Racusen et al., 1999). This feature is now one of the major 
criteria for diagnosing acute T cell-mediated rejection following allogeneic human renal 
transplantation (Section 1.6) (Sis et al., 2010). It has been reported that many activated 
T cells within the tubules during rejection express the αE(CD103)β7 integrin (Robertson 
et  al.,  2003).  Since T cell-mediated rejection is associated with chronic allograft 
fibrosis and leads  to approximately 6% of renal allograft loss (El-Zoghby et  al., 
2009), it was hypothesised that CD103+ T cells mediate  fibrosis  by the induction of 
EMT. 
The MOLT-16 T cell line was established as one of six cell lines from patients 
with acute  leukaemia  (Minowada  and  Moore,  1975).   MOLT-16 T cells have  been 
shown to strongly express αEβ7 integrin (CD103) and efficiently bind to primary renal 
epithelial cells in culture (Robertson et al., 2004). Furthermore, MOLT-16 T cells have 
been demonstrated to express latent TGF-β on their cell surface (Oida et  al.,  2003; 
Rygiel et al., 2008).  For these reasons, MOLT-16 T cells were used as a robust and 
reproducible model of intratubular T cells during co-culture experiments with HKC-8 
immortalised renal tubular epithelial cells. 
Previous studies by our group have shown up-regulation of the  mesenchymal 
marker   S100A4  following  co-culture   of   MOLT-16  T  cells   with   primary  renal 
epithelial cells. In addition, treatment with the TGF-β neutralising antibody  down-
regulated this  S100A4 induction, suggesting that active TGF-β on the cell surface of 
MOLT-16 T cells plays a  role  in the  induction  of  epithelial cell transformation 
(Robertson et al., 2004). In the current study, MOLT-16 T cells w e r e  co-cultured with 
t h e  immortalised proximal renal t u b u l a r  epithelial cell line, HKC-8 (Racusen et 
al., 1997). In order to examine the possible induction of EMT during these co-cultures, 
the expression of a range of antigens was examined. Although S100A4 was induced, this 
antigen  has  a  limitation  for  examination  of  EMT in  the  presence  of  T  cell  lines. 
Specifically,  it  is  known that S100A4 is  expressed by MOLT-16 T cells.  This might 
complicate quantification of this antigen in mixed renal cell-T cell co-cultures (Inoue et 
al.,  2005; Osterreicher et  al.,  2011).  Thus, α-SMA, which is a mesenchymal marker 
commonly used to identify  myofibroblast, was used in conjunction with S100A4 to 
identify  myofibroblast  differentiation  in  the co-culture  system.  However,  this  study 
found that 
MOLT-16 lymphocytes induce  typical changes of EMT in HKC-8 cells 
following  72 hours’ co-culture. The immunofluorescence labelling for E-cadherin 
showed a reduced,  punctate  expression pattern at the cell borders, whereas α-SMA 
labelling  showed the appearance of microfilament bundles. In addition, S100A4 
expression was up-regulated in renal epithelial  cells but  was  also  observed  in the 
MOLT-16 T cell line.  This  de-differentiation  of  co-cultured  renal  epithelial   cells 
was  similar  to   the features of these  cells following TGF-β1 treatment, supporting a 
key role of TGF-β1 in T cell-induced EMT. 
In order to specify the role of TGF-β in this co-culture experiment, SB-505124, 
a selective ALK5 inhibitor (DaCosta et  al., 2004), was pre-incubated with renal 
epithelial cells before the co-culture. Pre-treatment with the TGFβRI inhibitor showed 
a   protective   effect   against   T  c e l l - m e d i a t e d  loss   of   E-cadherin  expression 
and   the  expression of S100A4 and α-SMA on renal epithelial cells. This indicated 
that  MOLT-16  T cells  induced EMT through a  TGF-β-dependent mechanism. 
However, further studies are necessary to confirm  the role of CD103  expression in T 
cell-induced  EMT.  For example, by using the appropriate negative control cells 
(CD103-T cells) such as MOLT-4 T cell line and CD3/CD28 activated T cells. In 
addition, blocking CD103  with the anti-CD103 antibody  may  also provide useful 
information on contact-dependent mechanism of T cell-induced EMT.
This study has indicated an important role f o r  TGF-β in T cell-induced EMT. 
Potential sources of this profibrotic cytokine include secretion from parenchymal cells 
following tissue injury or from infiltrating T cells. It has been shown that renal 
tubular epithelial cells express TGF-β in kidney  diseases, including  diabetic 
nephropathy (Ziyadeh, 2004) and IgA nephropathy (Wu et  al., 2009), as well as in 
experimental models of chronic kidney disease such as UUO (Fukuda et al., 2001). In 
addition, several factors have been shown to induce TGF-β production by  renal 
epithelial cells in vitro, including Cyclosporine (Slattery et al., 2005; McMorrow et al., 
2005) and high glucose (Park et al., 2001). 
Infiltrating  T  cells  are  another  potential  source  of  TGF-β  during  acute 
rejection. The role of TGF-β produced by  T cells has been shown in a model of 
experimental autoimmune  encephalitis (EAE), which is induced by Th17 T cells  The 
inhibition of TGF-β prevents EAE (Veldhoen  et  al., 2006) whilst  overexpression 
promotes the  disease  (Bettelli  et  al., 2006).  Furthermore, T cell-specific  TGF-β 
knockout mice developed mild EAE and less IL-17 compared to the control, suggesting 
that TGF-β produced by T cells is required for Th17 differentiation. It has been shown 
that murine T cell culture supernatants do not contain active TGF-β when measured by 
ELISA (Oida and Weiner, 2011), suggesting that this factor remains bound to the T cell 
surface. This finding is consistent with our observation in which MOLT-16 T cells did 
not secrete active TGF-β in the culture medium when measured by MFB-F11 bioassay. 
Evidence of membrane-bound TGF-β on the T cell surface was first reported 
by Nakamura et al in 2001. This study demonstrated the expression of LAP-TGF-β on 
the  surface  of  murine  CD4+CD25+Treg)  and led  to  the  proposal  of  a  cell  contact-
dependent  immunosupression mechanism. Further study has also shown the 
expression of LAP on the surface of human Foxp3+ Treg (Tran et  al., 2009). As 
described above, surface LAP is expressed on MOLT-16 T cells (but not by MOLT-4 T 
cells). Thus, it is possible that TGF-β signalling in HKC-8 cells can be induced by 
MOLT-16 T cells  via a cell-cell contact mechanism dependent on the expression of 
surface LAP-TGF-β on the T cells. 
A previous study has shown that a small population (1.3%) of circulating 
CD4+ T cells express LAP (Gandhi et al., 2010). Gandhi et al also showed a significant 
induction of LAP expression after T cell activation by stimulation of CD3 and CD8 or by 
addition  of  IL-2  (2.8%) and IL-8  (3.6%).  The current study demonstrated a small 
proportion of  LAP+  T cells following CD3/CD28 activation for 72 hours (15%); the 
addition of TGF-β1 made no significant difference to the proportion of LAP-expressing 
T cells. More study is required to define any immunoregulatory activity of LAP+ T 
cells and the role of these cells in kidney transplantation.
CD103 is predominantly expressed on allograft infiltrating T cells during renal 
allograft rejection. The main function of CD103 appears to be targeting CD8+T cells to 
their ligand, E-cadherin on epithelial cells. This is shown by the failure of CD8+T cells 
from CD103 knockout mice to accumulate within islet allografts (Feng et al., 2002). 
Recently, immunoregulatory activity has been observed in CD103+CD8+ T cells (Uss et 
al.,  2006). However, the regulatory  function of this subset of T cells during renal 
allograft rejection remains controversial. Renal and liver biopsies in patients with early 
acute rejection reported the absence of CD103 expression on infiltrating  lymphocytes 
(Leteurtre et al., 2000). In contrast, CD103+CD8+  T cells are commonly associated 
with late allograft rejection (Hadley et al., 2001) and subclinical rejection (Rowshani 
et al., 2004). 
This study also focused on the potential for co-expression of CD103 and LAP 
by TGF-β1-induced T cells.  Clearly  such  co-expression would provide  a  potential 
mechanism for stabilisation of T cell-epithelial cell conjugates allowing the bound T 
cells  to present cell-surface TGF-β to adjacent renal cells.  It  was found that some 
17% of  CD103+T cells  did  express  LAP which  might  allow such a  mechanism to 
function.  However  a  similar  proportion  of  CD103-T  cells  also  expressed  LAP, 
suggesting  that  these  two  antigens  are  regulated  separately.  The  relatively  small 
proportion of activated primary T cells that expresses LAP is consistent with results 
from previous reports (Gandhi et al., 2010) and indicates that the potential for LAP 
presentation by MOLT-16 T cells  may be greater  than that  of activated primary T 
cells. Clearly, an unresolved issue is the mechanism by which LAP-associated TGF-β 
becomes activated in order to stimulate the TGF-β receptor system. This problem is 
addressed in the next chapter. 
Chapter 5: Mechanism of TGF-β activation by infiltrating T 
Cells: potential role of thrombospondin-1 and neuropilin-1
5.1 Introduction
As detailed earlier, TGF-β plays a critical role in kidney allograft fibrosis (section 1.9). 
Normally, TGF-β is secreted as a latent TGF-β complex. Since the activity of TGF-β requires 
cognate interaction between active TGF-β and its receptor, the activation of latent TGF-β is a 
vital step in the response to TGF-β. Several mechanisms have been proposed for latent TGF-β 
activation. These include the activity of protease enzymes (Jenkins, 2008), integrins (Sheppard, 
2005), thrombospondin-1 (TSP-1) (Hugo and Daniel, 2009) and neuropilin-1 (NRP1) Glinka 
and Prud’homme, 2008). Analysis of the literature suggests that the TGF-β-mediated immune 
regulation  may depend  less  on  proteolytic  pathways  than  on  the  cell-surface,  LAP-binding 
receptors  and conformational  activation  of  TGF-β  (Lawler  et  al.,  1998).  Spontaneous  lung 
inflammation was observed in mice with TSP-1 knocked out (Lawler et al., 1998). In addition, 
αVβ6 knockout mice showed exaggerated skin and lung inflammation after irritation (Huang et 
al., 1996). Furthermore, double TSP-1/β6 knockout mice showed severe inflammation in the 
lungs and other tissues (Ludlow et al., 2005).
Unpublished data from our group has shown that CD103 expression is induced equally 
by co-culture with normal proximal tubular epithelial cells (PTEC) or αVβ6 transfected PTECs. 
Interestingly, blockade of the β6 integrin with a specific peptide did not inhibit the induction of 
CD103 expression during co-culture with activated T cells (Figure 5.1). Thus, other factors such 
as TSP-1 or NRP-1 may play a role in TGF-β activation in this system. This chapter will focus 
on the mechanism of latent TGF-β activation by the non-protease molecules, TSP-1 and NRP-1.
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Figure 5.1 TGF-β induces the differentiation of activated T cells
(A) A flow cytometric dot plot showing that few (3%) activated T cells express CD103 in the 
absence of exogenous TGF-β1. (B) Significant induction of CD103 is observed on activated T 
cells  following co-culture  with  PTEC.  (C)  The level  of  induction  of  CD103 expression by 
activated  T  cells  is  not  increased  further  by  co-culture  with  PTEC  which  have  been 
transfected to express high levels of the β6 integrin.  (D) Blockade of the β6 integrin with a 
specific  peptide  did  not  inhibit  the  induction  of  CD103  expression  during  co-culture  with 
activated T cells. (This image shows unpublished data provided by Prof John A Kirby). 
5.2 Thrombospondin-1 (TSP-1)
 The thrombospondins (TSP) are a family of multifunctional proteins that exist as both 
secreted  proteins  and  insoluble  extracellular  matrix  molecules  (Adams  and  Lawler,  1993; 
Bornstein, 2001). This family consists of 5 isoforms which can be divided into 2 subgroups, A 
and B, according to their oligomerisation status and molecular architecture (Adam and Lawler, 
1993).  Subgroup A contains TSP-1 and TSP-2, whereas subgroup B contains TSP-3, TSP-4 and 
TSP-5.  TSP-1  and  TSP-2  are  highly  homologous  trimers  with  a  chain  molecular  mass  of 
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approximately 145 kDa, consisting of three identical subunits, whereas TSP-3, TSP-4 and TSP-
5  are  homopentamers  with  chain  molecular  masses  of  approximately 100 kDa.  TSP-1  is  a 
homotrimeric  matricellular  glycoprotein.  It  is  expressed  by a  variety  of  cell  types  such  as 
platelets, vascular smooth muscle cells and renal cells, including mesangial cells, podocytes, 
endothelial cells, tubular epithelial cells and interstitial cells (Hugo et al., 1995; Hugo et al., 
1998). In adults,  TSP-1  is  regulated  by  cytokines  including   platelet  derived  growth  factor 
(PDGF),  fibroblast  growth  factor  (FGF)-2  and  TGF-β;  thus,  it  is  commonly  expressed  in 
inflamed areas and during wound healing and tissue remodelling (Bornstein, 2001).
5.2.1 Structure of thrombospondin-1
TSP-1 is  comprised of multiple  domains  of  repeating subunits.  These include (i)  an 
amino-terminal  heparin  binding  region,  (ii)  a  procollagen-like  region  containing  the 
intermolecular  disulfide  bonds,  three  properdin-like  type  1  repeats,  three  EGF-like  type  2 
repeats, calcium-sensitive EF-hand-like type 3 repeats, and (iii) a C- terminal globular domain 
(Adams and Lawler, 1993; Bornstein, 2001) (Figure  5.2). The various biological activities of 
TSP-1 relate to specific domains of the complex molecule.
Figure 5.2 Structure of thrombospondin-1.
The homotrimer  TSP-1 comprised  of  three  major  domains  including an  N-terminal  heparin 
binding  domain  (HBD),  a  procollagen  domain  (PC)  containing  three  properdin-like  type  1 
repeats (1), three EGF-like type 2 repeats (2) and seven calcium sensitive EF-hand-like type 3 
repeats (3), and a C-terminal domain. The figure is from Murphy-Ullrich and Poczatek, 2000.
5.2.2 The mechanism of TGF-β activation by TSP-1
It  has  been suggested  that  TSP-1 is  an activator  of  TGF-β  in  vitro in  different  cell 
systems, as well as a cell-free system (Ribeiro et al., 1999; Daniel et al., 2007). TSP-1 forms a 
tri-molecular complex with the TGF-β procytokine complex by interacting with both mature 
TGF-β and LAP. Recent data has defined the two major binding sites which play an important 
role in TGF-β activation by TSP-1.
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I. The hexapeptides GGWXXW present in each of the three type 1 repeats: GGWSPW, 
GGWSHW  and  GGWGPW  respectively.  These  hexapeptides  bind  to  the  VLAL 
sequence of mature TGF-β (Figure 5.3) (Young and Murphy-Ullrich, 2004). This allows 
the molecular interaction of the KRFK amino acid sequence of the TSP-1 molecule with 
the  N-terminal  LSKL  (Leucine-Serine-Lysine-Leucine)  sequence  of  the  LAP  by 
hydropathic bonding (Schultz- Cherry et al., 1995).
II.  The  KRFK  (Lysine-Arginine-Phenylalanine-Lysine)  amino  acid  sequence  is  located 
between the first and second type I properdin-like repeats (Schultz-Cherry et al., 1995). 
With  the  contribution  of  the  GGWXXW,  the  KRFK  of  TSP-1  binds  to  the  LSKL 
sequence  at  N-terminal  of  the  LAP  (Figure  5.3)  (Ribeiro et al.,  1999;  Schultz-
Cherry and Murphy-Ullrich,  1993). KRFK peptide has been shown to activate latent 
TGF-β by disrupting interactions between LAP and mature TGF-β; additionally, it can 
competitively inhibit complex formation between the LAP and TSP-1 (Ribeiro et al., 
1999). Furthermore, the hexapeptide GGWSXW and LSKL peptide are able to block the 
activation of TGF-β by TSP-1 (Ribeiro et al., 1999; Schultz-Cherry and Murphy-Ullrich, 
1993).
Studies using an anti-Thy1 model have shown that renal arterial transfer of anti-sense 
phosphorothioate oligodeoxynucleotide against TSP-1 and continuous intravenous infusion of 
GGWSXW or LSKL peptides,  interfere  with the  activation  of  TGF-β (Daniel  et  al.,  2003; 
Daniel et al., 2004).  The  treated  mice  in  these  studies  showed  decreased  TGF-β  activity 
and   TGF-β  receptor  signalling,  as  assessed  by  trichrome  collagen  I&IV  and  fibronectin 
staining. Activation of latent TGF-β is a property unique to TSP-1. The TSP-2 family member 
lacks the KRFK sequence and does not activate TGF-β. This finding is  consistent with the 
observation that the corresponding peptide from TSP-2 (RIR) does not activate TGF-β (Schultz-
Cherry et al., 1995).
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Figure 5.3 The mechanism of latent TGF-β activation by TSP-1.
There are two major sites in properdin-like type I repeat of TSP-1 which bind to the latent TGF-
β.  Initially, GGWSXW sequence of TSP-1 binds to VLAL sequence of mature TGF-β.  This 
interaction facilitates the association between KRFK sequence of TSP-1 and LSKL sequence of 
LAP which results to the conformational change of latent TGF-β and exposes the mature TGF-β 
to the receptor. This image is obtained from Hugo and Daniel, 2009.
5.3 Neuropilin-1
Neuropilin-1  (NRP-1)  is  a  multifunctional  protein  expressed  by  several  cell  types, 
including endothelial cells, dendritic cells, regulatory T cells (Treg), malignant cells (Romeo et 
al., 2002; Beilenberg et al., 2006) and epithelial cells of the breast, uterus, endometrium, kidney 
and lung (Gagnon et al., 2000). The well known functions of NRP-1 are axonal guidance via the 
binding with chemorepulsive class 3 semaphorin (SEMA3) proteins (Kolodkin et al., 1997) and 
angiogenesis  through its  interaction with vascular  endothelial  growth factor  (VEGF) family 
members and their receptors (VEGFR1 and VEGFR2) (Pellet-Many et al., 2008).
Neuropilin-2 (NRP-2), which shares 45% homology with NRP-1, is mostly expressed by 
malignant cells (Gray et al., 2008). Interestingly, a recent study reported that TGF-β1, IL-1 and 
OSM (oncostatin M) were able to stimulate NRP-2 expression in renal proximal tubular cells 
(Schramek et al., 2009).
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5.3.1 Structure of Neuropilin-1
The molecular weight of NRPs is 120kDa. The basic structure of NRPs consists of four 
domains (Figure 5.4):
1.   A short cytoplasmic domain which binds to the PDZ protein. PDZ results from the first 
letters  of  three  proteins:  Post-synaptic  density  95,  Drosophila  disc  large  tumour 
suppressor and zonula occludens-1 protein (Wang et al., 2007).
2.   The three extracellular domains:
a. The CUB (a1/a2) domain (named for its identification in complement components 
C1r  and  C1s,  Uegf,  and  bmp1).  This  domain  is  commonly  found  in 
developmentally regulated proteins (Bork and Beckmann, 1993), and is involved in 
SEMA3 binding (Miao et al., 1999).
b.  The  FV/FVIII  (b1/b2)  domain,  which  is  involved  in  both  SEMA3  and  VEGF 
binding (Miao et al., 1999).
c. The MAM domain which is derived from Meprin, A-5 protein and protein-tyrosine 
phosphatase mu. 
Recent  studies  have  reported  NRP-1  can  bind  several  growth  factors,  including 
hepatocyte growth factor (HGF), the HGF receptor (c-Met), fibroblast growth factors (FGFs) 
and platelet derived growth factor (PDGF) (Matsushita et al., 2007; West et al., 2005; Dhar et 
al., 2010). It also has affinity for the β1 integrin (Fukasawa et al., 2007).
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Figure 5.4 The structure of Neuropilin-1.
NRP-1 consists of four domains, (i) CUB domain contains two repeats of complement (a1/a2, 
(ii) FV/FVIII  domain contains two repeats of coagulation factor (b1/b2), (iii) MAM domain, 
and (iv) a transmembrane or cytoplasmic region (d) which  possess a PDZ binding motif at the 
carboxyl termini. This image is obtained from Nakamura et al. 2002.
5.3.2 The mechanism of latent TGF-β activation by NRP-1.
A study  of  human  T cells  has  shown  that  the  proliferation  of  activated  T  cells  is 
suppressed  when  soluble  LAP-TGF-β1  is  added  (Glinka  and  Prud’homme,  2008).  This 
suppression is restored by addition of a blocking anti-TGF-β1 monoclonal antibody (Glinka and 
Prud’homme, 2008). Glinka et al suggest that NRP-1-Fc activates LAP-TGF-β1 via a sequence 
RKFK in the b2 domain, which is closely similar to the KRFK sequence of TSP-1 (Glinka and 
Prud’homme, 2008). Furthermore, both the RKFK and KRFK peptides are equally effective at 
activating  TGF-β1  by  binding  LSKL within  the  N-terminal  region  of  LAP,  leading  to  a 
conformational change which exposes the active growth factor (Figure 5.5) (Schultz-Cherry et 
al., 1995; Ribeiro et al., 1999; Crawford et al., 1998).
NRP-1  expression  has  been  observed  in  3-4% of  splenic  T cells,  with  CD4+T cells 
expressing  this  antigen  (Glinka  and  Prud’homme,  2008).  In  addition,  60%  of  murine 
CD4+CD25+ T cells co-express NRP-1 and LAP; however, 10-12% of CD4+CD25+NRP-  T cells 
also  express  LAP.  Thus,  NRP-1  is  not  the  only  LAP receptor  on  the  surface  of  T  cells. 
Furthermore, it has been reported that NRP-1 expression correlates with high FOXP3 expression 
in mice and humans (Battaglia et al., 2008).
7 | P a g e
Figure 5.5 Mechanism of latent TGF-β activation by NRP-1.
The RKFK sequence in the b2 domain of NRP-1 binds to LSKL sequence of LAP producing 
the conformational change in latent TGF-β. This image is adapted from Hugo and Daniel, 
2009.
8 | P a g e
5.4 Aim and objectives
TGF-β plays a central role in the induction of fibrosis in many organs. In addition, it is 
increasingly recognised that TGF-β-induced EMT is a potential inducer of renal fibrosis. Since 
TGF-β activation is a key step in TGF-β regulation, a series of experiment was designed to 
determine whether activated T cells can activate latent TGF-β by mechanisms involving TSP-1 
and NRP-1.
The objectives of this study are to:
• Detect and quantify the expression of TSP-1 and NRP-1 at both protein and mRNA 
levels in human T cells.
• Examine the expression of NRP-1 in human kidney allograft biopsies.
• Demonstrate  that  cytoplasmic  Smad3  is  phosphorylated  by  treatment  of  NRP-1 
expressing MDA231 cancer cells with latent TGF-β1 and determine whether this 
can be inhibited by addition of the LSKL inhibitory peptide.
• Demonstrate  that  activated  T cells  are  responsive  to  latent  TGF-β1  and  that  this 
response can be inhibited by addition of the LSKL peptide inhibitor of TSP-1 and 
NRP-1.
5.5 Materials and Methods
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5.5.1 MFB-11 Bioassay
As described in  section 2.7.1,  the MFB-F11 assay can be developed using either  P-
Nitrophenyl Phosphate (pNPP) or the Tropix® Phospha-Light™ system. The latter assay will be 
described in this chapter. The Tropix® Phospha-Light™ system is a chemiluminescent system 
designed  for  the  detection  of  secreted  placental  alkaline  phosphatase  (SEAP),  which  is  a 
truncated form of human placental alkaline phosphatase, in cell culture medium. Technically, 
cell culture medium is first heated to 65°C to inactivate endogenous alkaline phosphatase. The 
heated sample is then incubated with assay buffer solution, which contains a proprietary mixture 
of  non-placental  alkaline  phosphatase  inhibitors.  CSPD  (chemiluminescent  substrate  for 
alkaline phosphatase)-containing reaction buffer is then added and incubated until maximum 
light emission is reached. The chemiluminescent signal is then measured using a luminometer. 
This assay allows detection of less than 10 femtogram of SEAP (Chemiluminescent product 
guide, Applied Biosystem), which is more sensitive than colorimetric detection of SEAP.
5.5.1.1  Detection  of  secreted  placental  alkaline  phosphatase  by  Phospha- 
Light Assay
MFB-F11  4x104  cells  were  seeded  in  each  well  of  a  96-well  plate  and  cultured 
overnight. These cells were then washed and incubated in serum free medium for 2 hours. The 
cells were then incubated with 50µl of a serial TGF-β1 dilution (concentration 0-1nM) to make 
a standard curve (Figure 5.6) or with test samples for 24 hours. The Phospha-Light assay kit 
was prepared in accordance with the manufacturer’s instructions. 
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Figure 5.6 TGF-β1 standard curve for detecting secreted placental alkaline phosphatase 
using the Tropix Phospha-Light system.  The results are presented as mean values (n = 6) ± 
SEM.
5.5.2 Intracellular staining for flow cytometry
In order to detect antigens within the cytoplasm of cells, it is necessary to permeabilise 
the plasma membrane to allow large antibody molecules to penetrate the cell. As this process 
can  disrupt  cellular  architecture,  it  is  normally  necessary  to  first  fix  the  cell  structure  by 
chemical treatment.
5.5.2.1 Fixative agents
Fixative agents can be divided into 5 main groups, including (i) cross-linking agents 
which are the most popular fixatives, (ii) precipitating agents or alcohols, (iii) oxidising agents, 
(iv) mercurials and (v) picrates.
Paraformaldehyde (PFA) is a cross-linking fixative and was used in this study.  PFA 
fixes  cells  or  tissues  by  forming  covalent  chemical  bonds  in  the proteins, particularly 
between lysine residues. This anchors and stabilises most antigens and prevents antigen loss or 
migration.  Although  PFA provides  a  beneficial  effect  in  the  preservation  of  intracellular 
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structure  and  plasma  membrane  integrity,  adverse  effects  such  as  autofluorescence  or  cell 
shrinkage can be a problem.
5.5.2.2 Permeabilising agents
Following  fixation,  antibody  fluorescence  dyes  must  access  the  intracellular 
compartment. This can be achieved by treatment with detergents or organic solvents. Saponin 
(Sigma), which was used in this study, is a plant-derived glycoside detergent which acts mainly 
by solubilising cholesterol. Saponin is widely used to permeabilise the plasma membrane and 
intracellular membranes, depending on the concentration (Wassler et al., 1987).
5.5.2.3 Intracellular staining for flow cytometry procedure
Cells were harvested and washed two times in 2% FBS/PBS. The cells were fixed in 2% 
paraformaldehyde  at  room temperature  for  15  minutes  and then  washed in  0.1% saponin  in 
2%FBS/PBS by spinning at 500g for 5 minutes. After washing, the fixed cells were incubated 
with a biotin  conjugated  anti-TSP-1  antibody  (1:10),  which  was  diluted  in 0.1% saponin/2% 
FBS/PBS, on ice for 30 minutes. The wash step was repeated three times, followed by incubation 
with streptavidin conjugated anti-mouse IgG antibody (1:50) on ice for 30 minutes. The cells 
were washed three times before analysis using a FACSCalibur machine (BD Biosciences).
5.5.3 Cytocentrifugation
Centrifugation in a Cytospin (Shandon) is a method used to prepare suspension cells for 
microscopic viewing. Human T cells were activated with CD3/CD28 beads for 48 hours. The 
activated T cells were washed and diluted in 2% FBS/PBS at a concentration of 1x105cells/ml. 
Microscope slides were mounted with a paper pad and cuvette in the metal holder. 200µl of cell 
suspension was loaded into each cuvette before centrifugation at 1000rpm for 3 minutes. The 
slides were carefully detached from the paper pads and allowed to dry before being fixed in 
methanol at -20°C for 1 hour.  The fixed cells  were dried again in air before processing for 
immunofluorescence staining as described in section 2.5.2.4.
5.5.4 CFSE staining protocol
Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent cell staining dye which is 
commonly used for proliferation analysis. Initially, the dye enters cells in a diacetylated form, 
carboxyfluorescein  diacetate  succinimidyl  ester  (CFDA,  SE).  Then,  intracellular  esterases 
remove the acetate groups and convert the molecules into the fluorescent ester (CFSE), which is 
retained within the cells after covalently coupling, via the succinimidyl group, to intracellular 
proteins (Figure 5.7). Since CFSE is membrane impermeable, it can be retained within cells for 
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extremely long periods without being transferred to adjacent cells. When cells divide, the CFSE 
is equally split between the daughter cells, leading to CFSE signal reduction. The cells may then 
be analysed by flow cytometry to quantify CFSE within individual cells and dilution of the label 
produced by cell division (Quah et al., 2010).
5.5.4.1 CFSE labelling procedure
After  isolating  human  T  cells,  as  described  in  section  2.2.5.1,  6x106cells  were 
resuspended in 300µl of 0.1% FBS/PBS. The cell suspension was split equally into 2 tubes. The 
T cells were incubated with 150µl of 2µM CFSE at 37°C for 5 minutes. After incubation, 5ml 
of cold complete medium was added to both tubes, which were then placed on ice for 5 minutes. 
The T cells were washed by adding 10ml of complete medium and centrifuged twice at 800G 
for 10 min. Prior to activation the cells were incubated with medium overnight to allow early 
loss of CFSE. The cells were washed again before activation by CD3/CD28 beads.
Figure 5.7 Illustration of the chemical changes that fix CFSE within a cell  during the 
labelling process. The image is obtained from Quah et al. 2010.
5.5.5 Immunohistochemistry staining for paraffin section
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Immunohistochemistry  is  a  method  for  demonstrating  the  presence  and  location  of 
proteins  in  tissue  sections.  Immunohistochemical  staining  is  accomplished  using  antibodies 
specific  for  target  antigens.  The  antibody-antigen  interaction  is  then  visualised  using  either 
chromogenic detection, in which an enzyme conjugated to the antibody cleaves a substrate to 
produce a coloured precipitate, or fluorescent detection, in which a fluorophore is conjugated to 
the antibody and can be visualised directly by fluorescence microscopy.
IHC-P refers to immunohistochemical staining of tissues that have been fixed and then 
embedded in paraffin before being sectioned.  The basic  steps of the IHC-P protocol  are  as 
follows.
5.5.5.1 Deparaffinisation
Before  proceeding  with  the  staining  protocol,  the  slides  must  be  deparaffinised  and 
rehydrated. Incomplete removal of paraffin can cause poor staining of the section. The slides 
were placed in a rack and washed in a xylene tank for 10 minutes. The slides were then washed 
for 1 minute in 100% and 95% ethanol tanks respectively, before being held in tap water until 
antigen retrieval.
5.5.5.2 Endogenous peroxidase blocking
Endogenous peroxidase activity is found in many tissues and can be detected by reacting 
fixed tissue sections with DAB substrate. Endogenous peroxidase activity is inhibited by pre-
treatment of the tissue section with hydrogen peroxide prior to antigen retrieval or incubation 
with primary antibody.
5.5.5.3 Antigen retrieval
During the formalin fixation process, a methylene bridge is formed, which cross-links 
proteins and masks antigenic sites. Antigen retrieval is required to break the methylene bridges 
and expose  antigenic  sites  in  order  to  allow antibodies  to  bind.  There  are  two methods of 
antigen retrieval:  heat-induced and enzyme-mediated.  This study used heat-induced epitope 
retrieval.
1000ml of sodium citrate buffer (2.94g Tri-sodium citrate in 1000ml distilled water at 
pH6.0; 0.5ml Tween-20 was added before use) was added to a pressure cooker and heated to 
100C. Once boiling, the slides in a metal rack were transferred from tap water to the pressure 
cooker. The lid of the pressure cooker was secured following the manufacturer’s instructions, 
and  the  samples  were  heated  at  full  pressure  for  60  seconds.  After cooling in water, the 
lid was removed and the slides were washed in tap water for 5 minutes.
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5.5.5.4 Immunohistochemical staining
A. Control
Negative controls were performed to test for the specificity of each primary antibody 
involved. First, no staining must be shown when omitting the primary antibody or replacing a 
specific primary antibody with normal serum (of the same species as the primary antibody). 
This control is easy to achieve and can be used routinely in immunohistochemical staining.
B.  Blocking
The main cause of non-specific background staining is non-immunological binding of 
the specific immune sera by hydrophobic and electrostatic forces to certain sites within tissue 
sections.  This  form  of  background  staining  is  usually  uniform  and  can  be  reduced  by 
blocking non-specific  sites  with normal  serum.  Some tissues,  including  the  kidney,  contain 
endogenous biotin. To avoid unwanted avidin binding to endogenous biotin, if using a biotin-
avidin detection system, it is necessary to pre-treat these tissues with unconjugated avidin.
C.  Indirect staining: Avidin-Biotin Complex (ABC) method
The ABC method is one of the most widely used techniques for immunhistochemical 
staining. Avidin, a large glycoprotein, can be labelled with peroxidase or fluorescein and has a 
very high affinity for biotin. Biotin, a low molecular weight vitamin, can be conjugated to a 
variety of biological molecules, including antibodies. The technique involves three layers. The 
first layer is unlabelled primary antibody. The second layer is biotinylated secondary antibody. 
The third layer is a complex of avidin-biotin peroxidase. The peroxidase is then developed by 
reaction with3, 3’-diaminobenzidine (DAB), which is oxidised to give a brown colour.
Briefly,  endogenous biotin was blocked by incubating kidney sections with avidin at 
room temperature for 15 minutes, followed by biotin for 15 minutes (Avidin/Biotin Blocking 
kit, Vector). The slides were then washed in TBS twice for 5 minutes. The sections were then 
incubated in 20% swine serum at 4°C for 1 hour to block non-specific binding. After blocking, 
the  sections  were  incubated  with  primary  antibody,  rabbit  monoclonal  anti-NRP-1  (1:100) 
diluted in 20% swine serum at 4°C overnight. The next day, the slides were washed in TBS 
before incubating with biotinylated goat anti-rabbit IgG (1:200) at room temperature for 1 hour. 
The slides were washed twice in TBS for 5 minutes. The sections were then incubated with 
avidin-biotin peroxidase at room temperature for 30 minutes, followed by the washing step. The 
slides were then incubated with a solution containing DAB and H
2
O
2 
at room temperature for 2 
minutes, or until the colour changed to brown, then rinsed in running tap water.
5.5.5.5 Counterstain
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A counterstain is a stain with colour which contrasts with the principal stain, making the 
stained structures more easily visible. The slides were placed in a haematoxylin tank for 30 
seconds, and then rinsed in running water before being incubated in Scott’s tap water for 30 
seconds and washed again.
5.5.5.6 Dehydration
Dehydration  was  performed by placing  the  rack  of  slides  for  1  minute  each  in  50% 
ethanol, 70% ethanol, 95% ethanol, 100% ethanol and xylene, respectively.
5.5.5.7 Mounting the slide
The slides were mounted with DPX, which is a mixture of distyrene (a polystyrene), a 
plasticiser (tricresyl phosphate), and xylene.
5.5.6 Two colour immunofluorescence staining
This method was used to assess the co-expression of NRP-1 and CD3 in the transplant 
kidney  biopsy  sections.  The  sections  were  passed  through  the  following  processes: 
deparaffinisation,  rehydration and antigen retrieval as described in section 5.2. The sections 
were then incubated with normal serum at room temperature for 1 hour, followed by incubation 
overnight with primary rabbit monoclonal anti-NRP-1 (1:100) and mouse monoclonal anti-CD3 
(1:100) at 4°C. The following day, the sections were washed in TBS for 5 minutes 3 times 
before incubation with polyclonal anti-rabbit IgG FITC conjugated (1:150) at room temperature 
for  1  hour.  The  slides  were  washed in  TBS three  times.  After  washing,  the  sections  were 
incubated with polyclonal anti-mouse IgG TRITC conjugated (1:100) for 1 hour. After washing, 
the nuclei  were  stained  with  DAPI  for  2  minutes,   followed  by  one  wash.  Auto-
fluorescence was reduced by placing the slides in a Sudan Black solution for 10 minutes. After 
washing, the slides were mounted with fluorescence mounting medium. The slides were stored 
in the dark at 4°C until they were viewed by confocal microscopy.
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5.6 Results
5.6.1  NRP-1 expression by  normal  renal  tubular epithelial  cells  and graft 
infiltrating inflammatory cells
It has been suggested that NRP-1 is expressed by many cell types including endothelial 
cells, malignant cells, epithelial cells, and regulatory T cells (Kragbrun et al., 2002). However, 
the data of NRP-1 expression in transplanted kidney has rarely been reported. This experiment 
was performed in order to  examine the expression of NRP-1 in  transplanted kidney biopsy 
sections by using the immunoperoxidase technique. Normal and rejected kidney graft sections 
were processed as described in section 5.5.5, and, following the staining, the slides were viewed 
by light microscope at time 20 magnification.
In normal transplant kidney sections, NRP-1 was present along the luminal surface of 
some renal tubules (Figure 5.8A) while there was absence of NRP-1-positive interstitial cells. 
However, the expression of NRP-1 was reduced in the damaged tubules of kidney grafts with 
cell-mediated  rejection,  but  some  infiltrating  inflammatory  cells  did  express  NRP-1  in  the 
interstitium (Figure 5.8B). 
Several immune cell types, including macrophages and lymphocytes, have been reported 
to express NRP-1 (Ji et al., 2009). The potential association between CD3 and NRP-1 in kidney 
allograft sections was determined by performing 2-colour immunofluorescence to localise these 
antigens.
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 Figure 5.8 Microscopic analysis of NRP-1 expression in human kidney graft biopsies.
In a normal kidney allograft (A), NRP-1 was predominantly localized at the luminal surface of 
renal tubules (red arrows). However, NRP-1 preferentially appeared in inflammatory cells in the 
interstitial  areas  during  rejection  (white  arrows)  whereas  the  appearance  in  luminal  areas 
seemed  to  decrease.  The  images  were  captured  at  x200  magnification.  The  results  are 
representative of 2 similar experiments.
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5.6.2 NRP-1 was expressed on infiltrating CD3-expressing cells during graft 
rejection
In  order  to  determine  what  type  of  inflammatory  cells  expressed  NRP-1,  sections 
showing  renal  allograft  rejection  were  examined  by  2-colour  immunofluorescence  staining 
(section 5.5.6). Transplanted kidney biopsies including normal and rejecting grafts were stained 
with anti-NRP-1 and anti-CD3 monoclonal antibodies. The expression of NRP-1 and CD3 was 
localised intracytoplasmic by confocal microscopy. Interestingly, some infiltrating inflammatory 
cells  expressed  both  CD3 and  NRP-1 (Figure  5.9)  during  an  acute  rejection  episode.  This 
suggested that NRP-1 was expressed by activated T cells during graft rejection. 
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Figure 5.9 Immunofluorescence analysis of NRP-1 co-expression with CD3 in a kidney 
allograft biopsy showing acute rejection.
Two colour immunofluorescence staining of CD3 (Red) and NRP-1 (Green) in cell-mediated 
rejection showing some CD3+cells  co-expressed NRP-1 (white  arrows)  (B)  compared to  a 
negative control section (A). The images were taken at x 20 (A) and x 63 (B) magnification. 
The results are representative of 2 similar labelling experiments.
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5.6.3 NRP-1 was highly expressed by human T cells after activation for 48 
hours
A previous study has shown that 3-4% of mouse splenic T cells express NRP-1 (Glinka 
and Prud’homme, 2008). However, results for human T cells have been inconclusive (Milpied et 
al., 2009). To determine the exact number of NRP-1+ T cells, human T cells were isolated from 
the blood of healthy volunteers as described in section 2.2.5. Some of the resting T cells were 
then activated with CD3/CD28 beads (section 2.2.5.1). The time course of NRP-1 expression 
was determined by staining resting T cells and activated T cells after 24, 48 and 72 hours with 
an APC conjugated anti-NRP-1 monoclonal antibody. In addition, the T cells were co-stained 
with a FITC conjugated anti-CD4 antibody in order to identify the specific subtype of T cells 
which  expressed  NRP-1.  Following the  staining  process,  the  phenotype  of  the  T cells  was 
examined by flow cytometry. 
Approximately 1-2% of circulating human T cells expressed NRP-1. Interestingly, the 
population of NRP-1+ T cells increased after activation, and reached a maximum of 17.52 ± 3% 
(mean ± SEM; n=8) after 48 hours (Figure 5.10C). After 48 hours, the expression of NRP-1 
gradually declined (Figure 5.10D). Two parameter immunophenotyping showed that 80% of the 
cells expressing NRP-1 were CD4+  T cells (Figure 5.10A-D). Normally, T cells are activated 
during  antigen-specific  immune  processes  such  as  acute  rejection.  The  results  from  this 
experiment  suggest  that  NRP-1 may be  up-regulated  on  the  surface  of  CD4+ T cells  after 
activation by allogantigen-expressing cells within a renal allograft This is consistent with the 
finding of NRP-1 expressing T cells in kidney graft  biopsies from patients  with acute cell-
mediated rejection.
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Figure 5.10 Time course expression of NRP-1 by activated human T cells.
CD3/CD28 activated T cells were analyzed for NRP-1 expression at 0, 24, 48 and 72 hours by 
flow cytometry. The percentage of NRP-1 positive resting CD4+T cells (%) was 1.2 ± 0.13 (A), 
this increased to 8.5 ± 2.7 after 24 hours (B). Expression reached the highest value of 17.52 ± 3 
at 48 hours (C) and then gradually declined to 9.82 ± 2.6 at 72 hours (D). All data are presented 
as mean ± SEM; NRP-1 preferentially appeared in the CD4+ T cell sub-population. The dot-plot 
results  are  representative  of  4  similar  experiments.  The  bar  graph  (E)  summarizes  the 
percentage of NRP-1 expression by all T cells. The bars show mean value (n=4) and error bars 
are SEM. The quadrants were set by analysing of samples after labelling with isotype control 
antibodies. The table shows the percentage of NRP-1 expression by activated T cells after 48 
hours (data from 8 independent experiments using different T cell donors).
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5.6.4 Cytosmear showing the presence of NRP-1 in activated T cells.
Flow cytometric data showed the expression of NRP-1 on the surface of activated T cells. 
This  was  confirmed  by  cytocentrifugation  followed  by  immunofluorescence  staining  to 
determine  the  distribution  of  NRP-1  in  activated  T cells  (see  section  2.5.2.4).  Fluorescence 
microscopy was used to examine the presence of NRP-1(Figure 5.11).
Results  of  this  study  showed  the  expression  of  cytoplasmic  NRP-1  in  T  cells  after 
activation with CD3/CD28 beads for 24 hours. Interestingly, nearly all the cells expressed NRP-1 
by cytosmear staining. However, at this time the flow cytometer showed cell surface expression 
of  this  antigen  on  a  minority  of  the  cells.  This  might  suggest  that  NRP-1  is  stored  in  the 
cytoplasm of all activated T cells but is driven to the surface of only some cells after activation. A 
further experiment was designed to test whether cell-surface expression of NRP-1 is dependent 
on cell proliferation.
5.6.5 Cell division and NRP-1 expression
To ascertain whether the expression of NRP-1 is associated with the cell cycle, flow 
cytometric analysis was performed. Resting T cells were incubated with 2µM CFSE at 37°C for 
5 minutes, and then the excess CFSE was removed by washing in medium. The stained cells 
were left  overnight in  medium before activation by CD3/CD28. The activated T cells  were 
collected at 24, 48 and 72 hours and stained with APC conjugated anti-NRP-1 antibody. The 
presence of both CFSE and NRP-1 was determined by 2-colour flow cytometry collecting data 
o fluorescence channels 1 and 4 respectively.
After  activation  for  48  hours,  the  fluorescence  results  showed  clear  CFSE  peaks 
corresponding to undivided cells (M1) and cells which had undergone 1 (M2), 2 (M3) and 3 
(M4) cycles  of  proliferation;  a  few cells  had  undergone 4 cycles  of  division  (M5)  (Figure 
5.12A, B, C); the greatest proportion of T cells was in peak M4 at this time. Examination of 
NRP-1 expression in each cell cycle showed that 20% of the cells in each cycle (including 
undivided cells) expressed cell-surface NRP-1. Hence, the expression of cell surface NRP-1 is 
not dependent on T cell proliferation or the number of cycles of cells division. 
23 | P a g e
Figure 5.11 Localization of NRP-1 in CD3/CD28 activated T cells
The isolated T cells were activated with CD3/CD28 for 48 hours. Then the activated T cells 
were  attached  to  slides  by  cytocentrifugation,  and  stained  with  anti-NRP-1  mAb  (Green). 
Nuclei were visualized by DAPI stain (Blue). The images were taken at x 100 magnification. 
The result is representative of 2 similar experiments.
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Figure 5.12 Flow cytometric analysis of NRP-1 expression after 48 hours of T cell 
division.
Isolated human T cells were incubated in medium containing 2µM of CFSE overnight, followed 
by activating T cells with CD3/CD28 beads for 48 hours before flow cytometry analysis. (A and 
B) Dotplot and (C) histogram show T cells division at 48 hours. (D) The bar graph shows the 
percentage of NRP-1 expressing cells in each cell cycle (mean ± SEM, n = 3). The results are 
representative of 2  similar  experiments.  The quadrants were set  by analysing samples after 
labelling with appropriate isotype control antibodies.
5.6.6  Cytoplasmic  thrombospondin-1  was  mobilised  to  the  surface  of 
activated T cells after co-culture with renal epithelial cells
It has been demonstrated that TSP-1 plays an important role in the activation of latent 
TGF-β  in vivo (Ludlow et  al.,  2005).  The following series of experiments was designed to 
examine the expression of TSP-1 by human T cells.
Initially, flow cytometry was performed to quantify the expression of TSP-1 by activated 
T cells. The human T cells were activated with CD3/CD28 for 72 hours. The activated T cells 
were  then  incubated  with  a  biotin-conjugated  anti-TSP-1  antibody (Abcam) for  30  minutes, 
followed  by  incubation  with  FITC-conjugated  streptavidin  for  30  minutes.  The  cells  were 
examined by immunofluorescence flow cytometry using a FACSCalibur machine. 
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After activation, TSP-1  was  expressed  on  the  surface  of fewer than 10% of activated 
T  cells  (Figure  5.13A). A previous study has suggested that T cells cultured with fibronectin 
and  collagen  strongly  express  TSP-1,  with  a  possibility  that  this  antigen  is  moved  from 
cytoplasmic stores to the cell surface in response to cell contact with these matrix proteins (Li et 
al., 2002). To examine this possibility, activated T cells were either permeabilised with saponin or 
co-cultured with HK-2 before labelling with an anti-TSP-1 monoclonal antibody. Interestingly, 
the proportion of TSP-1 expressing cells increased to 36.6% following permeabilisation (Figure 
5.13B). Furthermore, 21.7% of the T cells expressed TSP-1 after co-culture with HK-2 cells for 
30 minutes (Figure 5.13C).  These results suggest that TSP-1 is expressed in the cytoplasm of a 
greater proportion of T cells than expresses this antigen on the cell surface. Furthermore, brief 
exposure of the t cells to HK-2 cells was sufficient to markedly increase T cell surface expression 
of TSP-1. It is possible that this induction of cell-surface TSP-1 expression is due to contact with 
matrix proteins produced by the immortalised kidney cells. This possibility will require further 
investigation. 
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Figure 5.13 Activated T cells co-cultured with renal tubular epithelial cells increased cell 
surface expression of TSP-1.
(A) A flow cytometric histogram shows TSP-1 on surface of <10% of activated T cells. (B) 
When activated T cells were permeabilized by saponin, 36.6% ± 1.3 (mean ± SEM, n = 4) of the 
cells expressed TSP-1. (C) Activated T cells co-cultured with HK-2 increased TSP-1 expression 
to 21.7%. In all cases, the shaded histogram shows fluorescence produced by labelling with an 
isotype-matched control antibody. The open histogram shows experimental labelling. Results 
are shown from 1 of 4 similar experiments.
5.6.7 Changes in gene expression following T cell activation
This  study  has  shown  that  NRP-1  protein  was  maximally  expressed  after  T  cell 
activation for 48 hours. In order to determine whether this resulted from significant induction of 
the NRP-1 gene, a series of quantitative real-time PCR analyses was performed. 
T cells were activated for 24 hours by stimulation with CD3/CD28 beads (section 2.2.5), 
followed by 24 hours incubation with no further stimulation or with 10ng/ml TGF-β1 or an 
equimolar  30ng/ml  of  latent  TGF-β1.  After  the  stimulation,  RNA was  prepared  for  cDNA 
synthesis  (section  2.3.4).  Real-time  PCR  was  performed  to  quantify  changes  in  the  basal 
expression of RNA encoding CD103, FoxP3, TGF-β, TSP-1 and NRP-1; 18s rRNA was used as 
an internal standard (section 2.4.3). 
After  CD3/CD28  activation  for  48  hours  the  expression  of  FOXP3  mRNA  was 
significantly increased, but none of the other assayed mRNA sequences showed a change in 
expression (Figure 5.14). T cells treated with TGF-β1 significantly increased their expression of 
the CD103, FOXP3, TSP-1 and TGF-β1 genes. Treatment with latent TGF-β1 also increased the 
expression of CD103, FOXP3 and TSP-1 (albeit to a lesser extent that the induction caused by 
TGF-β1);  latent  TGF-β1  did  not  significantly  increase  TGF-β1  mRNA expression.   The 
expression of mRNA encoding NRP-1 was not increased by T cell activation, suggesting that 
the  increase  in  protein  expression  observed  is  produced  by  post-transcriptional  regulation. 
However, the gene expression study did not have positive control for NRP-1 expression. Further 
study is required to explore this issue.
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Figure 5.14 Comparison of CD103, FOXP3, TGF-β1, TSP-1 and NRP-1 gene expression in 
activated T cells, TGF-β1 treated cells and latent TGF-β1 treated cells.
The isolated human T cells were activated by CD3/CD28 Beads for 24 hours followed by 24- 
hours of 10ng/ml TGF-β1 or equimolar  (30ng/ml) latent TGF-β incubation.  All  genes were 
normalized to 18S rRNA and are presented as mean values ± SEM (n=3). FOXP3 mRNA was 
significantly expressed in all treatment groups relative to resting T cells.  CD103 and TSP-1 
mRNA were significantly up-regulated in latent TGF-β1 and TGF-β1 treated T cells, whereas 
TGF-β1 mRNA was significantly expressed in T cells with TGF-β1 treatment. However, none 
of  treated T cells  up-regulated NRP-1 mRNA. These results  are  representative of 3 similar 
experiments. (* = p < 0.05, *** = p<0.001; ANOVA).
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5.6.8 LAP is necessary and sufficient to confer the latency to TGF-β
Latent TGF-β usually consists of active TGF-β and LAP. Thus, if active TGF-β is added 
to LAP, the activity of TGF-β should be inhibited by the formation of the latent complex. This 
hypothesis was tested by incubating MFB-F11 cells with 1nM TGF-β1 with or without LAP at 
concentrations  between 0.001-100nM for  24  hours.  The  culture  medium was collected  and 
response to active TGF-β1 was detected using the Phospha™-Light assay. 
No significant response to TGF-β was observed in control wells which contained serum-
free medium; LAP alone also produced no positive response in the assay. In contrast, TGF-β1 
samples showed the  highest  levels  SEAP production indicating the response to active  TGF-
β1; this  activity  was  significantly  reduced  in  the presence of increasing concentrations of 
LAP(Figure 5.15) with complete blockade observed after addition of 100nM LAP. 
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Figure 5.15 Bioassay analysis of active TGF-β activity of TGF-β1 in the presence of
LAP.
Semi-confluent MFB F-11 cells were incubated in medium or medium containing 1nM of TGF-
β1  or  TGF-β1 with  LAP at  concentrations  between  0.001 –  100 nM for  24  hours.  In  the 
presence of LAP, the level of TGF-β1 significantly decreased with complete blockade at a LAP 
concentration of 100nM. The bars shows mean and the error bars are SEM. The results are 
representative of 3 similar experiments. (** = p < 0.01, *** = p < 0.001; ANOVA).
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5.6.9 NRP-1 was expressed by the MDA231 human breast cancer cell line
MDA231 is a breast carcinoma cell line which strongly expresses NRP-1 (Ginkla et al., 
2008). These cells were used in this study as a positive control for NRP-1 expression. This cell 
line was first  validated for both NRP-1 and TSP-1 expression by flow cytometry.  Confluent 
MDA231  cells  were  harvested  and  incubated  with  APC  conjugated  anti-NRP-1  and  biotin 
conjugated  anti-TSP-1  for  30  minutes.  To  examine  the  expression  of  TSP-1,  the  cells  were 
incubated with FITC conjugated streptavidin before analysis. 
The flow cytometric results demonstrated that MDA231specifically expressed NRP-1 but 
did not express TSP-1 (Figure 5.18). The following experiments used this cell line to demonstrate 
a role for NRP-1 in the activation of latent TGF-β and also to validate the inhibitory effect of the 
LSKL peptide.
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Figure 5.16 Histogram demonstrating the expression of NRP-1 and TSP-1 by MDA231 
cells.
Confluent MDA231 cells were incubated with anti-NRP-1 (A) and anti-TSP-1 (B) antibodies 
before  analysis  by  flow  cytometry.  In  all  cases,  the  shaded  histogram shows  fluorescence 
produced by labelling with an isotype-matched control antibody. The open histogram shows 
experimental labelling. The results are a representative of 2 independent experiments and show 
that all the cells express NRP-1 at a high level but TSP-1 was not expressed.
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5.6.10 The LSKL peptide inhibited pSmad2/3 expression by MDA231 
cells.
Members  of  the  TGF-β  superfamily  predominantly  signal  via  activation  of  the 
intracellular Smad signalling pathway; in particular, the functions of TGF-β1, TGF-β2 and TGF-
β3, are generally mediated by the Smad2 and Smad3 signalling molecules (Feng et al., 2005). 
The LSKL peptide sequence of LAP is the binding site for KRFK and RKFK of TSP-1 and NRP-
1 respectively (section 5.2.2 and 5.3.2). Therefore, addition of LSKL peptide could competitive 
bind  to  KRFK  or  RKFK  sequence  leading  to  inhibition  of  latent  TGF-β  activation,  which 
subsequently phosphorylate intracellular Smad molecules. Although it is well known that the 
LSKL peptide can inhibit the activity of TSP-1 (Ribeiro et al., 1999), the potential of this peptide 
to inhibit the activation of latent TGF-β1 by NRP-1 has not been previously demonstrated. In this 
study a series of experiments was performed to validate this inhibition of NRP-1. 
MDA231 cells which express NRP-1 but no TSP-1 (section 5.6.9) were incubated with 
1nM TGF-β1 and an equimolar concentration of latent TGF-β1 with or without 50µM LSKL or 
SLLK peptides for 24 hours. After incubation, the cells were fixed with 4% paraformaldehyde 
at room temperature for 20 minutes. The fixed cells were then permeabilised with Tween 20 for 
30 minutes.  Non-specific antibody binding was blocked by incubation with 1%BSA/PBS at 
room  temperature  for  1  hour.  The  cells  were  then  incubated  with  anti-phosphoSmad  2/3 
antibody (1:100) at 4°C overnight. After washing in TBS three times for 5 minutes, the cells 
were incubated with FITC-conjugated anti-rabbit IgG at room temperature for 1 hour, followed 
by staining the nuclei  with DAPI. The slides were visualised by confocal microscopy at 63 
times magnification. 
Resting cells showed no expression of pSmad 2/3. However, when the cells were treated 
with  TGF-β1,  pSmad  2/3  expression  was  clearly  visible  (Figure  5.20).  The  latent  TGF-β1 
treated cells  also expressed pSmad 2/3,  though at a reduced intensity,  suggesting that latent 
TGF-β1  was  activated  in  the  culture  system.  Importantly,  the  LSKL peptide  inhibited  the 
potential  of  latent  TGF-β1 to  induce  the  expression  of  pSmad 2/3;  this  inhibition  was  not 
observed  when  the  control  SLLK  peptide  sequence  was  present  (Figure  5.17).  This  study 
provides evidence that the LSKL can inhibit  NRP-1 dependent activation of latent TGF-β1. 
However,  the  inhibition  observed  in  this  assay  was  incomplete,  suggesting  the  additional 
activity  of  non-inhibitable  mechanisms  of  TGF-β1  activation  during  the  prolonged  culture 
period. For this reason a second experiment was conducted across a shorter time period using a 
sensitive western blot system to detect phosphorylated Smad 3.
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Figure 5.17 The expression of pSmad2/3 in the MDA231 cell line.
Confluent MDA231 cells  were incubated in medium (A) or medium containing 10ng/ml of 
TGF-β1  (B)  or  equimolar (30ng/ml)  LAP-TGF-β1  (C)  with  50µM  LSKL  (D)  or  SLLK 
(E)  peptide for 72 hours.  pSmad2/3 was demonstrated by microscopic immunofluorescence 
staining (Green). Nuclei were visualized by DAPI staining (Blue). The images were recorded at 
x60 magnification. The quantitative analysis of fluorescence intensity showed that pSmad2/3 
was significantly increased in the TGF-β1-treated group. LAP-TGF-β1 also induced pSmad2/3 
expression, but this was significantly decreased after incubating with the LSKL peptide. The 
bars show mean (n=5 areas of fluorescent measurement) and error bars are SEM. The results are 
representative of 2 similar experiments. (* = p < 0.05, student’s t-test).
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5.6.11 Phospho (p)Smad3 expression by MDA231 cells was inhibited by the 
LSKL peptide.
The  inhibitory  effect  of  the  LSKL peptide  was  confirmed  using  the  Western  Blot 
method. MDA231 cells were treated with 1nM TGF-β1 or equimolar latent TGF-β1 with or 
without 50µM LSKL or SLLK for 30 minutes. After the treatment, the cells were lysed in a 
buffer containing mixed phosphatase inhibitors. After the reduction of disulphide bonds with 
SDS solubilisation (see section 2.6.3), an equal concentration of protein in each sample was 
loaded and run  in  10%SDS-PAGE at  100V for  2  hours.  The  separated  proteins  were  then 
transferred  to  a  PVDF membrane  at  100mA overnight.  The  membrane  was  incubated  with 
monoclonal  mouse  anti-pSmad3,  diluted  in  3%BSA/TBS  (1:2000)  at  4°C  overnight.  After 
washing in TBS three times, the membrane was incubated with anti-rabbit HRP for 1 hour at 
room temperature.  After  further  washing,  the  films  were  developed using  the  ECL method 
(section 2.6.5). Equal protein loading was monitored by probing with an anti-α tubulin antibody 
(1:5000). 
Resting MDA231 cells did not express pSmad3; however, following 30 minutes with 
TGF-β1  and  latent  TGF-β1,  pSmad3  was  up-regulated.  The  appearance  of  pSmad3  after 
treatment with latent TGF-β1 was inhibited by the LSKL inhibitor peptide (Figure 5.18); the 
control peptide was not active in this assay. 
In the absence of TGF-β1 there was no evidence of activation of the TGF-β signalling 
pathway in MDA231 cells.  However, in the presence of both active and latent TGF-β1, the 
TGF-β receptors were stimulated and Smad3 was phosphorylated, suggesting that the NRP-1 
expressed by the cells was activating latent TGF-β1. This was supported by the observation that 
the LSKL inhibitor almost completely inhibited the phosphorylation of Smad3 in response to 
latent TGF-β1. Since MDA231 cells specifically express NRP-1, this effect most likely was 
mediated by inhibition of the NRP-1 cell-surface protein.
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Figure 5.18 The expression of pSmad3 protein in MDA231 cells by Western Blotting.
Confluent MDA 231 cells were grown in medium (A) or medium containing 10ng/ml of TGF-
β1 (B) and 30ng/ml of LAP-TGF-β1 (C) with or without 50µM of LSKL (C) or SLLK (D) 
peptides for 72 hours. The expression of pSmad3 was analyzed by western blot experiment. α-
Tubulin was used as control between groups. pSmad3 was strikingly expressed in TGF-β1 (B) 
as well as in the LAP-TGF-β1 (C) groups, though the latter appeared in lower amount. The 
expression of pSmad3 was markedly decreased in LAP-TGF-β1 with LSKL peptide (D) but the 
SLLK control peptide was inactive (E). The results are representative of 3 separate experiments.
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5.6.12 LSKL peptide can inhibit the activation of latent TGF-β1 by T cells.
It has been reported that CD103 expression is induced in activated T cells by the action 
of active TGF-β1 (Wong et al.,  2003). Interestingly,  the results from real-time PCR (Figure 
5.14) showed an up-regulation of CD103 in T cells which had been treated with latent TGF-β1. 
This study has already shown that activated T cells can express both TSP-1 (section 5.6.3) and 
NRP-1 (section 5.6.6) on their cell surface, providing a candidate mechanism for the activation 
of  latent  TGF-β1.  It  has  also  been  shown that  the  LSKL peptide  sequence  can  inhibit  the 
potential of NRP-1 to interact with and activate latent TGF-β1 (section 5.6.10). In this study a 
series of experiments was performed to determine whether inhibition of both TSP-1 and NRP-1 
can block the response of activated human T cells to the latent, LAP-TGF-β1 complex.
Activated T cells were incubated with 30ng/ml LAP-TGF-β1 in the presence of 50µM 
LSKL peptides  and  50µM SLLK control  peptides.  After  6  hours  the  treated  T cells  were 
processed for RNA extraction followed by cDNA synthesis. The expression of CD103, Foxp3 
and TGF-β1 genes were quantified relative to 18S rRNA expression by real-time PCR. 
As expected, CD103mRNA and FoxP3 mRNA were up-regulated following stimulation 
with  latent  TGF-β1;  TGF-β1 mRNA also  showed a  small  increase  in  this  experiment.  The 
expression of each of these genes was reduced significantly in cultures containing both latent 
TGF-β1 and the LSKL peptide in comparison with matched cultures containing the scrambled 
control peptide, SLLK (Figure 5.19). However, in was also apparent that the LSKL peptide did 
not completely inhibit the response to latent TGF-β1, suggesting that another mechanism might 
contribute to the activation of TGF-β1 in this system
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Figure 5.19 The comparison of CD103, FOXP3 and TGF-β1 genes expression in LAP- 
TGF-β1 stimulated human T cells in the presence of LSKL and SLLK peptides.
Isolated human T cells were activated by CD3/CD28 Beads for 24 hours followed by 6-hour 
of 30ng/ml LAP-TGF-β1 stimulation in the presence of LSKL or SLLK peptide 50µM. The 
quantitative measurement of mRNA was analyzed by real time PCR. The CD103, Foxp3 and 
TGF-β1 mRNA levels were normalized to 18s rRNA and are presented as the means ± SEM 
(n=3). LSKL peptide significantly reduced CD103, Foxp3 and TGF-β1 mRNA expression 
compared  to  latent  TGF-β treated  group.  These  results  are  representative  from 3  similar 
experiments. (** = p < 0.001, * = p < 0.05; student’s t test).
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5.6.13 The induction of CD103 protein in response to treatment of activated 
human T cells with latent TGF-β1 was reduced by the LSKL peptide.
It has been shown that the induction of CD103 protein expression on activated human T 
cells is a consequence of stimulation of the TGF-β receptor (Wong et al., 2003). The following 
series of experiments was performed to test  whether latent TGF-β1 had a similar  effect  on 
CD103 induction as active TGF-β1 and to determine whether the response to latent TGF-β was 
sensitive to inhibition by addition of the LSKL peptide. 
Activated T cells were incubated with 1nM TGF-β1 with or without 50µM LSKL and 
SLLK peptides, and equimolar (3nM) latent TGF-β1 with or without 50µM LSKL and SLLK 
peptides for 72 hours. After this incubation, the cells were labelled with FITC conjugated anti-
CD103 and examined using the FACSCalibur flow cytometer. 
TGF-β1 treated T cells expressed a high level of CD103 (Figure 5.20B); as expected, 
this was not altered by addition of either the LSKL or SLLK peptides (Figure 5.20F, G). Neither 
the  LSKL  nor  the  SLLK  peptides  alone  induced  CD103  expression  (Figure  5.20D,  E). 
Stimulation of the cells with latent TGF-β1 also increased the expression of cell surface CD103 
(Figure 5.20C). Interestingly, addition of LSKL to latent TGF-β1  treated  T  cells  significantly 
reduced CD103 expression (Figure 5.20I) compared to latent TGF-β1 alone or latent TGF-β1 
with SLLK (Figure 5.20H).
These results are consistent with the mRNA data (section 5.6.12) and support a model in 
which  activated  T  cells  can  use  cell-surface  TSP-1  and  NRP-1  to  activate  latent  TGF-β1. 
However, as in the mRNA data, the flow cytometry experiment also shows that T cells can show 
a partial response to latent TGF-β1 in the presence of blockade of both TSP-1 and NRP-1 with 
the LSKL peptide sequence. 
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Figure 5.20 Induction of CD103 on activated T cells by latent TGF-β1 in the presence of 
LSKL or control peptides
Activated T cells were incubated in medium (A) or medium containing 1nM of TGF-β1 (B) or 
3nM LAP-TGF-β1 (C) or 50μM LSKL (D) or 50µM SLLK (E) or 1nM of TGF-β1 with LSKL 
(F) or SLLK (G) or LAP-TGF-β1 with LSKL (H) or SLLK (I) for 72 hours. CD103 expression 
was analyzed by flow cytometry. The bar graph (J) shows the percentage of CD103+ T cells was 
significantly  increased  after  TGF-β1  and  LAP-TGF-β1  stimulation.  The  expression  on  this 
integrin was reduced significantly in the presence of LSKL compared to LAP-TGF-β1 alone or 
LAP-TGF-β1 with SLLK. The bars shows mean (n=3) and error bars are SEM. The results are 
representative of 3 similar experiments. (* = p < 0.05 compared to control and # = p < 0.05 
compared to the LAP-TGF-β1 group).
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5.7 Summary and discussion
5.7.1 Results summary
• In  human  kidney  allograft  biopsy  tissue,  NRP-1  was  co-expressed  with  some  CD3-
expressing infiltrating cells during cellular rejection.
• Only 1% of resting CD4+ T cells expressed NRP-1; however, NRP-1 expression increased 
to  18%  following  CD3/CD28  activation  for  48  hours.  The  expression  of  NRP-1  was  not 
regulated by cell division.
• TSP-1 was predominantly stored in the cytoplasm of both resting and activated T cells. 
However, after co-culture with renal epithelial cells, surface TSP-1 expression was up-regulated.
• At the mRNA level, TSP-1 was significantly up-regulated following latent TGF-β1 and 
TGF-β1  treatment,  whereas  NRP-1  expression  was  not  significantly  increased  in  T  cells 
following CD3/CD28 activation and latent TGF-β1 and TGF-β1 treatment.
• FoxP3 mRNA was significantly expressed in activated T cells, latent TGF-β1-treated and 
TGF-β1-treated T cells. CD103 mRNA was also up-regulated in latent TGF-β1-treated and TGF-
β1-treated T cells, and TGF-β1 mRNA was significantly increased after TGF-β1 treatment.
• LAP had a capacity to confer latency to TGF-β, as demonstrated by the TGF-β bioassay.
• The MDA231 breast cancer cell line strongly expressed NRP-1 on the cell surface. In 
contrast, TSP-1 expression was absent on the surface of MDA231 cells.
• Both TGF-β1 and latent TGF-β1-treated MDA231 cells increased pSmad2/3 expression. 
This  was inhibited by the addition of the LSKL peptide demonstrating for the first  time the 
sensitivity of NRP-1 mediated activation of latent TGF-β to blockade with the LSKL peptide 
sequence.
• Addition  of  the  LSKL peptide  significantly  inhibited  latent  TGF-β1-induced  CD103, 
FoxP3 and TGF-β1 mRNA expression, compared to the latent TGF-β1- treated T cells and latent 
TGF-β1- treated T cells in the presence of the SLLK control peptide.
• CD103 induction on latent TGF-β1-treated T cells was significantly decreased following 
addition of the LSKL peptide; in contrast, the LSKL peptide had no effect on CD103 expression 
by TGF-β1-treated T cells.
5.7.2 Discussion
Fibrosis is one of the leading causes of late allograft loss in many organs, including the 
kidney.  It  is  clear  that  TGF-β  plays  a  central  role  in  the development of fibrosis.  
Normally, TGF-β is produced and secreted in an inactive or latent form, which is complexed 
with  LAP.  This  latent  TGF-β  must  be  activated  before  binding  to  its  receptors  to  induce 
intracellular  signal  transduction.  Several  mechanisms  have  been  proposed for  latent  TGF-β 
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activation (Taylor, 2009). However, the epithelial αVβ6 integrin and TSP-1 are both thought to 
play a dominant role in the activation of latent TGF-β in vivo (Lawler et al., 1998; Huang et al., 
1996; Ludlow et al., 2005). Data from our group have already shown that inhibition of the αVβ6 
integrin cannot inhibit CD103 induction by T cells during co-culture with HK-2 kidney cells 
(Figure 5.1). On this basis it is reasonable to propose the hypothesis that T cells can activate 
latent TGF-β by a different mechanism involving T cell surface molecules such as TSP-1. A 
recent study has also suggested that NRP-1 also binds to both the latent and active forms of 
TGF-β1 leading to activation through a molecular mechanism similar to that of TSP-1 (Glinka 
and Prud’homme, 2008).
5.7.2.1 The Expression of NRP-1 and TSP-1 on the surface of human T 
cells.
NRP-1 is associated with axonal guidance and angiogenesis via interaction with class III 
semaphorin and VEGF respectively (Neufeld et al., 2002). Furthermore, NRP-1 has been shown 
to promote interactions  between human dendritic  cells  and T cells  (Tordjman et  al.,  2002). 
Previous studies have reported that 3-4% of mouse splenic CD4+ T cells express NRP-1 (Glinka 
and  Prud’homme,  2008).  In  addition,  the  majority  of  these  NRP-1  expressing  cells  are 
CD4+CD25+  regulatory T cells (Bruder et al., 2004). However, recent data from humans have 
shown only very low expression of NRP-1 (0.5%) on peripheral blood T cells, but increased 
expression in lymph nodes (2.61%) and tonsils (5.43%) (Milpied et al., 2009). Milpied et al also 
demonstrated that NRP-1 expression can be induced in vitro by CD3/CD28 activation to reach a 
maximum level after between 48 and 72 hours. These data are consistent with the results from 
this  study,  which found 1-2% of  resting  CD4+  T cells  expressed  NRP-1,  with  this  number 
increasing to approximately 18% after CD3/CD28 activation for 48 hours. After this time, the 
expression of NRP-1 gradually decreased. In addition, the association between NRP-1 and T 
cell division was examined by quantification of CFSE dilution. This study suggested that NRP-
1 expression by activated T cells was cell cycle independent.
The  current  study also  demonstrated  the  presence  of  the  NRP-1 expressing  cells  in 
human kidney allograft biopsies from normal and acute cellular rejection patients. Renal tubular 
epithelial  cells  normally  expressed  NRP-1  on  the  luminal  surface.  However,  during  acute 
rejection,  this  NRP-1  was  reduced  but  the  expression  of  NRP-1  was  increased  on  some 
infiltrating  cells  within the  renal  interstitium.  A previous  study has  reported that  the  apical 
expression of NRP-1 by renal tubular epithelial cells is reduced by TGF-β (Schramek et al., 
2009).  Two-colour immunofluorescence staining showed some evidence of co-expression of 
CD3 (T cells) and NRP-1 within renal tissues. This is also supported by a previous study which 
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demonstrated  the  expression  of  NRP-1  by  human  T cells  in  vivo  (Tordjman  et  al.,  2002). 
However, further detailed morphometric study will be required to determine whether NRP-1 is 
preferentially expressed by T cells  or other inflammatory cells  such as macrophages during 
acute rejection.
TSP-1  is  a  trimeric  functional  glycoprotein.  It  was  originally  identified  with  alpha 
granules of human platelets (see section 5.2). It has been reported that lymphocytes can produce 
TSP-1 (Li et al., 2002). This study found that TSP-1 was predominantly stored in the cytoplasm 
of activated T cells, although some T cell-surface expression was observed. When activated T 
cells were co-cultured with renal tubular epithelial cells, TSP-1 expression on the T cell surface 
was increased. This finding is consistent with a previous study which showed that T cells in 
suspension express very low levels of TSP-1, in contrast to T cells cultured with fibronectin and 
collagen which strongly expressed surface TSP-1 (Li et al., 2002). This suggests that surface 
TSP-1 expression is associated with a cell adhesion-dependent mechanism. It has been reported 
that  TSP-1  connects  to  ECM through  an  interaction  with  fibronectin  (Sottile  e  al.,  2002). 
Fibronectin  is  an  important  component  of  the  interstitial  ECM  in  several  forms  of 
experimentally-induced renal fibrosis and chronic kidney disease (Sady et al., 1995). It has also 
been shown that human renal tubular epithelial cells produce fibronectin  in vitro (Niculescu-
Duvaz et al., 2007). In addition, TGF-β and PDGF have an ability to up-regulate fibronectin 
production by renal tubular epithelial cells (Bürger et al., 1998). Thus, it is possible that during 
co-culture,  activated  renal  epithelial  cells  express  fibronectin,  allowing  increased  TSP-1 
expression on the T cell surface.
5.7.2.2 The expression of NRP-1 and TSP-1 mRNA in human T cells.
At  the  mRNA level,  TSP-1  expression  by  T  cells  was  significantly  up-regulated 
following TGF-β1 and LAP-TGF-β1 treatment; the level of NRP-1mRNA was not changed in 
this study. A previous study of human T cells demonstrated that CD4+CD25+T cells up-regulated 
NRP-1 mRNA expression, whereas NRP-1 expression in non-Treg cells was down-regulated 
following CD3/CD28 activation (Bruder et  al.,  2004).  In addition,  it  has been reported that 
TGF-β suppressed NRP-1 expression by human proximal renal tubular cells (Schramek et al., 
2009). The inconsistent expression of NRP-1 protein and mRNA in this study may result from 
post-transcriptional control. Moreover, a limitation of the current study was lack of a positive 
control for real-time PCR; the MDA231 cell line would provide suitable RNA samples. Further 
studies need to be undertaken to clarify this issue. 
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5.7.2.3 The LSKL peptide inhibits the activation of latent TGF-β by human T 
cells.
MDA231 is a breast cancer cell line reported to strongly express NRP-1 (Glinka and 
Prud’homme, 2008). This  is  consistent  with  the  finding  in  this  study that  MDA231  cells 
expressed  a  high level  of NRP-1,  whereas  TSP-1 expression was absent.  It  is  known that 
activation of the TGF-β receptor system results in phosphorylation and nuclear translocation of 
Smad 2 and 3. The current study demonstrated increased expression of pSmad 2/3 in MDA231 
cells following stimulation with latent TGF-β. Furthermore, addition of the LSKL peptide to 
latent TGF-β1 significantly inhibited the expression of pSmad2/3 by MDA231 cells. This is the 
first practical demonstration that the LSKL peptide can inhibit activation of latent TGF-β1 by 
NRP-1.
Besides  its  role  in  TGF-β  activation,  a  recent  study  demonstrated  that  NRP-1  can 
regulate the balance between activation of the Smad2/3 and the Smad1/5/8 signalling pathways. 
Specifically, it was shown that knockdown of NRP-1 expression enhanced the phosphorylation 
of  Smad1/5  and  decreased  phosphorylation  of  Smad2/3  following  TGF-β  stimulation, 
suggesting a new role for NRP-1 in the regulation of Smad protein function and intracellular 
signalling (Cao et al., 2010). The current study also demonstrated that the association with LAP 
is sufficient to confer the latency of otherwise active TGF-β, supporting data from a previous 
study (Young et al., 2004). Thus, induction of the dissociation of LAP from active TGF-β can be 
seen as a key part of the activation of latent TGF-β.
CD103 expression by T cells is specifically induced by TGF-β1 in vitro  (Wong et al., 
2003). This allows the induction of CD103 to be used as a bioassay of the activation of latent 
TGF-β1 by activated T cells. It was found that latent TGF-β1 increased CD103 expression at 
both mRNA and protein levels in activated T cells in a similar way to the induction observed 
after TGF-β1 treatment. This indicates that latent TGF-β was activated by T cells through a 
mechanism which might include cell surface TSP-1 and/or NRP-1 molecules. Addition of the 
LSKL peptide produced a significant reduction inCD103 induction by latent TGF-β1 at both 
protein and mRNA levels,  compared to  treatment  with  the  SLLK negative control  peptide. 
However,  this  suppressive  effect  did  not  affect  TGF-β1-induced CD103 expression.   These 
results demonstrate that specific interaction between T cell surface TSP-1 and/or NRP-1 and the 
LSKL peptide motif in the LAP sequence contributes to the activation of latent TGF-β1 by 
human T cells. 
It  is  becoming clear that  this  mechanism for T cell-mediated activation of TGF-β is 
biologically important for regulation of the immune response. For example, a recent paper has 
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shown that a specific deficiency of NRP-1 in CD4+ T cells can potentiate central nervous system 
inflammation  in  experimental  autoimmune  encephalomyelitis  (Solomon  et  al.,  2011).  Work 
from the current study extends this concept by raising the possibility that graft infiltrating T 
cells can activate latent TGF-β1 leading to the induction of fibrosis via the EMT pathway.
This study demonstrated the potential role of surface TSP-1 and NRP-1 in activated T 
cells  to  activate  latent  TGF-β.  Although  TSP-1  and/or  NRP-1  inhibition  might  provide  an 
alternative strategy for fibrosis treatment, it is also possible that blocking these molecules on the 
surface  of  T  cells  impairs  the  physiological  immune  response  of  T  cells,  including  their 
migratory ability and regulatory function. Therefore, blocking latent TGF-β activation through 
αVβ6 integrin on activated renal epithelial cells seems to be a promising potential approach for 
renal allograft fibrosis treatment, since it would not interfere with the homeostasis of TGF-β.
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Chapter 6: Concluding discussion
6.1 EMT: a potential role in renal allograft fibrosis
Regardless of the primary cause, chronic renal allograft graft dysfunction is often 
characterized by the development of progressive interstitial fibrosis and tubular atrophy 
(IF/TA)  leading  to  the  deterioration  of  graft  function  (Racusen and Regele,  2010). 
Tubular  interstitial  fibrosis  is  caused  by  an  excessive  production  and  deposition  of 
extracellular matrix in the tubular interstitium by fibroblasts and myofibroblasts, which 
express S100A4 and α-SMA respectively. Both myofibroblasts and fibroblasts are highly 
active  in  synthesizing  extracellular  matrix  proteins  such  as  fibrillary  collagens  and 
fibronectin. The origin of these cells has been a topic of increasing interest over the last 
decade. To date, it has been reported that myofibroblasts are derived from the activation 
of renal interstitial fibroblasts (Strutz and Zeisberg, 2006), perivascular fibroblasts and 
pericytes (Lin et al., 2008), from the differentiation of bone marrow-derived stem cells 
(Broekema et al., 2007), and by direct phenotypic transition from endothelial (Zeisberg 
et  al.,  2008)  and tubular  epithelial  cells  (Strutz  et  al.,  1995;  Iwano et  al.,  2002)  to 
mesenchymal cells.  The mechanism of epithelial  to mesenchymal transition has been 
studied intensively in vitro and in vivo.
6.1.1 HKC-8 cells undergo EMT following stimulation with profibrotic 
cytokines
It has been shown previously that both primary and immortalised human renal 
epithelial cells have the capacity to become fibroblast-like cells following stimulation 
with  the  profibrotic  cytokine,  TGF-β1  (Robertson  et  al.,  2004).  Epithelial  to 
mesenchymal  transition  (EMT)  of  these  cells  has  been  demonstrated  by  both 
morphological and proteomic changes (Zeisberg et al., 2003; Robertson et al., 2004).
The current study also demonstrated clearly that cultured human renal proximal 
tubular  epithelial  cell  lines  can  transform into  fibroblasts.  In  the  resting  state,  renal 
tubular  epithelial  cells  show  typical  features  of  a  polarized  epithelium,  such  as 
cobblestone morphology and the presence of intercellular tight junctions. Stimulation of 
these cells with recombinant TGF-β1 resulted in the acquisition of elongated cells with a 
fibroblast-like morphology. In addition, TGFβ-1 treatment of the immortalised HKC-8 
cell line produced a loss of cell-surface expression together with a decrease in the overall 
expression of the epithelial marker E-cadherin and up-regulated the expression of the 
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mesenchymal proteins S100A4 and α-SMA. These changes are entirely consistent with 
the induction of EMT in vitro.
6.1.2 A potential role for EMT in chronic Cyclosporine nephrotoxicity
Cyclosporine is a potent immunosuppressive drug which greatly improves the 
survival of kidney allografts (Krönke et al., 1984). However, a major limiting factor in 
the  use  of  Cyclosporine  is  chronic  nephrotoxicity,  which  leads  to  irreversible  renal 
failure characterized by extensive tubulointerstitial fibrosis (Myers et al., 1984) (section 
3.4.2).  Several  factors  have  previously  been  implicated  as  playing  a  role  in  the 
development  of  renal  fibrosis  associated  with  Cyclosporine treatment.  These include 
angiotensin  II  (Shang  et  al.,  2008),  aldosterone  (Bobadilla  and  Gamba,  2007), 
endothelin-1  and  reactive  oxygen  species  (Jennings  et  al.,  2007),  and  nitric  oxide 
insufficiency (Shihab  et  al.,  2000).  A further  process  which  may be  relevant  is  the 
potential of Cyclosporine to stabilise the mitochondrial permeability transition pore by 
binding the cyclophilin D component of this pore (Crompton, 1999). By this mechanism, 
Cyclosporine  can  prevent  or  reduce  the  induction  of  apoptosis  in  some  cells  by 
inhibiting the release of cytochrome C from mitochondria (Kowaltowski et al., 2000). 
This might contribute to the Cyclosporine-induced cellular overgrowth observed in some 
tissues (Seymour et al., 1996). Although the exact mechanisms of Cyclosporine-induced 
tubulointerstitial fibrosis remain unclear, it has been hypothesized that EMT may play a 
role (Slattery et al., 2005; McMorrow et al., 2005).
In  this  study,  it  has  been  demonstrated  that  Cyclosporine  induced  the  de-
differentiation  of  cultured  renal  epithelial  cells  through  induction  of  a  decrease  in 
expression  of  the  epithelial  adhesion  molecule  E-cadherin  together  with  increased 
expression of the mesenchymal marker S100A4. Although S100A4 protein expression 
has  been  demonstrated  in  some  monocytes,  macrophages,  polymorphonuclear 
granulocytes and lymphocytes (Takenaga et al., 1994), it has not been detected in normal 
tissues obtained from the breast, colon, thyroid, lung, kidney, and pancreas (Ilg et al., 
1996).  Increased S100A4 expression following Cyclosporine treatment  suggested the 
acquisition of a mesenchymal phenotype by transformed renal epithelial cells. However, 
the increased expression of S100A4 protein occurred without an apparent increase in 
expression of the S100A4 gene.  Previous studies suggest that  the S100A4 protein is 
commonly present in a high molecular weight form (typically a tetramer) which can 
associate with other proteins (Klingelhöfer et al., 2007). It is considered most likely that 
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the poor relationship between the expression of S100A4 protein and mRNA results from 
a post-translational process which may alter S100A4 distribution and/or stability.
Besides  de  novo  expression  of  mesenchymal  markers,  a  reduction  in  the 
expression of epithelial markers is also one of the main features of the EMT process. 
This study focused on the expression of E-cadherin as an epithelial marker. E-cadherin is 
an important determinant for maintenance of the epithelial phenotype (Zeisberg et al., 
2003). The loss of this adherens junction protein is commonly used to demonstrate the 
presence of EMT. However, loss of E-cadherin expression is not always associated with 
EMT (Veerasamy et al., 2009). In addition, TGF-β may not always lead to a loss of E-
cadherin  expression.  A study  using  a  model  TGF-β1-containing  adenoviral  vector-
induced  peritoneal  fibrosis  showed  a  slightly  increased  E-cadherin  expression  in 
experimental  animals  (Margetts  et  al.,  2005).  Hypotonic  stretch-induced  E-cadherin 
expression has also been observed in a mouse model of UUO (Docherty et al., 2009). 
This  raises  some questions about  the reliability of  E-cadherin expression when used 
alone as a marker of EMT for in vivo studies. 
It has been reported that TGF-β1 is a crucial driver of renal tubular epithelial to 
mesenchymal  transition  in  vitro (Liu  et  al.,  2004).  Results  in  the  current  study are 
consistent  with  this  observation.  However,  this  study  also  provided  three  pieces  of 
evidence suggesting that  the phenotypic  changes produced in  renal  tubular  epithelial 
cells by culture with a high concentration of Cyclosporine are not associated with TGFβ.
• Blocking  the  TGF-β receptor  type  I  (ALK5) with the  effective  inhibitor  SB-
505124  failed  to  prevent  de  novo  expression  of  S100A4  following  Cyclosporine 
treatment. However, this ALK5 inhibitor was able partially to inhibit the reduction of E-
cadherin  expression.  This  might  suggest  that  Cyclosporine-induced  expression  of 
S100A4 by HKC-8 cells was not dependent on the TGF-β signalling pathway, whilst the 
Cyclosporine-induced loss of E-cadherin was partly regulated through this receptor. The 
limitation of this study is the lack of a proper negative and positive control.  Further 
studies should quantify the expression of both S100A4 and E-cadherin in HKC-8 cells 
incubated with SB-505124 alone and SB-505124 together with TGF-β.
• Real-time  PCR  showed  no  up-regulation  of  TGF-β1  mRNA  following 
Cyclosporine treatment of three different renal epithelial  cell  lines including HKC-8, 
HK-2 and primary renal cells. Although the TGF-β1 gene was induced in these cells by 
treatment with TGF-β1 as a positive control, further work should include examination of 
changes in the expression of the other isoforms of TGF-β. 
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• The concentration  of  active  TGF-β was  measured  in  medium conditioned by 
culture of renal epithelial cells in the presence of a high concentration of Cyclosporine. 
Two fundamentally different  assays  were  used,  but  each was sensitive to  all  TGF-β 
isoforms.  Firstly  the  MFB-F11  bioassay  was  used  to  quantify  TGF-β  following 
activation by heat and secondly an ELISA was used to measure active TGF-β following 
acidification  of  the  medium.  Neither  assay  provided  evidence  that  the  presence  of 
Cyclosporine increased the secretion of any isoform of TGF-β above levels produced by 
resting cells or present in fresh medium alone.
It  has  been  observed  that  other  growth  factors  have  a  capacity  to  induce  or 
augment EMT. These include FGF-2 (Strutz et al., 2002), PDGF-B (Patel et al., 2010), 
IGF-II (Morali et al., 2001), EGF (Lo et al., 2007) and CTGF (Burns et al., 2006). This 
variety of relevant growth factors suggests that one or more of a multitude of additional 
mechanisms may induce the development of an EMT-like phenotype following treatment 
of renal tubular epithelial cells with Cyclosporine. These could be explored by additional 
gene-profiling  experiments  using  an  appropriate  cytokine-targeted  PCR-array  after 
treatment with Cyclosporine. Previous studies have also demonstrated up-regulation of 
E2A mRNA expression  in  tubular  epithelial  cells  following  Cyclosporine  exposure 
(Slattery  et  al.,  2005).  The  E2A gene  encodes  two  basic  helix-loop-helix  (bHLH) 
proteins, E12 and E47 (Massari and Murre, 2000). Both E12 and E47 have effects on 
cell morphology and phenotypes, including a reduction in E-cadherin and induction of α-
SMA expression  after  Cyclosporine  treatment  (Slattery  et  al.,  2006).  This  provides 
further  evidence  for  the  existence  of  additional  mechanisms  to  explain  the  apparent 
absence of a direct role for TGF-β in the induction of EMT following treatment of renal 
tubular epithelial cells with Cyclosporine.
Overall this study supported a role for EMT during Cyclosporine-induced renal 
fibrosis  in vitro. However, the possibility that this action is mediated by an increase in 
the activity of TGF-β remains controversial. 
6.1.3 Examination of the role of TGF-β in T cell-mediated EMT
Chronic  graft  dysfunction  is  associated  with  T  cell–mediated  rejection, 
suggesting a mechanism that involves immunological damage of renal epithelial cells 
(Gourishankar  and  Halloran,  2002;  Robertson  et  al.,  2003).  A previous  study  has 
demonstrated  that  the  expression  of  S100A4  in  tubular  cells  during  renal  allograft 
rejection  is  associated  with  infiltration  of  the  tubules  by  CD8+  T cells,  potentially 
indicating the induction of EMT by these T cells (Robertson et al., 2004). It has also 
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been suggested that infiltrating T cells might present membrane bound active TGF-β 
during  adhesive contact  with renal  epithelial  cells,  leading to  the induction  of  EMT 
(Robertson et  al.,  2004). However,  unpublished work from our group failed to show 
active TGF-β when T cells were co-cultured with MFB-F11 reporter cells in vitro. As a 
consequence  of  this  work a  series  of  experiments  was  performed to  re-examine  the 
potential of activated T cells to induce EMT by a TGF-β dependent mechanism.
It has been widely reported that CD8+CD103+ T cells constitute the majority of 
intratubular  T  cells  during  renal  allograft  rejection (Robertson  et  al.,  2004).  This 
phenotype  is  characteristic  of  intraepithelial  T cells,  which  are  commonly  modelled 
using the human CD103+  MOLT-16 T cell line. In addition to a range of T cell markers, 
these  cells  are  known  to  express  both  the  LAP  component  of  TGF-β  and 
thrombospondin-1 (Oida et al., 2003).
The MOLT-16 T cell line was used in co-culture experiments with HKC-8 renal 
epithelial cells to model the cell contacts that occur during renal tubulitis. The epithelial 
marker for this experiment was E-cadherin, whilst S100A4 and α-SMA were selected as 
mesenchymal markers. It is known that S100A4 is expressed by some leukocytes (Le 
Hir  et  al.,  2005),  including  MOLT-16 and other  lymphoma cell  lines  (Rygiel  et  al., 
2010). This study showed that following addition of MOLT-16 T cells, the expression of 
E-cadherin by HKC-8 cells was reduced. By contrast, the expression of S100A4 and α-
SMA showed an increase; with S100A4 showing general expression whilst α-SMA was 
restricted to a small number of cells. This might suggest that during EMT in vitro, the 
epithelial cells were transformed into different fibroblastic cell types, since α-SMA is 
specific for myofibroblasts (Desmouliére et al., 1992). Interestingly, it has been reported 
that some activated intra-renal fibroblasts also fail to make the change to a myofibroblast 
phenotype in vivo (Okada et al., 2000).  
The role played by TGF-β during T cell-induced EMT was explored by blocking 
the TGF-β receptor  using the selective inhibitor  SB-505124.  Use of this  inhibitor  is 
superior to the application of TGF-β blocking antibodies which can sometimes fail to 
inhibit  signal transduction (Ganapathy et  al.,  2010).  The ALK5 inhibitor reduced the 
expression  of  both  S100A4  and  α-SMA,  and  also  reduced  the  loss  of  E-cadherin 
expression during co-culture of MOLT-16 T cells and HKC-8 renal cells.  This suggests 
a role for TGF-β in the epithelial phenotypic transition induced by MOLT-16 T cells. 
One limitation with this study is the failure to determine the role played by CD103-
mediated adhesion during the induction of EMT  in vitro. Further experiments should 
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include a CD103- T cell line; MOLT-4 T cells which lack both cell-surface CD103 and 
LAP might provide such a negative control. However, use of allospecific CD8+CD103+ 
activated primary T cells would provide the most robust model for further study. 
The  expression  of  LAP by activated  CD103+ and  CD103- human T cells  was 
examined  in  vitro by immunofluorescence  flow cytometry.  Approximately 15-16% of 
activated T cells expressed surface LAP. Stimulation of these cells with TGF-β1 did not 
induce additional LAP expression, although CD103 was induced by this treatment. 
Besides their potential role in the induction of EMT, CD103 and LAP have been 
proposed as cell-surface markers of efficient Treg. Indeed, it has been shown that up to 
20% of murine Treg express CD103 (Zelenika et al., 2002). In addition, a previous study 
has shown that TGF-β can induce cell surface LAP expression by murine T cells (Oida et 
al.,  2011).  In  humans,  CD103+LAP+  T  cells  have  been  classified  as  a  newly 
differentiated population of Tregs (Zhang et al., 2009). However the role of these Treg in 
clinical organ transplantation remains unknown. 
6.2  Potential  role  of  Thrombospondin-1  and  Neuropilin-1  in  TGF-β 
activation
Previous studies have demonstrated that T cells attach to the renal epithelial cell 
membrane at least partially by adhesive interaction between the αEβ7 integrin and E-
cadherin (Benmerah et  al.,  1994). The affinity of this  interaction is  enhanced by the 
presence  of  local  inflammatory  chemokines  (Al-Hamidi  et  al.,  2008).  This  cell–cell 
interaction may play an important role in regulating the EMT process as renal cells do 
not undergo this phenotypic transition in response to supplementation of the culture with 
T-cell conditioned medium (Robertson et al., 2004). 
Although  TGF-β  plays  an  essential  role  in  immune  homeostasis  (Shi  and 
Massagué, 2003), the over-expression of TGF-β results in excessive deposition of ECM 
leading to organ fibrosis. TGF-β is normally produced and secreted in an inactive form, 
the  latent  TGF-β complex.  Thus,  a  key step  in  regulation  of  TGF-β function  is  the 
activation of latent TGF-β. It has been suggested that the T cell-associated molecules 
TSP-1 and NRP-1 may play an important role in the activation of latent TGF-β (Li et al., 
2002; Glinka and Prud’homme, 2008); hence, these molecules may be relevant to the 
induction of T cell-mediated EMT. The final part of this study focused on examination of 
the function of these two molecules.
6.2.1 Expression of NRP-1 and TSP-1 on the human T cell surface
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NRP-1 is well known as a receptor for both VEGF and SEMA3A (Pellet-Many et 
al., 2008; Kolodkin et al., 1997). However, recent data has been demonstrated a new role 
of NRP-1 in latent TGF-β activation in vitro (Glinka and Prud’homme, 2008). TSP-1 is a 
matrix and cellular glycoprotein which has been long been recognised as a mediator of 
latent TGF-β activation both  in vitro and  in vivo (Hugo and Daniel, 2009). It has been 
suggested that the KRFK sequence of TSP-1 and the RKFK sequence of NRP-1 can both 
interact  with  the  LSKL sequence  of  LAP leading  to  a  conformational  change in  the 
structure  of  latent  TGF-β  which  exposes  the  active  form  of  TGF-β (Glinka  and 
Prud’homme, 2008; Ribeiro et al., 1999). 
This study demonstrated that human T cells express TSP-1, but this is normally 
stored within the cytoplasm. When activated T cells were co-cultured with PTEC, TSP-1 
was  mobilized  and  expressed  on  the  T  cell-surface.  A previous  study  demonstrated 
similar  mobilization  of  intracellular  TSP-1  following  stimulation  with  fibronectin, 
suggesting  a  role  for  endogenous  TSP-1  in  maintaining  T  cell  interactions  with 
fibronectin in the ECM (Li et al., 2002).
It  has  been  reported  that  0.01% of  human circulating  T cells  express  NRP-1 
(Battaglia  et  al.,  2008).  However,  sensitive  flow  cytometry  in  the  current  study 
demonstrated  that  1.3% of  resting  human  T cells  expressed  NRP-1.  In  addition,  the 
number of NRP-1 expressing CD4+ T cells increased to a mean of 18% after CD3/CD28 
activation for 48 hours. Interestingly, a parallel CFSE-labelling study demonstrated that 
this induction was independent of T cell division. 
The expression of mRNA encoding both TSP-1 and NRP-1 was measured by 
real-time PCR. TSP-1 mRNA was not changed when T cells were activated but was 
significantly up-regulated following treatment with either latent TGF-β1 or active TGF-
β1. In contrast, the expression of NRP-1 mRNA was similar between resting T cells, 
activated T cells, and latent or active TGF-β1-treated T cells. When considered the CT 
value, resting T cells showed a CT of 34 suggesting very low level expression of NRP-1 
in these cells. However, following CD3/CD28 activation and/or latent TGF-β1 and TGF-
β1 stimulation, the CT value was decreased to 32-33 indicting a trend towards increased 
NRP-1 mRNA expression; this was not statistically significant. It is possible that the 
apparently low level  NRP-1 mRNA expression  might  result  from poor  quality PCR 
templates, primers or reagents. A further study should be performed to investigate this 
possibility using RNA from an appropriate control such as the NRP-1 positive MDA231 
cell line. 
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6.2.2  The  LSKL  peptide  inhibits  the  induction  of  CD103  and 
phosphorylation of Smad2/3 expression by latent TGF-β1
This study demonstrated the expression of both TSP-1 and NRP-1 by activated T 
cells at the protein level. In order to identify a role for these two molecules in latent 
TGF-β activation,  a  peptide  sequence  specific  inhibitor  was  applied.  Hydropathic 
binding (Ribeiro et al., 1999) of the KRFK amino acid sequence of TSP-1 (Murphy-
Ullrich et al., 2000) and, potentially, the similar RKFK sequence of NRP-1 (Glinka and 
Prud’homme, 2008) to the LSKL sequence of LAP is thought to induce a conformational 
rearrangement  of  LAP  leading  to  exposure  of  the  functional  domain  of  TGF-β 
(section 5.2.2 and 5.3.2). Therefore, exogenous application of the LSKL peptide should 
inhibit  the activation of latent TGF-β by competitive binding to RKFK or KRFK on 
NRP-1 and TSP-1 respectively. In this study, the potential of this blocking peptide to 
inhibit  NRP-1  was  validated  for  the  first  time  using  the  positive  control  NRP-1-
expressing cell line, MDA231. 
TGF-β1 signalling  occurs  through  the  phosphorylation  of  Smad2  and Smad3 
(Nakao  et  al.,  1997).  The  current  study  demonstrated  increased  phosphorylation  of 
Smad2 and/or Smad3 following latent TGF-β1 treatment of MDA231 cells. Importantly, 
addition  of  the  LSKL peptide  decreased  this  phosphorylation  of  Smad2/3  indicating 
inhibition of the activation of latent TGF-β. This represents the first clear  demonstration 
that  the  activation  of  latent  TGF-β  by  NRP-1  can  be inhibited using the LSKL 
peptide  sequence.  Addition  of  the  LSKL  peptide  to  latent  TGF-β-treated  T  cells 
significantly reduced CD103 expression at both protein and mRNA levels compared to 
latent TGF-β alone, whereas the non-binding SLLK scrambled peptide control had no 
such inhibitory effect. This suggested that TSP-1 and/or NRP-1 on T cells played a role 
in the activation of latent TGF-β.
These data are significant as they indicate that activated human T cells have the 
potential to activate latent TGF-β. This activation can be mediated by NRP-1, which is 
expressed,  albeit  transiently,  by  a  significant  sub-population  of  activated  T  cells. 
However, activated T cells can also be induced to express cell-surface TSP-1 following 
interaction  with  renal  epithelial  cells  or  fibronectin,  providing  a  microenvironment-
sensitive second mechanism for the activation of latent TGF-β.
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Both NRP-1 and TSP-1 activate latent TGF-β in a way that retains immobilized 
TGF-β within the LAP complex; this provides an explanation for the requirement for T 
cell contact with renal epithelial cells before phenotypic transition can be induced.
6.3 A model of renal allograft fibrosis
Results from the current study are consistent with the following model of renal 
allograft fibrosis (Figure 6.1). Renal tubular epithelial cells exposed to a high but not 
directly  toxic  concentration  of  Cyclosporine  can  undergo  a  phenotypic  transition 
consistent  with EMT. However,   this   drug-induced  change  does  not  appear   to 
involve  an  increased production of TGF-β at mRNA, protein or functional levels. It is 
now clear that drug-stressed cells can undergo a range of life-preserving changes which 
includes the induction of replicative senescence (Jennings et al., 2007) and autophagy 
(Pallet  et  al.,  2008) as well  as  the epithelial  de-differentiation associated with EMT. 
States such as senescence are associated with specific cytokine secretomes (Kuilman and 
Peeper,  2009)  which  might  influence  epithelial  de-differentiation  by modification  of 
factors including ILK, IGF-II, CTGF and E12/E47.
A large number of T cells are recruited to activated renal tubules during periods 
of  allograft  rejection  in  response  to  locally  produced  chemokines  (Robertson  et  al., 
2000). It is known that many of these lymphocytes start to express CD103 within the 
tubular microenvironment. It is also known that renal tubular epithelial cells can undergo 
EMT. Both of these processes are induced by a response to active TGF-β. Importantly, 
both T cells and renal epithelial cells can also produce TGF-β, although this cytokine is 
always produced and sequestered in a latent form.
Stressed epithelial cells can activate latent TGF-β through a mechanism which 
involves local expression of the αvβ6 integrin. However, the mechanism by which T 
cells activate latent TGF-β has been less clear. The current study has focused specifically 
on this  problem and demonstrated that  both NRP-1 and TSP-1 can be expressed by 
activated human T cells  and can activate  latent  TGF-β.  Importantly,  the cell  surface 
expression of TSP-1 by T cells is increased by culture with RTEC or fibronectin.
Following  activation,  TGF-β  can  have  diverse  actions.  Firstly,  T  cells  are 
stimulated to differentiate. This can limit the potential of activated CD8+ T cells to lyse 
specific target cells (Robertson et al., 1996), can induce the development of FOXP3-
expressing regulatory T cells (Singh et al., 2007) and can promote the formation of pro-
inflammatory Th17 cells if further pro-inflammatory cytokines are present (Morishima 
et al., 2009). Secondly, epithelial cells can be stimulated to undergo EMT, resulting in 
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the  formation  of  a  de-differentiated  mesenchymal  phenotype  which  will  limit  renal 
function.
To  date,  it  remains  uncertain  whether  the  de-differentiated  epithelial  cells 
produced by EMT can fully transform to fibroblast or myofibroblasts in vivo. It has been 
shown in this study that complete de-differentiation and EMT of renal epithelial cells 
occurs  in  vitro.  However,  the renal  microenvironment  is  more complex,  providing a 
range of cytokines and other stimuli  which can signal epithelial  cells.  These include 
BMP-7 (Zeisberg et al., 2005) and hepatocyte growth factor (Shukla et al., 2009) which 
can both antagonize development of the EMT phenotype. For this reason, the  in vitro 
system may provide an incomplete model of the changes in epithelial phenotype that are 
observed in vivo.
Figure 6.1 Diagram illustrating a putative model of renal fibrosis.
(i) Cyclosporine can activate renal epithelial directly or in combinationwith factors such 
as angiotensin II, aldosterone and macrophage infiltration (section 3.5.7). Activated renal 
epithelial cells produce TGF-β or other factors such as ILK, IGF-II, CTGF and E12E47 
leading  to  epithelial  de-differentiation.  (ii)  After  transplantation,  recipient  T  cells 
recognize alloantigen resulting to the accumulation of activated intraepithelial T cells. 
These T cells can induce latent TGF-β production. (iii) Latent TGF-β is then activated by 
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two different mechanisms: TSP-1 and NRP-1 on the T cell surface and the αvβ6 integrin 
on activated renal epithelial  cells.  This active TGF-β causes  the de-differentiation of 
epithelial cells including loss of epithelial properties and acquisition of mesenchymal 
characteristics.  Although  these  cells  may  not  be  transformed  to  myofibroblasts  or 
fibroblast in vivo, they have capacity to induce fibrosis in vitro.
6.4 Conclusion
In  summary,  this  in  vitro  study provides  some evidence suggesting  that  both 
Cyclosporine and intratubular T cells contribute to chronic renal allograft failure by the 
activation  of  epithelial  to  mesenchymal  transition.  However,  the  mechanisms  for 
induction  of  this  phenotypic  transition  appear  to  differ,  with  TGF-β  playing  little 
apparent role in mediating Cyclosporine nephropathy but playing a more central role in 
T cell-mediated induction of EMT.
It was also shown that activated T cells can respond directly to latent TGF-β, 
leading to  T cell  differentiation and the  induction  of  markers  including  FOXP3 and 
CD103. This process was substantially inhibited using an LSKL peptide well known to 
block TSP-1 but shown for the first time in this study to also inhibit the activation of 
latent TGF-β by NRP-1. Demonstration of the potential of activated T cells to express 
both NRP-1 and TSP-1 on their cell surface suggests an important mechanism by which 
these cells can activate latent TGF-β encountered within the kidney, leading both to local 
T cell differentiation and T cell-mediated induction of graft-damaging EMT.    
6.5 Further work 
6.5.1 Cyclosporine-induced EMT
Further studies are required to completely define the role of Cyclosporine-induced EMT 
and the underlying pathways leading to this transition. These include:
• Use of a more clinically relevant concentration of Cyclosporine to model drug 
effects on renal epithelial cells
6.5.2 T cell-induced EMT
 Further  studies  to  define  the  role  of  infiltrating  T  cell-induced  epithelial  cell  de-
differentiation include:
• Determining  the  role  of  the  CD103 integrin  for  adhesion  of  T cells  to  renal 
epithelial cells during T cell-induced epithelial cell de-differentiation.
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• Investigating the role of surface LAP on T cells during the induction of epithelial 
transformation during T cell-mediated rejection.
• Studying  the  immunosuppressive  activity  of  CD103+LAP+  T cells  and  the 
potential role of this subset of T lymphocytes during renal allograft rejection.
• Further defining the possibility that T cells can activate latent TGF-β produced 
by renal epithelial cells.
6.5.3 Defining the roles of TSP-1 and NRP-1 in the activation of latent 
TGF-β
Further studies should include:
• Examination of the regulation of NRP-1 expression, since NRP-1 was found in 
the T cell cytoplasm and might be driven to surface under some conditions.
• Use an appropriate positive control cell line to optimize RT-PCR for NRP-1.
• Definition of the contribution of TSP-1 and NRP-1 on activated T cells and the 
αvβ6 integrin on activated epithelial cells to the activation of latent TGF-β   using siRNA 
or blocking antibodies.
• Determining  the  relative  expression  of  NRP-1  and  TSP-1  by  T  cells, 
macrophages and other inflammatory cells during acute rejection.
12 | P a g e
References
References
ABE, M., HARPEL, J. G., METZ, C. N., NUNES, I., LOSKUTOFF, D. J. & RIFKIN, D. B. 
1994.  An  assay  for  transforming  growth  factor-beta  using  cells  transfected  with  a 
plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem, 216, 276-84.
ADAMS, J. & LAWLER, J. 1993. Extracellular matrix:  the thrombospondin family.  Curr 
Biol, 3, 188-90.
AFZALI, B., LECHLER, R. I.  & HERNANDEZ-FUENTES, M. P. 2007. Allorecognition 
and the alloresponse: clinical implications. Tissue Antigens, 69, 545-56.
AL-HAMIDI, A., PEKALSKI, M., ROBERTSON, H., ALI, S. & KIRBY, J. A. 2008. Renal 
allograft  rejection:  the  contribution  of  chemokines  to  the  adhesion  and  retention  of 
alphaE(CD103)beta7 integrin-expressing intratubular T cells. Mol Immunol, 45, 4000-7.
AMOS, W. B. & WHITE, J. G. 2003. How the confocal laser scanning microscope entered 
biological research. Biol Cell, 95, 335-42.
ANDREONI, K. A., BRAYMAN, K. L., GUIDINGER, M. K., SOMMERS, C. M. & SUNG, 
R.  S.  2007.  Kidney and pancreas  transplantation  in  the  United  States,  1996-2005.  Am J 
Transplant, 7, 1359-75.
ANGST, B. D., MARCOZZI, C. & MAGEE, A. I. 2001. The cadherin superfamily: diversity 
in form and function. J Cell Sci, 114, 629-41.
ANNES, J. P., MUNGER, J. S. & RIFKIN, D. B. 2003. Making sense of latent TGFbeta 
activation. J Cell Sci, 116, 217-24.
APOSTOLOPOULOS, V.,  YURIEV, E.,  LAZOURA, E.,  YU, M. & RAMSLAND, P.  A. 
2008. MHC and MHC-like molecules:  structural  perspectives on the design of molecular 
vaccines. Hum Vaccin, 4, 400-9.
ARAYA, J., CAMBIER, S., MARKOVICS, J. A., WOLTERS, P., JABLONS, D., HILL, A., 
FINKBEINER,  W.,  JONES,  K.,  BROADDUS,  V.  C.,  SHEPPARD,  D.,  BARZCAK,  A., 
XIAO,  Y.,  ERLE,  D.  J.  &  NISHIMURA,  S.  L.  2007.  Squamous  metaplasia  amplifies 
pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest, 117, 3551-
62.
ARAYA, J., CAMBIER, S., MORRIS, A., FINKBEINER, W. & NISHIMURA, S. L. 2006. 
Integrin-mediated  transforming growth factor-beta  activation regulates  homeostasis  of  the 
pulmonary epithelial-mesenchymal trophic unit. Am J Pathol, 169, 405-15.
ARCINIEGAS, E., NEVES, Y. C. & CARRILLO, L. M. 2006. Potential role for insulin-like 
growth  factor  II  and  vitronectin  in  the  endothelial-mesenchymal  transition  process. 
Differentiation, 74, 277-92.
1 | P a g e
References
AREND, L. J., SMART, A. M. & BRIGGS, J. P. 2000. Mouse beta(6) integrin sequence, 
pattern of expression, and role in kidney development. J Am Soc Nephrol, 11, 2297-305.
ARESU, L., RASTALDI, M. P., PREGEL, P., VALENZA, F., RADAELLI, E., SCANZIANI, 
E. & CASTAGNARO, M. 2008. Dog as model for down-expression of E-cadherin and beta-
catenin in tubular epithelial cells in renal fibrosis. Virchows Arch, 453, 617-25.
ARIAS, A. M. 2001. Epithelial mesenchymal interactions in cancer and development. Cell, 
105, 425-31.
ASANO, Y., IHN, H., YAMANE, K., JINNIN, M., MIMURA, Y. & TAMAKI, K. 2005. 
Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine 
TGF-beta signaling in scleroderma fibroblasts. J Immunol, 175, 7708-18.
ASANO,  Y.,  IHN,  H.,  YAMANE,  K.,  JINNIN,  M.  &  TAMAKI,  K.  2006.  Increased 
expression  of  integrin  alphavbeta5  induces  the  myofibroblastic  differentiation  of  dermal 
fibroblasts. Am J Pathol, 168, 499-510.
ATABAI, K., JAME, S., AZHAR, N., KUO, A., LAM, M., MCKLEROY, W., DEHART, G., 
RAHMAN, S., XIA, D. D., MELTON, A. C., WOLTERS, P., EMSON, C. L., TURNER, S. 
M., WERB, Z. & SHEPPARD, D. 2009. Mfge8 diminishes the severity of tissue fibrosis in 
mice by binding and targeting collagen for uptake by macrophages. J Clin Invest, 119, 3713-
22.
AUCHINCLOSS, H., JR., LEE, R., SHEA, S.,  MARKOWITZ, J. S.,  GRUSBY, M. J. & 
GLIMCHER, L. H. 1993. The role of "indirect" recognition in initiating rejection of skin 
grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci U S 
A, 90, 3373-7.
BAGNIS, C., DERAY, G., DUBOIS, M., ADABRA, Y., JACQUIAUD, C., JAUDON, M. C. 
& JACOBS, C. 1997. Comparative acute nephrotoxicity of FK-506 and ciclosporin in an 
isolated in situ autoperfused rat kidney model. Am J Nephrol, 17, 17-24.
BAKKER, R. C., VAN KOOTEN, C., VAN DE LAGEMAAT-PAAPE, M. E., DAHA, M. R. 
& PAUL, L. C. 2002. Renal tubular epithelial cell death and cyclosporin A. Nephrol Dial 
Transplant, 17, 1181-8.
BARCELLOS-HOFF,  M.  H.  &  DIX,  T.  A.  1996.  Redox-mediated  activation  of  latent 
transforming growth factor-beta 1. Mol Endocrinol, 10, 1077-83.
BARRIENTOS, S., STOJADINOVIC, O., GOLINKO, M. S., BREM, H. & TOMIC-CANIC, 
M. 2008. Growth factors and cytokines in wound healing. Wound Repair Regen, 16, 585-601.
BARTH,  R.,  COUNCE,  S.,  SMITH,  P.  &  SNELL,  G.  D.  1956.  Strong  and  weak 
histocompatibility gene differences in mice and their role in the rejection of homografts of 
tumors and skin. Ann Surg, 144, 198-204.
2 | P a g e
References
BATTAGLIA,  A.,  BUZZONETTI,  A.,  MONEGO,  G.,  PERI,  L.,  FERRANDINA,  G., 
FANFANI, F., SCAMBIA, G. & FATTOROSSI, A. 2008. Neuropilin-1 expression identifies 
a  subset  of  regulatory T cells  in  human lymph nodes  that  is  modulated  by preoperative 
chemoradiation therapy in cervical cancer. Immunology, 123, 129-38.
BAUM,  B.  &  GEORGIOU,  M.  2011.  Dynamics  of  adherens  junctions  in  epithelial 
establishment, maintenance, and remodeling. J Cell Biol, 192, 907-17.
BECKER, G. J., PERKOVIC, V. & HEWITSON, T. D. 2001. Pharmacological intervention 
in renal fibrosis and vascular sclerosis. J Nephrol, 14, 332-9.
BELOT, N., POCHET, R., HEIZMANN, C. W., KISS, R. & DECAESTECKER, C. 2002. 
Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the 
organization of their actin cytoskeleton. Biochim Biophys Acta, 1600, 74-83.
BENMERAH, A., BADRICHANI, A., NGOHOU, K., MEGARBANE, B., BEGUE, B. & 
CERF-BENSUSSAN,  N.  1994.  Homotypic  aggregation  of  CD103  (alpha  E  beta  7)+ 
lymphocytes by an anti-CD103 antibody, HML-4. Eur J Immunol, 24, 2243-9.
BENSON, M. J., ERICKSON, L. D., GLEESON, M. W. & NOELLE, R. J. 2007. Affinity of 
antigen encounter and other early B-cell signals determine B-cell fate. Curr Opin Immunol, 
19, 275-80.
BETTELLI,  E.,  CARRIER,  Y.,  GAO,  W.,  KORN,  T.,  STROM,  T.  B.,  OUKKA,  M., 
WEINER, H. L.  & KUCHROO, V. K. 2006. Reciprocal  developmental  pathways for the 
generation of pathogenic effector TH17 and regulatory T cells. Nature, 441, 235-8.
BIELENBERG, D. R., PETTAWAY, C. A., TAKASHIMA, S. & KLAGSBRUN, M. 2006. 
Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res, 312, 584-93.
BLAND, R., WALKER, E. A., HUGHES, S. V., STEWART, P. M. & HEWISON, M. 1999. 
Constitutive  expression  of  25-hydroxyvitamin  D3-1alpha-hydroxylase  in  a  transformed 
human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by 
calcium. Endocrinology, 140, 2027-34.
BOBADILLA,  N.  A.  &  GAMBA,  G.  2007.  New  insights  into  the  pathophysiology  of 
cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol, 293, F2-9.
BOREL,  J.  F.  &  BAUMANN,  G.  1994.  Molecular  mechanisms  of  immunosuppressive 
agents. Bull Mem Acad R Med Belg, 149, 97-101; discussion 101-3.
BORK,  P.  &  BECKMANN,  G.  1993.  The  CUB  domain.  A  widespread  module  in 
developmentally regulated proteins. J Mol Biol, 231, 539-45.
BORNSTEIN, P. 2001. Thrombospondins as matricellular modulators of cell function. J Clin 
Invest, 107, 929-34.
3 | P a g e
References
BOTTINGER, E. P. & BITZER, M. 2002. TGF-beta signaling in renal disease. J Am Soc 
Nephrol, 13, 2600-10.
BRADHAM, D.  M.,  IGARASHI,  A.,  POTTER,  R.  L.  & GROTENDORST, G.  R.  1991. 
Connective  tissue  growth  factor:  a  cysteine-rich  mitogen  secreted  by  human  vascular 
endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell 
Biol, 114, 1285-94.
BRINKLEY,  B.  R.,  BEALL,  P.  T.,  WIBLE,  L.  J.,  MACE,  M.  L.,  TURNER,  D.  S.  & 
CAILLEAU, R. M. 1980. Variations in cell form and cytoskeleton in human breast carcinoma 
cells in vitro. Cancer Res, 40, 3118-29.
BROEKEMA, M., HARMSEN, M. C., VAN LUYN, M. J., KOERTS, J. A., PETERSEN, A. 
H., VAN KOOTEN, T. G., VAN GOOR, H., NAVIS, G. & POPA, E. R. 2007. Bone marrow-
derived  myofibroblasts  contribute  to  the  renal  interstitial  myofibroblast  population  and 
produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol, 18, 165-75.
BROWN,  P.  D.,  WAKEFIELD,  L.  M.,  LEVINSON,  A.  D.  &  SPORN,  M.  B.  1990. 
Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 
3. Growth Factors, 3, 35-43.
BRUDER, D., PROBST-KEPPER, M., WESTENDORF, A. M., GEFFERS, R., BEISSERT, 
S.,  LOSER, K., VON BOEHMER, H., BUER, J. & HANSEN, W. 2004. Neuropilin-1: a 
surface marker of regulatory T cells. Eur J Immunol, 34, 623-30.
BURNS, W. C., KANTHARIDIS, P. & THOMAS, M. C. 2007. The role of tubular epithelial-
mesenchymal transition in progressive kidney disease. Cells Tissues Organs, 185, 222-31.
BURNS, W. C.,  TWIGG, S.  M.,  FORBES, J.  M.,  PETE, J.,  TIKELLIS,  C.,  THALLAS-
BONKE, V., THOMAS, M. C., COOPER, M. E. & KANTHARIDIS, P. 2006. Connective 
tissue  growth  factor  plays  an  important  role  in  advanced  glycation  end  product-induced 
tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.  J Am 
Soc Nephrol, 17, 2484-94.
CABALLERO, A., FERNANDEZ, N., LAVADO, R., BRAVO, M. J., MIRANDA, J. M. & 
ALONSO, A. 2006. Tolerogenic response: allorecognition pathways. Transpl Immunol, 17, 3-
6.
CABEZON,  T.,  CELIS,  J.  E.,  SKIBSHOJ,  I.,  KLINGELHOFER,  J.,  GRIGORIAN,  M., 
GROMOV, P., RANK, F., MYKLEBUST, J. H., MAELANDSMO, G. M., LUKANIDIN, E. 
& AMBARTSUMIAN, N. 2007. Expression of S100A4 by a variety of cell types present in 
the tumor microenvironment of human breast cancer. Int J Cancer, 121, 1433-44.
CAMBIER,  S.,  GLINE,  S.,  MU,  D.,  COLLINS,  R.,  ARAYA,  J.,  DOLGANOV,  G., 
EINHEBER,  S.,  BOUDREAU,  N.  &  NISHIMURA,  S.  L.  2005.  Integrin  alpha(v)beta8-
mediated  activation  of  transforming  growth  factor-beta  by  perivascular  astrocytes:  an 
angiogenic control switch. Am J Pathol, 166, 1883-94.
4 | P a g e
References
CAMBIER, S.,  MU, D.  Z.,  O'CONNELL,  D.,  BOYLEN, K.,  TRAVIS,  W.,  LIU,  W. H., 
BROADDUS, V. C. & NISHIMURA, S. L. 2000. A role for the integrin alphavbeta8 in the 
negative regulation of epithelial cell growth. Cancer Res, 60, 7084-93.
CANTAROVICH,  D.,  RENOU,  M.,  MEGNIGBETO,  A.,  GIRAL-CLASSE,  M., 
HOURMANT, M., DANTAL, J., BLANCHO, G., KARAM, G. & SOULILLOU, J. P. 2005. 
Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or 
cyclosporine-induced adverse events. Transplantation, 79, 72-8.
CAO, G., LU, Y., GAO, R., XIN, Y., TENG, D.,  WANG, J.,  WANG, L. & LI,  Y. 2006. 
Comparison of cyclosporine versus mycophenolate mofetil on expression of Fractalkine and 
CX3CR1 in chronic allograft nephropathy. Transplant Proc, 38, 2234-6.
CAO, Y.,  SZABOLCS, A.,  DUTTA, S.  K.,  YAQOOB, U.,  JAGAVELU, K.,  WANG, L., 
LEOF, E. B., URRUTIA, R. A., SHAH, V. H. & MUKHOPADHYAY, D. 2010. Neuropilin-1 
mediates divergent R-Smad signaling and the myofibroblast phenotype. J Biol Chem, 285, 
31840-8.
CARLOS, C. P., MENDES, G. E., MIQUELIN, A. R., LUZ, M. A., DA SILVA, C. G., VAN 
ROOIJEN,  N.,  COIMBRA,  T.  M.  &  BURDMANN,  E.  A.  2010.  Macrophage  depletion 
attenuates chronic cyclosporine A nephrotoxicity. Transplantation, 89, 1362-70.
CARMAN, C. V. 2009. Mechanisms for transcellular diapedesis: probing and pathfinding by 
'invadosome-like protrusions'. J Cell Sci, 122, 3025-35.
CEPEK, K. L., SHAW, S. K., PARKER, C. M., RUSSELL, G. J., MORROW, J. S., RIMM, 
D.  L.  & BRENNER,  M.  B.  1994.  Adhesion  between epithelial  cells  and T lymphocytes 
mediated by E-cadherin and the alpha E beta 7 integrin. Nature, 372, 190-3.
CERF-BENSUSSAN,  N.,  JARRY,  A.,  BROUSSE,  N.,  LISOWSKA-GROSPIERRE,  B., 
GUY-GRAND, D. & GRISCELLI,  C. 1987. A monoclonal antibody (HML-1) defining a 
novel  membrane molecule present on human intestinal  lymphocytes.  Eur J  Immunol,  17, 
1279-85.
CHAKRAVORTY, S. J., HOWIE, A. J., GIRDLESTONE, J., GENTLE, D. & SAVAGE, C. 
O.  2001.  Potential  role  for  monocyte  chemotactic  protein-4  (MCP-4)  in 
monocyte/macrophage recruitment in acute renal inflammation. J Pathol, 194, 239-46.
CHEIFETZ, S. & MASSAGUE, J. 1991. Isoform-specific transforming growth factor-beta 
binding  proteins  with  membrane  attachments  sensitive  to  phosphatidylinositol-specific 
phospholipase C. J Biol Chem, 266, 20767-72.
CHEN, G., LIN, S. C., CHEN, J., HE, L., DONG, F., XU, J., HAN, S., DU, J., ENTMAN, M. 
L. & WANG, Y. 2011. CXCL16 recruits bone marrow-derived fibroblast precursors in renal 
fibrosis. J Am Soc Nephrol, 22, 1876-86.
CHEN, Q., SIVAKUMAR, P., BARLEY, C., PETERS, D. M., GOMES, R. R., FARACH-
CARSON, M. C. & DALLAS, S. L. 2007. Potential role for heparan sulfate proteoglycans in 
5 | P a g e
References
regulation of transforming growth factor-beta (TGF-beta) by modulating assembly of latent 
TGF-beta-binding protein-1. J Biol Chem, 282, 26418-30.
CHEN, Z., LING, J. & GALLIE, D. R. 2004. RNase activity requires formation of disulfide 
bonds and is regulated by the redox state. Plant Mol Biol, 55, 83-96.
CHENG, S. & LOVETT, D. H. 2003. Gelatinase A (MMP-2) is necessary and sufficient for 
renal tubular cell epithelial-mesenchymal transformation. Am J Pathol, 162, 1937-49.
CHENG, S., POLLOCK, A. S., MAHIMKAR, R., OLSON, J. L. & LOVETT, D. H. 2006. 
Matrix  metalloproteinase  2 and basement  membrane  integrity:  a  unifying  mechanism for 
progressive renal injury. FASEB J, 20, 1898-900.
CHOI, B. S., SHIN, M. J., SHIN, S. J., KIM, Y. S., CHOI, Y. J., KIM, Y. S., MOON, I. S.,  
KIM, S. Y., KOH, Y. B., BANG, B. K. & YANG, C. W. 2005. Clinical significance of an 
early protocol biopsy in living-donor renal transplantation: ten-year experience at a single 
center. Am J Transplant, 5, 1354-60.
CORNELL,  L.  D.  &  COLVIN,  R.  B.  2005.  Chronic  allograft  nephropathy.  Curr  Opin 
Nephrol Hypertens, 14, 229-34.
CORPS, E. M., ROBERTSON, A., DAUNCEY, M. J. & KILSHAW, P. J. 2003. Role of the 
alphaI domain in ligand binding by integrin alphaEbeta7. Eur J Immunol, 33, 2599-608.
CRAWFORD,  S.  E.,  STELLMACH,  V.,  MURPHY-ULLRICH,  J.  E.,  RIBEIRO,  S.  M., 
LAWLER, J., HYNES, R. O., BOIVIN, G. P. & BOUCK, N. 1998. Thrombospondin-1 is a 
major activator of TGF-beta1 in vivo. Cell, 93, 1159-70.
CROMPTON, M. 1999. The mitochondrial permeability transition pore and its role in cell 
death. Biochem J, 341 ( Pt 2), 233-49.
CUI,  X.,  ZHOU,  J.,  QIU,  J.,  JOHNSON,  M.  R.  &  MRUG,  M.  2009.  Validation  of 
endogenous internal real-time PCR controls in renal tissues. Am J Nephrol, 30, 413-7.
DACOSTA BYFIELD,  S.,  MAJOR,  C.,  LAPING, N.  J.  & ROBERTS,  A.  B.  2004.  SB-
505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, 
ALK5, and ALK7. Mol Pharmacol, 65, 744-52.
DALLAS, S. L., SIVAKUMAR, P., JONES, C. J., CHEN, Q., PETERS, D. M., MOSHER, 
D. F., HUMPHRIES, M. J. & KIELTY, C. M. 2005. Fibronectin regulates latent transforming 
growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding 
protein-1. J Biol Chem, 280, 18871-80.
DANIEL,  C.,  SCHAUB,  K.,  AMANN,  K.,  LAWLER,  J.  &  HUGO,  C.  2007. 
Thrombospondin-1  is  an  endogenous  activator  of  TGF-beta  in  experimental  diabetic 
nephropathy in vivo. Diabetes, 56, 2982-9.
6 | P a g e
References
DANIEL, C., TAKABATAKE, Y., MIZUI, M., ISAKA, Y., KAWASHI, H., RUPPRECHT, 
H.,  IMAI,  E.  &  HUGO,  C.  2003.  Antisense  oligonucleotides  against  thrombospondin-1 
inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol, 163, 
1185-92.
DANIEL,  C.,  WIEDE,  J.,  KRUTZSCH,  H.  C.,  RIBEIRO,  S.  M.,  ROBERTS,  D.  D., 
MURPHY-ULLRICH, J. E. & HUGO, C. 2004. Thrombospondin-1 is a major activator of 
TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int, 65, 459-68.
DELVA, E., TUCKER, D. K. & KOWALCZYK, A. P. 2009. The desmosome. Cold Spring 
Harb Perspect Biol, 1, a002543.
DERYNCK, R. & ZHANG, Y. E. 2003. Smad-dependent and Smad-independent pathways in 
TGF-beta family signalling. Nature, 425, 577-84.
DESMOULIERE,  A.,  RUBBIA-BRANDT,  L.,  ABDIU,  A.,  WALZ,  T.,  MACIEIRA-
COELHO,  A.  &  GABBIANI,  G.  1992.  Alpha-smooth  muscle  actin  is  expressed  in  a 
subpopulation of cultured and cloned fibroblasts and is modulated by gamma-interferon. Exp 
Cell Res, 201, 64-73.
DHAR, K., DHAR, G., MAJUMDER, M., HAQUE, I., MEHTA, S., VAN VELDHUIZEN, P. 
J.,  BANERJEE,  S.  K.  & BANERJEE,  S.  2010.  Tumor  cell-derived  PDGF-B potentiates 
mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction 
with NRP-1. Mol Cancer, 9, 209.
DICKSON, M. C., MARTIN, J. S., COUSINS, F. M., KULKARNI, A. B., KARLSSON, S. 
& AKHURST,  R.  J.  1995.  Defective  haematopoiesis  and  vasculogenesis  in  transforming 
growth factor-beta 1 knock out mice. Development, 121, 1845-54.
DOCHERTY,  N.  G.,  CALVO,  I.  F.,  QUINLAN,  M.  R.,  PEREZ-BARRIOCANAL,  F., 
MCGUIRE, B. B., FITZPATRICK, J. M. & WATSON, R. W. 2009. Increased E-cadherin 
expression in the ligated kidney following unilateral ureteric obstruction. Kidney Int, 75, 205-
13.
DREXLER,  H.  G.  &  MINOWADA,  J.  1989.  Morphological,  immunophenotypical  and 
isoenzymatic profiles of human leukemia cells and derived T-cell lines. Hematol Oncol, 7, 
115-25.
DRUML, W. 2002. The beginning of organ transplantation: Emerich Ullmann (1861-1937). 
Wien Klin Wochenschr, 114, 128-37.
DUBOIS, C. M.,  LAPRISE, M. H.,  BLANCHETTE, F.,  GENTRY, L. E.  & LEDUC, R. 
1995. Processing of transforming growth factor beta 1 precursor by human furin convertase. J 
Biol Chem, 270, 10618-24.
EEDY, D. J.  2005. Summary of inaugural meeting of the Skin Care in Organ Recipients 
Group, UK, held at the Royal Society of Medicine, 7 October 2004. Br J Dermatol, 153, 6-
10.
7 | P a g e
References
EINECKE, G., BRODERICK, G., SIS, B. & HALLORAN, P. F. 2007. Early loss of renal 
transcripts  in  kidney allografts:  relationship to  the  development  of  histologic  lesions  and 
alloimmune effector mechanisms. Am J Transplant, 7, 1121-30.
EINECKE,  G.,  FAIRHEAD,  T.,  HIDALGO,  L.  G.,  SIS,  B.,  TURNER,  P.,  ZHU,  L.  F., 
BLEACKLEY, R. C.,  HADLEY, G. A.,  FAMULSKI,  K.  S.  & HALLORAN, P.  F.  2006. 
Tubulitis and epithelial cell alterations in mouse kidney transplant rejection are independent 
of CD103, perforin or granzymes A/B. Am J Transplant, 6, 2109-20.
EINECKE, G., SIS, B., REEVE, J., MENGEL, M., CAMPBELL, P. M., HIDALGO, L. G., 
KAPLAN, B. & HALLORAN, P. F. 2009. Antibody-mediated microcirculation injury is the 
major cause of late kidney transplant failure. Am J Transplant, 9, 2520-31.
EL-ZOGHBY, Z. M., STEGALL, M. D., LAGER, D. J.,  KREMERS, W. K., AMER, H., 
GLOOR, J. M. & COSIO, F. G. 2009. Identifying specific causes of kidney allograft loss. Am 
J Transplant, 9, 527-35.
ESPOSITO, C., FORNONI, A., CORNACCHIA, F., BELLOTTI, N., FASOLI, G., FOSCHI, 
A., MAZZUCCHELLI, I., MAZZULLO, T., SEMERARO, L. & DAL CANTON, A. 2000. 
Cyclosporine induces different responses in human epithelial, endothelial and fibroblast cell 
cultures. Kidney Int, 58, 123-30.
ESSAWY, M., SOYLEMEZOGLU, O., MUCHANETA-KUBARA, E. C., SHORTLAND, J., 
BROWN, C. B. & EL NAHAS, A. M. 1997. Myofibroblasts and the progression of diabetic 
nephropathy. Nephrol Dial Transplant, 12, 43-50.
FAN, J. M., NG, Y. Y., HILL, P. A., NIKOLIC-PATERSON, D. J., MU, W., ATKINS, R. C. & 
LAN, H. Y. 1999. Transforming growth factor-beta regulates tubular epithelial-myofibroblast 
transdifferentiation in vitro. Kidney Int, 56, 1455-67.
FANG, Z., FORSLUND, N., TAKENAGA, K., LUKANIDIN, E. & KOZLOVA, E. N. 2006. 
Sensory  neurite  outgrowth  on  white  matter  astrocytes  is  influenced  by  intracellular  and 
extracellular S100A4 protein. J Neurosci Res, 83, 619-26.
FENG, X. H. & DERYNCK, R. 2005. Specificity and versatility in tgf-beta signaling through 
Smads. Annu Rev Cell Dev Biol, 21, 659-93.
FENG, Y., WANG, D., YUAN, R., PARKER, C. M., FARBER, D. L. & HADLEY, G. A. 
2002. CD103 expression is required for destruction of pancreatic islet allografts by CD8(+) T 
cells. J Exp Med, 196, 877-86.
FISCHER, G., WITTMANN-LIEBOLD, B., LANG, K., KIEFHABER, T. & SCHMID, F. X. 
1989.  Cyclophilin  and peptidyl-prolyl  cis-trans  isomerase  are  probably identical  proteins. 
Nature, 337, 476-8.
FUKASAWA,  M.,  MATSUSHITA,  A.  &  KORC,  M.  2007.  Neuropilin-1  interacts  with 
integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer 
Biol Ther, 6, 1173-80.
8 | P a g e
References
FUKUDA, K., YOSHITOMI, K., YANAGIDA, T.,  TOKUMOTO, M. & HIRAKATA, H. 
2001. Quantification of TGF-beta1 mRNA along rat nephron in obstructive nephropathy. Am 
J Physiol Renal Physiol, 281, F513-21.
GABBIANI, G. 1981. The myofibroblast: a key cell for wound healing and fibrocontractive 
diseases. Prog Clin Biol Res, 54, 183-94.
GABBIANI, G. 2003. The myofibroblast in wound healing and fibrocontractive diseases. J 
Pathol, 200, 500-3.
GAFFEN, S.  L.  & LIU, K. D. 2004. Overview of interleukin-2 function,  production and 
clinical applications. Cytokine, 28, 109-23.
GAGNON, M. L., BIELENBERG, D. R., GECHTMAN, Z., MIAO, H. Q., TAKASHIMA, 
S., SOKER, S. & KLAGSBRUN, M. 2000. Identification of a natural soluble neuropilin-1 
that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc 
Natl Acad Sci U S A, 97, 2573-8.
GAME,  D.  S.  &  LECHLER,  R.  I.  2002.  Pathways  of  allorecognition:  implications  for 
transplantation tolerance. Transpl Immunol, 10, 101-8.
GANAPATHY, V., GE, R., GRAZIOLI, A., XIE, W., BANACH-PETROSKY, W., KANG, Y., 
LONNING,  S.,  MCPHERSON,  J.,  YINGLING,  J.  M.,  BISWAS,  S.,  MUNDY,  G.  R.  & 
REISS, M. 2010. Targeting the Transforming Growth Factor-beta pathway inhibits human 
basal-like breast cancer metastasis. Mol Cancer, 9, 122.
GANDHI, R., FAREZ, M. F., WANG, Y., KOZORIZ, D., QUINTANA, F. J. & WEINER, H. 
L. 2010. Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell 
subset. J Immunol, 184, 4620-4.
GARRETT, S. C., VARNEY, K. M., WEBER, D. J. & BRESNICK, A. R. 2006. S100A4, a 
mediator of metastasis. J Biol Chem, 281, 677-80.
GHANNAD, F., NICA, D., FULLE, M. I., GRENIER, D., PUTNINS, E. E., JOHNSTON, S., 
ESLAMI, A., KOIVISTO, L., JIANG, G., MCKEE, M. D., HAKKINEN, L. & LARJAVA, 
H.  2008.  Absence  of  alphavbeta6  integrin  is  linked  to  initiation  and  progression  of 
periodontal disease. Am J Pathol, 172, 1271-86.
GLINKA, Y. & PRUD'HOMME, G. J.  2008. Neuropilin-1 is  a  receptor  for transforming 
growth factor  beta-1,  activates  its  latent  form,  and promotes  regulatory T cell  activity.  J 
Leukoc Biol, 84, 302-10.
GLINKA,  Y.,  STOILOVA,  S.,  MOHAMMED,  N.  &  PRUD'HOMME,  G.  J.  2011. 
Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and 
enhances responses to both latent and active TGF-beta. Carcinogenesis, 32, 613-21.
GOKMEN, M. R., LOMBARDI, G. & LECHLER, R. I. 2008. The importance of the indirect 
pathway of allorecognition in clinical transplantation. Curr Opin Immunol, 20, 568-74.
9 | P a g e
References
GOLDSCHMEDING, R., ATEN, J., ITO, Y., BLOM, I., RABELINK, T. & WEENING, J. J. 
2000. Connective tissue growth factor: just another factor in renal fibrosis? Nephrol Dial 
Transplant, 15, 296-9.
GOOCH, J.  L.,  BARNES,  J.  L.,  GARCIA,  S.  & ABBOUD, H.  E.  2003.  Calcineurin  is 
activated in diabetes and is required for glomerular hypertrophy and ECM accumulation. Am 
J Physiol Renal Physiol, 284, F144-54.
GOOCH, J.  L.,  GORIN,  Y.,  ZHANG,  B.  X.  & ABBOUD,  H.  E.  2004.  Involvement  of 
calcineurin in  transforming growth factor-beta-mediated regulation of  extracellular  matrix 
accumulation. J Biol Chem, 279, 15561-70.
GORDON,  K.  J.  &  BLOBE,  G.  C.  2008.  Role  of  transforming  growth  factor-beta 
superfamily signaling pathways in human disease. Biochim Biophys Acta, 1782, 197-228.
GOURISHANKAR, S. & HALLORAN, P. F. 2002. Late deterioration of organ transplants: a 
problem in injury and homeostasis. Curr Opin Immunol, 14, 576-83.
GRAEF,  I.  A.,  CHEN,  F.,  CHEN,  L.,  KUO,  A.  &  CRABTREE,  G.  R.  2001.  Signals 
transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell, 
105, 863-75.
GRAY, M. J.,  VAN BUREN, G.,  DALLAS, N.  A.,  XIA,  L.,  WANG, X.,  YANG, A.  D., 
SOMCIO,  R.  J.,  LIN,  Y.  G.,  LIM,  S.,  FAN,  F.,  MANGALA,  L.  S.,  ARUMUGAM,  T., 
LOGSDON,  C.  D.,  LOPEZ-BERESTEIN,  G.,  SOOD,  A.  K.  &  ELLIS,  L.  M.  2008. 
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine 
liver. J Natl Cancer Inst, 100, 109-20.
GRIMM, P. C., NICKERSON, P., JEFFERY, J., SAVANI, R. C., GOUGH, J., MCKENNA, 
R. M., STERN, E. & RUSH, D. N. 2001. Neointimal and tubulointerstitial infiltration by 
recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med, 345, 93-7.
GRONE,  H.  J.,  WEBER,  K.,  GRONE,  E.,  HELMCHEN,  U.  &  OSBORN,  M.  1987. 
Coexpression of keratin and vimentin in damaged and regenerating tubular epithelia of the 
kidney. Am J Pathol, 129, 1-8.
GROSCURTH,  P.  &  FILGUEIRA,  L.  1998.  Killing  Mechanisms  of  Cytotoxic  T 
Lymphocytes. News Physiol Sci, 13, 17-21.
GROTENDORST, G.  R.  1997.  Connective tissue  growth  factor:  a  mediator  of  TGF-beta 
action on fibroblasts. Cytokine Growth Factor Rev, 8, 171-9.
HADLEY, G. A., BARTLETT, S. T., VIA, C. S., ROSTAPSHOVA, E. A. & MOAINIE, S. 
1997. The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of 
alloreactive CD8+ CTL. J Immunol, 159, 3748-56.
10 | P a g e
References
HADLEY,  G.  A.,  CHARANDEE,  C.,  WEIR,  M.  R.,  WANG,  D.,  BARTLETT,  S.  T.  & 
DRACHENBERG, C. B. 2001. CD103+ CTL accumulate within the graft epithelium during 
clinical renal allograft rejection. Transplantation, 72, 1548-55.
HAHM, K., LUKASHEV, M. E., LUO, Y., YANG, W. J., DOLINSKI, B. M., WEINREB, P. 
H., SIMON, K. J., CHUN WANG, L., LEONE, D. R., LOBB, R. R., MCCRANN, D. J., 
ALLAIRE,  N.  E.,  HORAN,  G.  S.,  FOGO,  A.,  KALLURI,  R.,  SHIELD,  C.  F.,  3RD, 
SHEPPARD,  D.,  GARDNER,  H.  A.  &  VIOLETTE,  S.  M.  2007.  Alphav  beta6  integrin 
regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol, 170, 110-25.
HALLORAN,  P.  F.  2010.  T  cell-mediated  rejection  of  kidney  transplants:  a  personal 
viewpoint. Am J Transplant, 10, 1126-34.
HARIHARAN, S., JOHNSON, C. P., BRESNAHAN, B. A., TARANTO, S. E., MCINTOSH, 
M. J.  & STABLEIN, D.  2000.  Improved graft  survival  after  renal  transplantation  in  the 
United States, 1988 to 1996. N Engl J Med, 342, 605-12.
HAUGEN, M. H., FLATMARK, K., MIKALSEN, S. O. & MALANDSMO, G. M. 2008. 
The metastasis-associated protein S100A4 exists in several charged variants suggesting the 
presence of posttranslational modifications. BMC Cancer, 8, 172.
HELDIN, C. H., MIYAZONO, K. & TEN DIJKE, P. 1997. TGF-beta signalling from cell 
membrane to nucleus through SMAD proteins. Nature, 390, 465-71.
HERRERA, O. B., GOLSHAYAN, D., TIBBOTT, R., SALCIDO OCHOA, F., JAMES, M. 
J.,  MARELLI-BERG,  F.  M.  &  LECHLER,  R.  I.  2004.  A novel  pathway of  alloantigen 
presentation by dendritic cells. J Immunol, 173, 4828-37.
HEWITSON,  T.  D.  &  BECKER,  G.  J.  1995.  Interstitial  myofibroblasts  in  IgA 
glomerulonephritis. Am J Nephrol, 15, 111-7.
HEWITSON, T. D., DARBY, I. A., BISUCCI, T., JONES, C. L. & BECKER, G. J. 1998. 
Evolution of tubulointerstitial fibrosis in experimental renal infection and scarring. J Am Soc 
Nephrol, 9, 632-42.
HINZ, B., GABBIANI, G. & CHAPONNIER, C. 2002. The NH2-terminal peptide of alpha-
smooth muscle actin inhibits force generation by the myofibroblast in vitro and in vivo. J Cell 
Biol, 157, 657-63.
HO, S., CLIPSTONE, N., TIMMERMANN, L., NORTHROP, J., GRAEF, I., FIORENTINO, 
D., NOURSE, J. & CRABTREE, G. R. 1996. The mechanism of action of cyclosporin A and 
FK506. Clin Immunol Immunopathol, 80, S40-5.
HOLLAND, P. M., ABRAMSON, R. D., WATSON, R. & GELFAND, D. H. 1991. Detection 
of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of 
Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A, 88, 7276-80.
11 | P a g e
References
HORNICK, P. I.,  MASON, P. D., YACOUB, M. H., ROSE, M. L., BATCHELOR, R. & 
LECHLER, R. I. 1998. Assessment of the contribution that direct allorecognition makes to 
the progression of chronic cardiac transplant rejection in humans. Circulation, 97, 1257-63.
HUANG,  X.,  GRIFFITHS,  M.,  WU,  J.,  FARESE,  R.  V.,  JR.  &  SHEPPARD,  D.  2000. 
Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice. 
Mol Cell Biol, 20, 755-9.
HUANG, X. Z., WU, J. F., CASS, D., ERLE, D. J., CORRY, D., YOUNG, S. G., FARESE, 
R. V., JR. & SHEPPARD, D. 1996. Inactivation of the integrin beta 6 subunit gene reveals a 
role of epithelial integrins in regulating inflammation in the lung and skin. J Cell Biol, 133, 
921-8.
HUGO, C. & DANIEL, C. 2009. Thrombospondin in renal disease. Nephron Exp Nephrol, 
111, e61-6.
HUGO,  C.,  PICHLER,  R.,  MEEK,  R.,  GORDON,  K.,  KYRIAKIDES,  T.,  FLOEGE,  J., 
BORNSTEIN,  P.,  COUSER,  W.  G.  &  JOHNSON,  R.  J.  1995.  Thrombospondin  1  is 
expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. 
Kidney Int, 48, 1846-56.
HUGO, C., SHANKLAND, S. J., PICHLER, R. H., COUSER, W. G. & JOHNSON, R. J. 
1998. Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis 
in glomerular disease in the rat. Kidney Int, 53, 302-11.
HUMPHREYS, B. D.,  LIN, S. L.,  KOBAYASHI, A., HUDSON, T. E.,  NOWLIN, B. T., 
BONVENTRE, J. V., VALERIUS, M. T., MCMAHON, A. P. & DUFFIELD, J. S. 2010. Fate 
tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am 
J Pathol, 176, 85-97.
HYNES,  R.  O.  2004.  The  emergence  of  integrins:  a  personal  and  historical  perspective. 
Matrix Biol, 23, 333-40.
HYYTIAINEN, M.,  PENTTINEN, C.  & KESKI-OJA, J.  2004.  Latent  TGF-beta  binding 
proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab 
Sci, 41, 233-64.
ILG, E.  C.,  SCHAFER, B. W. & HEIZMANN, C. W. 1996. Expression pattern of S100 
calcium-binding proteins in human tumors. Int J Cancer, 68, 325-32.
INGULLI, E. 2010. Mechanism of cellular rejection in transplantation. Pediatr Nephrol, 25, 
61-74.
INOUE, T., PLIETH, D., VENKOV, C. D., XU, C. & NEILSON, E. G. 2005. Antibodies 
against macrophages that overlap in specificity with fibroblasts. Kidney Int, 67, 2488-93.
12 | P a g e
References
IWANO, M., PLIETH, D., DANOFF, T. M., XUE, C., OKADA, H. & NEILSON, E. G. 
2002. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest, 
110, 341-50.
JENKINS, G. 2008. The role of proteases in transforming growth factor-beta activation. Int J 
Biochem Cell Biol, 40, 1068-78.
JENKINS, R. G.,  SU, X.,  SU, G.,  SCOTTON, C. J.,  CAMERER, E.,  LAURENT, G. J., 
DAVIS, G. E., CHAMBERS, R. C., MATTHAY, M. A. & SHEPPARD, D. 2006. Ligation of 
protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation 
and promotes acute lung injury. J Clin Invest, 116, 1606-14.
JENNINGS,  P.,  KOPPELSTAETTER,  C.,  AYDIN,  S.,  ABBERGER,  T.,  WOLF,  A.  M., 
MAYER, G. & PFALLER, W. 2007. Cyclosporine A induces senescence in renal tubular 
epithelial cells. Am J Physiol Renal Physiol, 293, F831-8.
JI,  J.  D.,  PARK-MIN,  K.  H.  &  IVASHKIV,  L.  B.  2009.  Expression  and  function  of 
semaphorin 3A and its receptors in human monocyte-derived macrophages. Hum Immunol, 
70, 211-7.
JIANG,  S.,  HERRERA,  O.  & LECHLER,  R.  I.  2004.  New spectrum of  allorecognition 
pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol, 
16, 550-7.
KAARTINEN,  V.,  VONCKEN,  J.  W.,  SHULER,  C.,  WARBURTON,  D.,  BU,  D., 
HEISTERKAMP, N. & GROFFEN, J. 1995. Abnormal lung development and cleft palate in 
mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet, 
11, 415-21.
KALLURI,  R.  &  NEILSON,  E.  G.  2003.  Epithelial-mesenchymal  transition  and  its 
implications for fibrosis. J Clin Invest, 112, 1776-84.
KAPTURCZAK, M. H., MEIER-KRIESCHE, H. U. & KAPLAN, B. 2004. Pharmacology of 
calcineurin antagonists. Transplant Proc, 36, 25S-32S.
KELLY,  M.,  HWANG,  J.  M.  &  KUBES,  P.  2007.  Modulating  leukocyte  recruitment  in 
inflammation. J Allergy Clin Immunol, 120, 3-10.
KHALKHALI, H. R., GHAFARI, A., HAJIZADEH, E. & KAZEMNEJAD, A. 2010. Risk 
factors  of  long-term  graft  loss  in  renal  transplant  recipients  with  chronic  allograft 
dysfunction. Exp Clin Transplant, 8, 277-82.
KHANNA, A., PLUMMER, M., BROMBEREK, C., BRESNAHAN, B. & HARIHARAN, 
S.  2002.  Expression  of  TGF-beta  and  fibrogenic  genes  in  transplant  recipients  with 
tacrolimus and cyclosporine nephrotoxicity. Kidney Int, 62, 2257-63.
KIM, S. J. & GILL, J. S. 2009. H-Y incompatibility predicts short-term outcomes for kidney 
transplant recipients. J Am Soc Nephrol, 20, 2025-33.
13 | P a g e
References
KIM,  Y.  J.,  PARK,  Y.  H.  &  MOON,  H.  K.  1997.  Reduction  of  chronic  ciclosporin 
nephrotoxicity by thromboxane synthase inhibition with OKY-046. Kidney Blood Press Res, 
20, 38-43.
KIMMEL,  P.  L.,  COHEN,  D.  J.,  ABRAHAM, A.  A.,  BODI,  I.,  SCHWARTZ,  A.  M.  & 
PHILLIPS,  T.  M.  2003.  Upregulation  of  MHC  class  II,  interferon-alpha  and  interferon-
gamma receptor protein expression in HIV-associated nephropathy. Nephrol Dial Transplant, 
18, 285-92.
KINO, T., HATANAKA, H., HASHIMOTO, M., NISHIYAMA, M., GOTO, T., OKUHARA, 
M.,  KOHSAKA,  M.,  AOKI,  H.  &  IMANAKA,  H.  1987.  FK-506,  a  novel 
immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-
chemical and biological characteristics. J Antibiot (Tokyo), 40, 1249-55.
KLAGSBRUN, M.,  TAKASHIMA, S.  & MAMLUK, R.  2002.  The role  of  neuropilin  in 
vascular and tumor biology. Adv Exp Med Biol, 515, 33-48.
KLINGELHOFER,  J.,  SENOLT,  L.,  BASLUND,  B.,  NIELSEN,  G.  H.,  SKIBSHOJ,  I., 
PAVELKA,  K.,  NEIDHART,  M.,  GAY,  S.,  AMBARTSUMIAN,  N.,  HANSEN,  B.  S., 
PETERSEN, J., LUKANIDIN, E. & GRIGORIAN, M. 2007. Up-regulation of metastasis-
promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis 
of rheumatoid arthritis. Arthritis Rheum, 56, 779-89.
KLINTMALM, G. B., IWATSUKI, S. & STARZL, T. E. 1981. Cyclosporin A hepatotoxicity 
in 66 renal allograft recipients. Transplantation, 32, 488-9.
KLINTMALM, G. B., IWATSUKI, S. & STARZL, T. E. 1981. Nephrotoxicity of cyclosporin 
A in liver and kidney transplant patients. Lancet, 1, 470-1.
KOBAYASHI, A., YAMAMOTO, I., ITO, S., AKIOKA, Y., YAMAMOTO, H., TERAOKA, 
S., HATTORI, M., TANABE, K., HOSOYA, T. & YAMAGUCHI, Y. 2010. Medullary ray 
injury in renal allografts. Pathol Int, 60, 744-9.
KOLI, K., SAHARINEN, J., HYYTIAINEN, M., PENTTINEN, C. & KESKI-OJA, J. 2001. 
Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech, 52, 354-62.
KOLODKIN,  A.  L.,  LEVENGOOD, D.  V.,  ROWE,  E.  G.,  TAI,  Y.  T.,  GIGER,  R.  J.  & 
GINTY, D. D. 1997. Neuropilin is a semaphorin III receptor. Cell, 90, 753-62.
KOLODKIN,  A.  L.,  LEVENGOOD, D.  V.,  ROWE,  E.  G.,  TAI,  Y.  T.,  GIGER,  R.  J.  & 
GINTY, D. D. 1997. Neuropilin is a semaphorin III receptor. Cell, 90, 753-62.
KOSKI, C., SAHARINEN, J. & KESKI-OJA, J. 1999. Independent promoters regulate the 
expression of two amino terminally distinct forms of latent transforming growth factor-beta 
binding protein-1 (LTBP-1) in a cell type-specific manner. J Biol Chem, 274, 32619-30.
14 | P a g e
References
KOTH, L. L., ALEX, B., HAWGOOD, S., NEAD, M. A., SHEPPARD, D., ERLE, D. J. & 
MORRIS, D. G. 2007. Integrin beta6 mediates phospholipid and collectin homeostasis by 
activation of latent TGF-beta1. Am J Respir Cell Mol Biol, 37, 651-9.
KOWALTOWSKI, A. J., SMAILI, S. S., RUSSELL, J. T. & FISKUM, G. 2000. Elevation of 
resting mitochondrial membrane potential of neural cells by cyclosporin A, BAPTA-AM, and 
bcl-2. Am J Physiol Cell Physiol, 279, C852-9.
KREJCI,  K.,  TICHY,  T.,  AL-GABRI,  S.,  HORAK,  P.,  CIFERSKA,  H.,  HRUBY,  M., 
HORCICKA, V.,  JR.,  STREBL,  P.,  ZAMBOCH, K.,  BACHLEDA, P.  & ZADRAZIL,  J. 
2011.  Protocol  biopsy  of  a  transplanted  kidney  as  a  tool  for  monitoring  adequacy  of 
immunosuppressive  therapy:  10  years  of  experience  from  a  single  transplant  center. 
Transplant Proc, 43, 1576-82.
KRONKE,  M.,  LEONARD,  W.  J.,  DEPPER,  J.  M.,  ARYA,  S.  K.,  WONG-STAAL,  F., 
GALLO, R. C., WALDMANN, T. A. & GREENE, W. C. 1984. Cyclosporin A inhibits T-cell 
growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A, 
81, 5214-8.
KUILMAN, T. & PEEPER, D. S. 2009. Senescence-messaging secretome: SMS-ing cellular 
stress. Nat Rev Cancer, 9, 81-94.
KULKARNI, A. B. & KARLSSON, S. 1993. Transforming growth factor-beta 1 knockout 
mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol, 
143, 3-9.
KURUS, M., ESREFOGLU, M., BAY, A. & OZTURK, F. 2005. Protective effect of oral L-
arginine supplementation on cyclosporine induced nephropathy in rats. Int Urol Nephrol, 37, 
587-94.
LAFFERTY, K. J.,  BOOTES, A., DART, G. & TALMAGE, D. W. 1976. Effect of organ 
culture on the survival of thyroid allografts in mice. Transplantation, 22, 138-49.
LALLY, C., HEALY, E. & RYAN, M. P. 1999. Cyclosporine A-induced cell cycle arrest and 
cell death in renal epithelial cells. Kidney Int, 56, 1254-7.
LAN, H. Y., YANG, N., BROWN, F. G., ISBEL, N. M., NIKOLIC-PATERSON, D. J., MU, 
W.,  METZ,  C.  N.,  BACHER,  M.,  ATKINS,  R.  C.  &  BUCALA,  R.  1998.  Macrophage 
migration inhibitory factor expression in human renal allograft rejection. Transplantation, 66, 
1465-71.
LAWLER, J., SUNDAY, M., THIBERT, V., DUQUETTE, M., GEORGE, E. L., RAYBURN, 
H. & HYNES, R. O. 1998. Thrombospondin-1 is  required for normal murine pulmonary 
homeostasis and its absence causes pneumonia. J Clin Invest, 101, 982-92.
LAWRENCE, D. A. 2001. Latent-TGF-beta: an overview. Mol Cell Biochem, 219, 163-70.
15 | P a g e
References
LAZZERI,  E.,  ROTONDI,  M.,  MAZZINGHI,  B.,  LASAGNI,  L.,  BUONAMANO,  A., 
ROSATI, A., PRADELLA, F., FOSSOMBRONI, V., LA VILLA, G., GACCI, M., BERTONI, 
E., SERIO, M., SALVADORI, M. & ROMAGNANI, P. 2005. High CXCL10 expression in 
rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and 
chronic allograft nephropathy. Transplantation, 79, 1215-20.
LE HIR, M.,  HEGYI, I.,  CUENI-LOFFING, D., LOFFING, J.  & KAISSLING, B. 2005. 
Characterization  of  renal  interstitial  fibroblast-specific  protein  1/S100A4-positive  cells  in 
healthy and inflamed rodent kidneys. Histochem Cell Biol, 123, 335-46.
LE  MOINE,  A.,  GOLDMAN,  M.  &  ABRAMOWICZ,  D.  2002.  Multiple  pathways  to 
allograft rejection. Transplantation, 73, 1373-81.
LEE,  D.  A.  &  MOLINARO,  G.  A.  2003.  Activated  peripheral  T  lymphocytes  undergo 
apoptosis when cultured with monocytes activated by HLA class II ligation. Cell Immunol, 
225, 101-12.
LEE, R. S., GRUSBY, M. J., GLIMCHER, L. H., WINN, H. J. & AUCHINCLOSS, H., JR. 
1994. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes 
in vivo. J Exp Med, 179, 865-72.
LETEURTRE,  E.,  COPIN,  M.  C.,  LABALETTE,  M.,  NOEL,  C.,  ROUMILHAC,  D., 
PRUVOT,  F.  R.,  LECOMTE-HOUCKE,  M.,  GOSSELIN,  B.  & DESSAINT,  J.  P.  2000. 
Negative immunohistochemical detection of CD103 (alphaEbeta7 integrin) in the infiltrates 
of acute rejection in liver and kidney transplantation. Transplantation, 70, 227-9.
LI, S. S., IVANOFF, A., BERGSTROM, S. E., SANDSTROM, A., CHRISTENSSON, B., 
VAN  NERVEN,  J.,  HOLGERSSON,  J.,  HAUZENBERGER,  D.,  ARENCIBIA,  I.  & 
SUNDQVIST, K. G. 2002. T lymphocyte expression of thrombospondin-1 and adhesion to 
extracellular matrix components. Eur J Immunol, 32, 1069-79.
LI,  Y.,  YANG, J.,  DAI,  C.,  WU, C.  & LIU,  Y.  2003.  Role  for  integrin-linked kinase  in 
mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J 
Clin Invest, 112, 503-16.
LIANG, H., ZHAO, Y., SAN, Z., LIAO, C., SHA, C., XIE, B., CHEN, J., XIA, J., WANG, Y. 
& QI, Z. 2010. The recall alloresponse following retransplantation is more intense compared 
with the T cell memory-transfer model. Immunol Invest, 39, 39-53.
LIM, B. J., KIM, P. K., HONG, S. W. & JEONG, H. J. 2004. Osteopontin expression and 
microvascular injury in cyclosporine nephrotoxicity. Pediatr Nephrol, 19, 288-94.
LIN, S. L., KISSELEVA, T., BRENNER, D. A. & DUFFIELD, J. S. 2008. Pericytes and 
perivascular  fibroblasts  are  the  primary source  of  collagen-producing  cells  in  obstructive 
fibrosis of the kidney. Am J Pathol, 173, 1617-27.
LING, H., LI, X., JHA, S., WANG, W., KARETSKAYA, L., PRATT, B. & LEDBETTER, S. 
2003.  Therapeutic  role  of  TGF-beta-neutralizing  antibody  in  mouse  cyclosporin  A 
16 | P a g e
References
nephropathy: morphologic improvement associated with functional preservation. J Am Soc 
Nephrol, 14, 377-88.
LIPTAK, P. & IVANYI, B. 2006. Primer: Histopathology of calcineurin-inhibitor toxicity in 
renal allografts. Nat Clin Pract Nephrol, 2, 398-404; quiz following 404.
LIU, B. C., LI, M. X., ZHANG, J. D., LIU, X. C., ZHANG, X. L. & PHILLIPS, A. O. 2008. 
Inhibition of integrin-linked kinase via a siRNA expression plasmid attenuates connective 
tissue  growth  factor-induced  human  proximal  tubular  epithelial  cells  to  mesenchymal 
transition. Am J Nephrol, 28, 143-51.
LIU,  E.  H.,  SIEGEL,  R.  M.,  HARLAN,  D.  M.  &  O'SHEA,  J.  J.  2007.  T  cell-directed 
therapies: lessons learned and future prospects. Nat Immunol, 8, 25-30.
LIU,  Y.  2004.  Epithelial  to  mesenchymal  transition  in  renal  fibrogenesis:  pathologic 
significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol, 15, 1-
12.
LIU, Y. 2010. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am 
Soc Nephrol, 21, 212-22.
LO, H. W., HSU, S. C., XIA, W., CAO, X., SHIH, J. Y., WEI, Y., ABBRUZZESE, J. L., 
HORTOBAGYI, G. N. & HUNG, M. C. 2007. Epidermal growth factor receptor cooperates 
with  signal  transducer  and  activator  of  transcription  3  to  induce  epithelial-mesenchymal 
transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res, 67, 9066-
76.
LOVETT, D. H., JOHNSON, R. J., MARTI, H. P., MARTIN, J., DAVIES, M. & COUSER, 
W.  G.  1992.  Structural  characterization  of  the  mesangial  cell  type  IV  collagenase  and 
enhanced expression in  a  model  of  immune complex-mediated  glomerulonephritis.  Am J 
Pathol, 141, 85-98.
LU,  L.,  YU,  Y.,  LI,  G.,  PU,  L.,  ZHANG,  F.,  ZHENG,  S.  &  WANG,  X.  2009. 
CD8(+)CD103(+)  regulatory  T  cells  in  spontaneous  tolerance  of  liver  allografts.  Int 
Immunopharmacol, 9, 546-8.
LUDLOW, A.,  YEE, K. O.,  LIPMAN, R.,  BRONSON, R.,  WEINREB, P.,  HUANG, X., 
SHEPPARD,  D.  &  LAWLER,  J.  2005.  Characterization  of  integrin  beta6  and 
thrombospondin-1 double-null mice. J Cell Mol Med, 9, 421-37.
LUO, K. & LODISH, H. F. 1996. Signaling by chimeric erythropoietin-TGF-beta receptors: 
homodimerization  of  the  cytoplasmic  domain  of  the  type  I  TGF-beta  receptor  and 
heterodimerization  with  the  type  II  receptor  are  both  required  for  intracellular  signal 
transduction. EMBO J, 15, 4485-96.
LYONS,  R.  M.,  KESKI-OJA,  J.  & MOSES, H.  L.  1988.  Proteolytic  activation  of  latent 
transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol, 106, 1659-
65.
17 | P a g e
References
MA, L. J., YANG, H., GASPERT, A., CARLESSO, G., BARTY, M. M., DAVIDSON, J. M., 
SHEPPARD,  D.  &  FOGO,  A.  B.  2003.  Transforming  growth  factor-beta-dependent  and 
-independent  pathways  of  induction of  tubulointerstitial  fibrosis  in  beta6(-/-)  mice.  Am J 
Pathol, 163, 1261-73.
MACUNLUOGLU,  B.,  ARIKAN,  H.,  ATAKAN,  A.,  TUGLULAR,  S.,  ULFER,  G., 
CAKALAGAOGLU, F., OZENER, C. & AKOGLU, E. 2008. Effects of spironolactone in an 
experimental model of chronic cyclosporine nephrotoxicity. Transplant Proc, 40, 273-8.
MARCEN,  R.,  PASCUAL,  J.,  TERUEL,  J.  L.,  VILLAFRUELA,  J.  J.,  RIVERA,  M.  E., 
MAMPASO, F., BURGOS, F. J. & ORTUNO, J. 2001. Outcome of cadaveric renal transplant 
patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major 
cause of late graft loss? Transplantation, 72, 57-62.
MARENHOLZ, I., LOVERING, R. C. & HEIZMANN, C. W. 2006. An update of the S100 
nomenclature. Biochim Biophys Acta, 1763, 1282-3.
MARGETTS, P. J., BONNIAUD, P., LIU, L., HOFF, C. M., HOLMES, C. J., WEST-MAYS, 
J. A. & KELLY, M. M. 2005. Transient overexpression of TGF-{beta}1 induces epithelial 
mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol, 16, 425-36.
MARKOVICS, J. A., ARAYA, J., CAMBIER, S., JABLONS, D., HILL, A., WOLTERS, P. J. 
& NISHIMURA, S. L. 2010. Transcription of the transforming growth factor beta activating 
integrin beta8 subunit is regulated by SP3, AP-1, and the p38 pathway. J Biol Chem, 285, 
24695-706.
MASSARI, M. E. & MURRE, C. 2000. Helix-loop-helix proteins: regulators of transcription 
in eucaryotic organisms. Mol Cell Biol, 20, 429-40.
MATEVOSSIAN,  E.,  KERN,  H.,  HUSER,  N.,  DOLL,  D.,  SNOPOK,  Y.,  NAHRIG,  J., 
ALTOMONTE,  J.,  SINICINA,  I.,  FRIESS,  H.  &  THORBAN,  S.  2009.  Surgeon  Yurii 
Voronoy (1895-1961) - a pioneer in the history of clinical transplantation: in memoriam at the 
75th anniversary of the first human kidney transplantation. Transpl Int, 22, 1132-9.
MATSUSHITA, A., GOTZE, T. & KORC, M. 2007. Hepatocyte growth factor-mediated cell 
invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res, 67, 10309-16.
MAZA, A., MONTAUDIE, H., SBIDIAN, E., GALLINI, A., ARACTINGI, S., AUBIN, F., 
BACHELEZ, H., CRIBIER, B., JOLY, P.,  JULLIEN, D., LE MAITRE, M., MISERY, L., 
RICHARD, M. A.,  ORTONNE, J.  P.  & PAUL, C. 2011. Oral  cyclosporin in psoriasis:  a 
systematic review on treatment modalities, risk of kidney toxicity and evidence for use in 
non-plaque psoriasis. J Eur Acad Dermatol Venereol, 25 Suppl 2, 19-27.
MCFARLAND, R. D., DOUEK, D. C., KOUP, R. A. & PICKER, L. J. 2000. Identification of 
a human recent thymic emigrant phenotype. Proc Natl Acad Sci U S A, 97, 4215-20.
18 | P a g e
References
MCMORROW, T., GAFFNEY, M. M., SLATTERY, C., CAMPBELL, E. & RYAN, M. P. 
2005. Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal 
tubular epithelial cells. Nephrol Dial Transplant, 20, 2215-25.
MEIER-KRIESCHE, H. U., SCHOLD, J. D. & KAPLAN, B. 2004. Long-term renal allograft 
survival:  have  we  made  significant  progress  or  is  it  time  to  rethink  our  analytic  and 
therapeutic strategies? Am J Transplant, 4, 1289-95.
MIAO, H. Q., SOKER, S., FEINER, L., ALONSO, J. L., RAPER, J. A. & KLAGSBRUN, 
M.  1999.  Neuropilin-1  mediates  collapsin-1/semaphorin  III  inhibition  of  endothelial  cell 
motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J 
Cell Biol, 146, 233-42.
MIETTINEN, P. J., EBNER, R., LOPEZ, A. R. & DERYNCK, R. 1994. TGF-beta induced 
transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I 
receptors. J Cell Biol, 127, 2021-36.
MIGLIORE,  A.,  BIZZI,  E.,  MASSAFRA,  U.,  VACCA,  F.,  MARTIN  MARTIN,  L.  S., 
FERLITO, C., PODESTA, E., GRANATA, M. & LAGANA, B. 2010. Can Cyclosporine-A 
associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid 
arthritis patients? (Cynar pilot study). Int J Immunopathol Pharmacol, 23, 783-90.
MIHATSCH, M. J.,  KYO, M.,  MOROZUMI,  K.,  YAMAGUCHI,  Y.,  NICKELEIT,  V. & 
RYFFEL, B. 1998. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol, 49, 356-
63.
MILPIED, P., RENAND, A., BRUNEAU, J., MENDES-DA-CRUZ, D. A., JACQUELIN, S., 
ASNAFI, V., RUBIO, M. T., MACINTYRE, E., LEPELLETIER, Y. & HERMINE, O. 2009. 
Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur J Immunol, 39, 1466-71.
MINSKY, M. 1988. Memoir on inventing the confocal scanning microscope. Scanning, 10, 
128-138.
MINOWADA, J., DREXLER, H. G., MENON, M., RUBINSTEIN, H., MESSMORE, H., 
KRASNOW,  S.,  TAKEUCHI,  J.  &  SANDBERG,  A.  A.  1985.  A  model  scheme  of 
hematopoietic cell differentiation based on multiple marker analysis of leukemia-lymphomas: 
T cell lineage. Haematol Blood Transfus, 29, 426-9.
MINOWADA, J. & MOORE, G. E. 1975. T-lymphocyte cell lines derived from patients with 
acute lymphoblastic leukemia. Bibl Haematol, 251-61.
MINOWADA, J., NONOYAMA, M., MOORE, G. E., RAUCH, A. M. & PAGANO, J. S. 
1974. The presence of the Epstein-Barr viral genome in human lymphoblastoid B-cell lines 
and its absence in a myeloma cell line. Cancer Res, 34, 1898-903.
MIYAZAWA, K., SHINOZAKI, M., HARA, T., FURUYA, T. & MIYAZONO, K. 2002. Two 
major Smad pathways in TGF-beta superfamily signalling. Genes Cells, 7, 1191-204.
19 | P a g e
References
MIYAZONO, K., HELLMAN, U., WERNSTEDT, C. & HELDIN, C. H. 1988. Latent high 
molecular weight complex of transforming growth factor beta 1. Purification from human 
platelets and structural characterization. J Biol Chem, 263, 6407-15.
MIYAZONO, K., OLOFSSON, A., COLOSETTI, P. & HELDIN, C. H. 1991. A role of the 
latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J, 10, 
1091-101.
MOHAMED, M. A., ROBERTSON, H., BOOTH, T. A., BALUPURI, S., GERSTENKORN, 
C.,  KIRBY,  J.  A.  &  TALBOT,  D.  2000.  Active  TGF-beta1  expression  in  kidney 
transplantation:  a  comparative  study  of  cyclosporin-A  (CyA)  and  tacrolimus  (FK506). 
Transpl Int, 13 Suppl 1, S295-8.
MOHAMED, M. A., WALMSLEY, M., ROBERTSON, H., KIRBY, J. A. & TALBOT, D. 
1999. The effect of cyclosporin A and tacrolimus on cultured human epithelial cells: the role 
of TGF-beta. Transplant Proc, 31, 1173.
MOORE, G. E. & HOOD, D. B. 1993. Modified RPMI 1640 culture medium. In Vitro Cell 
Dev Biol Anim, 29A, 268.
MORALI, O. G., DELMAS, V., MOORE, R., JEANNEY, C., THIERY, J. P. & LARUE, L. 
2001.  IGF-II  induces  rapid  beta-catenin  relocation  to  the  nucleus  during  epithelium  to 
mesenchyme transition. Oncogene, 20, 4942-50.
MORISHIMA, N., MIZOGUCHI, I., TAKEDA, K., MIZUGUCHI, J. & YOSHIMOTO, T. 
2009. TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and 
IL-23. Biochem Biophys Res Commun, 386, 105-10.
MU,  D.,  CAMBIER,  S.,  FJELLBIRKELAND,  L.,  BARON,  J.  L.,  MUNGER,  J.  S., 
KAWAKATSU, H., SHEPPARD, D., BROADDUS, V. C. & NISHIMURA, S. L. 2002. The 
integrin  alpha(v)beta8  mediates  epithelial  homeostasis  through  MT1-MMP-dependent 
activation of TGF-beta1. J Cell Biol, 157, 493-507.
MULLER, G. A., ZEISBERG, M. & STRUTZ, F. 2000. The importance of tubulointerstitial 
damage in progressive renal disease. Nephrol Dial Transplant, 15 Suppl 6, 76-7.
MUNGER, J. S.,  HUANG, X., KAWAKATSU, H.,  GRIFFITHS, M. J.,  DALTON, S.  L., 
WU, J., PITTET, J. F., KAMINSKI, N., GARAT, C., MATTHAY, M. A., RIFKIN, D. B. & 
SHEPPARD, D. 1999. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a 
mechanism for regulating pulmonary inflammation and fibrosis. Cell, 96, 319-28.
MURPHY-ULLRICH,  J.  E.  & POCZATEK,  M.  2000.  Activation  of  latent  TGF-beta  by 
thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev, 11, 59-69.
MYERS,  B.  D.,  ROSS,  J.,  NEWTON,  L.,  LUETSCHER,  J.  &  PERLROTH,  M.  1984. 
Cyclosporine-associated chronic nephropathy. N Engl J Med, 311, 699-705.
20 | P a g e
References
MYERS,  B.  D.,  SIBLEY,  R.,  NEWTON,  L.,  TOMLANOVICH,  S.  J.,  BOSHKOS,  C., 
STINSON, E., LUETSCHER, J. A., WHITNEY, D. J., KRASNY, D., COPLON, N. S. & ET 
AL. 1988. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int, 
33, 590-600.
NAGATA,  K.  2003.  HSP47  as  a  collagen-specific  molecular  chaperone:  function  and 
expression in normal mouse development. Semin Cell Dev Biol, 14, 275-82.
NAKAMURA,  K.,  KITANI,  A.  &  STROBER,  W.  2001.  Cell  contact-dependent 
immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound 
transforming growth factor beta. J Exp Med, 194, 629-44.
NAKAO, A., IMAMURA, T., SOUCHELNYTSKYI, S., KAWABATA, M., ISHISAKI, A., 
OEDA, E., TAMAKI, K., HANAI, J., HELDIN, C. H., MIYAZONO, K. & TEN DIJKE, P. 
1997. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J, 
16, 5353-62.
NANKIVELL, B. J., BORROWS, R. J., FUNG, C. L., O'CONNELL, P. J., ALLEN, R. D. & 
CHAPMAN, J. R. 2003. The natural history of chronic allograft nephropathy. N Engl J Med, 
349, 2326-33.
NANKIVELL, B. J., BORROWS, R. J., FUNG, C. L., O'CONNELL, P. J., CHAPMAN, J. R. 
& ALLEN,  R.  D.  2004.  Calcineurin  inhibitor  nephrotoxicity:  longitudinal  assessment  by 
protocol histology. Transplantation, 78, 557-65.
NANKIVELL, B. J., FENTON-LEE, C. A., KUYPERS, D. R., CHEUNG, E., ALLEN, R. 
D., O'CONNELL, P. J. & CHAPMAN, J. R. 2001. Effect of histological damage on long-
term kidney transplant outcome. Transplantation, 71, 515-23.
NEUFELD, G.,  COHEN, T.,  SHRAGA, N., LANGE, T.,  KESSLER, O. & HERZOG, Y. 
2002. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon 
guidance and angiogenesis. Trends Cardiovasc Med, 12, 13-9.
NEUROHR, C., NISHIMURA, S. L. & SHEPPARD, D. 2006. Activation of transforming 
growth factor-beta by the integrin alphavbeta8 delays epithelial wound closure. Am J Respir 
Cell Mol Biol, 35, 252-9.
NEWTON, R. A. & HOGG, N. 1998. The human S100 protein MRP-14 is a novel activator 
of the beta 2 integrin Mac-1 on neutrophils. J Immunol, 160, 1427-35.
NICULESCU-DUVAZ, I., PHANISH, M. K., COLVILLE-NASH, P. & DOCKRELL, M. E. 
2007. The TGFbeta1-induced fibronectin in human renal proximal tubular epithelial cells is 
p38 MAP kinase dependent and Smad independent. Nephron Exp Nephrol, 105, e108-16.
NIEVES-CINTRON,  M.,  AMBERG,  G.  C.,  NICHOLS,  C.  B.,  MOLKENTIN,  J.  D.  & 
SANTANA, L. F.  2007. Activation of NFATc3 down-regulates the beta1 subunit  of large 
conductance,  calcium-activated K+ channels in arterial  smooth muscle and contributes to 
hypertension. J Biol Chem, 282, 3231-40.
21 | P a g e
References
NOBLE, P. B. & CUTTS, J. H. 1967. Separation of blood leukocytes by Ficoll gradient. Can 
Vet J, 8, 110-1.
OIDA, T. & WEINER, H. L. 2011. Murine CD4 T cells produce a new form of TGF-beta as 
measured by a newly developed TGF-beta bioassay. PLoS One, 6, e18365.
OIDA, T., ZHANG, X., GOTO, M., HACHIMURA, S., TOTSUKA, M., KAMINOGAWA, 
S. & WEINER, H. L. 2003. CD4+CD25- T cells that express latency-associated peptide on 
the  surface  suppress  CD4+CD45RBhigh-induced  colitis  by  a  TGF-beta-dependent 
mechanism. J Immunol, 170, 2516-22.
OKADA, H., BAN, S., NAGAO, S., TAKAHASHI, H., SUZUKI, H. & NEILSON, E. G. 
2000.  Progressive  renal  fibrosis  in  murine  polycystic  kidney  disease:  an 
immunohistochemical observation. Kidney Int, 58, 587-97.
OKADA, H., DANOFF, T. M., KALLURI, R. & NEILSON, E. G. 1997. Early role of Fsp1 
in epithelial-mesenchymal transformation. Am J Physiol, 273, F563-74.
OLIVER, J. A., BARASCH, J., YANG, J., HERZLINGER, D. & AL-AWQATI, Q. 2002. 
Metanephric mesenchyme contains embryonic renal stem cells. Am J Physiol Renal Physiol, 
283, F799-809.
OSTERREICHER, C. H., PENZ-OSTERREICHER, M., GRIVENNIKOV, S. I., GUMA, M., 
KOLTSOVA, E. K., DATZ, C., SASIK, R., HARDIMAN, G., KARIN, M. & BRENNER, D. 
A.  2011.  Fibroblast-specific  protein  1  identifies  an  inflammatory  subpopulation  of 
macrophages in the liver. Proc Natl Acad Sci U S A, 108, 308-13.
OZDEMIR, B. H., OZDEMIR, F. N., DEMIRHAN, B. & HABERAL, M. 2005. TGF-beta1 
expression in renal allograft rejection and cyclosporine A toxicity. Transplantation, 80, 1681-
5.
PADDOCK, S. W. 2000. Principles and practices of laser scanning confocal microscopy. Mol 
Biotechnol, 16, 127-49.
PALLET, N., BOUVIER, N., LEGENDRE, C., GILLERON, J., CODOGNO, P., BEAUNE, 
P., THERVET, E. & ANGLICHEAU, D. 2008. Autophagy protects renal tubular cells against 
cyclosporine toxicity. Autophagy, 4, 783-91.
PARK, S. H., CHOI, H. J., LEE, J. H., WOO, C. H., KIM, J. H. & HAN, H. J. 2001. High 
glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, 
and TGF-beta 1. Kidney Int, 59, 1695-705.
PATEL, P., WEST-MAYS, J., KOLB, M., RODRIGUES, J. C., HOFF, C. M. & MARGETTS, 
P.  J.  2010.  Platelet  derived  growth  factor  B  and  epithelial  mesenchymal  transition  of 
peritoneal mesothelial cells. Matrix Biol, 29, 97-106.
PATSENKER,  E.,  POPOV,  Y.,  STICKEL,  F.,  JONCZYK,  A.,  GOODMAN,  S.  L.  & 
SCHUPPAN,  D.  2008.  Inhibition  of  integrin  alphavbeta6  on  cholangiocytes  blocks 
22 | P a g e
References
transforming  growth  factor-beta  activation  and  retards  biliary  fibrosis  progression. 
Gastroenterology, 135, 660-70.
PELLET-MANY, C., FRANKEL, P., JIA, H. & ZACHARY, I. 2008. Neuropilins: structure, 
function and role in disease. Biochem J, 411, 211-26.
PETCHER, T. J., WEBER, H. & RUEGGER, A. 1976. Crystal and molecular structure of an 
iodo-derivative of the cyclic undecapeptide cyclosporin A. Helv Chim Acta, 59, 1480-9.
PFAFFL, M. W., HORGAN, G. W. & DEMPFLE, L. 2002. Relative expression software tool 
(REST) for group-wise comparison and statistical analysis of relative expression results in 
real-time PCR. Nucleic Acids Res, 30, e36.
PHANISH,  M.  K.,  WAHAB,  N.  A.,  COLVILLE-NASH,  P.,  HENDRY,  B.  M.  & 
DOCKRELL, M. E. 2006. The differential role of Smad2 and Smad3 in the regulation of pro-
fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J, 393, 601-
7.
PICARD, N., BAUM, O., VOGETSEDER, A., KAISSLING, B. & LE HIR, M. 2008. Origin 
of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. Histochem Cell 
Biol, 130, 141-55.
PICHLER,  R.  H.,  FRANCESCHINI,  N.,  YOUNG,  B.  A.,  HUGO,  C.,  ANDOH,  T.  F., 
BURDMANN, E. A., SHANKLAND, S. J., ALPERS, C. E., BENNETT, W. M., COUSER, 
W. G. & ET AL. 1995. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and 
osteopontin. J Am Soc Nephrol, 6, 1186-96.
PIEK,  E.,  JU,  W.  J.,  HEYER,  J.,  ESCALANTE-ALCALDE,  D.,  STEWART,  C.  L., 
WEINSTEIN, M., DENG, C., KUCHERLAPATI, R., BOTTINGER, E. P. & ROBERTS, A. 
B. 2001. Functional characterization of transforming growth factor beta signaling in Smad2- 
and Smad3-deficient fibroblasts. J Biol Chem, 276, 19945-53.
PIETRA, B. A., WISEMAN, A., BOLWERK, A., RIZEQ, M. & GILL, R. G. 2000. CD4 T 
cell-mediated cardiac allograft rejection requires donor but not host MHC class II. J Clin 
Invest, 106, 1003-10.
PILAT,  N.,  SAYEGH,  M.  H.  &  WEKERLE,  T.  2011.  Costimulatory  pathways  in 
transplantation. Semin Immunol, 23, 293-303.
PROCTOR, J. M., ZANG, K., WANG, D., WANG, R. & REICHARDT, L. F. 2005. Vascular 
development  of  the  brain  requires  beta8  integrin  expression  in  the  neuroepithelium.  J 
Neurosci, 25, 9940-8.
RACUSEN, L. C., MONTEIL, C., SGRIGNOLI, A., LUCSKAY, M., MAROUILLAT, S., 
RHIM, J. G. & MORIN, J. P. 1997. Cell lines with extended in vitro growth potential from 
human renal proximal tubule: characterization, response to inducers, and comparison with 
established cell lines. J Lab Clin Med, 129, 318-29.
23 | P a g e
References
RACUSEN, L. C. & REGELE, H. 2010. The pathology of chronic allograft  dysfunction. 
Kidney Int Suppl, S27-32.
RACUSEN,  L.  C.,  SOLEZ,  K.,  COLVIN,  R.  B.,  BONSIB,  S.  M.,  CASTRO,  M.  C., 
CAVALLO, T., CROKER, B. P., DEMETRIS, A. J., DRACHENBERG, C. B., FOGO, A. B., 
FURNESS, P., GABER, L. W., GIBSON, I. W., GLOTZ, D., GOLDBERG, J. C., GRANDE, 
J.,  HALLORAN,  P.  F.,  HANSEN,  H.  E.,  HARTLEY,  B.,  HAYRY,  P.  J.,  HILL,  C.  M., 
HOFFMAN, E. O., HUNSICKER, L. G., LINDBLAD, A. S., YAMAGUCHI, Y. & ET AL. 
1999. The Banff 97 working classification of renal allograft pathology. Kidney Int, 55, 713-
23.
RAMIREZ,  C.,  OLMO, A.,  O'VALLE,  F.,  MASSEROLI,  M.,  AGUILAR,  M.,  GOMEZ-
MORALES, M., REVELLES, F., GARCIA-CHICANO, M. J., ARREBOLA, F., REGUERO, 
M. E.  & DEL MORAL, R.  G.  2000.  Role  of  intrarenal  endothelin  1,  endothelin  3,  and 
angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats. Exp Nephrol, 8, 
161-72.
RESCIGNO,  M.  2010.  Functional  specialization  of  antigen  presenting  cells  in  the 
gastrointestinal tract. Curr Opin Immunol, 22, 131-6.
REYNOLDS,  L.  E.,  WYDER,  L.,  LIVELY,  J.  C.,  TAVERNA,  D.,  ROBINSON,  S.  D., 
HUANG,  X.,  SHEPPARD,  D.,  HYNES,  R.  O.  &  HODIVALA-DILKE,  K.  M.  2002. 
Enhanced  pathological  angiogenesis  in  mice  lacking  beta3  integrin  or  beta3  and  beta5 
integrins. Nat Med, 8, 27-34.
RIBEIRO, S. M., POCZATEK, M., SCHULTZ-CHERRY, S., VILLAIN, M. & MURPHY-
ULLRICH,  J.  E.  1999.  The  activation  sequence  of  thrombospondin-1  interacts  with  the 
latency-associated peptide to regulate activation of latent transforming growth factor-beta. J 
Biol Chem, 274, 13586-93.
ROBERTSON,  H.,  ALI,  S.,  MCDONNELL,  B.  J.,  BURT,  A.  D.  & KIRBY, J.  A.  2004. 
Chronic  renal  allograft  dysfunction:  the  role  of  T  cell-mediated  tubular  epithelial  to 
mesenchymal cell transition. J Am Soc Nephrol, 15, 390-7.
ROBERTSON, H., MORLEY, A. R., TALBOT, D., CALLANAN, K. & KIRBY, J. A. 2000. 
Renal  allograft  rejection:  beta-chemokine  involvement  in  the  development  of  tubulitis. 
Transplantation, 69, 684-7.
ROBERTSON, H., WHEELER, J., KIRBY, J. A. & MORLEY, A. R. 1996. Renal allograft 
rejection--in situ demonstration of cytotoxic intratubular cells. Transplantation, 61, 1546-9.
ROGERS,  T.  S.,  ELZINGA,  L.,  BENNETT,  W.  M.  &  KELLEY,  V.  E.  1988.  Selective 
enhancement  of  thromboxane  in  macrophages  and  kidneys  in  cyclosporine-induced 
nephrotoxicity. Dietary protection by fish oil. Transplantation, 45, 153-6.
24 | P a g e
References
ROMEO,  P.  H.,  LEMARCHANDEL,  V.  &  TORDJMAN,  R.  2002.  Neuropilin-1  in  the 
immune system. Adv Exp Med Biol, 515, 49-54.
RONCO, P.,  LELONGT, B.,  PIEDAGNEL, R.  & CHATZIANTONIOU, C. 2007. Matrix 
metalloproteinases  in  kidney disease  progression  and repair:  a  case  of  flipping  the  coin. 
Semin Nephrol, 27, 352-62.
ROSS, R., EVERETT, N. B. & TYLER, R. 1970. Wound healing and collagen formation. VI. 
The origin of the wound fibroblast studied in parabiosis. J Cell Biol, 44, 645-54.
ROWSHANI, A. T., FLORQUIN, S., BEMELMAN, F., KUMMER, J. A., HACK, C. E. & 
TEN BERGE, I. J. 2004. Hyperexpression of the granzyme B inhibitor PI-9 in human renal 
allografts:  a  potential  mechanism  for  stable  renal  function  in  patients  with  subclinical 
rejection. Kidney Int, 66, 1417-22.
RYAN,  M.  J.,  JOHNSON,  G.,  KIRK,  J.,  FUERSTENBERG,  S.  M.,  ZAGER,  R.  A.  & 
TOROK-STORB, B. 1994. HK-2: an immortalized proximal tubule epithelial cell line from 
normal adult human kidney. Kidney Int, 45, 48-57.
RYFFEL, B. 1993. Cyclosporin binding proteins. Identification,  distribution,  function and 
relation to FK binding proteins. Biochem Pharmacol, 46, 1-12.
RYGIEL,  K.  A.,  ROBERTSON,  H.,  MARSHALL,  H.  L.,  PEKALSKI,  M.,  ZHAO,  L., 
BOOTH, T. A., JONES, D. E., BURT, A. D. & KIRBY, J. A. 2008. Epithelial-mesenchymal 
transition contributes to portal  tract  fibrogenesis  during human chronic liver disease.  Lab 
Invest, 88, 112-23.
RYGIEL, K. A., ROBERTSON, H., WILLET, J. D., BRAIN, J. G., BURT, A. D., JONES, D. 
E. & KIRBY, J. A. 2010. T cell-mediated biliary epithelial-to-mesenchymal transition in liver 
allograft rejection. Liver Transpl, 16, 567-76.
SADY, S. P., GOYAL, M., THOMAS, P. E., WHARRAM, B. L. & WIGGINS, R. C. 1995. 
Fibronectin mRNA in the developing glomerular crescent in rabbit antiglomerular basement 
membrane disease. J Am Soc Nephrol, 5, 2087-90.
SAFINIA, N., AFZALI, B., ATALAR, K., LOMBARDI, G. & LECHLER, R. I. 2010. T-cell 
alloimmunity and chronic allograft dysfunction. Kidney Int Suppl, S2-12.
SAHARINEN, J.,  TAIPALE,  J.,  MONNI,  O.  & KESKI-OJA,  J.  1998.  Identification  and 
characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J 
Biol Chem, 273, 18459-69.
SANFORD,  L.  P.,  ORMSBY,  I.,  GITTENBERGER-DE GROOT,  A.  C.,  SARIOLA,  H., 
FRIEDMAN, R., BOIVIN, G. P., CARDELL, E. L. & DOETSCHMAN, T. 1997. TGFbeta2 
knockout  mice  have  multiple  developmental  defects  that  are  non-overlapping  with  other 
TGFbeta knockout phenotypes. Development, 124, 2659-70.
25 | P a g e
References
SAYEGH, M. H. 1999. Why do we reject a graft? Role of indirect allorecognition in graft 
rejection. Kidney Int, 56, 1967-79.
SCHENKEL, A. R., MAMDOUH, Z. & MULLER, W. A. 2004. Locomotion of monocytes 
on endothelium is a critical step during extravasation. Nat Immunol, 5, 393-400.
SCHMID,  H.,  COHEN,  C.  D.,  HENGER,  A.,  IRRGANG,  S.,  SCHLONDORFF,  D.  & 
KRETZLER, M. 2003. Validation of endogenous controls for gene expression analysis in 
microdissected human renal biopsies. Kidney Int, 64, 356-60.
SCHMIDT-HANSEN,  B.,  ORNAS,  D.,  GRIGORIAN,  M.,  KLINGELHOFER,  J., 
TULCHINSKY,  E.,  LUKANIDIN,  E.  &  AMBARTSUMIAN,  N.  2004.  Extracellular 
S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 
matrix metalloproteinase activity. Oncogene, 23, 5487-95.
SCHMOUDER, R. L., STREITER, R. M., WALZ, A. & KUNKEL, S. L. 1995. Epithelial-
derived neutrophil-activating factor-78 production in human renal tubule epithelial cells and 
in renal allograft rejection. Transplantation, 59, 118-24.
SCHNEIDER, M., HANSEN, J. L. & SHEIKH, S. P. 2008. S100A4: a common mediator of 
epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med (Berl), 
86, 507-22.
SCHNEIDER, M., KOSTIN, S., STROM, C. C., APLIN, M., LYNGBAEK, S., THEILADE, 
J.,  GRIGORIAN,  M.,  ANDERSEN,  C.  B.,  LUKANIDIN,  E.,  LERCHE HANSEN,  J.  & 
SHEIKH, S. P. 2007. S100A4 is upregulated in injured myocardium and promotes growth 
and survival of cardiac myocytes. Cardiovasc Res, 75, 40-50.
SCHRAMEK,  H.,  SARKOZI,  R.,  LAUTERBERG,  C.,  KRONBICHLER,  A., 
PIRKLBAUER,  M.,  ALBRECHT,  R.,  NOPPERT,  S.  J.,  PERCO,  P.,  RUDNICKI,  M., 
STRUTZ,  F.  M.  &  MAYER,  G.  2009.  Neuropilin-1  and  neuropilin-2  are  differentially 
expressed  in  human  proteinuric  nephropathies  and  cytokine-stimulated  proximal  tubular 
cells. Lab Invest, 89, 1304-16.
SCHULTZ-CHERRY,  S.,  CHEN,  H.,  MOSHER,  D.  F.,  MISENHEIMER,  T.  M., 
KRUTZSCH, H. C., ROBERTS, D. D. & MURPHY-ULLRICH, J. E. 1995. Regulation of 
transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol 
Chem, 270, 7304-10.
SCHULTZ-CHERRY,  S.  &  MURPHY-ULLRICH,  J.  E.  1993.  Thrombospondin  causes 
activation of latent transforming growth factor-beta secreted by endothelial cells by a novel 
mechanism. J Cell Biol, 122, 923-32.
SCOTTON, C. J., KRUPICZOJC, M. A., KONIGSHOFF, M., MERCER, P. F., LEE, Y. C., 
KAMINSKI,  N.,  MORSER,  J.,  POST,  J.  M.,  MAHER,  T.  M.,  NICHOLSON,  A.  G., 
MOFFATT, J. D., LAURENT, G. J., DERIAN, C. K., EICKELBERG, O. & CHAMBERS, R. 
26 | P a g e
References
C.  2009.  Increased  local  expression  of  coagulation  factor  X  contributes  to  the  fibrotic 
response in human and murine lung injury. J Clin Invest, 119, 2550-63.
SEMOV, A., MORENO, M. J., ONICHTCHENKO, A., ABULROB, A., BALL, M., EKIEL, 
I., PIETRZYNSKI, G., STANIMIROVIC, D. & ALAKHOV, V. 2005. Metastasis-associated 
protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated 
plasmin formation. J Biol Chem, 280, 20833-41.
SEYMOUR, R. A., THOMASON, J. M. & ELLIS, J. S. 1996. The pathogenesis of drug-
induced gingival overgrowth. J Clin Periodontol, 23, 165-75.
SHANG, M. H.,  YUAN, W. J.,  ZHANG, S.  J.,  FAN, Y. & ZHANG, Z. 2008. Intrarenal 
activation of renin angiotensin system in the development of cyclosporine A induced chronic 
nephrotoxicity. Chin Med J (Engl), 121, 983-8.
SHEPPARD, D. 2005. Integrin-mediated activation of latent transforming growth factor beta. 
Cancer Metastasis Rev, 24, 395-402.
SHI, Y. & MASSAGUE, J. 2003. Mechanisms of TGF-beta signaling from cell membrane to 
the nucleus. Cell, 113, 685-700.
SHIAU, M. Y., TSAI, S. T., TSAI, K. J., HAUNG, M. L., HSU, Y. T. & CHANG, Y. H. 2006. 
Increased  circulatory  MMP-2  and  MMP-9  levels  and  activities  in  patients  with  type  1 
diabetes mellitus. Mt Sinai J Med, 73, 1024-8.
SHIHAB,  F.  S.,  ANDOH,  T.  F.,  TANNER,  A.  M.  &  BENNETT,  W.  M.  1997.  Sodium 
depletion  enhances  fibrosis  and  the  expression  of  TGF-beta1  and  matrix  proteins  in 
experimental chronic cyclosporine nephropathy. Am J Kidney Dis, 30, 71-81.
SHIHAB, F. S., BENNETT, W. M., YI, H. & ANDOH, T. F. 2006. Effect of cyclosporine and 
sirolimus on the expression of connective tissue growth factor in rat experimental chronic 
nephrotoxicity. Am J Nephrol, 26, 400-7.
SHIHAB, F. S., WAID, T. H., CONTI, D. J., YANG, H., HOLMAN, M. J., MULLOY, L. C., 
HENNING, A. K., HOLMAN, J., JR., FIRST, M. R. & GROUP, C. S. 2008. Conversion from 
cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure:  60-month 
results of the CRAF Study. Transplantation, 85, 1261-9.
SHIHAB, F. S., YI, H., BENNETT, W. M. & ANDOH, T. F. 2000. Effect of nitric oxide 
modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney 
Int, 58, 1174-85.
SHIMIZU,  H.,  BOLATI,  D.,  ADIJIANG,  A.,  MUTELIEFU,  G.,  ENOMOTO,  A., 
NISHIJIMA, F.,  DATEKI, M. & NIWA, T.  2011.  NF-kappaB plays  an important  role  in 
indoxyl  sulfate-induced  cellular  senescence,  fibrotic  gene  expression,  and  inhibition  of 
proliferation in proximal tubular cells. Am J Physiol Cell Physiol, 301, C1201-12.
27 | P a g e
References
SHISHIDO,  S.,  ASANUMA,  H.,  NAKAI,  H.,  MORI,  Y.,  SATOH,  H.,  KAMIMAKI,  I., 
HATAYA, H., IKEDA, M., HONDA, M. & HASEGAWA, A. 2003. The impact of repeated 
subclinical acute rejection on the progression of chronic allograft  nephropathy.  J Am Soc 
Nephrol, 14, 1046-52.
SHUKLA,  M.  N.,  ROSE,  J.  L.,  RAY, R.,  LATHROP, K.  L.,  RAY, A.  & RAY, P.  2009. 
Hepatocyte  growth  factor  inhibits  epithelial  to  myofibroblast  transition  in  lung  cells  via 
Smad7. Am J Respir Cell Mol Biol, 40, 643-53.
SIBBRING, J. S., SHARMA, A., MCDICKEN, I. W., SELLS, R. A. & CHRISTMAS, S. E. 
1998. Localization of C-X-C and C-C chemokines to renal tubular epithelial cells in human 
kidney transplants is not confined to acute cellular rejection. Transpl Immunol, 6, 203-8.
SINGH, R. P., LA CAVA, A., WONG, M., EBLING, F. & HAHN, B. H. 2007. CD8+ T cell-
mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune 
tolerance depends on Foxp3 expression. J Immunol, 178, 7649-57.
SIS, B., MENGEL, M., HAAS, M., COLVIN, R. B., HALLORAN, P. F., RACUSEN, L. C., 
SOLEZ, K., BALDWIN, W. M., 3RD, BRACAMONTE, E. R., BROECKER, V., COSIO, F., 
DEMETRIS, A. J., DRACHENBERG, C., EINECKE, G., GLOOR, J., GLOTZ, D., KRAUS, 
E., LEGENDRE, C., LIAPIS, H., MANNON, R. B., NANKIVELL, B. J., NICKELEIT, V., 
PAPADIMITRIOU, J. C., RANDHAWA, P., REGELE, H., RENAUDIN, K., RODRIGUEZ, 
E. R., SERON, D., SESHAN, S., SUTHANTHIRAN, M., WASOWSKA, B. A., ZACHARY, 
A. & ZEEVI, A. 2010. Banff '09 meeting report: antibody mediated graft deterioration and 
implementation of Banff working groups. Am J Transplant, 10, 464-71.
SKALLI,  O.,  PELTE,  M.  F.,  PECLET,  M.  C.,  GABBIANI,  G.,  GUGLIOTTA,  P., 
BUSSOLATI,  G.,  RAVAZZOLA,  M.  &  ORCI,  L.  1989.  Alpha-smooth  muscle  actin,  a 
differentiation  marker  of  smooth muscle  cells,  is  present  in  microfilamentous  bundles  of 
pericytes. J Histochem Cytochem, 37, 315-21.
SLATTERY, C., CAMPBELL, E., MCMORROW, T. & RYAN, M. P. 2005. Cyclosporine A-
induced renal fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol, 167, 395-
407.
SLATTERY, C., MCMORROW, T. & RYAN, M. P. 2006. Overexpression of E2A proteins 
induces epithelial-mesenchymal transition in human renal proximal tubular epithelial cells 
suggesting a potential role in renal fibrosis. FEBS Lett, 580, 4021-30.
SOLEZ, K., COLVIN, R. B., RACUSEN, L. C., SIS, B., HALLORAN, P. F., BIRK, P. E., 
CAMPBELL,  P.  M.,  CASCALHO,  M.,  COLLINS,  A.  B.,  DEMETRIS,  A.  J., 
DRACHENBERG, C. B., GIBSON, I. W., GRIMM, P. C., HAAS, M., LERUT, E., LIAPIS, 
H., MANNON, R. B., MARCUS, P. B., MENGEL, M., MIHATSCH, M. J., NANKIVELL, 
B.  J.,  NICKELEIT,  V.,  PAPADIMITRIOU,  J.  C.,  PLATT,  J.  L.,  RANDHAWA,  P., 
ROBERTS, I., SALINAS-MADRIGA, L., SALOMON, D. R., SERON, D., SHEAFF, M. & 
WEENING, J. J. 2007. Banff '05 Meeting Report: differential diagnosis of chronic allograft 
injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant, 7, 518-26.
28 | P a g e
References
SOLOMON, B. D., MUELLER, C., CHAE, W. J., ALABANZA, L. M. & BYNOE, M. S. 
2011. Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. 
Proc Natl Acad Sci U S A, 108, 2040-5.
SOULA-ROTHHUT, M.,  COISSARD, C.,  SARTELET, H.,  BOUDOT, C.,  BELLON, G., 
MARTINY, L. & ROTHHUT, B. 2005. The tumor suppressor PTEN inhibits EGF-induced 
TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Exp Cell Res, 304, 187-
201.
STAHELIN, H. F. 1996. The history of cyclosporin A (Sandimmune) revisited: another point 
of view. Experientia, 52, 5-13.
STEGALL,  M.  D.,  PARK,  W.  D.,  LARSON,  T.  S.,  GLOOR,  J.  M.,  CORNELL,  L.  D., 
SETHI, S., DEAN, P. G., PRIETO, M., AMER, H., TEXTOR, S., SCHWAB, T. & COSIO, F. 
G. 2011. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J 
Transplant, 11, 698-707.
STEINERT, P.  M. & ROOP, D. R. 1988. Molecular  and cellular  biology of  intermediate 
filaments. Annu Rev Biochem, 57, 593-625.
STRUTZ,  F.  &  NEILSON,  E.  G.  1994.  The  role  of  lymphocytes  in  the  progression  of 
interstitial disease. Kidney Int Suppl, 45, S106-10.
STRUTZ, F., OKADA, H., LO, C. W., DANOFF, T., CARONE, R. L., TOMASZEWSKI, J. 
E. & NEILSON, E. G. 1995. Identification and characterization of a fibroblast marker: FSP1. 
J Cell Biol, 130, 393-405.
STRUTZ, F. & ZEISBERG, M. 2006. Renal fibroblasts and myofibroblasts in chronic kidney 
disease. J Am Soc Nephrol, 17, 2992-8.
SU,  H.,  KIM,  H.,  PAWLIKOWSKA,  L.,  KITAMURA,  H.,  SHEN,  F.,  CAMBIER,  S., 
MARKOVICS,  J.,  LAWTON,  M.  T.,  SIDNEY,  S.,  BOLLEN,  A.  W.,  KWOK,  P.  Y., 
REICHARDT, L.,  YOUNG, W. L.,  YANG, G. Y. & NISHIMURA, S.  L.  2010. Reduced 
expression  of  integrin  alphavbeta8  is  associated  with  brain  arteriovenous  malformation 
pathogenesis. Am J Pathol, 176, 1018-27.
SUGIMOTO,  T.,  HANEDA,  M.,  SAWANO, H.,  ISSHIKI,  K.,  MAEDA, S.,  KOYA, D., 
INOKI, K., YASUDA, H., KASHIWAGI, A. & KIKKAWA, R. 2001. Endothelin-1 induces 
cyclooxygenase-2  expression  via  nuclear  factor  of  activated  T-cell  transcription  factor  in 
glomerular mesangial cells. J Am Soc Nephrol, 12, 1359-68.
TADA, H. & ISOGAI, S. 1998. The fibronectin production is increased by thrombospondin 
via activation of TGF-beta in cultured human mesangial cells. Nephron, 79, 38-43.
TAIPALE, J., MIYAZONO, K., HELDIN, C. H. & KESKI-OJA, J. 1994. Latent transforming 
growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding 
protein. J Cell Biol, 124, 171-81.
29 | P a g e
References
TAKENAGA, K., NAKAMURA, Y. & SAKIYAMA, S. 1994. Cellular localization of pEL98 
protein,  an S100-related calcium binding protein,  in  fibroblasts  and its  tissue distribution 
analyzed by monoclonal antibodies. Cell Struct Funct, 19, 133-41.
TAN, R.,  HE, W.,  LIN, X., KISS, L.  P. & LIU, Y. 2008. Smad ubiquitination regulatory 
factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication. Am J 
Physiol Renal Physiol, 294, F1076-83.
TAPMEIER, T. T., FEARN, A., BROWN, K., CHOWDHURY, P., SACKS, S. H., SHEERIN, 
N. S. & WONG, W. 2010. Pivotal role of CD4+ T cells in renal fibrosis following ureteric 
obstruction. Kidney Int, 78, 351-62.
TARABYKINA,  S.,  KRIAJEVSKA,  M.,  SCOTT,  D.  J.,  HILL,  T.  J.,  LAFITTE,  D., 
DERRICK,  P.  J.,  DODSON,  G.  G.,  LUKANIDIN,  E.  &  BRONSTEIN,  I.  2000. 
Heterocomplex formation between metastasis-related protein S100A4 (Mts1) and S100A1 as 
revealed by the yeast two-hybrid system. FEBS Lett, 475, 187-91.
TAYLOR, A. W. 2009. Review of the activation of TGF-beta in immunity. J Leukoc Biol, 85, 
29-33.
TESSEUR, I.,  ZOU, K.,  BERBER, E.,  ZHANG, H.  & WYSS-CORAY, T.  2006.  Highly 
sensitive and specific bioassay for measuring bioactive TGF-beta. BMC Cell Biol, 7, 15.
THELLIN, O., ZORZI, W., LAKAYE, B., DE BORMAN, B., COUMANS, B., HENNEN, 
G., GRISAR, T., IGOUT, A. & HEINEN, E. 1999. Housekeeping genes as internal standards: 
use and limits. J Biotechnol, 75, 291-5.
THORNTON, A. M. & SHEVACH, E. M. 1998. CD4+CD25+ immunoregulatory T cells 
suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp 
Med, 188, 287-96.
THURMAN, J.  M. 2007.  Triggers  of  inflammation  after  renal  ischemia/reperfusion.  Clin 
Immunol, 123, 7-13.
TORDJMAN, R., LEPELLETIER, Y., LEMARCHANDEL, V., CAMBOT, M., GAULARD, 
P., HERMINE, O. & ROMEO, P. H. 2002. A neuronal receptor, neuropilin-1, is essential for 
the initiation of the primary immune response. Nat Immunol, 3, 477-82.
TRAN,  D.  Q.,  ANDERSSON,  J.,  HARDWICK,  D.,  BEBRIS,  L.,  ILLEI,  G.  G.  & 
SHEVACH, E. M. 2009. Selective expression of latency-associated peptide (LAP) and IL-1 
receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows 
for their purification from expansion cultures. Blood, 113, 5125-33.
TRAVIS, M. A., REIZIS, B., MELTON, A. C., MASTELLER, E., TANG, Q., PROCTOR, J. 
M., WANG, Y., BERNSTEIN, X., HUANG, X., REICHARDT, L. F., BLUESTONE, J. A. & 
SHEPPARD, D. 2007. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity 
and colitis in mice. Nature, 449, 361-5.
30 | P a g e
References
TREVILLIAN,  P.,  PAUL,  H.,  MILLAR,  E.,  HIBBERD,  A.  &  AGREZ,  M.  V.  2004. 
alpha(v)beta(6)  Integrin expression in  diseased  and transplanted kidneys.  Kidney Int,  66, 
1423-33.
TROXELL,  M.  L.,  GOPALAKRISHNAN,  S.,  MCCORMACK,  J.,  POTEAT,  B.  A., 
PENNINGTON, J.,  GARRINGER, S.  M.,  SCHNEEBERGER,  E.  E.,  NELSON, W. J.  & 
MARRS, J. A. 2000. Inhibiting cadherin function by dominant mutant E-cadherin expression 
increases the extent of tight junction assembly. J Cell Sci, 113 ( Pt 6), 985-96.
TULCHINSKY, E., GRIGORIAN, M., TKATCH, T., GEORGIEV, G. & LUKANIDIN, E. 
1995.  Transcriptional  regulation of the mts1 gene in  human lymphoma cells:  the role  of 
DNA-methylation. Biochim Biophys Acta, 1261, 243-8.
TUNGGAL, J. A., HELFRICH, I., SCHMITZ, A., SCHWARZ, H., GUNZEL, D., FROMM, 
M., KEMLER, R., KRIEG, T. & NIESSEN, C. M. 2005. E-cadherin is essential for in vivo 
epidermal barrier function by regulating tight junctions. EMBO J, 24, 1146-56.
TURVEY, M. R.,  WANG, Y. & GU, Y. 2010. The effects  of extracellular  nucleotides on 
[Ca2+]i  signalling  in  a  human-derived  renal  proximal  tubular  cell  line  (HKC-8).  J  Cell 
Biochem, 109, 132-9.
USS, E., ROWSHANI, A. T., HOOIBRINK, B., LARDY, N. M., VAN LIER, R. A. & TEN 
BERGE, I. J. 2006. CD103 is a marker for alloantigen-induced regulatory CD8+ T cells. J 
Immunol, 177, 2775-83.
VALCOURT, U., KOWANETZ, M., NIIMI, H., HELDIN, C. H. & MOUSTAKAS, A. 2005. 
TGF-beta  and the  Smad signaling  pathway support  transcriptomic  reprogramming during 
epithelial-mesenchymal cell transition. Mol Biol Cell, 16, 1987-2002.
VAN AMERONGEN, M. J., BOU-GHARIOS, G., POPA, E., VAN ARK, J., PETERSEN, A. 
H., VAN DAM, G. M., VAN LUYN, M. J. & HARMSEN, M. C. 2008. Bone marrow-derived 
myofibroblasts contribute functionally to scar formation after myocardial infarction. J Pathol, 
214, 377-86.
VAN WAARDE, M. A.,  VAN ASSEN, A. J.,  KAMPINGA, H. H.,  KONINGS, A.  W. & 
VUJASKOVIC,  Z.  1997.  Quantification  of  transforming  growth  factor-beta  in  biological 
material using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase 
construct. Anal Biochem, 247, 45-51.
VASCONCELLOS, L. M., SCHACHTER, A. D., ZHENG, X. X., VASCONCELLOS, L. H., 
SHAPIRO,  M.,  HARMON,  W.  E.  &  STROM,  T.  B.  1998.  Cytotoxic  lymphocyte  gene 
expression  in  peripheral  blood  leukocytes  correlates  with  rejecting  renal  allografts. 
Transplantation, 66, 562-6.
VEERASAMY,  M.,  NGUYEN,  T.  Q.,  MOTAZED,  R.,  PEARSON,  A.  L., 
GOLDSCHMEDING, R. & DOCKRELL, M. E. 2009. Differential regulation of E-cadherin 
31 | P a g e
References
and alpha-smooth muscle actin by BMP 7 in human renal proximal tubule epithelial cells and 
its implication in renal fibrosis. Am J Physiol Renal Physiol, 297, F1238-48.
VELDHOEN, M., HOCKING, R. J., FLAVELL, R. A. & STOCKINGER, B. 2006. Signals 
mediated  by  transforming  growth  factor-beta  initiate  autoimmune  encephalomyelitis,  but 
chronic inflammation is needed to sustain disease. Nat Immunol, 7, 1151-6.
VONGWIWATANA, A., TASANARONG, A., RAYNER, D. C., MELK, A. & HALLORAN, 
P. F. 2005. Epithelial to mesenchymal transition during late deterioration of human kidney 
transplants: the role of tubular cells in fibrogenesis. Am J Transplant, 5, 1367-74.
WAKEFIELD, L. M., SMITH, D. M., FLANDERS, K. C. & SPORN, M. B. 1988. Latent 
transforming growth factor-beta  from human platelets.  A high molecular  weight  complex 
containing precursor sequences. J Biol Chem, 263, 7646-54.
WALSH-REITZ,  M.  M.  &  TOBACK,  F.  G.  1992.  Phenol  red  inhibits  growth  of  renal 
epithelial cells. Am J Physiol, 262, F687-91.
WANG,  B.,  KOH,  P.,  WINBANKS,  C.,  COUGHLAN,  M.  T.,  MCCLELLAND,  A., 
WATSON, A., JANDELEIT-DAHM, K., BURNS, W. C., THOMAS, M. C., COOPER, M. E. 
& KANTHARIDIS, P.  2011. miR-200a Prevents renal  fibrogenesis  through repression of 
TGF-beta2 expression. Diabetes, 60, 280-7.
WANG, H.,  ZHANG, Y. & HEUCKEROTH, R. O. 2007. PAI-1 deficiency reduces liver 
fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett, 581, 3098-104.
WANG, L., DUTTA, S. K., KOJIMA, T., XU, X., KHOSRAVI-FAR, R., EKKER, S. C. & 
MUKHOPADHYAY,  D.  2007.  Neuropilin-1  modulates  p53/caspases  axis  to  promote 
endothelial cell survival. PLoS One, 2, e1161.
WANG, P. & HEITMAN, J. 2005. The cyclophilins. Genome Biol, 6, 226.
WANG, W.,  KOKA, V. & LAN, H. Y. 2005. Transforming growth factor-beta and Smad 
signalling in kidney diseases. Nephrology (Carlton), 10, 48-56.
WASSLER,  M.,  JONASSON,  I.,  PERSSON,  R.  &  FRIES,  E.  1987.  Differential 
permeabilization of membranes by saponin treatment of isolated rat hepatocytes. Release of 
secretory proteins. Biochem J, 247, 407-15.
WEST, D. C., REES, C. G., DUCHESNE, L., PATEY, S. J., TERRY, C. J., TURNBULL, J. 
E., DELEHEDDE, M., HEEGAARD, C. W., ALLAIN, F., VANPOUILLE, C., RON, D. & 
FERNIG,  D.  G.  2005.  Interactions  of  multiple  heparin  binding  growth  factors  with 
neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem, 280, 
13457-64.
WIPFF, P. J., RIFKIN, D. B., MEISTER, J. J. & HINZ, B. 2007. Myofibroblast contraction 
activates latent TGF-beta1 from the extracellular matrix. J Cell Biol, 179, 1311-23.
32 | P a g e
References
WITZGALL, R., BROWN, D., SCHWARZ, C. & BONVENTRE, J. V. 1994. Localization of 
proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. 
Evidence for a heterogenous genetic response among nephron segments, and a large pool of 
mitotically active and dedifferentiated cells. J Clin Invest, 93, 2175-88.
WOLTMAN,  A.  M.,  DE  FIJTER,  J.  W.,  VAN  DER  KOOIJ,  S.  W.,  JIE,  K.  E., 
MASSACRIER,  C.,  CAUX,  C.,  DAHA,  M.  R.  &  VAN  KOOTEN,  C.  2005.  MIP-
3alpha/CCL20  in  renal  transplantation  and  its  possible  involvement  as  dendritic  cell 
chemoattractant in allograft rejection. Am J Transplant, 5, 2114-25.
WONG,  M.  L.  &  MEDRANO,  J.  F.  2005.  Real-time  PCR  for  mRNA  quantitation. 
Biotechniques, 39, 75-85.
WONG,  W.  K.,  ROBERTSON,  H.,  CARROLL,  H.  P.,  ALI,  S.  &  KIRBY,  J.  A.  2003. 
Tubulitis in renal allograft rejection: role of transforming growth factor-beta and interleukin-
15 in development and maintenance of CD103+ intraepithelial T cells. Transplantation, 75, 
505-14.
WU,  C.  &  DEDHAR,  S.  2001.  Integrin-linked  kinase  (ILK)  and  its  interactors:  a  new 
paradigm  for  the  coupling  of  extracellular  matrix  to  actin  cytoskeleton  and  signaling 
complexes. J Cell Biol, 155, 505-10.
WU,  W.,  JIANG,  X.  Y.,  ZHANG,  Q.  L.,  MO,  Y.,  SUN,  L.  Z.  &  CHEN,  S.  M.  2009. 
Expression  and significance  of  TGF-beta1/Smad signaling  pathway in  children  with  IgA 
nephropathy. World J Pediatr, 5, 211-5.
WYNN,  T.  A.  2007.  Common  and  unique  mechanisms  regulate  fibrosis  in  various 
fibroproliferative diseases. J Clin Invest, 117, 524-9.
XU,  J.,  LAMOUILLE,  S.  &  DERYNCK,  R.  2009.  TGF-beta-induced  epithelial  to 
mesenchymal transition. Cell Res, 19, 156-72.
XU, Y., WAN, J., JIANG, D. & WU, X. 2010. BMP-7 blocks the cyclosporine-A-induced 
epithelial-to-mesenchymal transition in renal tubular epithelial cells. Nephron Exp Nephrol, 
114, e23-31.
YANG, J. & LIU, Y. 2001. Dissection of key events in tubular epithelial to myofibroblast 
transition and its implications in renal interstitial fibrosis. Am J Pathol, 159, 1465-75.
YANG, Q., O'HANLON, D., HEIZMANN, C. W. & MARKS, A. 1999. Demonstration of 
heterodimer  formation  between  S100B and  S100A6 in  the  yeast  two-hybrid  system and 
human melanoma. Exp Cell Res, 246, 501-9.
YANG, Z., MU, Z., DABOVIC, B., JURUKOVSKI, V., YU, D., SUNG, J., XIONG, X. & 
MUNGER,  J.  S.  2007.  Absence  of  integrin-mediated  TGFbeta1  activation  in  vivo 
recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol, 176, 787-93.
33 | P a g e
References
YANNARAKI, M., REBIBOU, J. M., DUCLOUX, D., SAAS, P., DUPERRIER, A., FELIX, 
S., RIFLE, G., CHALOPIN, J. M., HERVE, P., TIBERGHIEN, P. & FERRAND, C. 2006. 
Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant 
rejection. Transpl Int, 19, 759-68.
YOKOI,  H.,  MUKOYAMA, M.,  NAGAE,  T.,  MORI,  K.,  SUGANAMI,  T.,  SAWAI,  K., 
YOSHIOKA, T., KOSHIKAWA, M., NISHIDA, T., TAKIGAWA, M., SUGAWARA, A. & 
NAKAO,  K.  2004.  Reduction  in  connective  tissue  growth  factor  by antisense  treatment 
ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol, 15, 1430-40.
YOUNG, B. A., BURDMANN, E. A., JOHNSON, R. J., ALPERS, C. E., GIACHELLI, C. 
M., ENG, E., ANDOH, T., BENNETT, W. M. & COUSER, W. G. 1995. Cellular proliferation 
and macrophage influx precede interstitial  fibrosis  in cyclosporine nephrotoxicity.  Kidney 
Int, 48, 439-48.
YOUNG,  G.  D.  & MURPHY-ULLRICH,  J.  E.  2004.  The  tryptophan-rich  motifs  of  the 
thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-
beta complex. J Biol Chem, 279, 47633-42.
ZAMORA, R.,  DEREK,  B.  & YORAM, V.  2007.  Differential  activation  of  recombinant 
human latent transforming growth factor-β1 (TGF-β1) by acid and heat. Rev Fac Med, 15(2), 
177-179.
ZAVADIL,  J.  &  BOTTINGER,  E.  P.  2005.  TGF-beta  and  epithelial-to-mesenchymal 
transitions. Oncogene, 24, 5764-74.
ZEISBERG, E. M., POTENTA, S. E., SUGIMOTO, H., ZEISBERG, M. & KALLURI, R. 
2008. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am 
Soc Nephrol, 19, 2282-7.
ZEISBERG,  M.,  BONNER,  G.,  MAESHIMA,  Y.,  COLORADO,  P.,  MULLER,  G.  A., 
STRUTZ,  F.  & KALLURI,  R.  2001.  Renal  fibrosis:  collagen composition  and assembly 
regulates epithelial-mesenchymal transdifferentiation. Am J Pathol, 159, 1313-21.
ZEISBERG,  M.,  HANAI,  J.,  SUGIMOTO,  H.,  MAMMOTO,  T.,  CHARYTAN,  D., 
STRUTZ, F. & KALLURI, R. 2003. BMP-7 counteracts TGF-beta1-induced epithelial-to-
mesenchymal transition and reverses chronic renal injury. Nat Med, 9, 964-8.
ZEISBERG, M. & KALLURI, R. 2004. The role of epithelial-to-mesenchymal transition in 
renal fibrosis. J Mol Med (Berl), 82, 175-81.
ZEISBERG,  M.  &  NEILSON,  E.  G.  2009.  Biomarkers  for  epithelial-mesenchymal 
transitions. J Clin Invest, 119, 1429-37.
ZELENIKA, D., ADAMS, E., HUMM, S., GRACA, L., THOMPSON, S., COBBOLD, S. P. 
& WALDMANN, H. 2002. Regulatory T cells overexpress a subset of Th2 gene transcripts. J 
Immunol, 168, 1069-79.
34 | P a g e
References
ZHANG, H., TASNIM, F., YING, J. Y. & ZINK, D. 2009. The impact of extracellular matrix 
coatings  on  the  performance  of  human  renal  cells  applied  in  bioartificial  kidneys. 
Biomaterials, 30, 2899-911.
ZHANG, L., BERTUCCI, A. M., RAMSEY-GOLDMAN, R., BURT, R. K. & DATTA, S. K. 
2009. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem 
cell  transplantation,  and  TGF-beta-producing  CD8+  Treg  cells  are  associated  with 
immunological remission of lupus. J Immunol, 183, 6346-58.
ZHU, M. Q., DE BROE, M. E. & NOUWEN, E. J. 1996. Vimentin expression and distal 
tubular damage in the rat kidney. Exp Nephrol, 4, 172-83.
ZIYADEH, F. N. 2004. Mediators of diabetic renal disease: the case for tgf-Beta as the major 
mediator. J Am Soc Nephrol, 15 Suppl 1, S55-7.
35 | P a g e
